Details of Disease

General Information of Disease (ID: DISF8S70)

• Disease Name: Alzheimer disease
• Synonyms: Alzheimer disease, familial; Alzheimer dementia; AD; Alzheimers dementia; Alzheimer's disease; presenile and senile dementia; Alzheimer's dementia; Alzheimers disease; Alzheimer disease
• Disease Class: 8A20: Alzheimer disease
• Definition: A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
• Disease Hierarchy:
  DISY2IPA: Tauopathy
  DISXL1WY: Dementia
  DISF8S70: Alzheimer disease
• ICD Code:
  ICD-11: ICD-11: 8A20
  ICD-10: ICD-10: G30, G30.9
  ICD-9: ICD-9: 331
  Expand ICD-11: '8A20
  Expand ICD-10: 'G30; 'G30.9
  Expand ICD-9: 331
• Disease Identifiers:
  MONDO ID: MONDO_0004975
  MESH ID: D000544
  UMLS CUI: C0002395
  MedGen ID: 1853
  HPO ID: HP:0002511
  Orphanet ID: 238616
  SNOMED CT ID: 26929004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 24 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aducanumab	DM51JW4	Approved	NA	[1]
Colostrinin	DMN110U	Approved	NA	[2]
Dihydroergotoxine	DM5D6WZ	Approved	Small molecular drug	[3]
Donepezil	DMIYG7Z	Approved	Small molecular drug	[4]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Approved	Small molecular drug	[5]
Ergoloid mesylate	DMORPBA	Approved	Small molecular drug	[6]
F18-florbetaben	DMY5WFL	Approved	NA	[7]
F18-flutemetamol	DMT30LD	Approved	NA	[8]
Galantamine	DMEO794	Approved	Small molecular drug	[9]
GV-971	DMTMA5W	Approved in China	NA	[10]
Huperzine A	DMMAWLU	Approved	Small molecular drug	[2]
Immune globulin	DMX2OMJ	Approved	NA	[11]
Lecanemab	DMW03YD	Approved	Antibody	[12]
Lemborexant	DM3DGSG	Approved	NA	[13]
Memantine	DMD9WSC	Approved	Small molecular drug	[14]
Nirogacestat	DMUP5Z0	Approved	Small molecular drug	[15]
Pexidartinib	DMS2J0Z	Approved	NA	[16]
Propentofylline propionate	DM6JQ2I	Approved	Small molecular drug	[2]
Rivastigmine	DMG629M	Approved	Small molecular drug	[17]
Rosiglitazone XR	DMT45MU	Approved	Small molecular drug	[18]
Tacrine	DM51FY6	Approved	Small molecular drug	[19]
Thiazolidinedione	DMC1NBW	Approved	Small molecular drug	[20]
18F-AV-1451	DM0GMH4	Phase 4	NA	[21]
Guanfacine	DMPN5IH	Phase 4	NA	[22]

This Disease is Treated as An Indication in 300 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
(-)-Phenserine	DMNCY1I	Phase 3	Small molecular drug	[23]
AC-1204	DM3J99W	Phase 3	Small molecular drug	[13]
acelarin	DMY96O3	Phase 3	Small molecular drug	[24]
ALZT-OP1	DMG5BTD	Phase 3	NA	[13]
AMG 386	DMQJXL4	Phase 3	Small molecular drug	[25]
AR1001	DMLV939	Phase 3	Small molecule	[26]
ARC029	DMYNJHI	Phase 3	Small molecular drug	[27]
AV 133	DM0EQ9X	Phase 3	NA	[28]
AVP-786	DMV1SOR	Phase 3	NA	[29]
AXS-05	DM6WZG8	Phase 3	Small molecular drug	[29]
Bapineuzumab	DMHQ5GK	Phase 3	Antibody	[30]
BPDO-1603	DMJ82Y4	Phase 3	NA	[31]
Crenezumab	DM7QI29	Phase 3	Monoclonal antibody	[13]
Davunetide	DMD7K9X	Phase 3	NA	[32]
Donanemab	DMPGLIO	Phase 3	Monoclonal antibody	[33]
E-2609	DMTNUJ8	Phase 3	NA	[13]
Eltoprazine	DMW6C81	Phase 3	Small molecular drug	[13]
EVP-6124	DMLQO7F	Phase 3	Small molecular drug	[34]
Gantenerumab	DMWX90U	Phase 3	Monoclonal antibody	[35]
INM-176	DMLG96Z	Phase 3	NA	[36]
Lanabecestat	DMFJLB6	Phase 3	NA	[13]
LCS 16	DMV5EYE	Phase 3	NA	[37]
LMT-X	DMOFIBM	Phase 3	NA	[38]
MIM-D3	DMZHN5B	Phase 3	Small molecular drug	[39]
NE3107	DMEZNJI	Phase 3	Small molecule	[40]
NI-101	DMJ2KIE	Phase 3	Antibody	[41]
PF-4494700	DMJ7IKW	Phase 3	Small molecular drug	[13]
Remternetug	DMPSMEU	Phase 3	Antibody	[42]
SB-742457	DM6L4ZT	Phase 3	Small molecular drug	[43]
SI-657	DM0QGFL	Phase 3	Small molecular drug	[44]
Solanezumab	DM0HIU5	Phase 3	Monoclonal antibody	[45]
Tamibarotene	DM3G74J	Phase 3	Small molecular drug	[46]
Tirapazamine	DMBFE4K	Phase 3	Small molecular drug	[47]
Tramiprosate	DM7BSRH	Phase 3	Small molecular drug	[48]
TRx0237	DM0QNF4	Phase 3	Small molecular drug	[49]
verubecestat	DM4CGH5	Phase 3	Small molecular drug	[43]
Xaliproden	DM1JCW8	Phase 3	Small molecular drug	[50]
AMG520	DMBFOAZ	Phase 2/3	NA	[43]
Atuzaginstat	DM5T6BM	Phase 2/3	Small molecule	[51]
AZD3293	DMJQHXD	Phase 2/3	Small molecular drug	[52]
CAD-106	DM31VZT	Phase 2/3	Vaccine	[53]
CAD106	DMVJKNU	Phase 2/3	Vaccine	[54]
E2814	DMZ3Q59	Phase 2/3	Monoclonal antibody	[55]
Fosgonimeton	DMXMAJA	Phase 2/3	Small molecule	[56]
Ginkgo biloba	DMJZBXX	Phase 2/3	NA	[57]
Icosapent ethyl	DMKI68F	Phase 2/3	Small molecule	[58]
JNJ-54861911	DMGPJ5U	Phase 2/3	NA	[59]
Plasminogen	DM0EFQS	Phase 2/3	NA	[60]
SI-614	DMJ3D6B	Phase 2/3	NA	[61]
AADvac-1	DMDLWW9	Phase 2	Vaccine	[62]
ABBV-8E12	DMHLIQU	Phase 2	NA	[63]
ABBV-916	DMGSCJC	Phase 2	Monoclonal antibody	[64]
ABT-126	DM2OS51	Phase 2	NA	[65]
ABT-288	DM7X54F	Phase 2	Small molecular drug	[66]
ABT-384	DM7XW5Y	Phase 2	Small molecular drug	[67]
ABvac40	DMWJE7B	Phase 2	Vaccine	[68]
AD-35	DMVDQO6	Phase 2	Small molecule	[69]
AD02 vaccine	DMZYQNL	Phase 2	NA	[70]
AL002	DMOY8VA	Phase 2	Monoclonal antibody	[71]
ALZ-801	DM7ZQAT	Phase 2	NA	[13]
AN-1792	DM3JNXS	Phase 2	Small molecular drug	[72]
APH-1105	DMT2IWF	Phase 2	NA	[73]
AQW-051	DMD2RFO	Phase 2	Small molecular drug	[74]
AUS-131	DMUXO3Z	Phase 2	NA	[13]
AVN 101	DMJFLBC	Phase 2	NA	[75]
AVN 322	DMK2LGM	Phase 2	NA	[76]
AZD-1446	DM7B1AR	Phase 2	Small molecular drug	[77]
AZD-5213	DMOZ04X	Phase 2	NA	[78]
AZD4694	DM6S9JP	Phase 2	Small molecular drug	[79]
Basmisanil	DMQ8J0U	Phase 2	NA	[80]
Benfotiamine	DMJHC2Y	Phase 2	Small molecule	[81]
Bepranemab	DMRQIJO	Phase 2	Monoclonal antibody	[82]
BI-409306	DMJFDS0	Phase 2	NA	[13]
BIIB092	DM263RP	Phase 2	NA	[13]
BMS-708163	DM51LTG	Phase 2	Small molecular drug	[83]
BPN14770	DMWVPO0	Phase 2	NA	[84]
Bryostatin-1	DM1JOXY	Phase 2	Small molecule	[85]
CERE-110	DMNW5I9	Phase 2	NA	[86]
CHF-5074	DMTE071	Phase 2	Small molecular drug	[87]
Coluracetam	DMI2GSK	Phase 2	Small molecular drug	[88]
CPC-201	DM10RQH	Phase 2	NA	[89]
CSTC1	DMM0D1Q	Phase 2	NA	[13]
CT1812	DMBRKZ7	Phase 2	NA	[90]
CX-717	DMM65W1	Phase 2	Small molecular drug	[91]
CY6463	DM84AVQ	Phase 2	Small molecule	[92]
DCB-AD1	DMBD9MQ	Phase 2	NA	[93]
DHP1401	DMH8HF9	Phase 2	NA	[94]
DM-99	DM1HG3U	Phase 2	NA	[95]
E2027	DMK8SY6	Phase 2	Small molecular drug	[13]
EVP-0962	DM0AO5W	Phase 2	NA	[96]
EVT302	DM73XNG	Phase 2	NA	[13]
FK-962	DMV0MZ3	Phase 2	Small molecular drug	[97]
FRM-0962	DM9ORUW	Phase 2	NA	[98]
GM-602	DM8R4YU	Phase 2	NA	[99]
GSK239512	DMBJMZC	Phase 2	Small molecular drug	[100]
GSK933776A	DMX27Q1	Phase 2	NA	[101]
HF-0220	DMI4C90	Phase 2	NA	[102]
HSRx-888	DM3S3AS	Phase 2	NA	[13]
ICA-17043	DMRFY7I	Phase 2	Small molecular drug	[103]
ID1201	DM3LHAX	Phase 2	NA	[104]
IMD-1041	DMU1MR9	Phase 2	NA	[105]
JNJ-63733657	DMMKWGJ	Phase 2	Monoclonal antibody	[106]
JOT106	DMY56TP	Phase 2	NA	[43]
KPAX002	DMDT5WM	Phase 2	NA	[43]
Ladostigil	DMJSY3Q	Phase 2	Small molecular drug	[107]
LY2886721	DMV14LM	Phase 2	Small molecular drug	[108]
LY3002813	DM2T6CY	Phase 2	NA	[109]
LY3202626	DM7IFNB	Phase 2	NA	[13]
LY3372689	DMA2M7V	Phase 2	Small molecule	[110]
LymPro	DM9XV3C	Phase 2	NA	[111]
Mesenchymal stem cell therapy	DMW7QYT	Phase 2	NA	[13]
Methanesulfonyl fluoride	DMS7FRI	Phase 2	Small molecular drug	[112]
Mibampator	DME5CSV	Phase 2	Small molecular drug	[113]
MIQ-001	DM6QADB	Phase 2	NA	[114]
Mitoglitazone	DMIRPSA	Phase 2	Small molecular drug	[13]
MK-0752	DMLTAES	Phase 2	Small molecular drug	[115]
MK-1942	DMLD8DF	Phase 2	Small molecule	[116]
MK-7622	DM1Q18V	Phase 2	Small molecular drug	[117]
MLC901	DM67LGP	Phase 2	NA	[118]
MP-101	DMYCITZ	Phase 2	NA	[119]
MW150	DMBRVXB	Phase 2	Small molecule	[120]
Myo-inositol	DMQKSGI	Phase 2	Small molecular drug	[29]
NDD-094	DMULYI3	Phase 2	NA	[121]
Nefiracetam	DMCMIYZ	Phase 2	Small molecular drug	[122]
Neu-P11	DMIQDFW	Phase 2	Small molecular drug	[13]
NIC5-15	DMG7XOC	Phase 2	Small molecular drug	[123]
NLY01	DMI9OMV	Phase 2	Small molecule	[124]
NP001	DMVB5E1	Phase 2	Small molecular drug	[13]
Nuedexta	DM9DO9B	Phase 2	NA	[13]
Nuplazid	DMOJA5G	Phase 2	Small molecular drug	[125]
Oleoyl-estrone	DM0RA8F	Phase 2	Small molecular drug	[13]
ORM-12741	DM8ARQW	Phase 2	Small molecular drug	[126]
ORY-2001	DMYM0UY	Phase 2	Small molecule	[127]
PBT-2	DMKWGS1	Phase 2	Small molecular drug	[128]
PF-05212377	DMPVQYR	Phase 2	NA	[129]
PF-4447943	DM81D4I	Phase 2	Small molecular drug	[130]
Ponezumab	DMIAZ13	Phase 2	Antibody	[131]
PRX-3140	DMEVXS1	Phase 2	NA	[132]
PTI-125	DMV17HK	Phase 2	Small molecular drug	[133]
R-phenserine	DM4L5VJ	Phase 2	NA	[134]
RG1577	DMT1ZX0	Phase 2	NA	[135]
RG6100	DMEFD0B	Phase 2	NA	[136]
RP5063	DMKUE8O	Phase 2	NA	[29]
RPh201	DM09NZU	Phase 2	NA	[137]
S-38093	DMD8XOY	Phase 2	NA	[138]
SAGE-718	DM9RC7D	Phase 2	Small molecular drug	[139]
SAM-531	DMHVJZ6	Phase 2	Small molecular drug	[140]
SAR-110894	DMCLEXM	Phase 2	NA	[141]
Semorinemab	DMA17VD	Phase 2	Monoclonal antibody	[142]
ST-101	DMVUXLC	Phase 2	Small molecular drug	[143]
SUVN-502	DMQD753	Phase 2	Small molecular drug	[13]
SYN-120	DMPW0UL	Phase 2	NA	[144]
T-817MA	DMD72F4	Phase 2	Small molecular drug	[145]
T3D-959	DMR3245	Phase 2	NA	[146]
Tau-binding PET tracer	DM9QFW2	Phase 2	Small molecular drug	[147]
TB006	DMKN524	Phase 2	Monoclonal antibody	[148]
TD-8954	DM3C9NV	Phase 2	Small molecular drug	[149]
Tideglusib	DME4LA1	Phase 2	Small molecular drug	[150]
TPI 287	DM3I5NU	Phase 2	NA	[43]
TPI-287	DMC5TV6	Phase 2	Small molecular drug	[151]
Trontinemab	DMNCLHJ	Phase 2	Antibody	[152]
TTP-448	DMR37X8	Phase 2	NA	[153]
UB-311	DM4NXWE	Phase 2	NA	[154]
UE-2343	DMIERPK	Phase 2	NA	[13]
Vafidemstat	DM64ZGY	Phase 2	Small molecule	[127]
Vanutide cridificar	DMU2K8A	Phase 2	NA	[155]
VI-1121	DMDI3B4	Phase 2	NA	[156]
VX-745	DMJAEG6	Phase 2	Small molecular drug	[13]
ACI-24	DM5YDSU	Phase 1/2	Vaccine	[157]
AL 001	DMSNCPD	Phase 1/2	NA	[158]
APH-0703	DMVD56K	Phase 1/2	NA	[159]
AstroStem	DMAS46G	Phase 1/2	NA	[13]
BIIB080	DM6QH3U	Phase 1/2	NA	[13]
BIL010t	DMV1EA9	Phase 1/2	NA	[103]
EB-101	DMH2NKD	Phase 1/2	Vaccine	[160]
GB301	DMIPDDL	Phase 1/2	Cell therapy	[161]
IONIS-MAPTRx	DM7H7KH	Phase 1/2	NA	[43]
LM11A-31	DM095HQ	Phase 1/2	Small molecular drug	[162]
LX1001	DMXEJZO	Phase 1/2	Gene therapy	[163]
MIB-626	DM6RTN3	Phase 1/2	NA	[164]
MK-2461	DM21WBH	Phase 1/2	Small molecular drug	[165]
RVX-208	DM1LO8K	Phase 1/2	Small molecular drug	[166]
VAC20121	DMOH36A	Phase 1/2	Vaccine	[167]
VGH-AD1	DM4DPYS	Phase 1/2	NA	[168]
VLP norovirus bivalent vaccine	DMGL85U	Phase 1/2	NA	[169]
Xanamem	DM580GT	Phase 1/2	Small molecule	[170]
11C-6-Me-BTA-1	DMICUPT	Phase 1	NA	[171]
11C-AZD-2184	DMYVDXW	Phase 1	NA	[172]
123I-MNI-168	DM2GR7E	Phase 1	NA	[173]
123I-MNI-330	DMMBGH3	Phase 1	NA	[174]
18F-FEDAA-1106	DMZ5YMX	Phase 1	NA	[175]
AAB-003/PF-05236812	DM92RQT	Phase 1	NA	[176]
AAD-2004	DMG4RK0	Phase 1	Small molecular drug	[177]
AAV-hTERT	DMV1J21	Phase 1	Gene therapy	[178]
ABT-354	DMWN7D3	Phase 1	NA	[179]
ABT-957	DMB9N4J	Phase 1	NA	[180]
ACI-35	DMIP79L	Phase 1	NA	[181]
ACU193	DM5BISI	Phase 1	Antibody	[182]
AD03 vaccine	DMA20WE	Phase 1	Vaccine	[183]
AD101	DMJFNKZ	Phase 1	Small molecule	[184]
Affitope AD-01	DM0I8RZ	Phase 1	Vaccine	[185]
AL003	DMF6W5K	Phase 1	Monoclonal antibody	[186]
Aleplasinin	DMYTIP4	Phase 1	Small molecular drug	[187]
ALN-APP	DME8BPN	Phase 1	RNA interference	[188]
ANAVEX 2-73	DM67OU4	Phase 1	NA	[13]
Anti-N3pG-Abeta antibody	DMRWI7E	Phase 1	Antibody	[189]
ANVS301	DMHT1AS	Phase 1	NA	[190]
APH-1104	DMVQI2A	Phase 1	NA	[191]
APNmAb005	DMDVRPZ	Phase 1	Monoclonal antibody	[192]
ARC031	DMFUEYP	Phase 1	NA	[193]
ASN51	DMZWOYL	Phase 1	NA	[194]
ASP-0777	DM8DBT6	Phase 1	NA	[195]
ASP3662	DMQLLVL	Phase 1	NA	[196]
AV-965	DMVL87N	Phase 1	NA	[197]
AVN-322	DMNIVFJ	Phase 1	Small molecular drug	[198]
AZD-3839	DM72FOD	Phase 1	Small molecular drug	[199]
AZD2184	DMVDBS7	Phase 1	NA	[200]
AZD2995	DMDVNVI	Phase 1	NA	[200]
BAY-1006578	DMEUW6I	Phase 1	NA	[201]
BCI-632	DMZYCWT	Phase 1	Small molecular drug	[202]
BCI-838	DMRXDN3	Phase 1	NA	[203]
Begacestat	DMUR49N	Phase 1	Small molecular drug	[204]
BEY2153	DMCB2Z0	Phase 1	NA	[205]
BIIB076	DMOTBB4	Phase 1	NA	[13]
BIIB113	DM7U1AC	Phase 1	Small molecule	[206]
BMS-241027	DM6GB6B	Phase 1	NA	[207]
BMS-932481	DMTJLJH	Phase 1	NA	[153]
BMS-984923	DMFNDUL	Phase 1	Small molecule	[208]
COR-388	DM0MFDA	Phase 1	NA	[13]
COR588	DMPGTC8	Phase 1	Small molecule	[209]
CPC-212	DM3J1T9	Phase 1	NA	[13]
CPC-250	DMDQG4Y	Phase 1	NA	[13]
CTS-21166	DM68I93	Phase 1	NA	[210]
DNL104	DMOSCQ9	Phase 1	Small molecular drug	[211]
DNL747	DMNSC0O	Phase 1	Small molecular drug	[212]
DNL919	DMDFQLZ	Phase 1	Antibody	[213]
DSP-8658	DM2PYE0	Phase 1	NA	[214]
DWP-09031	DM4XZY9	Phase 1	NA	[215]
E-2212	DMQDKYV	Phase 1	NA	[216]
E2012	DMNEVKA	Phase 1	Small molecular drug	[217]
E2511	DM5GE7H	Phase 1	NA	[218]
Exebryl-1	DM5U0K9	Phase 1	NA	[219]
FGLL	DMY61GX	Phase 1	NA	[220]
GC021109	DMQBEYV	Phase 1	NA	[13]
GRF6019	DMVYEBN	Phase 1	NA	[13]
GSI-136	DMSR5HD	Phase 1	Small molecular drug	[221]
GSK2647544	DM3KARJ	Phase 1	NA	[222]
GSK2981710	DM7DBFF	Phase 1	NA	[223]
HPP-854	DMSLDHG	Phase 1	NA	[224]
IGCAD1	DMB3PVV	Phase 1	NA	[225]
J147	DMMWX7N	Phase 1	Small molecule	[226]
JES-9501	DMYR3IE	Phase 1	NA	[227]
Lu AF20513	DM40FFG	Phase 1	NA	[13]
Lu AF87908	DMFSPAT	Phase 1	Monoclonal antibody	[228]
LY-2811376	DM8LGWR	Phase 1	Small molecular drug	[229]
LY3303560	DMG6HLE	Phase 1	NA	[43]
LY3372993	DMACGI7	Phase 1	Monoclonal antibody	[230]
MCD-386	DMFIS4D	Phase 1	NA	[231]
MEDI1814	DM078GU	Phase 1	NA	[13]
MEDI1841	DMLQOD3	Phase 1	NA	[232]
MER5101	DMZ2D7H	Phase 1	Vaccine	[13]
MK-3328	DMW2O5D	Phase 1	Small molecular drug	[233]
MK-4334	DMQEQ33	Phase 1	NA	[234]
NDX-1017	DM6NF5F	Phase 1	NA	[13]
NGP 555	DMTVQH2	Phase 1	NA	[43]
NNI-362	DMPCV65	Phase 1	Small molecule	[235]
NPT088	DM157TU	Phase 1	NA	[13]
NsG-0202	DM1ITDN	Phase 1	NA	[236]
NTRX-07	DMF8AHP	Phase 1	NA	[237]
Palomid-529	DM428Y3	Phase 1	NA	[238]
PF-04995274	DMZ8QRI	Phase 1	Small molecular drug	[239]
PF-05251749	DMXLJJ6	Phase 1	NA	[43]
PF-06648671	DM056JD	Phase 1	Small molecular drug	[240]
PF-06751979	DMEOF7Q	Phase 1	NA	[43]
Posiphen R-phenserine	DMCU54M	Phase 1	NA	[241]
Protexia	DME1Y9W	Phase 1	NA	[242]
Protollin	DMBUU86	Phase 1	Vaccine	[243]
PRX-005	DMAL2OW	Phase 1	Antibody	[244]
PTI-80	DM0A6N9	Phase 1	NA	[245]
PU-AD	DMKSU35	Phase 1	NA	[13]
REM0046127	DMO4AJZ	Phase 1	Small molecule	[246]
RG6289	DMGLW0N	Phase 1	NA	[247]
RG7129	DMTWSM2	Phase 1	NA	[248]
RVT-104	DM1INL2	Phase 1	NA	[13]
SAR228810	DMTFAGU	Phase 1	Antibody	[249]
SGC-1061	DMLZY28	Phase 1	NA	[250]
SHR-1707	DMCESPF	Phase 1	Monoclonal antibody	[251]
SOR-C13	DMBKL6O	Phase 1	NA	[103]
SPI-014	DM5IPUS	Phase 1	NA	[252]
SUVN-D4010	DM6ZOD2	Phase 1	NA	[13]
TAK-071	DMKUT08	Phase 1	NA	[13]
TAu mAb	DMCZA4S	Phase 1	NA	[13]
TT-301	DM4QV8Y	Phase 1	NA	[253]
TTP-4000	DMCG01R	Phase 1	NA	[254]
V950 vaccine	DMBJOKG	Phase 1	NA	[255]
XEL 001HP	DM828IK	Phase 1	NA	[256]
alpha-ketothiazole analogue 36	DMN2I3P	Clinical trial	Small molecular drug	[257]
bimatoprost (free acid form)	DM531SA	Clinical trial	Small molecular drug	[258]
JNJ-479655	DMDU6GN	Clinical trial	Small molecular drug	[259]
methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate	DMW15TC	Clinical trial	Small molecular drug	[260]

This Disease is Treated as An Indication in 9 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-2	DMMAE3C	Patented	Small molecular drug	[261]
PMID27998201-Compound-22	DMS9QA7	Patented	Small molecular drug	[261]
PMID28350212-Compound-18	DMH8GC6	Patented	Small molecular drug	[262]
PMID28350212-Compound-19	DMI4US6	Patented	Small molecular drug	[262]
PMID28350212-Compound-20	DMM5G7S	Patented	Small molecular drug	[262]
PMID29334795-Compound-22	DM8N10A	Patented	Small molecular drug	[263]
Schiff base compound 1	DMQD6IL	Patented	Small molecular drug	[264]
Schiff base compound 2	DMWD20L	Patented	Small molecular drug	[264]
Thiadiazolyl carboxamide derivative 1	DMX93AI	Patented	Small molecular drug	[265]

This Disease is Treated as An Indication in 66 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-1913539	DMXEU14	Discontinued in Phase 3	Small molecular drug	[266]
Zanapezil	DMTCP8H	Discontinued in Phase 3	Small molecular drug	[267]
ABT-418	DMNP72I	Discontinued in Phase 2	Small molecular drug	[268]
Affitope AD-02	DMSF5VK	Discontinued in Phase 2	Vaccine	[269]
AVN 397	DMFCOZL	Discontinued in Phase 2	NA	[270]
AZD0328	DM4B7CM	Discontinued in Phase 2	Small molecular drug	[271]
DPC-543	DMSZHNB	Discontinued in Phase 2	NA	[272]
IPENOXAZONE	DM4WJDK	Discontinued in Phase 2	Small molecular drug	[273]
Ispronicline	DMKY2UE	Discontinued in Phase 2	Small molecular drug	[274]
NGD-97-1	DMBF46A	Discontinued in Phase 2	NA	[275]
S-18986	DMA01BV	Discontinued in Phase 2	Small molecular drug	[276]
SIB-1553A	DM7XC0U	Discontinued in Phase 2	Small molecular drug	[277]
Talsaclidine fumarate	DM2KH9Y	Discontinued in Phase 2	Small molecular drug	[278]
AZD-1080	DMIM9N1	Discontinued in Phase 1	Small molecular drug	[279]
C-9138	DML1OY7	Discontinued in Phase 1	NA	[280]
EVT-301	DMCZ8SF	Discontinued in Phase 1	NA	[281]
GR-253035	DMWY2F6	Discontinued in Phase 1	NA	[282]
NP-61	DMXI5YW	Discontinued in Phase 1	NA	[283]
PF-05236812	DM68PYA	Discontinued in Phase 1	NA	[284]
SL-25.1188	DMP0DLW	Discontinued in Phase 1	NA	[285]
TAK-065	DMWY2RH	Discontinued in Phase 1	NA	[286]
TRx-0037	DMMKSST	Discontinued in Phase 1	NA	[287]
VP-025	DM0HZBU	Discontinued in Phase 1	NA	[288]
A-72055	DM7FI3S	Terminated	NA	[300]
ABS-301	DMCW5DJ	Terminated	NA	[301]
Alvameline	DMLN0Y5	Terminated	Small molecular drug	[302]
AZD-2858	DMRCI96	Terminated	Small molecular drug	[303]
BIBN-140	DM019Y7	Terminated	Small molecular drug	[304]
BIBN-99	DMZTPCX	Terminated	Small molecular drug	[305]
Bifemelane	DMU73F0	Terminated	Small molecular drug	[306]
BU-4514N	DMJDMTK	Terminated	Small molecular drug	[307]
CEP-427	DMTI10C	Terminated	NA	[308]
CEP-431	DMDH0AM	Terminated	NA	[309]
CI-1002	DMJ2P1Q	Terminated	NA	[310]
DNP-004089	DMXR3V1	Terminated	NA	[311]
EHT-1864	DMYAMP5	Terminated	Small molecular drug	[312]
F-14413	DMGH3QD	Terminated	NA	[313]
F-3796	DMXB8SE	Terminated	NA	[314]
FR-121196	DMNRUGA	Terminated	Small molecular drug	[315]
FR-152558	DMOEYX2	Terminated	NA	[316]
GT-2016	DM42XHS	Terminated	Small molecular drug	[317]
GT-4001	DMYNZB7	Terminated	NA	[318]
GYKI-52466	DM3YG5P	Terminated	Small molecular drug	[319]
IDRA-21	DMG1FQW	Terminated	Small molecular drug	[320]
L-698544	DMLRBN1	Terminated	Small molecular drug	[321]
MDL-28170	DMYK31O	Terminated	Small molecular drug	[322]
MF-8615	DM47WS2	Terminated	NA	[323]
MF268	DMHV5OD	Terminated	Small molecular drug	[324]
Milacemide	DMJTR0U	Terminated	Small molecular drug	[325]
Nerve growth factor	DMHYQ8K	Terminated	NA	[326]
NNC-90-0270	DM1SXG9	Terminated	NA	[327]
NP-7557	DM4B1VF	Terminated	NA	[328]
NS-377	DM2MU98	Terminated	NA	[329]
NS-649	DMXKMRV	Terminated	NA	[330]
R-1315	DMIBCZ5	Terminated	NA	[331]
Ro-46-5934	DMU9JAH	Terminated	NA	[332]
RS 86	DMKQV9A	Terminated	Small molecular drug	[333]
RS-66252	DMT5DH0	Terminated	NA	[334]
RU-33965	DMSWFMQ	Terminated	Small molecular drug	[335]
SAN-61	DMGUA9Y	Terminated	NA	[336]
Sch-57790	DMGCYPE	Terminated	Small molecular drug	[337]
Sibopirdine	DMGZDOA	Terminated	Small molecular drug	[338]
Tenilsetam	DMNEF2N	Terminated	Small molecular drug	[339]
Z-4105	DM2F6T0	Terminated	Small molecular drug	[340]
ZK-91296	DMJYIVA	Terminated	Small molecular drug	[341]
ZK-93426	DMMDQ5T	Terminated	Small molecular drug	[342]

This Disease is Treated as An Indication in 15 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AAB-002	DMC7EQT	Phase 0	NA	[289]
ACC-002	DMTYPNN	Phase 0	NA	[290]
INP102	DMPIWDL	Phase 0	NA	[13]
ANAVEX 1-41	DM1MQON	Preclinical	NA	[291]
CDD-0199-J	DM842EE	Preclinical	NA	[292]
CX-1501	DMKZCBE	Preclinical	NA	[293]
humanin	DMUAPNF	Preclinical	Small molecular drug	[294]
Pepticlere	DMA5T3J	Preclinical	NA	[295]
SCH-1359113	DMLG682	Preclinical	Small molecular drug	[296]
SD1002	DMLAF6C	Preclinical	Small molecular drug	[297]
SD1003	DM29BW1	Preclinical	Small molecular drug	[297]
SPH-1285	DMMA2ZW	Preclinical	NA	[298]
TPT-43	DM06BUL	Preclinical	NA	[299]
VER-155008	DMIQAY4	Preclinical	Small molecular drug	[297]
Z-Phe-Ala-diazomethylketone	DMX23CZ	Preclinical	Small molecular drug	[297]

This Disease is Treated as An Indication in 72 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
11A1	DMFVP6K	Investigative	Antibody	[160]
123I-DRM-106	DMW172Q	Investigative	Small molecular drug	[160]
A-887755	DM8IWUE	Investigative	NA	[160]
Abloid	DMKN10X	Investigative	NA	[160]
AC-4402	DMDAM9P	Investigative	Small molecular drug	[343]
ACI-518	DM1O13Z	Investigative	NA	[343]
ACI-636	DMPLNTM	Investigative	NA	[160]
ACU-0101979	DM7ZWRN	Investigative	Vaccine	[160]
AD-0802	DM23QND	Investigative	Vaccine	[160]
ADepVac	DM9KPHE	Investigative	NA	[343]
AIKb2	DM6Z14C	Investigative	NA	[343]
ANA-5	DM3DPSO	Investigative	NA	[160]
Anticalin	DMQJ3ZL	Investigative	NA	[160]
ARC-069	DMSM1PV	Investigative	NA	[160]
ARN-2966	DMBE0H8	Investigative	Small molecular drug	[344]
AZ-AAV9	DMPWF71	Investigative	NA	[343]
AZD-6319	DMD4YO9	Investigative	NA	[345]
AZP-2006	DMZFEKB	Investigative	NA	[343]
BAN-2203	DMX6KTO	Investigative	NA	[160]
CBNU-06	DMC3H8P	Investigative	NA	[343]
CDD-0235-J	DMEG8TG	Investigative	NA	[343]
CDD-190	DML6489	Investigative	NA	[343]
COG-248	DM0E4YT	Investigative	NA	[343]
CWF-0804	DMB8BHX	Investigative	NA	[343]
Cystatin C	DMHLLCB	Investigative	NA	[343]
DBT-1339	DM09YI7	Investigative	NA	[160]
DWJ-209	DMNWGWI	Investigative	NA	[343]
EDN-OL1	DMHCGIS	Investigative	NA	[160]
ELND-007	DM5G1SF	Investigative	Small molecular drug	[346]
ESN-XX	DMKLQ1N	Investigative	NA	[343]
ETN-001	DMCND90	Investigative	NA	[343]
EVP-4473	DMHMFKE	Investigative	NA	[345]
F-18 T808	DM0BZWR	Investigative	NA	[343]
Gamma-secretase modulators	DMG7UPR	Investigative	Small molecular drug	[347]
Ginkgo biloba extract	DMKIDQO	Investigative	NA	[343]
GRL-11097	DMYQIQY	Investigative	NA	[343]
GT 1061	DMR4I8K	Investigative	NA	[343]
Haw-AD-14	DMDGSHS	Investigative	NA	[343]
HL-026	DM8BM5M	Investigative	NA	[343]
IMD-4482	DMSD7YJ	Investigative	NA	[343]
KD-501	DMIHJSE	Investigative	NA	[343]
KD-901	DMB8LZ5	Investigative	NA	[343]
KMS-88009	DM2K81B	Investigative	NA	[160]
KNX-Monoclonal204	DMNWXCA	Investigative	Antibody	[160]
Leptin	DM5LY1H	Investigative	NA	[348]
LNK-3186	DM0MQ96	Investigative	NA	[343]
LNK-3248	DME7DX6	Investigative	NA	[343]
Memex	DMMKAOE	Investigative	NA	[343]
Mimovax	DM7DT20	Investigative	Vaccine	[160]
Molecule 22	DM9K6Q4	Investigative	NA	[343]
NAChR alpha 7 APLs	DMO5UJZ	Investigative	NA	[343]
NAChR APLs	DMKRFPW	Investigative	NA	[343]
NGN-9079	DMNF845	Investigative	NA	[343]
NNI-AD	DM6RZPM	Investigative	NA	[343]
NP-103	DMPEDJG	Investigative	NA	[343]
NP-17	DMY3NLW	Investigative	NA	[343]
NXD-9062	DMOYQJY	Investigative	NA	[343]
PD-2015	DM32UIG	Investigative	NA	[343]
PN-403	DMX1LT7	Investigative	NA	[343]
PNB-04	DM4JRGT	Investigative	NA	[343]
RAP-310	DMP2DMB	Investigative	NA	[349]
RECALL-VAX	DM1XFE9	Investigative	Vaccine	[160]
ReN-004	DMC8DY5	Investigative	NA	[343]
SEL-103	DMW97WY	Investigative	NA	[343]
SEN-1500	DMKB2IJ	Investigative	NA	[160]
SP-08	DM2TRIZ	Investigative	NA	[160]
SPI-017	DMOOQ85	Investigative	NA	[343]
SX-AZD1	DM1KH2W	Investigative	NA	[343]
TKP-1001	DMDBUXR	Investigative	NA	[160]
Turmeric extracts	DM3QE8P	Investigative	NA	[160]
UC-1011	DMCRFT5	Investigative	NA	[350]
VK-11	DM7FQD0	Investigative	NA	[160]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 854 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACAT1	TTK3C21	Limited	Biomarker	[351]
AGTR1	TT8DBY3	Limited	Biomarker	[352]
ANK1	TTKFPMH	Limited	Posttranslational Modification	[353]
ANPEP	TTPHMWB	Limited	Biomarker	[354]
AQP1	TTSF1KH	Limited	Biomarker	[355]
BLVRA	TTJBPN3	Limited	Posttranslational Modification	[356]
C5AR1	TTHXFA1	Limited	Biomarker	[357]
CASR	TTBUYHA	Limited	Biomarker	[358]
CAV1	TTXUBN2	Limited	Biomarker	[359]
CCL11	TTCF05Y	Limited	Altered Expression	[360]
CD40LG	TTIJP3Q	Limited	Altered Expression	[361]
CHRNA7	TTLA931	Limited	Genetic Variation	[362]
CRHR1	TT7EFHR	Limited	Biomarker	[363]
CSNK1D	TTH30UI	Limited	Biomarker	[364]
CX3CR1	TT2T98G	Limited	Biomarker	[365]
CYP3A4	TTWP7HQ	Limited	Genetic Variation	[366]
ECE2	TT5U914	Limited	Autosomal dominant	[367]
EGR1	TTE8LGD	Limited	Altered Expression	[368]
FKBP4	TTHY0FT	Limited	Biomarker	[369]
FKBP5	TT0J5KQ	Limited	Biomarker	[370]
FLT1	TT1VAUK	Limited	Altered Expression	[371]
FUS	TTKGYZ9	Limited	Biomarker	[372]
GLO1	TTV9A7R	Limited	Biomarker	[373]
GNE	TT4DP5S	Limited	Genetic Variation	[374]
GPRC6A	TTI1PRE	Limited	Biomarker	[375]
GRIN2A	TTKJEMQ	Limited	Altered Expression	[376]
GSN	TTUH7OM	Limited	Biomarker	[377]
HLA-DRB1	TTUXSTW	Limited	Genetic Variation	[378]
HMGA1	TTBA219	Limited	Genetic Variation	[379]
HMGCR	TTPADOQ	Limited	Biomarker	[380]
HNMT	TT2B6EV	Limited	Genetic Variation	[381]
IFNB1	TT4TZ8J	Limited	Biomarker	[382]
IGF1	TTT6LOU	Limited	Altered Expression	[383]
IGF2R	TTPNE41	Limited	Biomarker	[384]
IGFBP3	TTZHNQA	Limited	Biomarker	[385]
IL13	TT0GVCH	Limited	Altered Expression	[386]
IL1RN	TT6GSR3	Limited	Biomarker	[387]
IL33	TT5MD4P	Limited	Biomarker	[388]
INPP5D	TTTP2Z1	Limited	Biomarker	[389]
KLK6	TTLPF4X	Limited	Biomarker	[390]
KLK8	TTH5MRS	Limited	Biomarker	[391]
LPAR3	TTE2YJR	Limited	Biomarker	[375]
LRP2	TTPH1AJ	Limited	Biomarker	[392]
MAOB	TTGP7BY	Limited	Genetic Variation	[393]
MARK2	TTAJ45Y	Limited	Genetic Variation	[394]
MRGPRX1	TTIX6PK	Limited	Biomarker	[375]
NLRP1	TTQX29T	Limited	Biomarker	[395]
NR1I2	TT7LCTF	Limited	Biomarker	[396]
NRG1	TTEH395	Limited	Altered Expression	[397]
NTRK1	TTTDVOJ	Limited	Biomarker	[398]
OGDH	TTH8T6I	Limited	Altered Expression	[399]
OLR1	TTKSND3	Limited	Genetic Variation	[400]
OXER1	TT7WBSV	Limited	Biomarker	[375]
P2RX7	TT473XN	Limited	Biomarker	[401]
PLA2G2A	TTO8QRU	Limited	Biomarker	[402]
PPID	TTNAFOU	Limited	Biomarker	[403]
PPIF	TTRFQTB	Limited	Biomarker	[403]
PREP	TTNGKET	Limited	Biomarker	[404]
PTGS1	TT8NGED	Limited	Biomarker	[405]
S100A9	TT0TMQG	Limited	Biomarker	[406]
SLC2A4	TTP6MT5	Limited	Altered Expression	[407]
SOX2	TTCNOT6	Limited	Genetic Variation	[408]
SOX5	TTXHSZK	Limited	Genetic Variation	[409]
SP1	TTZEP6S	Limited	Biomarker	[410]
SREBF2	TTRQ4AP	Limited	Biomarker	[411]
SYK	TT2HUPM	Limited	Biomarker	[412]
TKT	TT04R7I	Limited	Biomarker	[413]
TRPV1	TTMI6F5	Limited	Altered Expression	[414]
VCAM1	TTHCEF6	Limited	Biomarker	[415]
VDAC1	TTAMKGB	Limited	Altered Expression	[416]
ASRGL1	TT4WT91	Disputed	Biomarker	[417]
ADAM17	TT6AZXG	moderate	Genetic Variation	[418]
CDA	TTQ12RK	moderate	Biomarker	[419]
CHRNB2	TT5KPZR	moderate	Biomarker	[420]
CSF1R	TT7MRDV	moderate	Biomarker	[421]
DNM1	TTE3JW9	moderate	Altered Expression	[422]
ERN1	TTKIAT3	moderate	Altered Expression	[423]
HSF1	TTN6STZ	moderate	Altered Expression	[424]
LGR5	TTTSGRH	moderate	Biomarker	[425]
PTGES	TTYLQ8V	moderate	Biomarker	[426]
SLC6A3	TTVBI8W	moderate	Biomarker	[427]
STAR	TTEI40H	moderate	Biomarker	[428]
VCP	TTHNLSB	moderate	Genetic Variation	[429]
AAK1	TT0Z32T	Strong	Altered Expression	[430]
ABCA4	TTLB52K	Strong	Genetic Variation	[431]
ABCB1	TT3OT40	Strong	Biomarker	[432]
ABCB11	TTUXCAF	Strong	Genetic Variation	[433]
ABCC4	TTUEAFL	Strong	Altered Expression	[434]
ABCC9	TTEF5MJ	Strong	Genetic Variation	[435]
ABCG1	TTMWDGU	Strong	Biomarker	[436]
ABCG2	TTIMJ02	Strong	Biomarker	[437]
ACE2	TTUI5H7	Strong	Biomarker	[438]
ACKR1	TTKY2NS	Strong	Biomarker	[439]
ACKR3	TTRQJTC	Strong	Biomarker	[440]
ACO2	TTMTF2P	Strong	Altered Expression	[441]
ACTG1	TTGAZF9	Strong	Biomarker	[361]
ACVRL1	TTGYPTC	Strong	Biomarker	[442]
ADAM30	TTAJDQY	Strong	Biomarker	[443]
ADAM9	TTTYQNS	Strong	Biomarker	[444]
ADAMTS1	TTS2TEI	Strong	Biomarker	[445]
ADAMTS13	TTUREBK	Strong	Altered Expression	[446]
ADAMTS4	TTYG6BU	Strong	Biomarker	[447]
ADCY2	TTBQ9IM	Strong	Altered Expression	[448]
ADCYAP1	TTW4LYC	Strong	Biomarker	[449]
ADM	TTV14YH	Strong	Altered Expression	[450]
ADORA1	TTK25J1	Strong	Biomarker	[451]
ADORA2A	TTM2AOE	Strong	Biomarker	[452]
ADRA1A	TTNGILX	Strong	Biomarker	[440]
ADRA2A	TTWG9A4	Strong	Biomarker	[453]
ADRA2B	TTWM4TY	Strong	Biomarker	[440]
ADRB1	TTR6W5O	Strong	Biomarker	[454]
ADRB2	TTG8ZWP	Strong	Biomarker	[455]
AGTR2	TTQVOEI	Strong	Biomarker	[456]
AHSG	TTKF4WV	Strong	Biomarker	[457]
AIMP2	TTXWHGF	Strong	Biomarker	[458]
ALAD	TTJHKYD	Strong	Altered Expression	[459]
ALAS1	TTG1FXO	Strong	Altered Expression	[460]
ALOX12	TT12ABZ	Strong	Biomarker	[461]
ALOX15	TTN9T81	Strong	Altered Expression	[462]
ALOX5AP	TTDMBF5	Strong	Genetic Variation	[463]
ALPI	TTHYMUV	Strong	Genetic Variation	[464]
AMD1	TTBFROQ	Strong	Biomarker	[465]
ANG	TTURHFP	Strong	Biomarker	[466]
ANGPT1	TTWNQ1T	Strong	Altered Expression	[438]
ANXA1	TTUCK4B	Strong	Biomarker	[467]
ANXA5	TT2Z83I	Strong	Genetic Variation	[468]
AOC3	TT7HC21	Strong	Biomarker	[469]
APC2	TTSMK36	Strong	Biomarker	[470]
APCS	TTB7VAT	Strong	Biomarker	[471]
APEH	TTYWEDQ	Strong	Biomarker	[472]
APEX1	TTHGL48	Strong	Genetic Variation	[473]
APLN	TT87D3J	Strong	Altered Expression	[474]
APOA1	TT5S8DR	Strong	Biomarker	[475]
APOA2	TTGQA9W	Strong	Biomarker	[476]
APOA4	TTNC3WS	Strong	Biomarker	[477]
APOC3	TTXOZQ1	Strong	Biomarker	[478]
AQP9	TTQEI32	Strong	Biomarker	[479]
ARG1	TT7ZQEV	Strong	Biomarker	[480]
ARG2	TTV1AG6	Strong	Genetic Variation	[481]
ARRB1	TTMVD4A	Strong	Biomarker	[482]
ARRB2	TT8SO2I	Strong	Biomarker	[482]
ARSA	TTYQANR	Strong	Genetic Variation	[483]
ASIC2	TTVMWLP	Strong	Biomarker	[484]
ASPA	TT6TLZP	Strong	Biomarker	[485]
ATF4	TTQCKWT	Strong	Altered Expression	[486]
ATIC	TT9NVXQ	Strong	Altered Expression	[487]
ATP4A	TTF1QVM	Strong	Biomarker	[488]
ATXN3	TT6A17J	Strong	Biomarker	[489]
AVPR2	TTK8R02	Strong	Biomarker	[490]
BACH1	TT2ME4S	Strong	Biomarker	[491]
BAK1	TTFM7V0	Strong	Altered Expression	[492]
BAX	TTQ57WJ	Strong	Therapeutic	[493]
BCKDK	TT7WD2Q	Strong	Genetic Variation	[494]
BCL2	TTFOUV4	Strong	Altered Expression	[495]
BCL2A1	TTGT9C7	Strong	Genetic Variation	[496]
BCL2L2	TTQ79W8	Strong	Therapeutic	[497]
BDKRB2	TTGY8IW	Strong	Altered Expression	[498]
BECN1	TT5M7LN	Strong	Biomarker	[499]
BGN	TT0JPVF	Strong	Biomarker	[500]
BMP1	TT0L58T	Strong	Biomarker	[501]
BMP4	TTD3BSX	Strong	Biomarker	[502]
BMP6	TT07RIB	Strong	Biomarker	[503]
BRCA2	TTUARD6	Strong	Genetic Variation	[504]
BRD3	TTHE657	Strong	Biomarker	[505]
BRS3	TTKYEPM	Strong	Biomarker	[440]
BRSK1	TTV6WMQ	Strong	Genetic Variation	[506]
BRSK2	TTHZN4X	Strong	Genetic Variation	[506]
BSG	TT5UJWD	Strong	Altered Expression	[507]
C1QBP	TTWTD7F	Strong	Biomarker	[508]
C3	TTJGY7A	Strong	Biomarker	[509]
C3AR1	TTI6B3F	Strong	Genetic Variation	[510]
C5	TTKANGO	Strong	Biomarker	[511]
C9orf72	TTA4SHR	Strong	Biomarker	[512]
CA2	TTANPDJ	Strong	Biomarker	[513]
CACNA1C	TTZIFHC	Strong	Altered Expression	[514]
CACNA1G	TT729IR	Strong	Genetic Variation	[515]
CAD	TT2YT1K	Strong	Biomarker	[516]
CALCA	TTVSFJW	Strong	Biomarker	[517]
CALCR	TTLWS2O	Strong	Biomarker	[518]
CAMKK2	TTV298Y	Strong	Biomarker	[519]
CAMP	TTULOB6	Strong	Biomarker	[520]
CAPN1	TT1WBIJ	Strong	Biomarker	[521]
CAPN2	TTG5QB7	Strong	Biomarker	[522]
CASP1	TTCQIBE	Strong	Biomarker	[523]
CASP2	TT12VNG	Strong	Biomarker	[524]
CASP4	TT6KIOT	Strong	Altered Expression	[525]
CASP7	TTM7Y45	Strong	Biomarker	[526]
CASP8	TT6SZNG	Strong	Biomarker	[527]
CASP9	TTB6T7O	Strong	Therapeutic	[528]
CCKAR	TTCG0AL	Strong	Biomarker	[529]
CCL21	TTLZK1U	Strong	Biomarker	[530]
CCL3	TT8I4WB	Strong	Biomarker	[531]
CCL5	TT9DWLC	Strong	Altered Expression	[532]
CCNE2	TTLDRGX	Strong	Altered Expression	[533]
CCR2	TTFZYTO	Strong	Biomarker	[534]
CCR3	TTD3XFU	Strong	Biomarker	[535]
CD200	TT0BE68	Strong	Biomarker	[536]
CD209	TTBXIM9	Strong	Biomarker	[537]
CD320	TT0KV32	Strong	Genetic Variation	[538]
CD36	TTPJMCU	Strong	Genetic Variation	[539]
CD38	TTPURFN	Strong	Biomarker	[540]
CD40	TT1ERKL	Strong	Biomarker	[541]
CD46	TTMS7DF	Strong	Biomarker	[542]
CD47	TT28S46	Strong	Genetic Variation	[464]
CD55	TT5Z9WY	Strong	Genetic Variation	[543]
CD59	TTBGTEJ	Strong	Altered Expression	[544]
CD69	TTPQE9F	Strong	Biomarker	[540]
CD74	TTCMYP9	Strong	Biomarker	[508]
CD80	TT89Z17	Strong	Biomarker	[537]
CDC25B	TTR0SWN	Strong	Biomarker	[545]
CDC25C	TTESBNC	Strong	Biomarker	[546]
CDH2	TT1WS0T	Strong	Altered Expression	[547]
CDK1	TTH6V3D	Strong	Altered Expression	[548]
CDK18	TTUMFAR	Strong	Biomarker	[549]
CDK5	TTL4Q97	Strong	Biomarker	[550]
CDK9	TT1LVF2	Strong	Altered Expression	[551]
CEBPB	TTUI35N	Strong	Altered Expression	[552]
CES1	TTMF541	Strong	Biomarker	[553]
CFB	TTA0P7K	Strong	Genetic Variation	[554]
CFD	TT8D13I	Strong	Biomarker	[555]
CFI	TT6ATLX	Strong	Biomarker	[556]
CFLAR	TTJZQYH	Strong	Biomarker	[557]
CGA	TTFC29G	Strong	Biomarker	[558]
CGB3	TTUH273	Strong	Biomarker	[558]
CHEK1	TTTU902	Strong	Biomarker	[559]
CHIT1	TTDYX6T	Strong	Biomarker	[560]
CHN2	TT39YVO	Strong	Genetic Variation	[561]
CHRM1	TTZ9SOR	Strong	Biomarker	[562]
CHRM2	TTYEG6Q	Strong	Genetic Variation	[563]
CHRM3	TTQ13Z5	Strong	Biomarker	[564]
CHRNA2	TTF4E0J	Strong	Genetic Variation	[378]
CHRNA4	TT4H1MQ	Strong	Biomarker	[565]
CIT	TT3BKTU	Strong	Biomarker	[566]
CLCF1	TTI6V13	Strong	Altered Expression	[567]
CLCN3	TT8XNZ7	Strong	Biomarker	[568]
CLK1	TTE6YDG	Strong	Biomarker	[569]
CLK2	TT85TPS	Strong	Biomarker	[570]
CLN3	TTORF9W	Strong	Genetic Variation	[571]
CNP	TT71P0H	Strong	Genetic Variation	[572]
CNR1	TT6OEDT	Strong	Biomarker	[573]
CNR2	TTMSFAW	Strong	Altered Expression	[574]
CNTF	TTGEM5Q	Strong	Altered Expression	[575]
CNTFR	TTT2F9E	Strong	Biomarker	[575]
CNTN1	TTPR8FK	Strong	Biomarker	[468]
CNTN2	TT2Z1WB	Strong	Biomarker	[576]
COASY	TT4YO0Z	Strong	Biomarker	[577]
COPS5	TTSTNJR	Strong	Biomarker	[578]
CPB1	TT4UJX5	Strong	Biomarker	[579]
CPE	TTXPWO6	Strong	Genetic Variation	[580]
CPN1	TT8V2KD	Strong	Genetic Variation	[581]
CPS1	TT42M75	Strong	Genetic Variation	[582]
CREB1	TTH4AN3	Strong	Altered Expression	[583]
CRHBP	TT3PKZE	Strong	Biomarker	[584]
CRK	TTFEUYR	Strong	Biomarker	[458]
CRTC1	TT4GO0F	Strong	Altered Expression	[585]
CRYAB	TT7RUHB	Strong	Altered Expression	[586]
CRYZ	TTP6UO8	Strong	Genetic Variation	[587]
CS	TTZA6B3	Strong	Biomarker	[588]
CSE1L	TTTRULD	Strong	Biomarker	[589]
CSF1	TT0IQER	Strong	Altered Expression	[590]
CSF2RB	TTPYS82	Strong	Biomarker	[591]
CSF3R	TTC70AJ	Strong	Biomarker	[592]
CSNK1E	TTA8PLI	Strong	Biomarker	[593]
CSNK1G2	TT0UZJ9	Strong	Biomarker	[594]
CSNK1G3	TT34L5N	Strong	Biomarker	[594]
CSNK2A1	TTER6YH	Strong	Altered Expression	[595]
CSPG4	TT7MYXI	Strong	Biomarker	[596]
CTCFL	TTY0RZT	Strong	Genetic Variation	[597]
CTF1	TTXGTZU	Strong	Biomarker	[598]
CTNS	TT1W2ZS	Strong	Biomarker	[543]
CTSB	TTF2LRI	Strong	Altered Expression	[599]
CTSK	TTDZN01	Strong	Biomarker	[600]
CTSS	TTUMQVO	Strong	Biomarker	[601]
CX3CL1	TT1OFBQ	Strong	Biomarker	[365]
CXCL11	TTWG0RE	Strong	Biomarker	[602]
CXCL2	TTZF0K2	Strong	Biomarker	[603]
CXCR1	TTMWT8Z	Strong	Biomarker	[535]
CXCR2	TT30C9G	Strong	Biomarker	[604]
CXCR6	TT2BVUA	Strong	Biomarker	[440]
CYBB	TT5T8MR	Strong	Biomarker	[605]
CYP11A1	TTSYVO6	Strong	Genetic Variation	[606]
CYP17A1	TTRA5BZ	Strong	Genetic Variation	[607]
CYP19A1	TTSZLWK	Strong	Biomarker	[608]
CYP1A2	TTS1DTU	Strong	Biomarker	[609]
CYP26A1	TTD7Q0R	Strong	Genetic Variation	[610]
CYP2B6	TTMH124	Strong	Genetic Variation	[611]
CYP2C9	TTR40YJ	Strong	Genetic Variation	[366]
CYP2J2	TTNE1C7	Strong	Genetic Variation	[612]
DAO	TT7Y3EJ	Strong	Biomarker	[613]
DDIT4	TTVEOY6	Strong	Altered Expression	[614]
DDR1	TTI1FPZ	Strong	Biomarker	[615]
DEFB4A	TTIVY12	Strong	Genetic Variation	[616]
DEK	TT1NMGV	Strong	Biomarker	[617]
DEPTOR	TTLYP6D	Strong	Altered Expression	[618]
DGKZ	TTSBBXL	Strong	Genetic Variation	[619]
DIO1	TTU3X26	Strong	Genetic Variation	[620]
DKK1	TTE3RAC	Strong	Biomarker	[621]
DKK2	TTST5KX	Strong	Genetic Variation	[622]
DLG4	TT9PB26	Strong	Biomarker	[623]
DLL1	TT9CFQD	Strong	Altered Expression	[624]
DNAJB1	TTPXAWS	Strong	Biomarker	[625]
DNASE1	TTYWGOJ	Strong	Altered Expression	[626]
DNM2	TTVRA5G	Strong	Genetic Variation	[627]
DNMT3B	TT6VZ78	Strong	Biomarker	[628]
DPP4	TTDIGC1	Strong	Biomarker	[629]
DRD1	TTZFYLI	Strong	Biomarker	[630]
DRD3	TT4C8EA	Strong	Genetic Variation	[610]
DRD4	TTE0A2F	Strong	Posttranslational Modification	[631]
DTL	TT8396I	Strong	Biomarker	[632]
DUSP1	TTG8HIM	Strong	Biomarker	[633]
DYRK1A	TTSBVFO	Strong	Biomarker	[634]
DYSF	TTA7MXQ	Strong	Genetic Variation	[635]
EEF2K	TT1QFLA	Strong	Biomarker	[636]
EHMT1	TTOFXD7	Strong	Biomarker	[637]
EHMT2	TTS6RZT	Strong	Altered Expression	[638]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[639]
EIF2AK3	TT79U1M	Strong	Biomarker	[640]
EIF2AK4	TT9U4EP	Strong	Biomarker	[641]
EIF4E	TTZGCP6	Strong	Biomarker	[642]
ELANE	TTPLTSQ	Strong	Altered Expression	[643]
ENPEP	TT9PBIL	Strong	Biomarker	[644]
ENPP2	TTSCIM2	Strong	Biomarker	[645]
EPHA4	TTG84D3	Strong	Biomarker	[646]
EPHA8	TTHZ2LW	Strong	Biomarker	[647]
EPHB2	TTKPV6O	Strong	Biomarker	[648]
EPHX2	TT7WVHI	Strong	Genetic Variation	[494]
EPOR	TTAUX24	Strong	Altered Expression	[649]
ERBB4	TTWALCO	Strong	Biomarker	[650]
ESRRA	TTPNQAC	Strong	Biomarker	[651]
F11	TTDM4ZU	Strong	Biomarker	[652]
F11R	TT3C8EG	Strong	Biomarker	[653]
F12	TTRJSMV	Strong	Biomarker	[654]
F13A1	TTXI2RA	Strong	Biomarker	[655]
F13B	TTAXGIP	Strong	Biomarker	[656]
F2	TT6L509	Strong	Genetic Variation	[657]
F2R	TTL935N	Strong	Biomarker	[658]
F2RL1	TTQR74A	Strong	Biomarker	[659]
F2RL2	TTVSEBF	Strong	Biomarker	[660]
F2RL3	TTD0652	Strong	Altered Expression	[661]
FABP3	TT3TGLR	Strong	Altered Expression	[662]
FABP5	TTNT2S6	Strong	Altered Expression	[663]
FAF1	TTSKL3G	Strong	Altered Expression	[664]
FAT1	TTGUJYV	Strong	Biomarker	[665]
FCGR1A	TTZK4I3	Strong	Biomarker	[534]
FCGR3A	TTIFOC0	Strong	Biomarker	[534]
FDPS	TTIKWV4	Strong	Genetic Variation	[666]
FES	TTLBY21	Strong	Biomarker	[667]
FFAR1	TTB8FUC	Strong	Biomarker	[668]
FGF10	TTNPEFX	Strong	Genetic Variation	[561]
FGF14	TTKJX1V	Strong	Altered Expression	[669]
FGF21	TTQ916P	Strong	Biomarker	[670]
FGFR4	TT1KX2S	Strong	Biomarker	[647]
FKBP1A	TTMW94E	Strong	Biomarker	[671]
FLT4	TTDCBX5	Strong	Biomarker	[672]
FOLH1	TT9G4N0	Strong	Biomarker	[673]
FOLR1	TTVC37M	Strong	Altered Expression	[674]
FOLR2	TTT54CI	Strong	Altered Expression	[674]
FOXQ1	TTEJZOL	Strong	Altered Expression	[675]
FPR2	TTOJ1NF	Strong	Biomarker	[543]
FSHR	TTZFDBT	Strong	Genetic Variation	[676]
FTH1	TT975ZT	Strong	Biomarker	[677]
FTO	TTFW3BT	Strong	Biomarker	[678]
FYN	TT2B9KF	Strong	Biomarker	[679]
G3BP1	TTG0R8Z	Strong	Genetic Variation	[561]
GABRA2	TTBMV1G	Strong	Genetic Variation	[561]
GABRG3	TTEX6LM	Strong	Genetic Variation	[515]
GAD1	TTKGEP3	Strong	Altered Expression	[680]
GAD2	TT7UY6K	Strong	Biomarker	[681]
GAL	TTXZAJ5	Strong	Biomarker	[682]
GALNS	TTT9YPO	Strong	Biomarker	[683]
GART	TTEXB9Z	Strong	Altered Expression	[684]
GAS6	TT69QD2	Strong	Biomarker	[685]
GBA	TT1B5PU	Strong	Genetic Variation	[686]
GCG	TT6Y4PN	Strong	Biomarker	[637]
GDNF	TTF23ML	Strong	Altered Expression	[687]
GGT1	TTZVT7O	Strong	Genetic Variation	[688]
GHR	TTHJWYD	Strong	Biomarker	[689]
GHSR	TTWDC17	Strong	Biomarker	[690]
GIP	TT40HS5	Strong	Biomarker	[691]
GJB6	TTAU8SJ	Strong	Biomarker	[692]
GLB1	TTNGJPH	Strong	Biomarker	[693]
GLP1R	TTVIMDE	Strong	Biomarker	[637]
GLUL	TTURQ2G	Strong	Genetic Variation	[582]
GNAI1	TTL1HWR	Strong	Altered Expression	[448]
GPBAR1	TTSDVTR	Strong	Altered Expression	[694]
GPER1	TTDSB34	Strong	Altered Expression	[695]
GPI	TT19JIZ	Strong	Genetic Variation	[696]
GPNMB	TT7315J	Strong	Biomarker	[697]
GPR17	TTMPART	Strong	Biomarker	[698]
GPR20	TT26C7Z	Strong	Genetic Variation	[699]
GPR3	TTHZVSK	Strong	Altered Expression	[700]
GPR39	TTTPCNU	Strong	Biomarker	[701]
GPR6	TTSDWS5	Strong	Biomarker	[702]
GPX1	TTYAHBP	Strong	Genetic Variation	[703]
GRB2	TTEYRJ9	Strong	Biomarker	[704]
GRIA1	TTVPQTF	Strong	Biomarker	[705]
GRIA2	TTWM461	Strong	Biomarker	[706]
GRIA4	TTPJR0G	Strong	Biomarker	[707]
GRIK4	TTQV6BO	Strong	Biomarker	[708]
GRIN1	TTLD29N	Strong	Biomarker	[709]
GRM1	TTVBPDM	Strong	Biomarker	[710]
GRM2	TTXJ47W	Strong	Altered Expression	[711]
GRM3	TT8A9EF	Strong	Altered Expression	[712]
GRM5	TTHS256	Strong	Biomarker	[713]
GSK3A	TTQWAU1	Strong	Biomarker	[714]
GSR	TTEP6RV	Strong	Altered Expression	[715]
GUSB	TTHS7CM	Strong	Altered Expression	[716]
GZMB	TTKEPHX	Strong	Altered Expression	[530]
HAMP	TTRV5YJ	Strong	Biomarker	[717]
HCAR1	TTVK4ZO	Strong	Biomarker	[718]
HCAR2	TTWNV8U	Strong	Biomarker	[718]
HCK	TT42OGM	Strong	Biomarker	[719]
HCN1	TTNB6UQ	Strong	Biomarker	[720]
HCRT	TTU5HJP	Strong	Altered Expression	[721]
HCRTR2	TT9N02I	Strong	Genetic Variation	[722]
HDAC1	TT6R7JZ	Strong	Altered Expression	[723]
HDAC3	TT4YWTO	Strong	Biomarker	[724]
HDAC4	TTTQGH8	Strong	Biomarker	[724]
HDAC6	TT5ZKDI	Strong	Biomarker	[725]
HDAC9	TT8M4E1	Strong	Biomarker	[726]
HDC	TTV9GOF	Strong	Altered Expression	[727]
HHAT	TT1VNCG	Strong	Biomarker	[728]
HMBS	TTT0HW3	Strong	Altered Expression	[729]
HMGB2	TTA78JQ	Strong	Biomarker	[730]
HMGCS2	TTS0EZJ	Strong	Biomarker	[731]
HNRNPA1	TTPJ9XK	Strong	Genetic Variation	[732]
HNRNPA2B1	TT8UPW6	Strong	Biomarker	[733]
HPGDS	TTCYE56	Strong	Genetic Variation	[734]
HPSE	TTR7GJO	Strong	Biomarker	[735]
HRC	TTR4FKD	Strong	Genetic Variation	[736]
HRH3	TT9JNIC	Strong	Biomarker	[737]
HSD11B1	TTN7BL9	Strong	Biomarker	[738]
HSD17B1	TTIWB6L	Strong	Biomarker	[739]
HSD17B13	TTDJYZR	Strong	Biomarker	[740]
HSD17B4	TTL1WGS	Strong	Biomarker	[741]
HSP90AA1	TT78R5H	Strong	Biomarker	[742]
HSP90AB1	TTH5YN2	Strong	Altered Expression	[743]
HSPA5	TTW26OG	Strong	Altered Expression	[744]
HSPA8	TTMQL3K	Strong	Biomarker	[745]
HSPB1	TT9AZWY	Strong	Biomarker	[746]
HSPB8	TTY0OJN	Strong	Biomarker	[747]
HSPD1	TT9HL5R	Strong	Biomarker	[748]
HTR1A	TTSQIFT	Strong	Altered Expression	[749]
HTR1B	TTK8CXU	Strong	Altered Expression	[750]
HTR2C	TTWJBZ5	Strong	Biomarker	[751]
HTR4	TT07C3Y	Strong	Biomarker	[752]
HTR7	TTO9X1H	Strong	Biomarker	[753]
HTT	TTIWZ0O	Strong	Biomarker	[754]
IAPP	TTHN8EM	Strong	Biomarker	[755]
IDO1	TTZJYKH	Strong	Biomarker	[756]
IFNAR1	TTSYFMA	Strong	Biomarker	[757]
IFNL3	TTRF4Q2	Strong	Genetic Variation	[758]
IGF1R	TTQFBMY	Strong	Altered Expression	[383]
IGF2	TTE8WGO	Strong	Biomarker	[759]
IGFBP1	TTCJTWF	Strong	Altered Expression	[760]
IGFBP2	TTU4QSN	Strong	Altered Expression	[761]
IGFBP5	TTDWEA8	Strong	Biomarker	[762]
IGFBP7	TTUQ01B	Strong	Biomarker	[763]
IKBKB	TTJ3E9X	Strong	Biomarker	[764]
IL12A	TTRTK6Y	Strong	Biomarker	[467]
IL16	TTW4R0B	Strong	Altered Expression	[534]
IL17A	TTG0MT6	Strong	Biomarker	[765]
IL19	TT87RWS	Strong	Genetic Variation	[766]
IL1R1	TTWOTEA	Strong	Genetic Variation	[767]
IL1RAP	TTWS50K	Strong	Biomarker	[768]
IL1RL1	TT4GZA4	Strong	Biomarker	[769]
IL23A	TTC1GLB	Strong	Biomarker	[765]
IL2RB	TT9721Y	Strong	Altered Expression	[770]
IL31	TT1RJXK	Strong	Altered Expression	[771]
IL31RA	TT9HPX0	Strong	Altered Expression	[772]
IL4	TTLGTKB	Strong	Biomarker	[773]
IL4R	TTDWHC3	Strong	Biomarker	[534]
IL5	TTPREZD	Strong	Altered Expression	[534]
IL9	TT0JTFD	Strong	Biomarker	[774]
ILK	TT7ALZG	Strong	Biomarker	[775]
INS	TTZOPHG	Strong	Biomarker	[543]
INSR	TTCBFJO	Strong	Biomarker	[776]
IRAK1	TTXAJWN	Strong	Biomarker	[777]
IRAK4	TTILUKB	Strong	Genetic Variation	[778]
IRF3	TTYR7OH	Strong	Altered Expression	[779]
IRF8	TTHUBNK	Strong	Biomarker	[780]
IRS1	TTAJSQ0	Strong	Posttranslational Modification	[781]
IRS2	TTF95B8	Strong	Biomarker	[781]
ITGAL	TT48WR6	Strong	Biomarker	[782]
ITGAV	TTT1R2L	Strong	Biomarker	[783]
ITGB3	TTJA1ZO	Strong	Genetic Variation	[784]
ITPR1	TT5HWAT	Strong	Biomarker	[785]
ITPR2	TTK9OV3	Strong	Altered Expression	[786]
JAG2	TTOJY1B	Strong	Biomarker	[787]
JUN	TTS7IR5	Strong	Biomarker	[788]
KCNB1	TT5OEKU	Strong	Biomarker	[789]
KCNC4	TTODZF1	Strong	Altered Expression	[790]
KCNMA1	TTE87WJ	Strong	Biomarker	[791]
KCNN2	TT2T5M0	Strong	Genetic Variation	[561]
KDM1B	TT8VP2T	Strong	Genetic Variation	[561]
KDM4A	TTZHPB8	Strong	Biomarker	[792]
KIF11	TTBGTCW	Strong	Genetic Variation	[793]
KIF5A	TTCJPAH	Strong	Altered Expression	[794]
KIR2DL2	TTU0P73	Strong	Altered Expression	[795]
KLK3	TTS78AZ	Strong	Biomarker	[796]
KLK4	TT4319X	Strong	Biomarker	[797]
KLK7	TTE6GTB	Strong	Biomarker	[798]
KLKB1	TTN0PCX	Strong	Biomarker	[799]
KLRC1	TTC4IMS	Strong	Biomarker	[530]
KMO	TTIY56R	Strong	Biomarker	[800]
KNG1	TTDJ4MY	Strong	Biomarker	[801]
L1CAM	TTC9D3K	Strong	Biomarker	[653]
LAMP1	TTC214J	Strong	Biomarker	[802]
LANCL1	TTZW8NS	Strong	Biomarker	[803]
LBP	TTVQJLY	Strong	Altered Expression	[804]
LCAT	TTGZ91P	Strong	Biomarker	[805]
LCK	TT860QF	Strong	Biomarker	[806]
LCT	TTA0OSE	Strong	Genetic Variation	[807]
LGMN	TTPTWV5	Strong	Altered Expression	[808]
LHCGR	TT2O4W9	Strong	Biomarker	[809]
LIF	TTGZ5WN	Strong	Biomarker	[810]
LIFR	TTID542	Strong	Altered Expression	[811]
LILRB1	TTC0QRJ	Strong	Altered Expression	[812]
LILRB2	TTHC6XU	Strong	Biomarker	[813]
LIN28A	TTO50LN	Strong	Genetic Variation	[408]
LINGO1	TTZYQ80	Strong	Biomarker	[814]
LIPA	TTS8T1M	Strong	Biomarker	[815]
LIPG	TTHSZXO	Strong	Genetic Variation	[816]
LNPEP	TTY2KP7	Strong	Biomarker	[817]
LPA	TTU9LGY	Strong	Biomarker	[818]
LPAR2	TTB7Y8I	Strong	Biomarker	[440]
LRP6	TTSXOWE	Strong	Genetic Variation	[819]
LTB	TTHQ6US	Strong	Biomarker	[508]
LTC4S	TTW7OTG	Strong	Biomarker	[820]
LTF	TTSZDQU	Strong	Biomarker	[821]
LYN	TT1RWNJ	Strong	Altered Expression	[822]
LYZ	TTAOZBW	Strong	Altered Expression	[823]
MAG	TT9XFON	Strong	Biomarker	[824]
MANF	TT56RYE	Strong	Biomarker	[825]
MAOA	TT3WG5C	Strong	Genetic Variation	[826]
MAP2K2	TT8H9GB	Strong	Biomarker	[827]
MAP3K10	TT9FN4J	Strong	Biomarker	[828]
MAP3K5	TTOQCD8	Strong	Biomarker	[829]
MAPK10	TT056SO	Strong	Biomarker	[830]
MAPK14	TTQBR95	Strong	Biomarker	[458]
MAPK7	TTU6FSC	Strong	Biomarker	[831]
MAPK8	TT0K6EO	Strong	Biomarker	[668]
MAPK9	TT3IVG2	Strong	Biomarker	[832]
MAPKAP1	TTWDKCL	Strong	Biomarker	[833]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[834]
MAPKAPK5	TT3UJ7Z	Strong	Biomarker	[835]
MARCKS	TTHRM39	Strong	Biomarker	[836]
MARK3	TT3DCYJ	Strong	Biomarker	[837]
MAS1	TTOISYB	Strong	Biomarker	[838]
MAT2A	TTSMPXQ	Strong	Altered Expression	[839]
MAZ	TT059DA	Strong	Biomarker	[840]
MBOAT4	TTSYOWR	Strong	Biomarker	[841]
MBP	TT2RY5P	Strong	Biomarker	[842]
MBTPS1	TTNSM2I	Strong	Altered Expression	[843]
MC1R	TT0MV2T	Strong	Genetic Variation	[844]
MCOLN1	TT9XBVO	Strong	Biomarker	[845]
MELTF	TT8OBT3	Strong	Biomarker	[846]
METAP2	TTZL0OI	Strong	Biomarker	[357]
MFGE8	TT1GLAJ	Strong	Biomarker	[847]
MGAM	TTXWASR	Strong	Biomarker	[848]
MGLL	TTZ963I	Strong	Biomarker	[849]
MMP14	TTJ4QE7	Strong	Biomarker	[850]
MMP8	TTGA1IV	Strong	Biomarker	[851]
MOBP	TTYUK4F	Strong	Genetic Variation	[515]
MOG	TTQAFX5	Strong	Genetic Variation	[852]
MPO	TTVCZPI	Strong	Biomarker	[853]
MSH2	TTCAWRT	Strong	Genetic Variation	[561]
MSI1	TTSM4BA	Strong	Altered Expression	[854]
MSI2	TTTXQF6	Strong	Altered Expression	[854]
MSR1	TT2TDH9	Strong	Altered Expression	[387]
MSRB1	TT1QUZV	Strong	Altered Expression	[855]
MSTN	TTM8I2X	Strong	Biomarker	[856]
MTNR1A	TT0WAIE	Strong	Biomarker	[857]
MTNR1B	TT32JK8	Strong	Altered Expression	[858]
MUTYH	TTNB0ZK	Strong	Biomarker	[859]
MYD88	TTB6Q2O	Strong	Biomarker	[860]
NAAA	TTMN4HY	Strong	Altered Expression	[861]
NACC1	TT4AQ5F	Strong	Biomarker	[862]
NCF1	TTZ4JC3	Strong	Genetic Variation	[863]
NCL	TTK1V5Q	Strong	Biomarker	[864]
NEDD4	TT1QU6G	Strong	Altered Expression	[865]
NEDD9	TT1UREA	Strong	Genetic Variation	[866]
NES	TTHZ752	Strong	Biomarker	[867]
NFKB2	TTKLNRV	Strong	Biomarker	[868]
NLRP3	TT4EN8X	Strong	Altered Expression	[869]
NOTCH3	TTVX7IA	Strong	Biomarker	[870]
NOTCH4	TTXDIK2	Strong	Genetic Variation	[871]
NPEPPS	TT371QC	Strong	Biomarker	[872]
NPM1	TTHBS98	Strong	Biomarker	[864]
NQO2	TTJLP0R	Strong	Altered Expression	[873]
NR1H3	TTECBXN	Strong	Genetic Variation	[874]
NR3C1	TTOZRK6	Strong	Biomarker	[370]
NR4A3	TTJQB49	Strong	Genetic Variation	[875]
NRN1	TTS05MJ	Strong	Altered Expression	[876]
NTF4	TTIM2WO	Strong	Biomarker	[877]
NTN1	TT0AH4L	Strong	Biomarker	[878]
OAT	TTTSCQ2	Strong	Altered Expression	[879]
ODC1	TTUMGNO	Strong	Biomarker	[880]
OPRD1	TT27RFC	Strong	Genetic Variation	[881]
OPRK1	TTQW87Y	Strong	Biomarker	[882]
OSCAR	TT71Q5Y	Strong	Genetic Variation	[883]
OSM	TTIVXSE	Strong	Altered Expression	[884]
OTC	TT5KIO9	Strong	Biomarker	[885]
P2RX1	TTJW7B3	Strong	Genetic Variation	[886]
P2RX3	TT2THBD	Strong	Genetic Variation	[886]
P2RX4	TT1NLOA	Strong	Genetic Variation	[886]
P2RY1	TTA93TL	Strong	Biomarker	[887]
P2RY2	TTOZHQC	Strong	Biomarker	[888]
P2RY4	TT24DGP	Strong	Altered Expression	[889]
P2RY6	TTNVSKA	Strong	Altered Expression	[889]
PADI4	TTQHAXM	Strong	Genetic Variation	[890]
PAK1	TTFN95D	Strong	Genetic Variation	[891]
PAWR	TT3I4WV	Strong	Altered Expression	[661]
PCSK1	TTED9LZ	Strong	Biomarker	[892]
PCSK9	TTNIZ2B	Strong	Genetic Variation	[893]
PCYT1B	TTUAIKM	Strong	Biomarker	[894]
PDCD1LG2	TTW14O3	Strong	Genetic Variation	[561]
PDE10A	TTJW4LU	Strong	Biomarker	[895]
PDE2A	TTJGW1Z	Strong	Biomarker	[896]
PDE4D	TTSKMI8	Strong	Biomarker	[897]
PDE5A	TTJ0IQB	Strong	Genetic Variation	[898]
PDE7A	TT1BC3A	Strong	Biomarker	[899]
PDE7B	TTWIEY9	Strong	Genetic Variation	[515]
PDE9A	TTZOEBC	Strong	Biomarker	[900]
PDF	TT9SL3Q	Strong	Biomarker	[901]
PDGFB	TTQA6SX	Strong	Genetic Variation	[902]
PDGFRB	TTI7421	Strong	Biomarker	[903]
PDK1	TTCZOF2	Strong	Biomarker	[904]
PEBP1	TT1BGU8	Strong	Biomarker	[905]
PEMT	TT735V2	Strong	Genetic Variation	[906]
PFKFB3	TTTHMQJ	Strong	Biomarker	[907]
PGD	TTZ3IFB	Strong	Biomarker	[908]
PGRMC1	TTY3LAZ	Strong	Biomarker	[909]
PHB	TT6U071	Strong	Biomarker	[904]
PI4KA	TTCUS9F	Strong	Biomarker	[910]
PIKFYVE	TTA4M1N	Strong	Biomarker	[911]
PKM	TT4LOT8	Strong	Biomarker	[912]
PLA2G1B	TT9V5JH	Strong	Biomarker	[913]
PLAU	TTGY7WI	Strong	Genetic Variation	[914]
PLAUR	TTNOSTX	Strong	Altered Expression	[915]
PLD1	TT3T17P	Strong	Biomarker	[916]
PLD2	TTRLMKF	Strong	Biomarker	[917]
PLK2	TT976FS	Strong	Biomarker	[918]
PLTP	TTZF6SN	Strong	Biomarker	[919]
PMEL	TT8MK59	Strong	Biomarker	[868]
PNMT	TT0NZIC	Strong	Altered Expression	[920]
PNP	TTMCF1Y	Strong	Biomarker	[921]
POLB	TTA0XPV	Strong	Biomarker	[922]
POR	TTOQ9GZ	Strong	Biomarker	[923]
PPARA	TTJ584C	Strong	Biomarker	[924]
PPARGC1B	TTKSQ3W	Strong	Altered Expression	[925]
PPIA	TTL2ADK	Strong	Altered Expression	[926]
PPIB	TT6ZFQ4	Strong	Biomarker	[927]
PPME1	TTXQ54R	Strong	Biomarker	[928]
PPP1CA	TTFLH0E	Strong	Biomarker	[929]
PPP2CA	TTHTKNY	Strong	Biomarker	[930]
PPP3CA	TTA4LDE	Strong	Genetic Variation	[931]
PPT1	TTSQC14	Strong	Biomarker	[932]
PPY	TTIB95A	Strong	Biomarker	[933]
PRDX4	TTPBL9I	Strong	Biomarker	[934]
PRKACA	TT5U49F	Strong	Altered Expression	[935]
PRKCA	TTFJ8Q1	Strong	Genetic Variation	[619]
PRKCB	TTYPXQF	Strong	Biomarker	[936]
PRKCD	TT7A1BO	Strong	Biomarker	[937]
PRKCE	TT57MT2	Strong	Altered Expression	[938]
PRMT5	TTR1D7X	Strong	Biomarker	[939]
PROC	TTZUXYS	Strong	Biomarker	[940]
PSCA	TT9T4AV	Strong	Biomarker	[941]
PSIP1	TTH9LDP	Strong	Altered Expression	[770]
PSMB6	TT8EPLT	Strong	Biomarker	[942]
PSMB9	TTOUSTQ	Strong	Biomarker	[943]
PTBP1	TTWMX0U	Strong	Biomarker	[763]
PTGDR	TTNVEIR	Strong	Altered Expression	[944]
PTGER1	TTG1QMU	Strong	Biomarker	[945]
PTGER2	TT1ZAVI	Strong	Biomarker	[946]
PTGER3	TTPNGDE	Strong	Biomarker	[947]
PTGES2	TTWU04I	Strong	Altered Expression	[948]
PTK2B	TTTEFBV	Strong	Biomarker	[949]
PTN	TTA9EJK	Strong	Biomarker	[950]
PTPN1	TTELIN2	Strong	Biomarker	[951]
PTPN13	TT405FP	Strong	Biomarker	[952]
PYY	TTVFJLX	Strong	Biomarker	[953]
RAB7A	TTF6WAQ	Strong	Biomarker	[954]
RAC1	TT2M9CG	Strong	Biomarker	[955]
RACK1	TTJ10AL	Strong	Altered Expression	[956]
RASA1	TTPNZ1F	Strong	Biomarker	[957]
REG3A	TTL4H8N	Strong	Biomarker	[958]
RENBP	TTZCG0Q	Strong	Biomarker	[959]
RGS2	TTKB7T3	Strong	Altered Expression	[960]
RGS4	TTGTKX9	Strong	Biomarker	[961]
RGS6	TTJ96M8	Strong	Biomarker	[957]
RHD	TTLCKI8	Strong	Genetic Variation	[962]
RHO	TTH0KSX	Strong	Biomarker	[963]
RIPK1	TTVJHX8	Strong	Posttranslational Modification	[211]
RNMT	TTG45HY	Strong	Biomarker	[964]
ROCK1	TTZN7RP	Strong	Biomarker	[965]
ROCK2	TTGWKQJ	Strong	Biomarker	[965]
RORA	TT1TYN7	Strong	Biomarker	[736]
ROS1	TTSZ6Y3	Strong	Biomarker	[966]
RPL15	TTQRVC9	Strong	Altered Expression	[788]
RPS6KB1	TTG0U4H	Strong	Biomarker	[967]
RPS6KB2	TTMVQXO	Strong	Genetic Variation	[968]
RTN4	TT7GXMU	Strong	Biomarker	[969]
RTN4R	TTVRZUO	Strong	Biomarker	[970]
RXRA	TT6PEUO	Strong	Biomarker	[436]
S100A12	TTQ4ESF	Strong	Biomarker	[971]
S100A6	TT716MY	Strong	Altered Expression	[972]
S100B	TTQ0V86	Strong	Biomarker	[973]
SAA1	TTY0DN9	Strong	Biomarker	[974]
SCARB1	TTRE324	Strong	Genetic Variation	[816]
SCD	TT6RIOV	Strong	Biomarker	[975]
SCG3	TTY5R9H	Strong	Biomarker	[976]
SCN1A	TTANOZH	Strong	Biomarker	[862]
SDC2	TT5H2F0	Strong	Genetic Variation	[977]
SEMA3A	TTVKD3S	Strong	Biomarker	[978]
SEMA4D	TT5UT28	Strong	Biomarker	[978]
SERPINA1	TTA7UJC	Strong	Biomarker	[979]
SERPINC1	TT4QPUL	Strong	Biomarker	[980]
SERPINF1	TTR59S1	Strong	Altered Expression	[981]
SERPING1	TTVQ6R9	Strong	Biomarker	[982]
SETD7	TTJ0FSU	Strong	Genetic Variation	[561]
SGCA	TTS9Q5V	Strong	Biomarker	[983]
SGCG	TTSMT9W	Strong	Biomarker	[984]
SGK1	TTTV8EJ	Strong	Biomarker	[985]
SGO1	TTBPKGD	Strong	Genetic Variation	[986]
SGSH	TTPJ2SH	Strong	Biomarker	[987]
SIGMAR1	TT5TPI6	Strong	Biomarker	[988]
SIRT2	TTLKF5M	Strong	Biomarker	[989]
SIRT5	TTH0IOD	Strong	Altered Expression	[990]
SIRT6	TTUXYWF	Strong	Biomarker	[991]
SLC10A2	TTPI1M5	Strong	Biomarker	[992]
SLC16A3	TTG6VD5	Strong	Biomarker	[993]
SLC18A3	TTV8KWS	Strong	Biomarker	[994]
SLC19A3	TT9BTWM	Strong	Genetic Variation	[995]
SLC1A1	TTG2A6F	Strong	Biomarker	[996]
SLC1A2	TT2F078	Strong	Biomarker	[997]
SLC1A3	TT8WRDA	Strong	Biomarker	[998]
SLC22A2	TT0XOJN	Strong	Biomarker	[999]
SLC22A8	TTTQR47	Strong	Biomarker	[999]
SLC25A4	TTU5A6Q	Strong	Biomarker	[1000]
SLC29A1	TTLXAKE	Strong	Biomarker	[1001]
SLC29A4	TTTR957	Strong	Altered Expression	[1002]
SLC2A12	TTZO36H	Strong	Altered Expression	[407]
SLC33A1	TTL69WB	Strong	Biomarker	[1003]
SLC40A1	TT6Y1PG	Strong	Genetic Variation	[1004]
SLC44A4	TT0NYDG	Strong	Biomarker	[1005]
SLC47A1	TTMHCGA	Strong	Altered Expression	[1002]
SLC52A2	TT6TKEN	Strong	Biomarker	[658]
SLC5A2	TTF8JAT	Strong	Biomarker	[1006]
SLC6A1	TTPRKM0	Strong	Altered Expression	[1007]
SLC6A12	TTQBMPI	Strong	Altered Expression	[1007]
SLC6A15	TT4LRUE	Strong	Biomarker	[879]
SLC6A2	TTAWNKZ	Strong	Altered Expression	[1008]
SLC7A11	TTBZMIO	Strong	Biomarker	[1009]
SLC7A5	TTPH2JB	Strong	Altered Expression	[1010]
SLC8A1	TTCF82X	Strong	Genetic Variation	[1011]
SLIT2	TTDWK85	Strong	Altered Expression	[1012]
SMAD1	TT9GR53	Strong	Altered Expression	[1013]
SMPD1	TTJTM88	Strong	Biomarker	[1014]
SMPD2	TTE5VI6	Strong	Biomarker	[1015]
SNAP25	TTYQWA0	Strong	Genetic Variation	[1016]
SNCG	TT5TQNZ	Strong	Altered Expression	[1017]
SORT1	TTRX9AV	Strong	Biomarker	[1018]
SPHK1	TTOHFIY	Strong	Biomarker	[1019]
SPHK2	TTCN0M9	Strong	Biomarker	[1020]
SQLE	TTE14XG	Strong	Biomarker	[1021]
SRPK2	TTCZEJ9	Strong	Altered Expression	[1022]
SRR	TTZFUY6	Strong	Altered Expression	[1023]
SST	TTWF7UG	Strong	Biomarker	[1024]
SSTR2	TTZ6T9E	Strong	Biomarker	[1025]
SSTR3	TTJX3UE	Strong	Genetic Variation	[1026]
SSTR4	TTAE1BR	Strong	Biomarker	[440]
ST14	TTPRO7W	Strong	Altered Expression	[1027]
STAB1	TTJFEOC	Strong	Biomarker	[1028]
STC1	TTDLUER	Strong	Biomarker	[1029]
STK16	TTFGN19	Strong	Biomarker	[1030]
STK32B	TT4D2GZ	Strong	Genetic Variation	[515]
STMN1	TT7W5OT	Strong	Altered Expression	[1031]
STS	TTHM0R1	Strong	Biomarker	[1032]
SYVN1	TT8XKYM	Strong	Biomarker	[1033]
TACR2	TTYO0A3	Strong	Biomarker	[1034]
TBK1	TTMP03S	Strong	Genetic Variation	[1035]
TBX21	TTNF9PH	Strong	Genetic Variation	[1036]
TCF3	TTULOD8	Strong	Altered Expression	[770]
TCF7L2	TT80QAL	Strong	Genetic Variation	[816]
TCIRG1	TTVRN05	Strong	Altered Expression	[1037]
TDO2	TTXNCBV	Strong	Altered Expression	[1038]
TDP1	TT64IHJ	Strong	Genetic Variation	[1039]
TDP2	TTYF26D	Strong	Genetic Variation	[1039]
TERF1	TT1Y6J2	Strong	Biomarker	[1040]
TERF2	TT5XSLT	Strong	Biomarker	[1040]
TF	TT8WXAV	Strong	Genetic Variation	[1041]
TFF1	TTNOJIZ	Strong	Genetic Variation	[1042]
TFRC	TT8MG4S	Strong	Biomarker	[1043]
TGFB2	TTI0KH6	Strong	Biomarker	[1044]
TGFB3	TTWOMY8	Strong	Biomarker	[1045]
TGFBR1	TTP4520	Strong	Altered Expression	[1046]
TGM1	TT7A949	Strong	Biomarker	[656]
TGM2	TT2F4OL	Strong	Altered Expression	[1047]
TLR2	TTY7ZHS	Strong	Biomarker	[1048]
TLR5	TTCXP8J	Strong	Altered Expression	[685]
TLR6	TTWRI8V	Strong	Biomarker	[1049]
TLR9	TTSHG0T	Strong	Biomarker	[530]
TMEM97	TT9NXW4	Strong	Biomarker	[1050]
TMPRSS6	TTL9KE7	Strong	Altered Expression	[858]
TNFRSF1A	TTG043C	Strong	Biomarker	[1051]
TNFRSF1B	TT63WSF	Strong	Biomarker	[1052]
TNFRSF21	TT8UA0T	Strong	Biomarker	[1053]
TNK1	TTWS7I3	Strong	Genetic Variation	[1054]
TNNI3	TTNLDK6	Strong	Biomarker	[1055]
TP53BP1	TTX4UE9	Strong	Biomarker	[1056]
TPH1	TTZSJHV	Strong	Genetic Variation	[1057]
TPH2	TT3KLDP	Strong	Biomarker	[1058]
TPP1	TTOVYPT	Strong	Biomarker	[1059]
TPT1	TT3PTB6	Strong	Biomarker	[1060]
TPX2	TT0PHL4	Strong	Biomarker	[868]
TREM1	TTHZQP0	Strong	Biomarker	[1061]
TRH	TT2Z39D	Strong	Biomarker	[801]
TRIM27	TTTO3QN	Strong	Biomarker	[543]
TRPA1	TTELV3W	Strong	Altered Expression	[1062]
TRPC1	TTA76X0	Strong	Altered Expression	[1063]
TRPM1	TTTDAI9	Strong	Genetic Variation	[561]
TRPM2	TTEBMN7	Strong	Biomarker	[1064]
TRPM7	TTFPVZO	Strong	Biomarker	[1065]
TSG101	TTHU7JA	Strong	Biomarker	[1066]
TSPAN7	TTMT6VE	Strong	Biomarker	[1067]
TTBK1	TTYFAM9	Strong	Altered Expression	[1068]
TXN	TTZJ5U9	Strong	Biomarker	[1069]
TXNIP	TTTLDZK	Strong	Biomarker	[1070]
TXNRD1	TTR7UJ3	Strong	Biomarker	[1071]
TYR	TTULVH8	Strong	Genetic Variation	[1072]
TYRO3	TTIEMFN	Strong	Biomarker	[685]
TYRP1	TTFRV98	Strong	Genetic Variation	[1073]
UBC	TTBP3XA	Strong	Altered Expression	[788]
UBE3A	TTUZX6V	Strong	Biomarker	[1074]
UGCG	TTPHEX3	Strong	Biomarker	[1075]
USP10	TT5IH09	Strong	Biomarker	[1076]
USP13	TTVJIO2	Strong	Altered Expression	[1077]
USP14	TTVSYP9	Strong	Biomarker	[1078]
USP2	TTUEQ1W	Strong	Posttranslational Modification	[1079]
UTRN	TTNO1VA	Strong	Biomarker	[1080]
VDR	TTK59TV	Strong	Genetic Variation	[1081]
WAS	TTE8T73	Strong	Biomarker	[1082]
WEE1	TTJFOAL	Strong	Genetic Variation	[1083]
WNK1	TTJ9UMX	Strong	Biomarker	[1084]
YES1	TT0SQ8J	Strong	Altered Expression	[723]
ZAP70	TTUMHT8	Strong	Biomarker	[1085]
ZNF217	TTY3BRA	Strong	Biomarker	[1086]
ZNF224	TT1CDXL	Strong	Genetic Variation	[1087]
COL18A1	TT63DI9	Definitive	Genetic Variation	[561]
GDF2	TTAP4T1	Definitive	Biomarker	[1088]
NR4A2	TT9HKN3	Definitive	Altered Expression	[1089]
NTF3	TTZHKV9	Definitive	Biomarker	[1090]
PLA2G7	TTDNFMT	Definitive	Biomarker	[1091]

This Disease Is Related to 34 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC30A4	DT280XI	Limited	Biomarker	[1092]
SLC32A1	DTXQYLR	Limited	Biomarker	[1093]
SLC30A6	DTKPRIL	moderate	Biomarker	[1094]
ABCA2	DTJ4NEG	Strong	Genetic Variation	[1095]
ABCA8	DT9NXMV	Strong	Genetic Variation	[561]
ABCD1	DTKM9DZ	Strong	Biomarker	[1096]
ATP12A	DT5NLZA	Strong	Biomarker	[488]
ATP7A	DT0LT17	Strong	Genetic Variation	[1097]
SLC11A1	DT650XW	Strong	Biomarker	[1098]
SLC16A7	DTLT3UG	Strong	Biomarker	[1099]
SLC18A1	DTM953D	Strong	Genetic Variation	[1100]
SLC22A17	DTXI9E6	Strong	Biomarker	[1101]
SLC22A5	DT3HUVD	Strong	Biomarker	[1002]
SLC24A2	DTKRWE8	Strong	Altered Expression	[1102]
SLC24A3	DTO18LP	Strong	Biomarker	[1103]
SLC25A20	DTQOUM4	Strong	Biomarker	[1104]
SLC25A27	DT0HW5C	Strong	Altered Expression	[1105]
SLC25A37	DTLBGTZ	Strong	Biomarker	[1106]
SLC25A38	DTV8SWX	Strong	Biomarker	[1107]
SLC26A7	DTOTME4	Strong	Altered Expression	[1108]
SLC2A14	DT18YD9	Strong	Genetic Variation	[1109]
SLC2A3	DT9SQ3L	Strong	Genetic Variation	[1110]
SLC2A8	DT2I7BM	Strong	Biomarker	[1111]
SLC30A1	DT1BO38	Strong	Altered Expression	[1112]
SLC30A10	DTYBI73	Strong	Biomarker	[1113]
SLC31A1	DTP8L4F	Strong	Biomarker	[1114]
SLC35A1	DTVZIRG	Strong	Biomarker	[1115]
SLC35A2	DT0567K	Strong	Genetic Variation	[1116]
SLC38A10	DT2LGOY	Strong	Biomarker	[1117]
SLC4A8	DTW40Z7	Strong	Genetic Variation	[515]
SLC7A9	DTP7AEQ	Strong	Biomarker	[1118]
SLC8A3	DTYFRQT	Strong	Genetic Variation	[995]
SLC9A6	DTN0JXW	Strong	Altered Expression	[1119]
SLC24A4	DTQWF14	Definitive	Genetic Variation	[378]

This Disease Is Related to 58 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HSD17B7	DEDMWFX	Limited	Biomarker	[740]
NAT10	DEZV4AP	Disputed	Biomarker	[417]
CYP27A1	DEBS639	moderate	Altered Expression	[1120]
ACP3	DEDW5H6	Strong	Altered Expression	[1121]
ACSS2	DEE76VW	Strong	Biomarker	[1122]
ADH1B	DEEN9RD	Strong	Altered Expression	[1123]
ADH6	DE017IC	Strong	Altered Expression	[1124]
AKR1A1	DED2FW3	Strong	Biomarker	[1125]
AKR1C2	DEOY5ZM	Strong	Biomarker	[739]
ALDH1A2	DEKN1H4	Strong	Genetic Variation	[816]
AOC2	DE8DP90	Strong	Biomarker	[469]
APRT	DE2MV1R	Strong	Biomarker	[1126]
CES2	DETHCPD	Strong	Biomarker	[1127]
COLGALT2	DE8RIZD	Strong	Genetic Variation	[433]
CRMP1	DE0EUXB	Strong	Biomarker	[1080]
CYP7B1	DE36TMY	Strong	Biomarker	[1128]
CYP8B1	DETL4WB	Strong	Genetic Variation	[1129]
DDAH1	DEY0TQC	Strong	Altered Expression	[1130]
DDO	DE8PQ7T	Strong	Altered Expression	[1131]
FAAH	DEUM1EX	Strong	Biomarker	[1132]
GLS	DE3E0VT	Strong	Altered Expression	[1133]
GNPDA2	DEPJGQB	Strong	Biomarker	[1134]
GPT	DER5HFI	Strong	Altered Expression	[1135]
GSTZ1	DEQPEMB	Strong	Biomarker	[1136]
HAGH	DE05IKP	Strong	Biomarker	[1137]
HK1	DEDMAGE	Strong	Biomarker	[1138]
HSD17B10	DEGSPC9	Strong	Altered Expression	[1139]
MARS1	DE0K52I	Strong	Genetic Variation	[1140]
MAT1A	DEQ6NC9	Strong	Altered Expression	[1141]
MMEL1	DEYCUQ2	Strong	Biomarker	[1142]
MSRA	DEU2ZBY	Strong	Altered Expression	[1143]
MSRB2	DEMQOF7	Strong	Biomarker	[1144]
MT2A	DEFKGT7	Strong	Altered Expression	[858]
MTRR	DE6NIY9	Strong	Genetic Variation	[1145]
NAT1	DE7OAB3	Strong	Genetic Variation	[1146]
NAT2	DER7TA0	Strong	Genetic Variation	[1147]
NAT8	DEA742Z	Strong	Biomarker	[1148]
NMNAT1	DE4D159	Strong	Biomarker	[1149]
NMNAT2	DE2HB58	Strong	Altered Expression	[1150]
PARK7	DEPOVCH	Strong	Biomarker	[1151]
PCK1	DEPLH5Z	Strong	Genetic Variation	[1152]
PCYT1A	DEQYXD4	Strong	Genetic Variation	[1153]
PER1	DE9HF0I	Strong	Genetic Variation	[1154]
PGPEP1	DEVDR46	Strong	Biomarker	[500]
PMM2	DEBRX3L	Strong	Biomarker	[1155]
PON3	DETXQZ1	Strong	Genetic Variation	[1156]
PSAT1	DEBS17P	Strong	Biomarker	[872]
PTGDS	DER3H9C	Strong	Biomarker	[1157]
SI	DE5EO4Y	Strong	Biomarker	[848]
SMOX	DEOH5V3	Strong	Biomarker	[1158]
SULT2A1	DE0P6LK	Strong	Biomarker	[1085]
TGM6	DEUWCVD	Strong	Genetic Variation	[515]
THOP1	DE95LJC	Strong	Biomarker	[1159]
UBASH3B	DE10BJ5	Strong	Biomarker	[1160]
WARS1	DEPVE0M	Strong	Biomarker	[1161]
WARS2	DEPTKBQ	Strong	Biomarker	[1161]
XPNPEP1	DE8E6X9	Strong	Biomarker	[1162]
FXN	DEXVHDB	Definitive	Genetic Variation	[1163]

This Disease Is Related to 1411 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ALDH1L1	OT15HOJX	Limited	Biomarker	[1164]
APLP1	OTD176ZS	Limited	Biomarker	[1165]
ATF6	OTAFHAVI	Limited	Altered Expression	[423]
BRAP	OTB7BAFQ	Limited	Biomarker	[1166]
C1D	OTI9PMN1	Limited	Altered Expression	[1167]
CALB2	OTSNMCG9	Limited	Biomarker	[1168]
CDC42	OT5QBC5M	Limited	Biomarker	[1169]
CH25H	OT9S2BSW	Limited	Genetic Variation	[1170]
COL25A1	OT7M23Z9	Limited	Altered Expression	[1171]
COLQ	OT4BHUGQ	Limited	Genetic Variation	[1172]
DNAH8	OTGES2OU	Limited	Biomarker	[1173]
ECE2	OTZLNQVL	Limited	Autosomal dominant	[367]
ESCO1	OTZ9P12A	Limited	Biomarker	[1174]
FOXO3	OTHXQG4P	Limited	Altered Expression	[1175]
FZD4	OTGLZIE0	Limited	Biomarker	[375]
GPR151	OT7EACU6	Limited	Biomarker	[375]
HLA-DRB5	OTUX5TWM	Limited	Genetic Variation	[1176]
HSPA1A	OTKGIE76	Limited	Biomarker	[625]
IMPA1	OTBUVW1Z	Limited	Biomarker	[1166]
IQCK	OT4QNL67	Limited	Biomarker	[445]
LGR6	OTPZ1PWR	Limited	Biomarker	[375]
MAP1A	OTHO8K43	Limited	Biomarker	[1177]
MARK1	OTP7KL47	Limited	Biomarker	[1178]
MEFV	OTRJ6S6K	Limited	Biomarker	[1179]
MEOX2	OTKZCJCB	Limited	Genetic Variation	[1180]
MRGPRX3	OTRKCCDS	Limited	Biomarker	[375]
MRGPRX4	OTOBHZVA	Limited	Biomarker	[375]
MS4A4A	OTWV82RP	Limited	Genetic Variation	[378]
MYO5C	OTKLOCWZ	Limited	Biomarker	[1181]
NCSTN	OT5QBTA4	Limited	Biomarker	[1182]
NECTIN2	OTIE0W6O	Limited	Genetic Variation	[816]
NFIA	OTDHQ9CG	Limited	Biomarker	[1174]
NFIB	OTX94PD0	Limited	Biomarker	[1174]
NFIC	OTLMCUIB	Limited	Genetic Variation	[1183]
NFIX	OT1DPZAE	Limited	Biomarker	[1174]
NLRP12	OTGR132Z	Limited	Biomarker	[1184]
OGDHL	OT1AZK6R	Limited	Biomarker	[1185]
OLIG2	OTMCN6D3	Limited	Biomarker	[1186]
PAEP	OTQA0NV4	Limited	Biomarker	[1187]
PDIK1L	OTISF4KG	Limited	Biomarker	[1188]
PHF1	OTW2PSIR	Limited	Biomarker	[1189]
PHYHD1	OTTKHTAC	Limited	Biomarker	[1181]
PLA2G6	OT5FL0WU	Limited	Biomarker	[1190]
PLB1	OTZ6TTYV	Limited	Biomarker	[913]
POTEF	OTV3WXYE	Limited	Altered Expression	[422]
PRRT2	OTCJUBDO	Limited	Biomarker	[936]
PRUNE2	OTGW2974	Limited	Biomarker	[1191]
RAB5A	OTFR2KM4	Limited	Biomarker	[1192]
RELN	OTLKMW1O	Limited	Altered Expression	[1193]
S100A1	OT1F2G4J	Limited	Biomarker	[1194]
SCARB2	OTN929M8	Limited	Altered Expression	[1195]
SCFD1	OTN4T7JI	Limited	Genetic Variation	[1196]
SET	OTGYYQJO	Limited	Biomarker	[1197]
SGSM3	OTIB1P8A	Limited	Biomarker	[1198]
SORCS1	OTP8PAKU	Limited	Biomarker	[1199]
SUMO1	OTJFD4P5	Limited	Biomarker	[1200]
TFCP2	OTA246TE	Limited	Biomarker	[1201]
TMED10	OTUXSHH7	Limited	Altered Expression	[1202]
TMEM230	OTAFALFV	Limited	Biomarker	[1203]
TPI1	OT14KP4B	Limited	Biomarker	[1204]
ATRNL1	OTY5JUX2	Disputed	Biomarker	[417]
CCL27	OTUZYC61	Disputed	Biomarker	[417]
PDLIM3	OTVXQC81	Disputed	Biomarker	[417]
TAX1BP1	OTGJMGJ9	Disputed	Genetic Variation	[417]
ADAMTS3	OT2U6VF5	moderate	Biomarker	[1205]
ALPP	OTZU4G9W	moderate	Biomarker	[417]
APLP2	OTTFE53M	moderate	Biomarker	[1206]
ASAH1	OT1DNGXL	moderate	Altered Expression	[428]
CASS4	OTGPIPUS	moderate	Genetic Variation	[378]
CELF1	OT6JQ5RS	moderate	Genetic Variation	[1207]
MARK4	OT6Z2TGV	moderate	Genetic Variation	[378]
MFN2	OTPYN8A3	moderate	Altered Expression	[1208]
MS4A6A	OTK4BXQS	moderate	Genetic Variation	[378]
PCDH11X	OTLICG18	moderate	Genetic Variation	[1209]
PRDX6	OTS8KC8A	moderate	Altered Expression	[1210]
SCRN1	OTELM5C2	moderate	Biomarker	[1211]
SIL1	OTDI85I5	moderate	Biomarker	[1212]
SLPI	OTUNFUU8	moderate	Biomarker	[417]
SNCB	OTELSEK6	moderate	Genetic Variation	[1213]
SNPH	OTL6XBFA	moderate	Biomarker	[1214]
SRA1	OTYOGMTG	moderate	Altered Expression	[1215]
SYNJ1	OTTE02XC	moderate	Biomarker	[1216]
A1CF	OTJBKFA1	Strong	Biomarker	[485]
AATF	OT1QOKLD	Strong	Biomarker	[1217]
ABCG4	OT2XJIOG	Strong	Altered Expression	[1218]
ACADVL	OT50L4XB	Strong	Altered Expression	[1219]
ACAP1	OTPFQ2QC	Strong	Biomarker	[1220]
ACCS	OTHIHI9D	Strong	Biomarker	[1122]
ACKR2	OTWYY14H	Strong	Genetic Variation	[1129]
ACMSD	OTPSXPSF	Strong	Genetic Variation	[1221]
ACO1	OT2VUR7L	Strong	Biomarker	[1222]
ACOT7	OT7C68YV	Strong	Biomarker	[361]
ACOT8	OTHY684G	Strong	Altered Expression	[1223]
ACSL6	OT0TT8P8	Strong	Genetic Variation	[1224]
ACTB	OT1MCP2F	Strong	Altered Expression	[422]
ACTBL2	OTD6B81U	Strong	Biomarker	[361]
ACTG2	OTRDWUO0	Strong	Biomarker	[361]
ADAM12	OTZKOTDB	Strong	Genetic Variation	[1225]
ADAM19	OTH88TXU	Strong	Biomarker	[1226]
ADAMTS10	OTNJ9VSU	Strong	Biomarker	[1227]
ADAMTS2	OTTK22NO	Strong	Biomarker	[1228]
ADAP1	OTM4CHU1	Strong	Biomarker	[1229]
ADARB1	OTGKSZEV	Strong	Altered Expression	[1230]
ADCY10	OTYSTB0R	Strong	Biomarker	[718]
ADD3	OTDRSHAZ	Strong	Biomarker	[1231]
ADI1	OT8IOD03	Strong	Biomarker	[1232]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[1233]
ADNP	OTEGICWR	Strong	Genetic Variation	[1234]
ADRM1	OTOU4EY6	Strong	Biomarker	[797]
AEBP1	OTBI1RZ6	Strong	Altered Expression	[876]
AFF1	OTT2C78E	Strong	Genetic Variation	[515]
AGAP2	OTEYO9TM	Strong	Biomarker	[1235]
AGBL1	OT8NQLH0	Strong	Genetic Variation	[561]
AGFG2	OTXQZHCR	Strong	Genetic Variation	[494]
AGO1	OTD3R434	Strong	Biomarker	[1236]
AGPS	OTFBFPV4	Strong	Genetic Variation	[1237]
AGRN	OTWJENAZ	Strong	Altered Expression	[1238]
AHCYL1	OTX8L3M5	Strong	Genetic Variation	[561]
AHI1	OT8K2YWY	Strong	Biomarker	[1239]
AHNAK	OT6KH1WG	Strong	Genetic Variation	[561]
AHSA1	OTC7AFHT	Strong	Biomarker	[458]
AIM2	OT86QUI8	Strong	Biomarker	[1240]
AIMP1	OTTA5C3U	Strong	Biomarker	[1241]
AIRE	OTA7G1Y1	Strong	Biomarker	[1242]
AKAP5	OTE2AGPC	Strong	Biomarker	[1013]
AKAP9	OT7Z2YRP	Strong	Genetic Variation	[1243]
ALDH7A1	OTV57BZD	Strong	Biomarker	[1244]
ALPK2	OTWZZDQ9	Strong	Genetic Variation	[378]
ALS2	OT8BAM04	Strong	Biomarker	[1245]
AMFR	OTQRX7LC	Strong	Biomarker	[1246]
AMIGO1	OT2EPDFC	Strong	Genetic Variation	[1247]
AMIGO2	OTPAIT1O	Strong	Genetic Variation	[1248]
AMPH	OTWPGWZX	Strong	Genetic Variation	[1249]
ANGPT4	OT881M3K	Strong	Biomarker	[644]
ANK3	OTJ3IRBP	Strong	Biomarker	[1250]
ANKK1	OT0OM1O0	Strong	Genetic Variation	[1251]
ANKRD31	OTBDW2F2	Strong	Genetic Variation	[1252]
ANKRD55	OT62KZII	Strong	Genetic Variation	[515]
ANKS1B	OT26DGM9	Strong	Altered Expression	[1253]
ANO3	OTM34U6Q	Strong	Genetic Variation	[433]
ANO4	OT8E2PMA	Strong	Genetic Variation	[515]
ANP32A	OTRHPFO2	Strong	Biomarker	[1254]
ANTXR1	OT5W1GPC	Strong	Genetic Variation	[1255]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[1160]
AP2A2	OTD1UGUN	Strong	Genetic Variation	[1256]
AP4M1	OT2BG2Z3	Strong	Genetic Variation	[494]
APBA1	OTUH9JPD	Strong	Biomarker	[1257]
APBA2	OTXD8ID1	Strong	Biomarker	[713]
APBA3	OTAAATXF	Strong	Biomarker	[1258]
APBB2	OT1VD51B	Strong	Biomarker	[1259]
APBB3	OTNUTR0N	Strong	Genetic Variation	[1260]
APCDD1	OTV9AD0L	Strong	Biomarker	[1261]
APH1A	OT97F1TU	Strong	Biomarker	[1262]
APMAP	OT1P2GJA	Strong	Biomarker	[1263]
APOA5	OTEVKLVA	Strong	Genetic Variation	[1170]
APOC1	OTA58CED	Strong	Genetic Variation	[1170]
APOC4	OTE8ZUXY	Strong	Genetic Variation	[494]
APOD	OTT77XW8	Strong	Biomarker	[1264]
APOF	OT12S5QS	Strong	Genetic Variation	[1265]
APOM	OTI3FQQC	Strong	Biomarker	[1265]
APPL1	OT8VR95S	Strong	Biomarker	[1266]
AQP4	OTA9MYD5	Strong	Biomarker	[1267]
ARAP2	OTBXYFRH	Strong	Genetic Variation	[433]
ARAP3	OTUWZTH7	Strong	Biomarker	[1268]
ARC	OTN2QQPG	Strong	Biomarker	[1269]
ARHGAP20	OTG1STV8	Strong	Genetic Variation	[515]
ARHGEF15	OTGHDJFP	Strong	Altered Expression	[1270]
ARHGEF2	OTBQTFRT	Strong	Altered Expression	[1271]
ARHGEF5	OTUVGFT9	Strong	Altered Expression	[1272]
ARHGEF7	OT9BPJCL	Strong	Biomarker	[1273]
ARID4B	OTYLPILE	Strong	Biomarker	[1274]
ARL17B	OTXZD3DG	Strong	Genetic Variation	[1252]
ARMCX5-GPRASP2	OT2N7NQR	Strong	Biomarker	[1275]
ARMH1	OTTJC0D6	Strong	Biomarker	[803]
ARMS2	OTUXHJ9H	Strong	Genetic Variation	[1276]
ARPP19	OTZS3IT6	Strong	Biomarker	[1277]
ARTN	OTWIWGL6	Strong	Biomarker	[1278]
ARVCF	OT78DKOU	Strong	Genetic Variation	[561]
ASCC1	OTH4VAP9	Strong	Biomarker	[1273]
ASCC2	OT3B204T	Strong	Biomarker	[868]
ASL	OTI2NGQR	Strong	Biomarker	[1279]
ASPM	OTKXQMNA	Strong	Biomarker	[485]
ASTN2	OTF0W2FJ	Strong	Genetic Variation	[1280]
ATCAY	OTSIAM08	Strong	Biomarker	[1281]
ATF2	OTNIZPEA	Strong	Altered Expression	[1282]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[1283]
ATG12	OTJRO09Y	Strong	Biomarker	[1284]
ATG4B	OTQ4RNRM	Strong	Biomarker	[1202]
ATG4C	OTD9HN3X	Strong	Genetic Variation	[1285]
ATG5	OT4T5SMS	Strong	Biomarker	[1284]
ATP2B4	OTMWFDAC	Strong	Biomarker	[1286]
ATP5F1A	OT3FZDLX	Strong	Biomarker	[1287]
ATP5F1B	OTLFZUQK	Strong	Altered Expression	[1288]
ATP5MC1	OTOLSYOI	Strong	Altered Expression	[1289]
ATP5MC2	OTA5F480	Strong	Altered Expression	[1289]
ATP5PD	OTAJDLE2	Strong	Genetic Variation	[1290]
ATP5PF	OTDAE8FP	Strong	Altered Expression	[1289]
ATP5PO	OTU3MCTN	Strong	Biomarker	[403]
ATP6V0D1	OT9GU2NW	Strong	Biomarker	[1291]
ATP6V0E1	OTZZIUYY	Strong	Altered Expression	[513]
ATP6V1B2	OTNX2V4Z	Strong	Biomarker	[1292]
ATP6V1E1	OT76J5R9	Strong	Altered Expression	[513]
ATP6V1H	OTX17GQ9	Strong	Genetic Variation	[1293]
ATXN1	OTQF0HNR	Strong	Biomarker	[754]
ATXN7L1	OT5EZO0M	Strong	Genetic Variation	[1294]
AZI2	OT61Q7Q8	Strong	Altered Expression	[1223]
AZIN2	OT8OB7CG	Strong	Biomarker	[1295]
AZU1	OTHXU264	Strong	Genetic Variation	[1296]
B3GALT4	OTLKSMQE	Strong	Biomarker	[1297]
B3GAT1	OTXFP98E	Strong	Altered Expression	[1298]
BAG1	OTRQNIA4	Strong	Biomarker	[1299]
BAG2	OTI6LD27	Strong	Biomarker	[1299]
BAG3	OTVXYUDQ	Strong	Biomarker	[1300]
BAG5	OT0J97C6	Strong	Altered Expression	[1301]
BARHL1	OTIUTWBD	Strong	Biomarker	[1090]
BARHL2	OTASKG2P	Strong	Biomarker	[1302]
BCAM	OTHZOPSD	Strong	Genetic Variation	[378]
BCAN	OTPVY3ZR	Strong	Biomarker	[1303]
BCAP31	OTKSACR4	Strong	Biomarker	[1304]
BCAR1	OTKT2C2N	Strong	Biomarker	[589]
BCAS3	OTDVAX6B	Strong	Genetic Variation	[515]
BCL2L11	OTNQQWFJ	Strong	Altered Expression	[1305]
BCS1L	OT5PY5CY	Strong	Biomarker	[1306]
BHLHE23	OTLSVD17	Strong	Biomarker	[1307]
BHLHE40	OTITX14U	Strong	Genetic Variation	[1308]
BIN2	OT4S45WJ	Strong	Biomarker	[1309]
BLM	OTEJOAJX	Strong	Biomarker	[1310]
BLNK	OTSSPF6F	Strong	Genetic Variation	[1311]
BLOC1S3	OTNRFFLW	Strong	Genetic Variation	[378]
BMPER	OTBYON4H	Strong	Genetic Variation	[1312]
BMS1	OTEGQ8ZO	Strong	Biomarker	[1313]
BNC1	OTGJ5WUF	Strong	Biomarker	[484]
BNIP3	OT4SO7J4	Strong	Genetic Variation	[1314]
BPTF	OTD1RZAD	Strong	Biomarker	[840]
BRI3	OT1RWIH7	Strong	Biomarker	[1315]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[1316]
BZW2	OTBT0A1B	Strong	Genetic Variation	[515]
C10orf71	OT5NXMLV	Strong	Genetic Variation	[561]
C1orf52	OT8RQW3W	Strong	Altered Expression	[1317]
C1QA	OT6XKVVA	Strong	Altered Expression	[1318]
C1QL1	OTNQ0G3E	Strong	Biomarker	[1319]
C1R	OTA0ZNIU	Strong	Biomarker	[1320]
C2	OTHMF4YM	Strong	Biomarker	[1321]
C20orf203	OT3D1FOY	Strong	Altered Expression	[1322]
C9	OT7I5FDX	Strong	Biomarker	[1323]
CACUL1	OT6P1ZVP	Strong	Altered Expression	[1324]
CACYBP	OTJMZD2T	Strong	Biomarker	[1134]
CALB1	OTM7IXDG	Strong	Genetic Variation	[1325]
CALCOCO2	OTRGX0OV	Strong	Biomarker	[1326]
CALM2	OTNYA92F	Strong	Biomarker	[1327]
CALML5	OTOFJLFA	Strong	Biomarker	[1328]
CAMK1D	OTU24HAU	Strong	Biomarker	[1329]
CAMK2A	OTJGX19T	Strong	Genetic Variation	[1330]
CAMK4	OT47RDGV	Strong	Biomarker	[1331]
CAMKMT	OTLJBRUW	Strong	Biomarker	[1332]
CAPG	OTJ86KI6	Strong	Biomarker	[1333]
CARD8	OTXXZYWU	Strong	Genetic Variation	[1334]
CASP12	OTY2W6FG	Strong	Therapeutic	[1335]
CAST	OTBXZZGF	Strong	Biomarker	[1336]
CASZ1	OTWJ2OR8	Strong	Biomarker	[1115]
CBFA2T2	OTNOIB23	Strong	Biomarker	[1337]
CBLC	OT3RKZI9	Strong	Genetic Variation	[378]
CBLIF	OTNE20WU	Strong	Altered Expression	[1338]
CBLN4	OTO7QW6Y	Strong	Biomarker	[1339]
CBX5	OT8VYY84	Strong	Genetic Variation	[1340]
CCDC134	OT70OQQV	Strong	Genetic Variation	[1341]
CCDC83	OTF1ETS6	Strong	Genetic Variation	[1342]
CCDC89	OT864TCD	Strong	Genetic Variation	[561]
CCHCR1	OT22C116	Strong	Genetic Variation	[1343]
CCL1	OT23NON8	Strong	Biomarker	[1344]
CCL19	OTQ2UJMH	Strong	Biomarker	[530]
CCL26	OT2B7HR9	Strong	Biomarker	[1345]
CCL4	OT6B8P25	Strong	Biomarker	[1346]
CCL4L2	OTDBSXOU	Strong	Altered Expression	[1347]
CCL8	OTCTWYN8	Strong	Genetic Variation	[1348]
CCNC	OTMVK4K4	Strong	Biomarker	[1349]
CCRL2	OT5PX0RX	Strong	Genetic Variation	[1129]
CCS	OTXHT3QO	Strong	Biomarker	[1136]
CCT2	OTW1VV4E	Strong	Altered Expression	[422]
CD177	OTS79FNF	Strong	Altered Expression	[1347]
CD200R1	OT65Q9M6	Strong	Genetic Variation	[722]
CD226	OT4UG0KB	Strong	Altered Expression	[1350]
CD2AP	OTC76KQM	Strong	Biomarker	[1351]
CD5L	OTPY4WQR	Strong	Genetic Variation	[1352]
CD63	OT2UGZA9	Strong	Biomarker	[1353]
CD68	OTOYEY3J	Strong	Biomarker	[480]
CD81	OTQFXNAZ	Strong	Genetic Variation	[1354]
CD8A	OTDWQJXK	Strong	Biomarker	[1355]
CDC42SE2	OT8SG9I1	Strong	Genetic Variation	[1224]
CDCA5	OTZLCQ5U	Strong	Biomarker	[467]
CDH13	OTD2CYM5	Strong	Altered Expression	[1356]
CDK5R2	OTNUTLPU	Strong	Biomarker	[1291]
CDK5RAP2	OTRKEVTY	Strong	Genetic Variation	[1357]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[561]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[1060]
CDNF	OT1TP2T8	Strong	Biomarker	[1358]
CDR2	OTD3ZJST	Strong	Genetic Variation	[1359]
CDSN	OTQW4HV6	Strong	Biomarker	[1360]
CEACAM19	OTMECF5R	Strong	Genetic Variation	[494]
CEACAM20	OTHP9H9O	Strong	Genetic Variation	[378]
CEBPD	OTNBIPMY	Strong	Altered Expression	[1361]
CEBPZ	OT11BATG	Strong	Biomarker	[1362]
CELF2	OTLJJ4VT	Strong	Genetic Variation	[1363]
CENPK	OTKPUF8K	Strong	Biomarker	[508]
CENPV	OTPQ0KT9	Strong	Biomarker	[1364]
CERT1	OTNUCNHX	Strong	Biomarker	[1365]
CETN1	OTGQ8JOZ	Strong	Biomarker	[1366]
CFAP410	OTJ94J99	Strong	Altered Expression	[1367]
CFAP97	OT0RSQO4	Strong	Biomarker	[1368]
CFC1	OT5DHGI8	Strong	Biomarker	[1369]
CFDP1	OTXY7J96	Strong	Altered Expression	[1370]
CFL1	OTT6D5MH	Strong	Biomarker	[1371]
CHAF1B	OTOMK4KH	Strong	Altered Expression	[1367]
CHCHD10	OTCDHAM6	Strong	Genetic Variation	[1372]
CHD1	OT9R9G0H	Strong	Biomarker	[410]
CHGA	OTXYX5JH	Strong	Biomarker	[1373]
CHGB	OT7SAQT2	Strong	Biomarker	[1374]
CHL1	OT6E6E8P	Strong	Biomarker	[1375]
CHMP2B	OTZA7RJB	Strong	Biomarker	[1376]
CHRDL1	OTGMWVVA	Strong	Biomarker	[1158]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[1377]
CIB1	OT4BVCRU	Strong	Altered Expression	[1378]
CINP	OTZ31XOT	Strong	Biomarker	[1379]
CIP2A	OTVS2GXA	Strong	Biomarker	[1380]
CISD2	OTVS7S2H	Strong	Biomarker	[1381]
CISD3	OT0MM1MW	Strong	Biomarker	[1382]
CISH	OT8T5NYL	Strong	Altered Expression	[1383]
CKB	OTUCKOTT	Strong	Biomarker	[1384]
CLASRP	OT7B1H28	Strong	Genetic Variation	[378]
CLC	OTYMYR85	Strong	Biomarker	[1385]
CLDN1	OT27KV99	Strong	Biomarker	[1386]
CLDN17	OTQCEYBY	Strong	Biomarker	[1387]
CLDN5	OTUX60YO	Strong	Biomarker	[1388]
CLDN8	OT7IIWXG	Strong	Altered Expression	[1367]
CLEC16A	OTLGV5SV	Strong	Genetic Variation	[1209]
CLEC1B	OTO38TRG	Strong	Altered Expression	[1389]
CLEC7A	OTRTBH27	Strong	Biomarker	[1390]
CLMN	OT7U5J3T	Strong	Genetic Variation	[515]
CLN5	OTY265P6	Strong	Genetic Variation	[571]
CLPTM1	OT14QP7N	Strong	Genetic Variation	[378]
CLSTN3	OTPUFK4C	Strong	Altered Expression	[1391]
CLUH	OTCDYPZV	Strong	Biomarker	[1392]
CNTNAP2	OT48T2ZP	Strong	Genetic Variation	[378]
COG5	OTZEG7K0	Strong	Genetic Variation	[1393]
COIL	OTP4I4DL	Strong	Biomarker	[1394]
COL12A1	OTHLTV53	Strong	Genetic Variation	[561]
COL17A1	OTID5AH2	Strong	Biomarker	[1395]
COL3A1	OTT1EMLM	Strong	Biomarker	[1396]
COL4A4	OT9G0MCT	Strong	Genetic Variation	[561]
COQ2	OTDAKEY4	Strong	Biomarker	[1397]
CORO1A	OTVAZOHC	Strong	Biomarker	[1371]
COTL1	OT6YCNLF	Strong	Biomarker	[1398]
COX1	OTG3O9BN	Strong	Biomarker	[405]
COX10	OTCYIS0L	Strong	Genetic Variation	[1399]
COX15	OTUIYHIW	Strong	Genetic Variation	[1400]
COX3	OTNNGBYJ	Strong	Genetic Variation	[588]
COX6B1	OTNKXYQI	Strong	Genetic Variation	[1399]
CP	OTM8JE4Y	Strong	Biomarker	[1401]
CPLX1	OT7UIGTP	Strong	Altered Expression	[1402]
CPLX2	OTU5QWFH	Strong	Altered Expression	[1402]
CPO	OTOIG8C9	Strong	Biomarker	[1403]
CPT1A	OTI862QH	Strong	Altered Expression	[1404]
CPVL	OTOJL31C	Strong	Biomarker	[1405]
CR1L	OTX3KR7U	Strong	Genetic Variation	[494]
CRADD	OT02TZ4S	Strong	Genetic Variation	[515]
CREB3	OT9617UO	Strong	Biomarker	[1406]
CREB3L1	OT2JHIHM	Strong	Genetic Variation	[1407]
CRISPLD2	OTVSFHTL	Strong	Biomarker	[1408]
CRYL1	OT0SJSJM	Strong	Biomarker	[1409]
CSMD1	OTIVDSC4	Strong	Genetic Variation	[1410]
CSN2	OT22C0PD	Strong	Biomarker	[1411]
CST7	OTQWZUVQ	Strong	Altered Expression	[1412]
CTBP1	OTVYH2DH	Strong	Biomarker	[1413]
CTBS	OT135K92	Strong	Biomarker	[894]
CTCF	OT8ZB70U	Strong	Genetic Variation	[1414]
CTDSP2	OTT2BOJG	Strong	Altered Expression	[1415]
CTNNA2	OTJ8G92T	Strong	Genetic Variation	[515]
CTNNA3	OT9Z0P1E	Strong	Genetic Variation	[1416]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[1417]
CTNND1	OTUMPSHR	Strong	Biomarker	[589]
CTNND2	OTYKE30Y	Strong	Genetic Variation	[1418]
CTRL	OTB6NA5O	Strong	Biomarker	[1419]
CTSZ	OTSCX2LL	Strong	Altered Expression	[1420]
CTTN	OTJRG4ES	Strong	Altered Expression	[1421]
CTXN3	OT534FDX	Strong	Biomarker	[1422]
CUL4A	OTTBV70J	Strong	Biomarker	[1423]
CUX1	OTU1LCNJ	Strong	Altered Expression	[770]
CYCS	OTBFALJD	Strong	Genetic Variation	[515]
CYLD	OT37FKH0	Strong	Biomarker	[543]
CYP2D7	OTYJTL3S	Strong	Genetic Variation	[1424]
CYTB	OTAHB98A	Strong	Altered Expression	[422]
CYTH4	OTOR82ID	Strong	Genetic Variation	[1425]
DAB1	OTPL9MA3	Strong	Posttranslational Modification	[1426]
DAPK1	OTNCNUCO	Strong	Biomarker	[1427]
DAPK2	OTWODUQG	Strong	Biomarker	[1080]
DAXX	OTX6O7PL	Strong	Genetic Variation	[1428]
DBI	OT884QY9	Strong	Genetic Variation	[1429]
DBN1	OTZVKG8A	Strong	Biomarker	[1430]
DCAF7	OT3W5DYL	Strong	Genetic Variation	[561]
DCDC2	OTSUFH1H	Strong	Biomarker	[1431]
DCX	OTISR7K3	Strong	Altered Expression	[1432]
DDIT3	OTI8YKKE	Strong	Biomarker	[1433]
DDX25	OTF36NBP	Strong	Genetic Variation	[561]
DDX39A	OT0Z6E1K	Strong	Biomarker	[1118]
DDX39B	OTEVCFVU	Strong	Biomarker	[1118]
DECR1	OTCDIR6X	Strong	Biomarker	[1434]
DEFA1	OT5N1B9B	Strong	Altered Expression	[616]
DEFB104A	OTLQZR6K	Strong	Genetic Variation	[616]
DEGS1	OT4WXPKW	Strong	Biomarker	[1435]
DENR	OTXP9HOY	Strong	Biomarker	[1080]
DGKQ	OT8OEPYT	Strong	Genetic Variation	[1221]
DHRS11	OTU3J0ZL	Strong	Biomarker	[740]
DHX40	OTOL02QN	Strong	Genetic Variation	[890]
DIAPH1	OTZBYPLH	Strong	Biomarker	[1436]
DIO2	OTGPNSLH	Strong	Genetic Variation	[1437]
DISC1	OT43AW4H	Strong	Altered Expression	[1438]
DLD	OT378CU9	Strong	Biomarker	[1439]
DLG1	OTCRZYWT	Strong	Biomarker	[1440]
DLG2	OTQ3BD8U	Strong	Posttranslational Modification	[1441]
DLG3	OTH591WK	Strong	Biomarker	[1442]
DLX5	OTEEFBEU	Strong	Genetic Variation	[561]
DMRT1	OT5PU9U1	Strong	Altered Expression	[1443]
DMXL1	OTWVL31L	Strong	Genetic Variation	[515]
DNA2	OT4DJFFU	Strong	Biomarker	[1444]
DNAJA3	OT61924T	Strong	Biomarker	[1445]
DNAJC27	OTJRPCUR	Strong	Genetic Variation	[1446]
DNAJC5	OTCZDXAL	Strong	Altered Expression	[1447]
DNM1L	OTXK1Q1G	Strong	Biomarker	[1080]
DNTT	OTFSEF12	Strong	Genetic Variation	[1448]
DOCK2	OTZTS3PA	Strong	Biomarker	[1449]
DOCK8	OTNQLL21	Strong	Biomarker	[1450]
DPEP2	OTIKZDTG	Strong	Biomarker	[820]
DPPA2	OT8Y55RY	Strong	Genetic Variation	[1451]
DPYSL3	OTINJV20	Strong	Altered Expression	[1452]
DPYSL5	OT6F9T6F	Strong	Biomarker	[706]
DROSHA	OTCE68KZ	Strong	Genetic Variation	[1453]
DSC1	OTNII6GZ	Strong	Genetic Variation	[1454]
DSC3	OTYG47F8	Strong	Biomarker	[1455]
DSCAML1	OT7QURQT	Strong	Genetic Variation	[433]
DSG1	OT11HC3A	Strong	Biomarker	[1456]
DSG2	OTJPB2TO	Strong	Genetic Variation	[378]
DSPP	OT1TYNDN	Strong	Genetic Variation	[1457]
DST	OTHZBM4X	Strong	Biomarker	[1458]
DUSP22	OTEZ3U85	Strong	Posttranslational Modification	[1459]
DUSP6	OT4H6RKW	Strong	Posttranslational Modification	[1235]
DVL1	OTD67RF1	Strong	Biomarker	[1460]
DYM	OTQ670WI	Strong	Biomarker	[1461]
EBF3	OTB0IWLW	Strong	Biomarker	[1462]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[803]
ECD	OT3L3PCU	Strong	Genetic Variation	[1463]
ECHDC3	OTKU2RMC	Strong	Genetic Variation	[1464]
ECSCR	OT9L72MD	Strong	Altered Expression	[1465]
ECSIT	OTJX1YC7	Strong	Biomarker	[1466]
EDAR	OT3W2UQS	Strong	Biomarker	[1467]
EDEM2	OTQXYD65	Strong	Genetic Variation	[1468]
EEF1A1	OT00THXS	Strong	Biomarker	[1469]
EEF2	OTZ7SZ39	Strong	Biomarker	[1470]
EFHD2	OTM9VMN3	Strong	Biomarker	[1471]
EFNA5	OTOH4DRR	Strong	Biomarker	[1472]
EGR2	OTAVQ78J	Strong	Biomarker	[1473]
EID1	OT3OI5H4	Strong	Altered Expression	[1474]
EIF1	OTB4GZ0V	Strong	Altered Expression	[1475]
EIF2S1	OTM0GDTP	Strong	Altered Expression	[1476]
EIF2S2	OTXF0B09	Strong	Biomarker	[1477]
EIF2S3	OTARRES9	Strong	Biomarker	[1477]
EIF3E	OTI0WG98	Strong	Genetic Variation	[1478]
EIF4A1	OTMTBX6N	Strong	Biomarker	[1479]
EIF4A2	OT08H03R	Strong	Biomarker	[1479]
EIF4G2	OTEO98CR	Strong	Altered Expression	[1370]
EIF5	OT79PQUN	Strong	Biomarker	[1480]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[1481]
ELAVL4	OT3YH6J6	Strong	Biomarker	[1482]
ELK1	OTH9MXD6	Strong	Biomarker	[1483]
ELMO1	OTY2ORXK	Strong	Genetic Variation	[515]
ELOC	OT0XHHWP	Strong	Biomarker	[961]
EMP1	OTSZHUHQ	Strong	Genetic Variation	[1484]
ENDOU	OTB7OF7Y	Strong	Genetic Variation	[1485]
ENO1	OTB1KWJS	Strong	Biomarker	[1486]
EOMES	OTB9VQFA	Strong	Genetic Variation	[1083]
EPC2	OTTG0W9R	Strong	Biomarker	[1341]
EPDR1	OT5JW5RB	Strong	Genetic Variation	[378]
EPG5	OT3P5HQD	Strong	Genetic Variation	[1487]
EVA1A	OTCY3Q2M	Strong	Genetic Variation	[1488]
EXOC3L4	OTFD17IL	Strong	Biomarker	[1489]
EXOC4	OT5EWXAN	Strong	Genetic Variation	[515]
EXOSC6	OTAC10N6	Strong	Genetic Variation	[1485]
EYA4	OTINGR3Z	Strong	Genetic Variation	[561]
FABP6	OTIRQWLW	Strong	Biomarker	[1490]
FABP7	OTRE2H4G	Strong	Biomarker	[1491]
FAM181A	OTBQCMNL	Strong	Genetic Variation	[561]
FAM20C	OTW5YZ7X	Strong	Biomarker	[1492]
FAM3C	OTBR6U9G	Strong	Biomarker	[1493]
FAM72A	OTBZYSR3	Strong	Biomarker	[1494]
FAM72B	OT6AOG64	Strong	Biomarker	[1494]
FANCD2	OTVEB5LF	Strong	Genetic Variation	[504]
FANCG	OT7MC8TZ	Strong	Altered Expression	[1495]
FARP1	OTL1EBTM	Strong	Genetic Variation	[561]
FBXL2	OT5EZ7PD	Strong	Altered Expression	[1496]
FBXL7	OTNUK1DJ	Strong	Genetic Variation	[1497]
FBXO2	OTF3677S	Strong	Altered Expression	[1498]
FBXO7	OTGTN8TJ	Strong	Biomarker	[1499]
FCGR3B	OTSLSPZG	Strong	Biomarker	[534]
FCN2	OTTHJBKZ	Strong	Biomarker	[467]
FERMT2	OTZNPWWX	Strong	Biomarker	[1500]
FGF13	OTHNNVSG	Strong	Biomarker	[1501]
FGF9	OT2SKDGM	Strong	Biomarker	[1502]
FHL2	OT0OAYWT	Strong	Biomarker	[1503]
FHL5	OT6C00Z1	Strong	Biomarker	[361]
FIS1	OT2HL10J	Strong	Biomarker	[1504]
FKBPL	OTR9ND6K	Strong	Biomarker	[1505]
FLG	OTE9QDV6	Strong	Genetic Variation	[1506]
FLVCR1	OT9XCFOC	Strong	Biomarker	[1507]
FMN2	OTUY7BSV	Strong	Biomarker	[1508]
FMR1	OTWEV0T5	Strong	Genetic Variation	[1509]
FNDC5	OT5CSK9X	Strong	Biomarker	[1510]
FNIP1	OTB1CC41	Strong	Genetic Variation	[1224]
FOCAD	OT83QOSI	Strong	Genetic Variation	[1511]
FOSB	OTW6C05J	Strong	Biomarker	[1512]
FOXA1	OTEBY0TD	Strong	Altered Expression	[1513]
FOXA2	OTJOCVOY	Strong	Altered Expression	[1513]
FRK	OTEKV1SC	Strong	Genetic Variation	[1514]
FRMD4A	OTJDTIK2	Strong	Biomarker	[1515]
FRMD6	OTY6X9V5	Strong	Biomarker	[1516]
FTMT	OTIUX6XG	Strong	Biomarker	[1517]
FXYD1	OTNKT6GP	Strong	Biomarker	[1518]
FXYD6	OTHOQXGF	Strong	Biomarker	[1519]
FZD3	OTIWDN78	Strong	Altered Expression	[1520]
FZD5	OTXFFY56	Strong	Altered Expression	[1521]
GAB1	OTQKE6V4	Strong	Biomarker	[1522]
GABBR1	OTU5A52J	Strong	Genetic Variation	[1523]
GABPA	OT9YB2SA	Strong	Altered Expression	[1524]
GADD45A	OTDRV63V	Strong	Altered Expression	[1525]
GADD45GIP1	OT4IZ4TP	Strong	Altered Expression	[1526]
GADL1	OTJM4A0R	Strong	Biomarker	[1295]
GAL3ST1	OTSFFZRD	Strong	Biomarker	[1115]
GAPDHS	OT7YUSA5	Strong	Biomarker	[420]
GAPT	OT6C2WXX	Strong	Biomarker	[1527]
GAS7	OT0M5TNY	Strong	Biomarker	[1528]
GBF1	OTY1KEHY	Strong	Biomarker	[1529]
GCA	OTAJ7ZHG	Strong	Genetic Variation	[1530]
GCHFR	OTEOT8GI	Strong	Biomarker	[467]
GDE1	OTU6FSBF	Strong	Altered Expression	[1531]
GDF11	OTOSNMND	Strong	Biomarker	[1532]
GDF7	OTNZY74B	Strong	Biomarker	[1533]
GEMIN7	OTWA67L6	Strong	Genetic Variation	[378]
GFER	OTVK43OK	Strong	Biomarker	[987]
GFRA1	OT3WBVYB	Strong	Altered Expression	[1534]
GGACT	OTGPZHR9	Strong	Genetic Variation	[561]
GKN1	OT7ZYFQ9	Strong	Biomarker	[1535]
GLIS1	OTBDNB26	Strong	Biomarker	[1536]
GLS2	OT08MSHL	Strong	Biomarker	[1537]
GLYAT	OT3WWYXD	Strong	Altered Expression	[1007]
GMFB	OTR1JN1D	Strong	Biomarker	[1538]
GMNC	OTMORU7G	Strong	Genetic Variation	[1539]
GMPR	OTERWHYM	Strong	Posttranslational Modification	[1540]
GNA12	OT3IRZH3	Strong	Biomarker	[1541]
GNB3	OTA6HYBA	Strong	Genetic Variation	[1542]
GNPAT	OTF6LWPO	Strong	Altered Expression	[1543]
GOLGA2	OT5S9KYM	Strong	Biomarker	[1544]
GOLGA4	OTCMEHNJ	Strong	Biomarker	[1545]
GOLGA6A	OTHU9MRX	Strong	Biomarker	[1546]
GOLIM4	OTB5NV8A	Strong	Genetic Variation	[433]
GOLPH3	OTDLGYM3	Strong	Biomarker	[1547]
GORASP1	OTQS91S7	Strong	Biomarker	[1084]
GPAA1	OTWVRR35	Strong	Genetic Variation	[1103]
GPC1	OTQKRSSV	Strong	Altered Expression	[1238]
GPC6	OTNJBESF	Strong	Genetic Variation	[515]
GPHN	OTAKK1SV	Strong	Genetic Variation	[1548]
GPM6A	OT8G13EG	Strong	Biomarker	[1549]
GPR141	OTJ8WSSW	Strong	Genetic Variation	[378]
GPR37L1	OTOV08EV	Strong	Posttranslational Modification	[1235]
GPR42	OTEB0ROY	Strong	Biomarker	[440]
GPR50	OT0EJBM4	Strong	Posttranslational Modification	[1550]
GPRC5B	OTF3S5E3	Strong	Genetic Variation	[1446]
GPX4	OTRAFFX2	Strong	Genetic Variation	[703]
GRAMD4	OT1HXEPM	Strong	Biomarker	[1551]
GRAP2	OTS5NIZ3	Strong	Biomarker	[458]
GREM2	OTE91EWT	Strong	Genetic Variation	[1552]
GRHL3	OT1V4ZEH	Strong	Altered Expression	[1553]
GRIN3A	OTQS9GYY	Strong	Biomarker	[1554]
GRIP1	OT958HK1	Strong	Altered Expression	[1555]
GSAP	OT33HG7E	Strong	Biomarker	[1556]
GSKIP	OTEYSV5M	Strong	Biomarker	[1557]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[793]
GSTT2B	OTCMRDLE	Strong	Genetic Variation	[1558]
GTDC1	OT8OBXKK	Strong	Biomarker	[1559]
GULP1	OT1WMVDH	Strong	Biomarker	[1560]
GYPC	OTOEDR7O	Strong	Biomarker	[1561]
H2BC12	OTQ8V0KG	Strong	Biomarker	[468]
H4C1	OTB71W46	Strong	Biomarker	[603]
HAP1	OT6SG0JQ	Strong	Genetic Variation	[1562]
HARS1	OTHOEOTS	Strong	Genetic Variation	[1563]
HAS1	OTJIAG1W	Strong	Altered Expression	[1564]
HAS3	OTPM8IL8	Strong	Altered Expression	[1564]
HBG2	OT4J48JJ	Strong	Genetic Variation	[1565]
HCLS1	OTX7WGYN	Strong	Altered Expression	[770]
HCN3	OTMO1ZYQ	Strong	Altered Expression	[1566]
HDLBP	OTKDEEYX	Strong	Genetic Variation	[1296]
HEBP1	OTR9MPDX	Strong	Genetic Variation	[1296]
HECTD2	OTDIBGQV	Strong	Biomarker	[1567]
HECW1	OT1PVAZA	Strong	Genetic Variation	[515]
HECW2	OTP2IN12	Strong	Biomarker	[1285]
HERC2	OTNQYKOB	Strong	Genetic Variation	[561]
HEY2	OTU4J3ZI	Strong	Altered Expression	[1568]
HGS	OTCYYCAC	Strong	Genetic Variation	[1563]
HHEX	OTLIUVYX	Strong	Biomarker	[1569]
HHIP	OT77RQYS	Strong	Biomarker	[958]
HIP1	OT7AKCFQ	Strong	Biomarker	[1285]
HLA-DRA	OT7KZMP2	Strong	Altered Expression	[1570]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[1571]
HNRNPC	OT47AK4C	Strong	Altered Expression	[1572]
HNRNPDL	OTB3BFCV	Strong	Altered Expression	[1572]
HNRNPK	OTNPRM8U	Strong	Biomarker	[1573]
HOMER1	OTWFD3SI	Strong	Biomarker	[1574]
HOMER2	OT4JGKJF	Strong	Genetic Variation	[1083]
HOOK1	OTTTKV7V	Strong	Altered Expression	[1575]
HOOK2	OTPO4NQV	Strong	Biomarker	[1575]
HOOK3	OT0OE8SX	Strong	Biomarker	[1575]
HP1BP3	OTTJ5LX2	Strong	Biomarker	[1576]
HPCA	OTERUPP6	Strong	Altered Expression	[1577]
HPS1	OTKS5I7T	Strong	Genetic Variation	[1578]
HPSE2	OTGEPP8V	Strong	Altered Expression	[1579]
HS3ST1	OT5DVN9P	Strong	Altered Expression	[1580]
HSD17B6	OTSB55D2	Strong	Biomarker	[1071]
HSPA14	OTZCA5LK	Strong	Biomarker	[748]
HSPA2	OTSDET7B	Strong	Biomarker	[1581]
HSPA4	OT5HR0AR	Strong	Biomarker	[1582]
HSPB2	OTS01646	Strong	Biomarker	[746]
HSPB6	OTFPLGZI	Strong	Altered Expression	[1583]
HSPH1	OTVRR73T	Strong	Altered Expression	[1584]
HTRA2	OTC7616F	Strong	Biomarker	[1585]
HYI	OTFPNOTN	Strong	Genetic Variation	[561]
HYLS1	OT3SW5UC	Strong	Biomarker	[1586]
HYOU1	OTBGBSOV	Strong	Altered Expression	[1587]
IARS1	OT9WXH5N	Strong	Biomarker	[1588]
IFIT3	OTPGHZB9	Strong	Altered Expression	[1272]
IFITM3	OT2QP8D3	Strong	Biomarker	[1589]
IFT43	OTKWYQ5C	Strong	Altered Expression	[1590]
IGSF23	OTORIW79	Strong	Genetic Variation	[378]
IL27RA	OTSQBAKI	Strong	Biomarker	[1591]
IL6ST	OT1N9C70	Strong	Biomarker	[1592]
IL9R	OTILCLXA	Strong	Altered Expression	[1593]
IMMT	OTBDSLE7	Strong	Biomarker	[1594]
INAVA	OTGXNB86	Strong	Biomarker	[639]
ING1	OTEZBRKW	Strong	Biomarker	[508]
INPP5K	OTQFLQKA	Strong	Altered Expression	[1595]
INPPL1	OTCDAVBQ	Strong	Biomarker	[1268]
INS-IGF2	OTZR74BO	Strong	Biomarker	[1596]
INSIG1	OTZF5X1D	Strong	Genetic Variation	[561]
INSRR	OT3F75WA	Strong	Biomarker	[1597]
IPO9	OT1DGLQE	Strong	Biomarker	[1598]
IQCJ	OTOC5U9H	Strong	Biomarker	[1599]
IREB2	OT747D24	Strong	Genetic Variation	[1600]
IRF2	OTAZRUW3	Strong	Genetic Variation	[433]
IRF6	OTKJ44EV	Strong	Biomarker	[1601]
IRF7	OTC1A2PQ	Strong	Genetic Variation	[1602]
IRS4	OTTOL40K	Strong	Genetic Variation	[1603]
ITGAX	OTOGIMHE	Strong	Biomarker	[1604]
ITGBL1	OTJDHE17	Strong	Biomarker	[403]
ITIH4	OT460OO1	Strong	Biomarker	[1605]
ITPKB	OTSVVPAV	Strong	Altered Expression	[1606]
ITSN1	OT8YF3S5	Strong	Biomarker	[1607]
ITSN2	OT8S0OO8	Strong	Genetic Variation	[561]
JAM2	OTHVJJRJ	Strong	Genetic Variation	[1083]
KALRN	OT8WRCBH	Strong	Biomarker	[1608]
KAT8	OT5LPQTR	Strong	Genetic Variation	[378]
KAZN	OTPM7BYM	Strong	Genetic Variation	[433]
KCNE3	OTKWKR91	Strong	Biomarker	[1609]
KCNH4	OTHJ8WTU	Strong	Biomarker	[1483]
KCNH8	OT3I5FLB	Strong	Biomarker	[1483]
KCNIP3	OTCQPEM4	Strong	Biomarker	[1610]
KCNJ13	OTG1CNND	Strong	Biomarker	[1611]
KCNMB2	OTBXUQGK	Strong	Genetic Variation	[435]
KCTD2	OT8TGV8R	Strong	Genetic Variation	[1290]
KHDRBS2	OTEKL45T	Strong	Genetic Variation	[1612]
KHSRP	OTDHZARB	Strong	Altered Expression	[770]
KIAA0319	OTN42Y77	Strong	Altered Expression	[1613]
KIAA1217	OTRMK3PU	Strong	Biomarker	[1614]
KIDINS220	OTLBH2MA	Strong	Biomarker	[1615]
KIF17	OTHASX9G	Strong	Biomarker	[1616]
KIF1B	OTI1XQTO	Strong	Altered Expression	[1617]
KIF21B	OTFXFIU3	Strong	Altered Expression	[1617]
KIF6	OTDH3MR4	Strong	Genetic Variation	[1618]
KLC1	OTSTTTW7	Strong	Altered Expression	[1619]
KLF2	OTIP1UFX	Strong	Biomarker	[1620]
KLF8	OTUC5CDB	Strong	Altered Expression	[1621]
KLHDC8B	OTKP6LCR	Strong	Biomarker	[1158]
KLHL20	OTC0SFS9	Strong	Biomarker	[1622]
KLK10	OTD573EL	Strong	Altered Expression	[390]
KPRP	OTRJF3OY	Strong	Altered Expression	[1623]
KRBOX1	OT4463UB	Strong	Genetic Variation	[1129]
KRIT1	OT58AP1I	Strong	Biomarker	[1332]
KRT14	OTUVZ1DW	Strong	Biomarker	[1624]
KRT18	OTVLQFIP	Strong	Biomarker	[1625]
L3MBTL2	OTKX1XIX	Strong	Altered Expression	[879]
L3MBTL4	OTERBGKR	Strong	Genetic Variation	[561]
LAMA1	OTQZMP86	Strong	Genetic Variation	[561]
LAMC1	OTIG527N	Strong	Altered Expression	[1626]
LAMC3	OTKNAYJO	Strong	Genetic Variation	[995]
LARS1	OT4557NF	Strong	Genetic Variation	[561]
LAYN	OT9A9Q1X	Strong	Biomarker	[1433]
LBH	OT87AT1X	Strong	Biomarker	[1627]
LBR	OT1HG3HG	Strong	Biomarker	[1628]
LCMT1	OTRJQ16X	Strong	Genetic Variation	[928]
LGALS4	OTKQCG0H	Strong	Altered Expression	[792]
LGALS9	OT7MF91K	Strong	Genetic Variation	[1490]
LHX2	OTK61NP8	Strong	Biomarker	[1629]
LIG1	OTEEQS43	Strong	Genetic Variation	[1630]
LIG3	OT48SKET	Strong	Altered Expression	[1631]
LIMS1	OT729S0T	Strong	Biomarker	[1632]
LIN28B	OTVWP0FN	Strong	Biomarker	[759]
LMF2	OT0XBGEM	Strong	Biomarker	[1633]
LMNB1	OT100T3P	Strong	Biomarker	[693]
LMO4	OT5NDCT9	Strong	Altered Expression	[1634]
LMTK2	OT93MVIC	Strong	Biomarker	[1635]
LRAT	OTB7CJKY	Strong	Genetic Variation	[1209]
LRIG3	OT6TKZTU	Strong	Biomarker	[1636]
LRP10	OT8490HT	Strong	Biomarker	[1637]
LRP1B	OT4YZG2N	Strong	Biomarker	[1638]
LRPPRC	OTXSK5LP	Strong	Biomarker	[1592]
LRRC15	OTX7JL8H	Strong	Biomarker	[1639]
LRRC4	OT7XJ70N	Strong	Altered Expression	[1317]
LRRTM3	OTCS7EM6	Strong	Biomarker	[1640]
LRSAM1	OTOKWR6C	Strong	Biomarker	[1641]
LSM2	OTHL77NY	Strong	Biomarker	[1642]
LSR	OTR8Y32X	Strong	Biomarker	[1643]
LTBP2	OTS88GSD	Strong	Genetic Variation	[1209]
LUZP2	OTGGOSPW	Strong	Genetic Variation	[1644]
LYNX1	OTK4103B	Strong	Biomarker	[1645]
LYZL4	OTO605LY	Strong	Altered Expression	[823]
MACF1	OTVIHD77	Strong	Biomarker	[1646]
MADD	OTUFYVGG	Strong	Genetic Variation	[816]
MAFF	OT9B7MX0	Strong	Biomarker	[1647]
MAGEC3	OT0KDWZN	Strong	Biomarker	[718]
MAGEE1	OTOQQO2X	Strong	Biomarker	[718]
MAGT1	OTQSAV5C	Strong	Genetic Variation	[464]
MAK16	OTD546E5	Strong	Biomarker	[763]
MAP1B	OTVXW089	Strong	Altered Expression	[1648]
MAP1LC3A	OTPMGIU4	Strong	Biomarker	[1649]
MAP1LC3B	OTUYHB84	Strong	Altered Expression	[1650]
MAP2	OT6UYT3X	Strong	Altered Expression	[762]
MAP2K3	OTI2OREX	Strong	Biomarker	[1651]
MAP2K4	OTZPZX11	Strong	Biomarker	[835]
MAP3K12	OT5HODDD	Strong	Biomarker	[1652]
MAPK8IP3	OT0X8ACY	Strong	Biomarker	[1653]
MASP1	OTWWCNZP	Strong	Biomarker	[1654]
MCCC1	OTLOHEQE	Strong	Genetic Variation	[1221]
MCF2L	OTEURA8N	Strong	Biomarker	[392]
MCM2	OTGGORIQ	Strong	Biomarker	[1655]
MCU	OTQZAYWQ	Strong	Biomarker	[1656]
MDH1	OTJEO4E8	Strong	Altered Expression	[422]
MDH2	OT7364GY	Strong	Altered Expression	[422]
MED12	OTQZ4D2X	Strong	Biomarker	[1657]
MED12L	OTT0HR5M	Strong	Genetic Variation	[1410]
MED23	OTKZQT0R	Strong	Genetic Variation	[758]
MEF2A	OTV2SF6E	Strong	Altered Expression	[1658]
MEF2C	OTZGF1Y5	Strong	Biomarker	[1659]
MEF2D	OT7CEIG0	Strong	Altered Expression	[1660]
MFAP1	OTZN4FT3	Strong	Biomarker	[1126]
MFF	OTEVIXOM	Strong	Biomarker	[1208]
MFSD2A	OTVG1VG0	Strong	Altered Expression	[1661]
MGAT3	OTXI5X4T	Strong	Biomarker	[1662]
MICAL2	OT04OQQJ	Strong	Genetic Variation	[561]
MICB	OTS2DVDW	Strong	Biomarker	[1433]
MID1	OTWN1PGU	Strong	Biomarker	[1663]
MILR1	OT0O30C7	Strong	Biomarker	[1664]
MINDY4	OTBZ2SZB	Strong	Biomarker	[1665]
MLKL	OTDSLC81	Strong	Biomarker	[1666]
MLLT3	OTXH4DDG	Strong	Genetic Variation	[1667]
MMP24	OTF8T3JM	Strong	Genetic Variation	[1668]
MMUT	OTBBBV70	Strong	Biomarker	[1310]
MNAT1	OTXLOYCB	Strong	Biomarker	[467]
MOAP1	OTVF3LUG	Strong	Biomarker	[1654]
MOGAT3	OTPGLUBS	Strong	Altered Expression	[1669]
MOV10	OT0KAY9G	Strong	Biomarker	[1670]
MPG	OTAHW80B	Strong	Altered Expression	[1631]
MPHOSPH6	OT6E2S48	Strong	Biomarker	[1671]
MPI	OTBH6ZK1	Strong	Biomarker	[1155]
MPST	OTCDPH5D	Strong	Biomarker	[828]
MPZ	OTAR2YXH	Strong	Biomarker	[1672]
MPZL1	OTJSUUHR	Strong	Genetic Variation	[1294]
MRE11	OTGU8TZM	Strong	Biomarker	[1673]
MS4A2	OTMCAS2D	Strong	Biomarker	[1674]
MS4A3	OT0CEJOO	Strong	Biomarker	[1675]
MSC	OTBRPZL5	Strong	Biomarker	[1676]
MSRB3	OT4UZXMN	Strong	Biomarker	[1677]
MSTO1	OT37XCNP	Strong	Biomarker	[828]
MT3	OTVCZ7HI	Strong	Biomarker	[1678]
MTCH2	OTV3E4GU	Strong	Biomarker	[1679]
MTERF4	OT50CTOJ	Strong	Biomarker	[1680]
MTHFD1	OTMKHVWC	Strong	Genetic Variation	[1681]
MTUS1	OTBPALMU	Strong	Altered Expression	[433]
MX1	OT6X8G5T	Strong	Genetic Variation	[1682]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[408]
MYH6	OT3YNCH1	Strong	Biomarker	[1683]
MYH9	OT94Z706	Strong	Altered Expression	[1684]
MYLIP	OTL0PFGV	Strong	Biomarker	[1685]
MYO16	OTMS3D8W	Strong	Genetic Variation	[1686]
MYO6	OTJQYRC7	Strong	Biomarker	[1683]
MYOCD	OTSJNHTH	Strong	Altered Expression	[1687]
MZB1	OT071TET	Strong	Altered Expression	[1688]
MZF1	OTMVZCPW	Strong	Genetic Variation	[1689]
NAA25	OTS3QVF1	Strong	Altered Expression	[1223]
NACA	OTLP1KR3	Strong	Biomarker	[1690]
NAE1	OTMC6F3Y	Strong	Genetic Variation	[1691]
NANOG	OTUEY1FM	Strong	Genetic Variation	[408]
NANOS3	OTGX9IQU	Strong	Altered Expression	[1692]
NANS	OTMQ2FUH	Strong	Biomarker	[1693]
NAP1L1	OTI7WBZV	Strong	Altered Expression	[1223]
NAPSA	OT6F8IAL	Strong	Altered Expression	[1223]
NARS2	OTL5X535	Strong	Altered Expression	[1694]
NAV2	OTGAOL01	Strong	Genetic Variation	[1695]
NAV3	OT97M1TR	Strong	Altered Expression	[1696]
NBEAL1	OTLJ11N3	Strong	Biomarker	[1697]
NBEAL2	OTMCAXWR	Strong	Biomarker	[1698]
NCALD	OTJZ8UEL	Strong	Altered Expression	[1699]
NCAM2	OT8LBJN8	Strong	Biomarker	[1700]
NCAPD2	OT8VGE2O	Strong	Biomarker	[1701]
NCAPH2	OTSASNX6	Strong	Biomarker	[1633]
NCKAP1	OTEZQXXJ	Strong	Altered Expression	[1223]
NCOA6	OTOMIGTV	Strong	Genetic Variation	[1702]
NCS1	OT6JHAWM	Strong	Genetic Variation	[515]
ND1	OTCLGIXV	Strong	Genetic Variation	[1703]
ND2	OTG9OHOX	Strong	Genetic Variation	[1704]
ND4	OT4RQVAA	Strong	Altered Expression	[1705]
NDE1	OT2N8Q17	Strong	Biomarker	[1706]
NDFIP1	OTIORSWF	Strong	Biomarker	[1707]
NDP	OTGDJ4US	Strong	Altered Expression	[1708]
NDRG2	OT5L6KD7	Strong	Biomarker	[942]
NDUFA12	OTCD6I5M	Strong	Genetic Variation	[1709]
NDUFA5	OTR848KZ	Strong	Biomarker	[1519]
NDUFA6	OTEOIIOL	Strong	Biomarker	[1710]
NDUFA9	OTMKQJJ8	Strong	Biomarker	[1711]
NDUFAF6	OTRJMIGT	Strong	Genetic Variation	[1252]
NDUFB8	OTW4A4Q0	Strong	Altered Expression	[1712]
NECAB3	OTRASC9G	Strong	Altered Expression	[1713]
NEFH	OTMSCW5I	Strong	Posttranslational Modification	[1714]
NEFM	OT8VCBNF	Strong	Biomarker	[1715]
NETO1	OTXP9A63	Strong	Genetic Variation	[1285]
NEU1	OTH9BY8Y	Strong	Biomarker	[1716]
NEUROD1	OTZQ7QJ2	Strong	Altered Expression	[867]
NEUROD6	OTLFL6K8	Strong	Genetic Variation	[1717]
NEUROG2	OTAEMIGT	Strong	Biomarker	[1718]
NFASC	OTBDUXZT	Strong	Biomarker	[1373]
NFATC2	OTK5T6HZ	Strong	Biomarker	[1719]
NFATC3	OTYOORME	Strong	Altered Expression	[1720]
NFATC4	OTTDCUAO	Strong	Biomarker	[1721]
NFE2L1	OT1QHOS2	Strong	Biomarker	[1722]
NGB	OTW0SIUY	Strong	Altered Expression	[1723]
NHLRC2	OTY4HPWB	Strong	Biomarker	[1724]
NINJ2	OTUG1AOV	Strong	Genetic Variation	[1725]
NIT2	OTC1RAH3	Strong	Genetic Variation	[1410]
NKAIN2	OTI4H30Z	Strong	Genetic Variation	[515]
NLGN1	OTGHRRFQ	Strong	Posttranslational Modification	[1726]
NLN	OTFRITPU	Strong	Biomarker	[1300]
NLRC4	OTAIA3NA	Strong	Biomarker	[523]
NME2	OTCYGLHV	Strong	Altered Expression	[1727]
NME8	OT4RULP5	Strong	Genetic Variation	[1571]
NOC2L	OTNT7R33	Strong	Biomarker	[1728]
NOC3L	OTYOR3PV	Strong	Biomarker	[1729]
NOCT	OTVSYP2D	Strong	Biomarker	[543]
NOG	OTGRHHPG	Strong	Biomarker	[1730]
NOL3	OT1K0L0D	Strong	Biomarker	[1731]
NOLC1	OTKDZU0D	Strong	Biomarker	[1732]
NOP53	OTA2YKO6	Strong	Altered Expression	[1272]
NPC1	OTRIPICX	Strong	Altered Expression	[1020]
NPC2	OTE9UEJC	Strong	Biomarker	[1733]
NPHP1	OTZHCFFQ	Strong	Genetic Variation	[1552]
NPL	OTA7P0TO	Strong	Genetic Variation	[1734]
NPM3	OTIAM1A3	Strong	Altered Expression	[1480]
NPPA	OTMQNTNX	Strong	Biomarker	[1735]
NPS	OTEG25A2	Strong	Biomarker	[1736]
NPTN	OTAQKSAU	Strong	Biomarker	[1350]
NPTX1	OTKVHCV0	Strong	Biomarker	[1737]
NR2C2	OTDZWVOJ	Strong	Altered Expression	[1738]
NR2F6	OTNVO2B6	Strong	Biomarker	[1739]
NRBF2	OTXSUYCD	Strong	Biomarker	[1740]
NRCAM	OT80HHQ2	Strong	Altered Expression	[1741]
NRDC	OTWBBCXO	Strong	Biomarker	[1229]
NRF1	OTOXWNV8	Strong	Biomarker	[1742]
NRG3	OTIFZ5CT	Strong	Genetic Variation	[1743]
NRIP1	OTIZOJQV	Strong	Altered Expression	[1744]
NRXN1	OTJN1JQA	Strong	Biomarker	[1373]
NRXN3	OTJ0I7HJ	Strong	Biomarker	[1745]
NT5C3A	OT67KZJA	Strong	Genetic Variation	[1746]
NTN4	OTDRRMP3	Strong	Genetic Variation	[995]
NTS	OTPGDNQS	Strong	Altered Expression	[1747]
NUBP1	OTE8RAKZ	Strong	Biomarker	[577]
NUBPL	OTQMCSXT	Strong	Biomarker	[1748]
NUCKS1	OTL4VJC5	Strong	Genetic Variation	[1221]
NUDT1	OTZSES3W	Strong	Altered Expression	[1749]
NUDT11	OTFDXJA1	Strong	Genetic Variation	[1750]
NUFIP2	OTZBZ224	Strong	Biomarker	[1572]
NUMB	OTMB586Q	Strong	Biomarker	[1751]
NUP153	OTCAS0AR	Strong	Altered Expression	[1752]
NUP160	OTUKVV3I	Strong	Altered Expression	[1753]
NUP98	OTNT12G2	Strong	Altered Expression	[1230]
NXF1	OTEFHXG6	Strong	Genetic Variation	[1754]
OAS3	OT6E5FYS	Strong	Biomarker	[868]
OCA2	OTDWIGBF	Strong	Genetic Variation	[1755]
OCIAD2	OTSWB4SZ	Strong	Altered Expression	[1756]
OCLN	OTSUTVWL	Strong	Biomarker	[1757]
OCM	OTQRML29	Strong	Biomarker	[1758]
ODF1	OTTSURLA	Strong	Biomarker	[1759]
OGA	OT7ZBWT1	Strong	Biomarker	[1760]
OGT	OT1Z1ZXE	Strong	Biomarker	[1761]
OLFM1	OTOYPEWW	Strong	Biomarker	[1762]
OMA1	OT0JRVY7	Strong	Biomarker	[1763]
OMP	OT7JH0DY	Strong	Altered Expression	[1764]
OPN1LW	OTFNUZ7O	Strong	Biomarker	[1765]
OPN1MW	OTPJ7LX4	Strong	Biomarker	[1766]
OPN4	OT1LZ7TS	Strong	Biomarker	[1767]
OPTN	OT2UXWH9	Strong	Biomarker	[372]
OR2AG1	OTEITRP4	Strong	Genetic Variation	[1768]
OR8J1	OTWWGQW0	Strong	Altered Expression	[1769]
ORM1	OTZKSBRE	Strong	Biomarker	[1770]
ORM2	OTRJGZP8	Strong	Biomarker	[1771]
OSBPL6	OT0NCUUA	Strong	Genetic Variation	[561]
OSTN	OTL4A57N	Strong	Genetic Variation	[1539]
OTOF	OTXQMJY8	Strong	Genetic Variation	[561]
OTUB1	OT8WWM9O	Strong	Biomarker	[1772]
OXA1L	OTS0BFRD	Strong	Genetic Variation	[1773]
OXT	OT48M72Z	Strong	Altered Expression	[1774]
P2RX2	OT0LF34A	Strong	Genetic Variation	[886]
P2RX5	OTLBR20R	Strong	Genetic Variation	[886]
P2RX6	OT1FNTXA	Strong	Genetic Variation	[886]
P4HB	OTTYNYPF	Strong	Biomarker	[1775]
PABPC4	OTICKKBQ	Strong	Biomarker	[1162]
PABPN1	OT3MC5SE	Strong	Biomarker	[1776]
PADI1	OT13WAQX	Strong	Biomarker	[1777]
PADI2	OTT40K94	Strong	Biomarker	[1778]
PAFAH1B2	OTRDWN2V	Strong	Genetic Variation	[732]
PAG1	OTFOJUIQ	Strong	Biomarker	[1765]
PAGR1	OTXR5PQ8	Strong	Biomarker	[683]
PAK3	OT80M3BV	Strong	Altered Expression	[1779]
PALM2AKAP2	OTI618VF	Strong	Genetic Variation	[1780]
PANK2	OTFBW889	Strong	Biomarker	[987]
PARD3	OTH5BPLO	Strong	Biomarker	[660]
PARN	OTTG4PE3	Strong	Altered Expression	[1781]
PARVB	OT9OGVWX	Strong	Genetic Variation	[515]
PAXIP1	OTRHTKG3	Strong	Genetic Variation	[1782]
PC	OT6O0V51	Strong	Biomarker	[1783]
PCBP4	OTDLL4NB	Strong	Biomarker	[1765]
PCLAF	OTMVIOUU	Strong	Biomarker	[1784]
PCP4	OTM1XXYX	Strong	Biomarker	[1785]
PCSK1N	OT7ZRW2F	Strong	Biomarker	[1786]
PDC	OT1UUVYY	Strong	Biomarker	[1787]
PDCD4	OTZ6NXUX	Strong	Biomarker	[1788]
PDCL3	OTD3WGV1	Strong	Biomarker	[561]
PDE8B	OT4217NK	Strong	Biomarker	[1789]
PDIA2	OTC2WMXS	Strong	Biomarker	[1777]
PDIA6	OT8YBR17	Strong	Altered Expression	[1790]
PDP1	OT82RTMT	Strong	Biomarker	[1791]
PDSS2	OTEOQBMX	Strong	Biomarker	[1792]
PDYN	OTEJ6430	Strong	Biomarker	[1793]
PDZD2	OTPPVRGY	Strong	Genetic Variation	[1794]
PELI1	OTMLBCLC	Strong	Biomarker	[1795]
PENK	OT8P3HMP	Strong	Altered Expression	[1796]
PER2	OTU2B1DJ	Strong	Genetic Variation	[1154]
PFDN5	OTTKPTUP	Strong	Altered Expression	[1797]
PGP	OT6QQ7OR	Strong	Biomarker	[1798]
PHB2	OTCAX3AW	Strong	Altered Expression	[904]
PHF13	OT89FV4A	Strong	Biomarker	[1799]
PHF14	OTZT3GV1	Strong	Genetic Variation	[561]
PHF6	OT8DXI40	Strong	Biomarker	[1800]
PICK1	OT8QE6EU	Strong	Biomarker	[1801]
PIEZO1	OTBG1FU4	Strong	Altered Expression	[1802]
PIK3C3	OTLUM9L7	Strong	Biomarker	[1649]
PIK3R2	OTZSUQK5	Strong	Biomarker	[1417]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[448]
PILRA	OTBE0PLF	Strong	Genetic Variation	[378]
PIN4	OT403QC1	Strong	Biomarker	[1803]
PINK1	OT50NR57	Strong	Biomarker	[1804]
PITX2	OTWMXAOY	Strong	Biomarker	[1805]
PIWIL1	OT7CRGZ3	Strong	Genetic Variation	[1616]
PIWIL4	OTDA9MY0	Strong	Genetic Variation	[1616]
PKP4	OTQHOF8L	Strong	Biomarker	[1806]
PLA2G15	OT6VJTPA	Strong	Biomarker	[1122]
PLA2G3	OT3K7TMY	Strong	Biomarker	[1807]
PLAAT1	OTM3M6P4	Strong	Genetic Variation	[1808]
PLAG1	OTT9AJQY	Strong	Biomarker	[872]
PLCG2	OTGVC9MY	Strong	Genetic Variation	[1809]
PLCL1	OTJL2C79	Strong	Genetic Variation	[1810]
PLD4	OT5I74II	Strong	Biomarker	[1811]
PLEK	OTB73XXA	Strong	Biomarker	[1266]
PLEKHG5	OTL0S21W	Strong	Genetic Variation	[1812]
PLEKHM2	OT4ZYV73	Strong	Altered Expression	[1595]
PLIN2	OTRXJ9UN	Strong	Genetic Variation	[799]
PLP1	OT8CM9CX	Strong	Biomarker	[1813]
PLPP4	OTH5EXZC	Strong	Genetic Variation	[515]
PLXNA2	OTNNBJMQ	Strong	Biomarker	[1814]
PLXNA3	OTMZIBVG	Strong	Biomarker	[1815]
PLXNA4	OT5XKB3Q	Strong	Biomarker	[1816]
PLXNB1	OTCA7JIT	Strong	Biomarker	[1817]
PM20D1	OTXXNQ5K	Strong	Biomarker	[597]
PNO1	OT010GIS	Strong	Biomarker	[763]
PNPLA2	OTR3ERMR	Strong	Biomarker	[981]
PNPLA7	OT5VSJX2	Strong	Genetic Variation	[561]
POLD1	OTWO4UCJ	Strong	Biomarker	[1818]
POLDIP2	OT8SZSJ6	Strong	Biomarker	[458]
POLE3	OTOELRF6	Strong	Biomarker	[1494]
POTEM	OT7L2HGH	Strong	Biomarker	[361]
POU2F1	OTK7ELJ0	Strong	Biomarker	[1819]
POU2F3	OTIOOJWD	Strong	Biomarker	[1820]
POU3F4	OTKF5AF7	Strong	Altered Expression	[1821]
POU5F1	OTDHHN7O	Strong	Genetic Variation	[408]
PPARGC1A	OTHCDQ22	Strong	Biomarker	[1822]
PPFIA1	OTYYFA9C	Strong	Biomarker	[1823]
PPIC	OTY5Q42N	Strong	Biomarker	[1803]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[1824]
PPIL1	OTS5S837	Strong	Biomarker	[1505]
PPL	OTTM4WDO	Strong	Biomarker	[1825]
PPP1CB	OTYFTYFR	Strong	Altered Expression	[1826]
PPP1R15A	OTYG179K	Strong	Biomarker	[1790]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[1827]
PPP1R1B	OTSIJMQ9	Strong	Biomarker	[1828]
PPP1R37	OTQQ3E4X	Strong	Genetic Variation	[494]
PPP1R3B	OTVCRXEZ	Strong	Genetic Variation	[1342]
PPP1R42	OTN1HRBN	Strong	Genetic Variation	[561]
PPP1R9B	OTDCTHTT	Strong	Biomarker	[1829]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[1830]
PPP2R2B	OTSFVC82	Strong	Genetic Variation	[1831]
PPP2R5E	OT8GPFT5	Strong	Altered Expression	[1832]
PPP3R1	OTGQNFJQ	Strong	Biomarker	[1833]
PPP4R3A	OTXTCULM	Strong	Biomarker	[1834]
PQBP1	OTXCBEAH	Strong	Biomarker	[1835]
PRB1	OTV0SYMD	Strong	Genetic Variation	[1836]
PRDM6	OTKY12D9	Strong	Biomarker	[1795]
PRDX1	OTZ3BEC4	Strong	Biomarker	[1837]
PRDX3	OTLB2WEU	Strong	Altered Expression	[1838]
PRG2	OT0BCPQG	Strong	Biomarker	[1839]
PRIMA1	OT9ITT3P	Strong	Biomarker	[1840]
PRKAA1	OT7TNF0L	Strong	Biomarker	[1841]
PRKAA2	OTU1KZPV	Strong	Biomarker	[1841]
PRKAB1	OT1OG4QZ	Strong	Biomarker	[1841]
PRKACB	OT6RMDCE	Strong	Genetic Variation	[968]
PRKAR1B	OT777OHS	Strong	Genetic Variation	[1842]
PRKN	OTJBN41W	Strong	Biomarker	[1843]
PRKRA	OTUTVZZU	Strong	Biomarker	[1844]
PRLH	OTJBP360	Strong	Posttranslational Modification	[1845]
PRM3	OT6574BF	Strong	Genetic Variation	[1846]
PRND	OTH4EEMI	Strong	Genetic Variation	[1847]
PROK2	OT70IFEZ	Strong	Biomarker	[1848]
PROM2	OTT8IVS7	Strong	Posttranslational Modification	[1849]
PROS1	OTXQWNOI	Strong	Biomarker	[1850]
PRPF19	OTQ1STV3	Strong	Biomarker	[1851]
PRPF6	OT3U0ABN	Strong	Biomarker	[1000]
PRRC2C	OTBX3MXM	Strong	Genetic Variation	[515]
PRRX1	OTTZK5G8	Strong	Biomarker	[1852]
PRRX2	OT8UR4AU	Strong	Biomarker	[1853]
PRSS21	OT8ZYC7G	Strong	Genetic Variation	[1854]
PRSS3	OTN3S5YB	Strong	Biomarker	[1855]
PRX	OT34Z10B	Strong	Biomarker	[1856]
PSD	OTUZIXUZ	Strong	Biomarker	[1857]
PSMB2	OTX0UG5W	Strong	Biomarker	[1858]
PSMD2	OT6HZHN7	Strong	Altered Expression	[1370]
PSMD3	OT585WY8	Strong	Biomarker	[1858]
PSMD7	OT7PZZ4K	Strong	Biomarker	[803]
PTBP2	OTF4S7NE	Strong	Biomarker	[1859]
PTCD1	OT7U0C5Y	Strong	Genetic Variation	[1860]
PTCD2	OTXQ59IZ	Strong	Biomarker	[1861]
PTCRA	OTQTO5QZ	Strong	Biomarker	[652]
PTDSS1	OTXLIBD7	Strong	Biomarker	[1360]
PTF1A	OT7SWA57	Strong	Biomarker	[1862]
PTGES3	OTPPQWI0	Strong	Biomarker	[1060]
PTPA	OTRGFOI7	Strong	Altered Expression	[1441]
PTPN4	OT6SXU5Y	Strong	Biomarker	[1863]
PTPN5	OT2H1KDK	Strong	Altered Expression	[1864]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[561]
PURA	OT975ELW	Strong	Biomarker	[1865]
PVALB	OTZW1WVQ	Strong	Biomarker	[1866]
PVR	OT3N91T7	Strong	Genetic Variation	[816]
PYCARD	OT67RON3	Strong	Biomarker	[1032]
QRFP	OTX5FZDJ	Strong	Biomarker	[1867]
QRFPR	OT31N14I	Strong	Biomarker	[1867]
QRICH1	OTPVAX04	Strong	Biomarker	[1551]
RAB10	OT8ZN26V	Strong	Biomarker	[1868]
RAB11A	OTC4FW0J	Strong	Biomarker	[1869]
RAB11B	OT6GI23M	Strong	Biomarker	[1869]
RAB21	OTH3WGLG	Strong	Biomarker	[1870]
RAB27A	OT9SQRWY	Strong	Altered Expression	[1871]
RAB27B	OTPF9D0K	Strong	Biomarker	[1872]
RAB29	OTDZT6LP	Strong	Genetic Variation	[1221]
RAB31	OTMLXQZ0	Strong	Biomarker	[1873]
RAB38	OTU0NZU0	Strong	Genetic Variation	[1316]
RAB3A	OT2GIUO5	Strong	Biomarker	[1874]
RAB3D	OTGKRR3C	Strong	Genetic Variation	[561]
RAB3GAP1	OT4DQ8F2	Strong	Biomarker	[1732]
RAB4A	OT7BL9WW	Strong	Biomarker	[1875]
RAB6A	OTLS86J5	Strong	Biomarker	[1876]
RAB7B	OT60A0E9	Strong	Biomarker	[802]
RABEP1	OTQROTGT	Strong	Biomarker	[1877]
RABEPK	OTCZSREH	Strong	Biomarker	[803]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[1878]
RAC2	OTAOHFNH	Strong	Biomarker	[1879]
RAD23B	OT0PGOG3	Strong	Biomarker	[1880]
RAD52	OT0OTDHI	Strong	Altered Expression	[1881]
RAMP2	OTGQXLH5	Strong	Biomarker	[1882]
RAN	OT2TER5M	Strong	Altered Expression	[1883]
RANBP9	OTM8COM5	Strong	Biomarker	[1598]
RAP1A	OT5RH6TI	Strong	Biomarker	[1878]
RAPGEF6	OTR1QQA3	Strong	Genetic Variation	[1224]
RARRES2	OT1BJE8K	Strong	Biomarker	[1884]
RASGRF1	OTNWJ7EN	Strong	Biomarker	[1192]
RBBP6	OTTVG4HU	Strong	Biomarker	[1844]
RBFOX1	OTFPKEL7	Strong	Biomarker	[1885]
RBL2	OTBQSOE6	Strong	Biomarker	[1732]
RBM3	OTAJ7R31	Strong	Biomarker	[1886]
RBM45	OTWTHD77	Strong	Genetic Variation	[1887]
RBM8A	OT5SR6G0	Strong	Altered Expression	[961]
RBMS3	OTFSC9MR	Strong	Biomarker	[763]
RCAN1	OT1MVXC7	Strong	Biomarker	[1888]
RCBTB1	OTAYELI8	Strong	Biomarker	[1546]
RCOR1	OTREADPC	Strong	Altered Expression	[1889]
REEP5	OTZU4TJI	Strong	Altered Expression	[944]
RELB	OTU3QYEF	Strong	Genetic Variation	[378]
REM1	OTUXL0HC	Strong	Genetic Variation	[1890]
RER1	OTTBAUBP	Strong	Biomarker	[1891]
RETN	OTW5Z1NH	Strong	Genetic Variation	[1892]
RFC1	OT3L5PK3	Strong	Genetic Variation	[1893]
RGCC	OTYJMLWM	Strong	Biomarker	[1894]
RGN	OTD04KB1	Strong	Altered Expression	[1895]
RHBDD1	OTL5J132	Strong	Biomarker	[1668]
RHBDL3	OTZ7Y93J	Strong	Biomarker	[1896]
RIN3	OT5Z6F8O	Strong	Genetic Variation	[1351]
RMDN1	OTE1NB6U	Strong	Biomarker	[1897]
RMDN2	OTK5WSFI	Strong	Biomarker	[1897]
RMDN3	OTKO7AUM	Strong	Biomarker	[1897]
RNASE1	OTKZ7CO9	Strong	Biomarker	[955]
RNF112	OT0Q9OUQ	Strong	Biomarker	[1898]
RNF146	OTE4CO7E	Strong	Altered Expression	[1899]
RNF19A	OTKWCV80	Strong	Biomarker	[458]
RNF213	OT4OVE9O	Strong	Biomarker	[468]
RNFT2	OTGIY43B	Strong	Genetic Variation	[961]
ROM1	OTE7H0YV	Strong	Biomarker	[1900]
ROPN1L	OTRWZJ68	Strong	Biomarker	[485]
RPA1	OT76POLP	Strong	Biomarker	[1631]
RPL13	OTFKNTD6	Strong	Biomarker	[1901]
RPL29	OTUFIBJL	Strong	Biomarker	[958]
RPS21	OT6P58W6	Strong	Biomarker	[1902]
RPS23	OTAJMUPF	Strong	Altered Expression	[1903]
RPS3A	OTUEP7CL	Strong	Genetic Variation	[1904]
RPS6	OTT4D1LN	Strong	Biomarker	[1905]
RRAS	OTBBF28C	Strong	Biomarker	[1060]
RREB1	OT62460U	Strong	Genetic Variation	[1906]
RSPO4	OTFX5N3G	Strong	Genetic Variation	[433]
RTL1	OTOT33IM	Strong	Biomarker	[1907]
RTN3	OTGZ51QF	Strong	Biomarker	[1304]
RYR2	OT0PF19E	Strong	Biomarker	[1908]
RYR3	OT4EHIP4	Strong	Genetic Variation	[1909]
S100A10	OTI71243	Strong	Genetic Variation	[1485]
SAA2	OTYAVJWG	Strong	Altered Expression	[1910]
SAMD4A	OT4MKCC8	Strong	Biomarker	[1911]
SAMD9	OTDG48P0	Strong	Genetic Variation	[1912]
SAP30L	OTI15CY4	Strong	Genetic Variation	[515]
SAR1B	OT0JZOMY	Strong	Genetic Variation	[1913]
SARDH	OTQ49Q27	Strong	Biomarker	[396]
SART3	OTC1AM7S	Strong	Biomarker	[868]
SBNO1	OTNX3RL0	Strong	Biomarker	[1914]
SBNO2	OT1C6J3K	Strong	Biomarker	[1914]
SBSN	OT89RKJH	Strong	Biomarker	[1915]
SCD5	OTSSUQ3Z	Strong	Biomarker	[1916]
SCG2	OTXWUQQL	Strong	Biomarker	[1373]
SCGN	OTGD7SKH	Strong	Biomarker	[1134]
SCIMP	OT9BF7RC	Strong	Genetic Variation	[1252]
SCP2	OTPAFCPQ	Strong	Altered Expression	[1415]
SDC3	OT1P0LJM	Strong	Altered Expression	[1917]
SDCBP2	OT1AT2OL	Strong	Altered Expression	[1918]
SDF4	OTQ7WFYW	Strong	Biomarker	[1366]
SDS	OT5WTJ2M	Strong	Genetic Variation	[1919]
SEL1L	OTC0FB7T	Strong	Genetic Variation	[1920]
SELENOM	OTJ7PORS	Strong	Genetic Variation	[1921]
SELENOP	OT02B8IR	Strong	Biomarker	[1922]
SELENOS	OTUEWIU9	Strong	Altered Expression	[1923]
SEMA5A	OTUOIOJV	Strong	Genetic Variation	[1924]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[1925]
SEPTIN1	OT4GVSU3	Strong	Biomarker	[1926]
SEPTIN2	OT3G33TM	Strong	Biomarker	[1926]
SEPTIN8	OTSZLI64	Strong	Altered Expression	[1927]
SERPINB1	OT5RDUFO	Strong	Genetic Variation	[1536]
SERPINB6	OT7G55IK	Strong	Biomarker	[1928]
SERPINE2	OTYF5340	Strong	Altered Expression	[1929]
SERPINF2	OTZGAF8B	Strong	Genetic Variation	[1930]
SERPINI1	OTUJHIJW	Strong	Biomarker	[1931]
SESN3	OTJRY1Y5	Strong	Biomarker	[1932]
SETMAR	OTE2MIMZ	Strong	Biomarker	[1907]
SETX	OTG3JNOQ	Strong	Genetic Variation	[1933]
SEZ6	OTCD8K5D	Strong	Biomarker	[1934]
SEZ6L2	OTUIKN2I	Strong	Biomarker	[1030]
SFPQ	OTLCIAPJ	Strong	Biomarker	[763]
SFTPA1	OT87XL1U	Strong	Biomarker	[1935]
SFTPC	OTIZJD09	Strong	Biomarker	[1936]
SGK3	OTQ6QO99	Strong	Genetic Variation	[561]
SGMS1	OTZQE7PW	Strong	Biomarker	[1937]
SGMS2	OT3NHO99	Strong	Altered Expression	[1937]
SH2B1	OTJZO2CI	Strong	Biomarker	[1938]
SH2D3C	OTAGXO0N	Strong	Biomarker	[1939]
SH2D4B	OTM0KLPH	Strong	Genetic Variation	[1224]
SH3GL2	OTOE443G	Strong	Biomarker	[1388]
SH3GLB1	OTAZ5OP8	Strong	Biomarker	[1208]
SH3PXD2A	OTYRQJIH	Strong	Genetic Variation	[1225]
SH3RF1	OT7MYGYO	Strong	Genetic Variation	[561]
SHANK1	OTK8PV0S	Strong	Biomarker	[1940]
SHANK2	OTSQTPFQ	Strong	Genetic Variation	[1941]
SHBG	OTPWU5IW	Strong	Genetic Variation	[1343]
SIDT2	OTU2L002	Strong	Altered Expression	[1942]
SIGLEC7	OTNDLURR	Strong	Altered Expression	[770]
SIM2	OT0QWHK4	Strong	Biomarker	[1943]
SIMC1	OT3GKXGI	Strong	Genetic Variation	[1478]
SIRPB1	OTGHALWJ	Strong	Biomarker	[762]
SIT1	OT7MDF09	Strong	Biomarker	[1944]
SKIL	OTNBXH32	Strong	Biomarker	[1914]
SLA2	OTNVE666	Strong	Genetic Variation	[1140]
SLBP	OTVYYQRT	Strong	Genetic Variation	[1296]
SLC16A4	OT1YXBKC	Strong	Biomarker	[993]
SLC25A48	OTAMLAGE	Strong	Genetic Variation	[433]
SLIT3	OTU8MKEU	Strong	Biomarker	[1012]
SLN	OTERIU75	Strong	Biomarker	[1945]
SLTM	OT0VRZA6	Strong	Biomarker	[964]
SMIM10L2B	OT04IG2N	Strong	Altered Expression	[1946]
SMIM20	OTZI1KFR	Strong	Altered Expression	[1947]
SMPD3	OTHQBETH	Strong	Biomarker	[1948]
SNAP91	OTE3EXWZ	Strong	Biomarker	[1327]
SNCAIP	OTH8VNOK	Strong	Altered Expression	[1949]
SND1	OTT734JN	Strong	Biomarker	[868]
SNRNP70	OTP52YZ3	Strong	Biomarker	[1950]
SNRPG	OTWX4XK1	Strong	Biomarker	[1911]
SNTG1	OT6GBQHI	Strong	Genetic Variation	[1280]
SNW1	OTKWG3PS	Strong	Altered Expression	[1595]
SNX12	OTARRSWB	Strong	Altered Expression	[1951]
SNX27	OTVPS7S0	Strong	Biomarker	[1952]
SNX3	OTXL5W8F	Strong	Genetic Variation	[1953]
SNX8	OTMG63Z6	Strong	Biomarker	[1954]
SNX9	OTLNQ0ZM	Strong	Genetic Variation	[561]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[351]
SOCS4	OTIRULFZ	Strong	Biomarker	[1383]
SOCS7	OT503VJG	Strong	Biomarker	[1383]
SOD3	OTIOZQAB	Strong	Biomarker	[1955]
SORBS2	OTJSX44Y	Strong	Biomarker	[1245]
SORBS3	OTVEUODC	Strong	Biomarker	[1956]
SORCS2	OTBF3DYK	Strong	Genetic Variation	[1957]
SORCS3	OT4VOMBC	Strong	Genetic Variation	[561]
SOS1	OTTCWXC3	Strong	Biomarker	[1192]
SOS2	OTV3XRE5	Strong	Biomarker	[1958]
SOX3	OT1CRCOB	Strong	Altered Expression	[1959]
SOX6	OTT0W0LE	Strong	Altered Expression	[1960]
SP6	OTRAB1PN	Strong	Genetic Variation	[515]
SPAG11A	OTNQ9UB0	Strong	Biomarker	[946]
SPAG9	OT45AHMB	Strong	Biomarker	[987]
SPARCL1	OT74DWMV	Strong	Altered Expression	[1961]
SPAST	OTIF3AJI	Strong	Genetic Variation	[1962]
SPC25	OTCAS0OH	Strong	Biomarker	[1839]
SPCS1	OTUHQ4UC	Strong	Altered Expression	[1963]
SPECC1	OTPEML48	Strong	Genetic Variation	[1964]
SPEN	OT37A2MD	Strong	Biomarker	[1382]
SPHKAP	OT5RHUYJ	Strong	Altered Expression	[1595]
SPNS2	OTPODAPU	Strong	Biomarker	[1965]
SPPL2A	OTCVF6MM	Strong	Biomarker	[1966]
SPPL2B	OTI1PHMP	Strong	Biomarker	[1967]
SPRED2	OTUX685J	Strong	Genetic Variation	[561]
SREK1	OT3F6ZCB	Strong	Altered Expression	[1968]
SREK1IP1	OTI29LKO	Strong	Altered Expression	[1968]
SRF	OTW18FQN	Strong	Altered Expression	[1687]
SRL	OT7IEBWZ	Strong	Biomarker	[396]
SRM	OT4N5MDP	Strong	Biomarker	[1969]
SRRM2	OTSIMMC9	Strong	Biomarker	[763]
SRSF1	OTF61HOV	Strong	Biomarker	[1970]
SRSF2	OTVDHO6U	Strong	Genetic Variation	[1971]
SRSF3	OTOFT707	Strong	Altered Expression	[1972]
SRSF5	OTC5WP98	Strong	Genetic Variation	[1563]
SRSF6	OTGLOSYE	Strong	Biomarker	[1973]
ST13	OTNML6UP	Strong	Biomarker	[958]
ST18	OTPRIMTA	Strong	Genetic Variation	[515]
ST3GAL4	OTNENJZQ	Strong	Biomarker	[1676]
ST6GAL1	OT7US3NO	Strong	Genetic Variation	[1974]
ST8SIA1	OTGND2YZ	Strong	Genetic Variation	[1975]
STAG3	OTEV0AOD	Strong	Genetic Variation	[378]
STAM2	OT9OBWPH	Strong	Genetic Variation	[1296]
STEAP1B	OTZJDFWK	Strong	Genetic Variation	[1976]
STIM1	OT8CLQ1W	Strong	Altered Expression	[1977]
STIM2	OTYNXAW0	Strong	Altered Expression	[1978]
STING1	OTDAP4G0	Strong	Biomarker	[1979]
STIP1	OT7TXLOX	Strong	Biomarker	[1980]
STMN2	OT0FUHLH	Strong	Biomarker	[1981]
STOX1	OTED3YVO	Strong	Altered Expression	[1982]
STRADA	OTG1Z6TY	Strong	Genetic Variation	[561]
STUB1	OTSUYI9A	Strong	Altered Expression	[1983]
STX1A	OTSBUZB4	Strong	Genetic Variation	[1016]
STX1B	OTSW59X0	Strong	Biomarker	[769]
STX8	OTFOJCHI	Strong	Biomarker	[1984]
STXBP1	OTRYA8C3	Strong	Biomarker	[1985]
SUCLG2	OT0KHLY2	Strong	Altered Expression	[1986]
SUGP1	OT7W0EB8	Strong	Altered Expression	[1572]
SUMO2	OT1Y5IKN	Strong	Genetic Variation	[1987]
SUOX	OTEJQ9FC	Strong	Altered Expression	[1222]
SURF1	OTAINRSS	Strong	Biomarker	[1399]
SV2B	OTAO5WIU	Strong	Biomarker	[1988]
SV2C	OTIH108W	Strong	Biomarker	[1988]
SYBU	OT3FQV7N	Strong	Biomarker	[1897]
SYCP2	OTBH622S	Strong	Altered Expression	[1415]
SYN1	OTMNPWC1	Strong	Biomarker	[1989]
SYN2	OTK0DEGH	Strong	Altered Expression	[1990]
SYNE1	OTSBSLUH	Strong	Altered Expression	[1991]
SYNGR1	OT0MBUK5	Strong	Biomarker	[1402]
SYNGR3	OTWXOOPZ	Strong	Biomarker	[1992]
SYNM	OTOI8TRJ	Strong	Biomarker	[1993]
SYNPO	OTICDJAB	Strong	Biomarker	[1994]
SYPL2	OT6CV0CA	Strong	Altered Expression	[1995]
SYT1	OTVTPOI6	Strong	Biomarker	[1005]
SZT2	OTB4FVP4	Strong	Genetic Variation	[561]
TAB3	OT1ECMDL	Strong	Altered Expression	[1223]
TANK	OTZSGFIK	Strong	Biomarker	[1996]
TAOK2	OTNUMOZ1	Strong	Biomarker	[1030]
TAP2	OTWSYFI7	Strong	Genetic Variation	[1477]
TAPBPL	OTTS1YNP	Strong	Genetic Variation	[1997]
TARBP2	OT1QQ8H3	Strong	Genetic Variation	[1453]
TAT	OT2CJ91O	Strong	Biomarker	[1998]
TBC1D8	OT2011SS	Strong	Biomarker	[1999]
TBP	OT6C0S52	Strong	Genetic Variation	[2000]
TBPL1	OT4I143E	Strong	Biomarker	[1040]
TBX2	OTTOT7A9	Strong	Altered Expression	[2001]
TCL1B	OT4CSO39	Strong	Biomarker	[2002]
TCN2	OT41D0L3	Strong	Genetic Variation	[2003]
TCP1	OT1MGUX9	Strong	Genetic Variation	[1153]
TDRD9	OTS4UBI8	Strong	Biomarker	[1586]
TECPR2	OT1UFECZ	Strong	Biomarker	[1379]
TERF2IP	OT3M5P3G	Strong	Biomarker	[1878]
TET1	OTZDHT1D	Strong	Biomarker	[2004]
TFDP1	OT6RZ7VT	Strong	Altered Expression	[944]
TFEB	OTJUJJQY	Strong	Biomarker	[2005]
TFF3	OTJJDRTU	Strong	Biomarker	[2006]
TFIP11	OT7NVSWU	Strong	Biomarker	[2007]
TFPI2	OTZCRWOR	Strong	Altered Expression	[2008]
THSD4	OTXDBMDC	Strong	Genetic Variation	[561]
THY1	OTVONVTB	Strong	Biomarker	[2009]
TIA1	OTGPN3P8	Strong	Biomarker	[854]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[2010]
TIMP1	OTOXC51H	Strong	Biomarker	[2011]
TIMP2	OT8S1RRP	Strong	Biomarker	[2012]
TIMP4	OT8A68SW	Strong	Biomarker	[466]
TLE1	OT50MRZ1	Strong	Biomarker	[2013]
TLE3	OTR9PH95	Strong	Biomarker	[2014]
TLE5	OTEH0BFG	Strong	Genetic Variation	[2015]
TLN2	OT10QQBC	Strong	Biomarker	[2016]
TM2D3	OT6MS96W	Strong	Genetic Variation	[1724]
TM7SF2	OTILU5S7	Strong	Altered Expression	[438]
TMC5	OTO5D86M	Strong	Genetic Variation	[561]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[2017]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[435]
TMEM11	OTL9HDEY	Strong	Biomarker	[1155]
TMEM119	OT0HFEIC	Strong	Biomarker	[2018]
TMEM132C	OT3297S6	Strong	Genetic Variation	[561]
TMEM163	OTCT1Y1L	Strong	Genetic Variation	[1221]
TMEM175	OT6DUIYC	Strong	Genetic Variation	[1221]
TMEM176B	OTEGF2BV	Strong	Biomarker	[2019]
TMEM201	OTZBZ4MC	Strong	Biomarker	[2013]
TMEM54	OTPQEFR0	Strong	Altered Expression	[1324]
TNFAIP1	OT37EWR0	Strong	Biomarker	[2020]
TNFAIP6	OT1SLUZH	Strong	Biomarker	[2021]
TNFAIP8L2	OTII0RM0	Strong	Altered Expression	[2022]
TNFRSF6B	OTKAN9G7	Strong	Biomarker	[2023]
TNMD	OTHLVA9G	Strong	Biomarker	[543]
TNR	OTVJGAFN	Strong	Biomarker	[2024]
TNRC6A	OT493IOM	Strong	Genetic Variation	[515]
TNS3	OTPG2D8Z	Strong	Biomarker	[2025]
TOLLIP	OTYEO4NR	Strong	Biomarker	[2026]
TOM1	OT30QA56	Strong	Altered Expression	[2027]
TOMM20	OT76TPR2	Strong	Biomarker	[2028]
TOMM70	OT8QBYZ0	Strong	Biomarker	[2028]
TOPORS	OT1ERFFQ	Strong	Biomarker	[1433]
TP53BP2	OTOWJ2Y4	Strong	Biomarker	[2029]
TP53INP1	OT2363Z9	Strong	Biomarker	[2030]
TPK1	OTCHPUD0	Strong	Genetic Variation	[2031]
TPM1	OTD73X6R	Strong	Biomarker	[2032]
TPSG1	OTDESHKT	Strong	Biomarker	[2033]
TRA2B	OTZYQW52	Strong	Altered Expression	[2034]
TRADD	OTBOSJHO	Strong	Altered Expression	[2035]
TRAF2	OT1MEZZN	Strong	Biomarker	[1996]
TRAM1	OT3I0H8E	Strong	Biomarker	[2036]
TRAT1	OTMPUNPD	Strong	Biomarker	[2037]
TREML1	OTMJD2HI	Strong	Genetic Variation	[2038]
TREML2	OTKQGKVJ	Strong	Genetic Variation	[2039]
TREX1	OTQG7K12	Strong	Biomarker	[2040]
TRIB3	OTG5OS7X	Strong	Biomarker	[2041]
TRIM13	OTQIUACB	Strong	Biomarker	[2042]
TRIML2	OT5QWTD2	Strong	Biomarker	[2037]
TRIQK	OT2BXCL0	Strong	Genetic Variation	[433]
TRIT1	OTCU9FS5	Strong	Biomarker	[2043]
TRMO	OTNJ7K9K	Strong	Altered Expression	[1223]
TRPC4AP	OTNJ9IFS	Strong	Genetic Variation	[1468]
TSC22D3	OT03UM03	Strong	Altered Expression	[2044]
TSHZ1	OTYQ9ECW	Strong	Biomarker	[2040]
TSPAN15	OTNQXXIG	Strong	Altered Expression	[2045]
TSPAN16	OTIWCL05	Strong	Genetic Variation	[561]
TSPAN3	OT7WS6ZI	Strong	Altered Expression	[2046]
TSPAN31	OT8WQ83R	Strong	Biomarker	[1693]
TSPOAP1	OTAM8SGF	Strong	Genetic Variation	[1046]
TSPY1	OTPY57X4	Strong	Biomarker	[2047]
TSPY3	OTQK3AKI	Strong	Biomarker	[2047]
TTBK2	OT90YSM5	Strong	Biomarker	[2048]
TTC7A	OTDHLPQM	Strong	Biomarker	[910]
ABI3	OTQTDSHP	Definitive	Genetic Variation	[2049]
BCL3	OT1M5B95	Definitive	Genetic Variation	[816]
CADPS2	OTV1FW0M	Definitive	Genetic Variation	[2050]
DCHS2	OTGZJ6KS	Definitive	Genetic Variation	[2051]
GLIS3	OTBC960E	Definitive	Biomarker	[2052]
IL34	OTZ15VVK	Definitive	Genetic Variation	[433]
IL6R	OTCQL07Z	Definitive	Genetic Variation	[1129]
MEGF10	OTILSPJ6	Definitive	Biomarker	[2053]
SPI1	OTVCA1D0	Definitive	Biomarker	[1658]
TRIP4	OTA8OASA	Definitive	Biomarker	[2054]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761178.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6599).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1051).
• [6] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 081113.
• [7] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [8] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693).
• [10] A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease. Sci Eng Ethics. 2023 Jan 10;29(1):2.
• [11] Clinical pipeline report, company report or official report of Octapharma.
• [12] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761269.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4253).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7746).
• [16] ClinicalTrials.gov (NCT02371369) PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS). U.S. National Institutes of Health.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6602).
• [18] Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131-46.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6687).
• [20] Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther. 2000 Autumn;2(3):429-40.
• [21] ClinicalTrials.gov (NCT00950430) Imaging of Brain Amyloid Plaques in the Aging Population. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT03116126) Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease. U.S.National Institutes of Health.
• [23] Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. PLoS One. 2013;8(1):e54887.
• [24] Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol. 2012 Nov;4(6):341-6.
• [25] Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009 Sep;8(9):733-50.
• [26] ClinicalTrials.gov (NCT05531526) A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD). U.S.National Institutes of Health.
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031727)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027191)
• [29] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6930).
• [31] ClinicalTrials.gov (NCT04229927) A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease. U.S.National Institutes of Health.
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014948)
• [33] ClinicalTrials.gov (NCT05108922) A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
• [34] ClinicalTrials.gov (NCT02004392) Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025. U.S. National Institutes of Health.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6933).
• [36] ClinicalTrials.gov (NCT01245530) An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT00528112) Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study. U.S. National Institutes of Health.
• [38] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
• [39] ClinicalTrials.gov (NCT01960010) A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye. U.S. National Institutes of Health.
• [40] ClinicalTrials.gov (NCT04669028) A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease. U.S.National Institutes of Health.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8325).
• [42] ClinicalTrials.gov (NCT05463731) Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
• [43] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [44] Clinical pipeline report, company report or official report of SEIKAGAKU.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932).
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2648).
• [47] ClinicalTrials.gov (NCT00262821) Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer. U.S. National Institutes of Health.
• [48] ClinicalTrials.gov (NCT00314912) Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [49] ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [50] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001601)
• [51] ClinicalTrials.gov (NCT03823404) GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease. U.S.National Institutes of Health.
• [52] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7789).
• [53] ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
• [54] ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S1). U.S. National Institutes of Health.
• [55] ClinicalTrials.gov (NCT05269394) A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease. U.S.National Institutes of Health.
• [56] ClinicalTrials.gov (NCT04886063) Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [57] ClinicalTrials.gov (NCT03090516) Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets. U.S.National Institutes of Health.
• [58] ClinicalTrials.gov (NCT02719327) Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults. U.S.National Institutes of Health.
• [59] ClinicalTrials.gov (NCT02569398) An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia.
• [60] ClinicalTrials.gov (NCT01554956) Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients. U.S. National Institutes of Health.
• [61] ClinicalTrials.gov (NCT02205840) A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.. U.S. National Institutes of Health.
• [62] ClinicalTrials.gov (NCT02579252) 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT). U.S. National Institutes of Health.
• [63] ClinicalTrials.gov (NCT03712787) An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD). U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT05291234) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease. U.S.National Institutes of Health.
• [65] ClinicalTrials.gov (NCT01655680) A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia. U.S. National Institutes of Health.
• [66] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6927).
• [67] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7357).
• [68] ClinicalTrials.gov (NCT03461276) A Multi-center, Randomized, Double-blind, Placebo-controlled, 24 Months Study in Patients With Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease to Investigate the Safety, Tolerability and Immune Response of Repeated Subcutaneous Injections of ABvac40. U.S.National Institutes of Health.
• [69] ClinicalTrials.gov (NCT03790982) A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [70] Clinical pipeline report, company report or official report of Affiris.
• [71] ClinicalTrials.gov (NCT04592874) A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.
• [72] ClinicalTrials.gov (NCT00021723) Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT03806478) Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD). U.S.National Institutes of Health.
• [74] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7371).
• [75] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030006)
• [76] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031585)
• [77] ClinicalTrials.gov (NCT01012375) Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.. U.S. National Institutes of Health.
• [78] ClinicalTrials.gov (NCT01548287) A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment. U.S. National Institutes of Health.
• [79] ClinicalTrials.gov (NCT00991419) To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden. U.S. National Institutes of Health.
• [80] ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age.
• [81] ClinicalTrials.gov (NCT02292238) Benfotiamine in Alzheimer's Disease: A Pilot Study. U.S.National Institutes of Health.
• [82] ClinicalTrials.gov (NCT04867616) A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period. U.S.National Institutes of Health.
• [83] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6489).
• [84] ClinicalTrials.gov (NCT03817684) Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT03560245) A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment. U.S.National Institutes of Health.
• [86] ClinicalTrials.gov (NCT00876863) Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [87] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7339).
• [88] ClinicalTrials.gov (NCT00621270) Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety. U.S. National Institutes of Health.
• [89] ClinicalTrials.gov (NCT02185053) A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT04735536) Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG. U.S. National Institutes of Health.
• [91] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7842).
• [92] ClinicalTrials.gov (NCT04798989) A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology. U.S.National Institutes of Health.
• [93] ClinicalTrials.gov (NCT00154635) Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT03055741) A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA). U.S.National Institutes of Health.
• [95] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030024)
• [96] ClinicalTrials.gov (NCT01661673) Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease. U.S. National Institutes of Health.
• [97] ClinicalTrials.gov (NCT00087724) A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [98] Clinical pipeline report, company report or official report of Forum pharmaceuticals.
• [99] ClinicalTrials.gov (NCT01221246) Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours. U.S. National Institutes of Health.
• [100] ClinicalTrials.gov (NCT01772199) Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health.
• [101] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027328)
• [102] ClinicalTrials.gov (NCT00357357) European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients. U.S. National Institutes of Health.
• [103] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [104] ClinicalTrials.gov (NCT03363269) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease. U.S.National Institutes of Health.
• [105] Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
• [106] ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.
• [107] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [108] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6475).
• [109] ClinicalTrials.gov (NCT03367403) A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ). U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT05063539) Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
• [111] Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test
• [112] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033430)
• [113] ClinicalTrials.gov (NCT00843518) Treatment for Aggression and Agitation in Patients With Alzheimer's Disease. U.S. National Institutes of Health.
• [114] Clinical pipeline report, company report or official report of Meta-IQ Aps.
• [115] Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
• [116] ClinicalTrials.gov (NCT05602727) A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia. U.S.National Institutes of Health.
• [117] ClinicalTrials.gov (NCT01852110) Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012). U.S. National Institutes of Health.
• [118] ClinicalTrials.gov (NCT03038035) The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial. U.S.National Institutes of Health.
• [119] ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
• [120] ClinicalTrials.gov (NCT05194163) A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [121] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006456)
• [122] ClinicalTrials.gov (NCT00001933) Nefiracetam in the Treatment of Alzheimer's Disease. U.S. National Institutes of Health.
• [123] ClinicalTrials.gov (NCT01928420) A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health.
• [124] Clinical pipeline report, company report or official report of Neuraly
• [125] ClinicalTrials.gov (NCT02035553) A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis. U.S. National Institutes of Health.
• [126] ClinicalTrials.gov (NCT02471196) Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease.
• [127] ClinicalTrials.gov (NCT03867253) A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [128] ClinicalTrials.gov (NCT01590888) Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease. U.S. National Institutes of Health.
• [129] ClinicalTrials.gov (NCT01712074) Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil. U.S. National Institutes of Health.
• [130] ClinicalTrials.gov (NCT00930059) A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [131] ClinicalTrials.gov (NCT01821118) Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy. U.S. National Institutes of Health.
• [132] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021864)
• [133] ClinicalTrials.gov (NCT04388254) Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (PTI-125). U.S. National Institutes of Health.
• [134] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021506)
• [135] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026046)
• [136] ClinicalTrials.gov (NCT03289143) A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease. U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT03462121) A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease. U.S.National Institutes of Health.
• [138] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032202)
• [139] ClinicalTrials.gov (NCT04602624) An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health.
• [140] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7356).
• [141] ClinicalTrials.gov (NCT01266525) Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil. U.S. National Institutes of Health.
• [142] ClinicalTrials.gov (NCT03828747) A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [143] ClinicalTrials.gov (NCT00842673) Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease. U.S. National Institutes of Health.
• [144] ClinicalTrials.gov (NCT02258152) SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE). U.S. National Institutes of Health.
• [145] ClinicalTrials.gov (NCT02079909) Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202). U.S. National Institutes of Health.
• [146] ClinicalTrials.gov (NCT04251182) A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [147] ClinicalTrials.gov (NCT02414347) F 18 T807 Tau PET Imaging of Alzheimer's Disease. U.S. National Institutes of Health.
• [148] ClinicalTrials.gov (NCT05476783) A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease. U.S.National Institutes of Health.
• [149] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8426).
• [150] A Phase II Trial of Tideglusib in Alzheimer's Disease. J Alzheimers Dis. 2015;45(1):75-88.
• [151] ClinicalTrials.gov (NCT01966666) A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease. U.S. National Institutes of Health.
• [152] Clinical pipeline report, company report or official report of Roche
• [153] Biopharmaceutical Research Companies are Developing Nearly 100 Medicines for Alzheimer's Disease and Other Dementias. Pharmaceutical Research and Manufacturers of America report. 2012.
• [154] ClinicalTrials.gov (NCT02551809) Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients.
• [155] ClinicalTrials.gov (NCT01284387) Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [156] ClinicalTrials.gov (NCT01428362) VI-1121 for the Treatment Alzheimer's Disease. U.S. National Institutes of Health.
• [157] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031074)
• [158] ClinicalTrials.gov (NCT05363293) A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer\'s Disease and Healthy Adult Subjects ("MAD Study"). U.S.National Institutes of Health.
• [159] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030376)
• [160] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
• [161] ClinicalTrials.gov (NCT03865017) A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [162] ClinicalTrials.gov (NCT03069014) Study of LM11A-31-BHS in Mild-moderate AD Patients. U.S. National Institutes of Health.
• [163] ClinicalTrials.gov (NCT03634007) A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease. U.S.National Institutes of Health.
• [164] ClinicalTrials.gov (NCT05040321) A Proof of Concept Trial of a Sirtuin-NAD Activator in Alzheimer's Disease. U.S.National Institutes of Health.
• [165] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [166] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7034).
• [167] ClinicalTrials.gov (NCT04445831) A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease. U.S.National Institutes of Health.
• [168] ClinicalTrials.gov (NCT04249869) The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study. U.S.National Institutes of Health.
• [169] ClinicalTrials.gov (NCT01609257) Norovirus Bivalent-Vaccine Efficacy Study. U.S. National Institutes of Health.
• [170] ClinicalTrials.gov (NCT04983368) XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem? in Healthy Elderly Volunteers. U.S.National Institutes of Health.
• [171] List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegener Dis. 2012;9(4):210-83.
• [172] ClinicalTrials.gov (NCT00838877) Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for A Amyloid. U.S. National Institutes of Health.
• [173] ClinicalTrials.gov (NCT00870519) Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects. U.S. National Institutes of Health.
• [174] ClinicalTrials.gov (NCT00657813) Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition. U.S. National Institutes of Health.
• [175] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031827)
• [176] ClinicalTrials.gov (NCT01369225) Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [177] Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61.
• [178] ClinicalTrials.gov (NCT04133649) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for the Treatment of Aging: AAV- hTERT. U.S.National Institutes of Health.
• [179] ClinicalTrials.gov (NCT01908010) Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors. U.S. National Institutes of Health.
• [180] ClinicalTrials.gov (NCT02220738) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors. U.S. National Institutes of Health.
• [181] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [182] ClinicalTrials.gov (NCT04931459) A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health.
• [183] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033932)
• [184] ClinicalTrials.gov (NCT01397539) A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [185] ClinicalTrials.gov (NCT00495417) Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [186] ClinicalTrials.gov (NCT03822208) A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL003 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease.. U.S.National Institutes of Health.
• [187] ClinicalTrials.gov (NCT00739037) Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease. U.S. National Institutes of Health.
• [188] ClinicalTrials.gov (NCT05231785) A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD). U.S.National Institutes of Health.
• [189] ClinicalTrials.gov (NCT01837641) A Study of LY3002813 in Participants With Alzheimer's Disease. U.S. National Institutes of Health.
• [190] Clinical pipeline report, company report or official report of Annovis Bio
• [191] Clinical pipeline report, company report or official report of Aphios
• [192] ClinicalTrials.gov (NCT05344989) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APNmAb005 in Healthy Subjects. U.S.National Institutes of Health.
• [193] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031729)
• [194] ClinicalTrials.gov (NCT04759365) A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease. U.S.National Institutes of Health.
• [195] ClinicalTrials.gov (NCT01406145) A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil. U.S. National Institutes of Health.
• [196] Clinical pipeline report, company report or official report of Astellas Pharma.
• [197] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025412)
• [198] 5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress. Neurol Ther. 2018 Jun;7(1):51-58.
• [199] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6931).
• [200] ClinicalTrials.gov (NCT00692705) Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for Amyloid. U.S. National Institutes of Health.
• [201] ClinicalTrials.gov (NCT01153607) Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers. U.S. National Institutes of Health.
• [202] ClinicalTrials.gov (NCT01548703) A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers. U.S. National Institutes of Health.
• [203] ClinicalTrials.gov (NCT01546051) A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers. U.S. National Institutes of Health.
• [204] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6979).
• [205] ClinicalTrials.gov (NCT04476303) A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers. U.S.National Institutes of Health.
• [206] ClinicalTrials.gov (NCT05195008) A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants. U.S.National Institutes of Health.
• [207] ClinicalTrials.gov (NCT01492374) Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease. U.S. National Institutes of Health.
• [208] ClinicalTrials.gov (NCT05804383) A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease. U.S.National Institutes of Health.
• [209] ClinicalTrials.gov (NCT04920903) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects. U.S.National Institutes of Health.
• [210] ClinicalTrials.gov (NCT00621010) Safety Study of CTS21166 to Treat Alzheimer Disease. U.S. National Institutes of Health.
• [211] DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
• [212] ClinicalTrials.gov (NCT03757325) Study to Evaluate DNL747 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health.
• [213] ClinicalTrials.gov (NCT05450549) A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants. U.S.National Institutes of Health.
• [214] ClinicalTrials.gov (NCT01042106) Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults. U.S. National Institutes of Health.
• [215] ClinicalTrials.gov (NCT01522586) Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031. U.S. National Institutes of Health.
• [216] ClinicalTrials.gov (NCT01221259) A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects. U.S. National Institutes of Health.
• [217] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7358).
• [218] Clinical pipeline report, company report or official report of Eisai
• [219] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 700036191)
• [220] An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.
• [221] ClinicalTrials.gov (NCT00719394) Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males. U.S. National Institutes of Health.
• [222] ClinicalTrials.gov (NCT01924858) A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.. U.S. National Institutes of Health.
• [223] ClinicalTrials.gov (NCT01702480) Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects. U.S. National Institutes of Health.
• [224] ClinicalTrials.gov (NCT01482013) Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease. U.S. National Institutes of Health.
• [225] ClinicalTrials.gov (NCT04749563) A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health.
• [226] ClinicalTrials.gov (NCT03838185) A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers. U.S.National Institutes of Health.
• [227] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [228] ClinicalTrials.gov (NCT04149860) Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease. U.S.National Institutes of Health.
• [229] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6936).
• [230] ClinicalTrials.gov (NCT04451408) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants. U.S.National Institutes of Health.
• [231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009639)
• [232] Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.
• [233] ClinicalTrials.gov (NCT00954538) Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001). U.S. National Institutes of Health.
• [234] ClinicalTrials.gov (NCT03740178) A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil. U.S.National Institutes of Health.
• [235] ClinicalTrials.gov (NCT04074837) Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age. U.S.National Institutes of Health.
• [236] ClinicalTrials.gov (NCT01163825) Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer Disease Patients. U.S. National Institutes of Health.
• [237] Clinical pipeline report, company report or official report of NeuroTherapia
• [238] Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7.
• [239] ClinicalTrials.gov (NCT01193062) Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274. U.S. National Institutes of Health.
• [240] ClinicalTrials.gov (NCT02407353) A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on beta-Amyloid (Abeta) Concentrations in Cerebrospinal Fluid (CSF). U.S. National Institutes of Health.
• [241] The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13).
• [242] ClinicalTrials.gov (NCT00744146) First Time in Human Study of Protexia. U.S. National Institutes of Health.
• [243] Clinical pipeline report, company report or official report of I-Mab Biopharma
• [244] Clinical pipeline report, company report or official report of Prothena
• [245] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028705)
• [246] ClinicalTrials.gov (NCT04672135) A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With an Adaptive Dose Design to Evaluate the Safety, Tolerability, and Pharmacokinetics of REM0046127 in Healthy Subjects. U.S.National Institutes of Health.
• [247] Clinical pipeline report, company report or official report of Genentch
• [248] ClinicalTrials.gov (NCT01592331) A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers. U.S. National Institutes of Health.
• [249] ClinicalTrials.gov (NCT01485302) Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients. U.S. National Institutes of Health.
• [250] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036473)
• [251] ClinicalTrials.gov (NCT04973189) A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707 in Healthy Young Adult and Elderly Subjects. U.S.National Institutes of Health.
• [252] ClinicalTrials.gov (NCT01560884) Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb. U.S. National Institutes of Health.
• [253] ClinicalTrials.gov (NCT01357421) Effects of TT301 on Cytokine Levels Post Endotoxin Challenge. U.S. National Institutes of Health.
• [254] ClinicalTrials.gov (NCT01548430) A Safety Study of TTP4000 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health.
• [255] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027767)
• [256] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021230)
• [257] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6549).
• [258] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1959).
• [259] The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci. 2013 Mar;53:52-62.
• [260] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6553).
• [261] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [262] Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
• [263] Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
• [264] MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226.
• [265] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [266] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021875)
• [267] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004496)
• [268] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004036)
• [269] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029150)
• [270] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031584)
• [271] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7697).
• [272] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009278)
• [273] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003027)
• [274] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011083)
• [275] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011312)
• [276] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4304).
• [277] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009631)
• [278] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001956)
• [279] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7819).
• [280] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020415)
• [281] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024230)
• [282] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009546)
• [283] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028783)
• [284] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030748)
• [285] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012921)
• [286] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028311)
• [287] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033289)
• [288] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017461)
• [289] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024936)
• [290] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025887)
• [291] 2011 Pipeline of Anavex.
• [292] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023654)
• [293] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013391)
• [294] ClinicalTrials.gov (NCT03431844) Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation. U.S. National Institutes of Health.
• [295] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023984)
• [296] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021196)
• [297] Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
• [298] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015422)
• [299] Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv. 2013;2013:898146.
• [300] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001856)
• [301] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007119)
• [302] In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
• [303] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8478).
• [304] Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci. 1993;52(5-6):497-503.
• [305] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002066)
• [306] 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
• [307] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005173)
• [308] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006555)
• [309] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003560)
• [310] PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106.
• [311] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020178)
• [312] Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007 Dec 7;282(49):35666-78.
• [313] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019997)
• [314] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004498)
• [315] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001380)
• [316] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006757)
• [317] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001957)
• [318] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004819)
• [319] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4210).
• [320] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4219).
• [321] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003218)
• [322] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003692)
• [323] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006922)
• [324] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007171)
• [325] Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey. Neurochem Int. 1990;17(2):325-9.
• [326] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000658)
• [327] Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol. 2005 Jun;25(3-4):513-52.
• [328] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017551)
• [329] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005356)
• [330] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005353)
• [331] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017252)
• [332] A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors. Biochem Soc Trans. 1994 Aug;22(3):755-8.
• [333] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000634)
• [334] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007561)
• [335] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001729)
• [336] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
• [337] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 350).
• [338] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004137)
• [339] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000565)
• [340] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005755)
• [341] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000552)
• [342] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4347).
• [343] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [344] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7530).
• [345] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
• [346] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7337).
• [347] Novel -secretase enzyme modulators directly target presenilin protein. J Biol Chem. 2011 Oct 28;286(43):37181-6
• [348] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5015).
• [349] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
• [350] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [351] Brain Targeting of Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor K-604 via the Intranasal Route Using a Hydroxycarboxylic Acid Solution.ACS Omega. 2019 Oct 2;4(16):16943-16955. doi: 10.1021/acsomega.9b02307. eCollection 2019 Oct 15.
• [352] Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease.Neurobiol Dis. 2020 Feb;134:104644. doi: 10.1016/j.nbd.2019.104644. Epub 2019 Oct 24.
• [353] Parallel profiling of DNA methylation and hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimer's disease.Clin Epigenetics. 2019 Mar 21;11(1):52. doi: 10.1186/s13148-019-0636-y.
• [354] Serum Adiponectin is Related to Dementia.J Gerontol A Biol Sci Med Sci. 2020 Mar 9;75(4):779-783. doi: 10.1093/gerona/glz102.
• [355] Significant enhanced expressions of aquaporin-1, -4 and -9 in the brains of various prion diseases.Prion. 2019 Jan;13(1):173-184. doi: 10.1080/19336896.2019.1660487.
• [356] Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease.Neurobiol Dis. 2019 May;125:176-189. doi: 10.1016/j.nbd.2019.02.003. Epub 2019 Feb 6.
• [357] C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta.ASN Neuro. 2017 Feb;9(1):1759091416687871. doi: 10.1177/1759091416687871.
• [358] Family C G-Protein-Coupled Receptors in Alzheimer's Disease and Therapeutic Implications.Front Pharmacol. 2019 Oct 28;10:1282. doi: 10.3389/fphar.2019.01282. eCollection 2019.
• [359] Alteration in memory cognition due to activation of caveolin-1 and oxidative damage in a model of dementia of Alzheimer's type.Indian J Pharmacol. 2019 May-Jun;51(3):173-180. doi: 10.4103/ijp.IJP_81_17.
• [360] Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline.Neurobiol Aging. 2019 Apr;76:125-132. doi: 10.1016/j.neurobiolaging.2018.12.019. Epub 2019 Jan 7.
• [361] Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies.J Neurol Neurosurg Psychiatry. 2019 May;90(5):590-598. doi: 10.1136/jnnp-2018-319148. Epub 2019 Jan 10.
• [362] Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.Curr Drug Targets. 2017;18(10):1179-1190. doi: 10.2174/1389450116666151001111826.
• [363] Corticotropin-releasing factor receptor-1 modulates biomarkers of DNA oxidation in Alzheimer's disease mice.PLoS One. 2017 Jul 27;12(7):e0181367. doi: 10.1371/journal.pone.0181367. eCollection 2017.
• [364] Phosphorylated NF-B subunit p65 aggregates in granulovacuolar degeneration and neurites in neurodegenerative diseases with tauopathy.Neurosci Lett. 2019 Jun 21;704:229-235. doi: 10.1016/j.neulet.2019.03.036. Epub 2019 Apr 1.
• [365] Activated CX3CL1/Smad2 Signals Prevent Neuronal Loss and Alzheimer's Tau Pathology-Mediated Cognitive Dysfunction.J Neurosci. 2020 Jan 29;40(5):1133-1144. doi: 10.1523/JNEUROSCI.1333-19.2019. Epub 2019 Dec 10.
• [366] Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):302-307. doi: 10.1177/1533317519848237. Epub 2019 May 7.
• [367] Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene. JCI Insight. 2020 Feb 27;5(4):e135119. doi: 10.1172/jci.insight.135119.
• [368] The effect of early growth response 1 on levels of Amyloid- 40 peptide in U87MG cells.J Cell Biochem. 2019 Mar;120(3):3514-3519. doi: 10.1002/jcb.27627. Epub 2018 Dec 12.
• [369] Structure and pro-toxic mechanism of the human Hsp90/PPIase/Tau complex.Nat Commun. 2018 Oct 31;9(1):4532. doi: 10.1038/s41467-018-06880-0.
• [370] Anxiolytic impact of Apelin-13 in a rat model of Alzheimer's disease: Involvement of glucocorticoid receptor and FKBP5.Peptides. 2019 Aug;118:170102. doi: 10.1016/j.peptides.2019.170102. Epub 2019 Jun 11.
• [371] VEGF receptor-1 modulates amyloid 1-42 oligomer-induced senescence in brain endothelial cells.FASEB J. 2019 Mar;33(3):4626-4637. doi: 10.1096/fj.201802003R. Epub 2018 Dec 21.
• [372] Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders.Curr Pharm Des. 2020;25(43):4560-4569. doi: 10.2174/1381612825666191210154535.
• [373] Reduced expression of glyoxalase-1 mRNA in mood disorder patients.Neurosci Lett. 2008 Jun 20;438(2):196-9. doi: 10.1016/j.neulet.2008.04.024. Epub 2008 Apr 12.
• [374] Fighting the Cause of Alzheimer's and GNE Myopathy.Front Neurosci. 2018 Oct 15;12:669. doi: 10.3389/fnins.2018.00669. eCollection 2018.
• [375] Monoamines and their Derivatives on GPCRs: Potential Therapy for Alzheimer's Disease.Curr Alzheimer Res. 2019;16(10):871-894. doi: 10.2174/1570159X17666190409144558.
• [376] Curcumin Treatment is Associated with Increased Expression of the N-Methyl-D-Aspartate Receptor (NMDAR) Subunit, NR2A, in a Rat PC12 Cell Line Model of Alzheimer's Disease Treated with the Acetyl Amyloid- Peptide, A(25-35).Med Sci Monit. 2018 May 1;24:2693-2699. doi: 10.12659/MSM.906933.
• [377] Structure, regulation and related diseases of the actin-binding protein gelsolin.Expert Rev Mol Med. 2019 Jan 30;20:e7. doi: 10.1017/erm.2018.7.
• [378] Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan 7.
• [379] HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells.J Steroid Biochem Mol Biol. 2018 Sep;182:21-26. doi: 10.1016/j.jsbmb.2018.04.007. Epub 2018 Apr 17.
• [380] Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.Assay Drug Dev Technol. 2017 Oct/Nov;15(7):342-351. doi: 10.1089/adt.2017.804. Epub 2017 Oct 27.
• [381] No association between histamine N-methyltransferase functional polymorphism Thr105Ile and Alzheimer's disease.Neurosci Lett. 2011 Feb 4;489(2):119-21. doi: 10.1016/j.neulet.2010.11.078. Epub 2010 Dec 5.
• [382] Prestimulation of Microglia Through TLR4 Pathway Promotes Interferon Beta Expression in a Rat Model of Alzheimer's Disease.J Mol Neurosci. 2019 Apr;67(4):495-503. doi: 10.1007/s12031-018-1249-1. Epub 2019 Jan 4.
• [383] Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of A Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.Mol Neurobiol. 2020 Mar;57(3):1473-1483. doi: 10.1007/s12035-019-01827-y. Epub 2019 Nov 23.
• [384] Overexpression of the Insulin-Like Growth Factor II Receptor Increases -Amyloid Production and Affects Cell Viability.Mol Cell Biol. 2015 Jul;35(14):2368-84. doi: 10.1128/MCB.01338-14. Epub 2015 May 4.
• [385] Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study.Neurology. 2018 Jan 23;90(4):e291-e297. doi: 10.1212/WNL.0000000000004854. Epub 2017 Dec 27.
• [386] Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma.Exp Gerontol. 2019 Jul 1;121:91-98. doi: 10.1016/j.exger.2019.04.003. Epub 2019 Apr 11.
• [387] Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease.J Geriatr Psychiatry Neurol. 2019 Jul;32(4):211-220. doi: 10.1177/0891988719841728. Epub 2019 Apr 24.
• [388] Critical Roles of IL-33/ST2 Pathway in Neurological Disorders.Mediators Inflamm. 2018 Feb 4;2018:5346413. doi: 10.1155/2018/5346413. eCollection 2018.
• [389] Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis.J Cell Sci. 2020 Jan 10;133(5):jcs238030. doi: 10.1242/jcs.238030.
• [390] Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET.Transl Neurodegener. 2019 Aug 27;8:25. doi: 10.1186/s40035-019-0168-6. eCollection 2019.
• [391] Inhibition of excessive kallikrein-8 improves neuroplasticity in Alzheimer's disease mouse model.Exp Neurol. 2020 Feb;324:113115. doi: 10.1016/j.expneurol.2019.113115. Epub 2019 Nov 14.
• [392] Deep brain stimulation of the nucleus basalis of Meynert attenuates early EEG components associated with defective sensory gating in patients with Alzheimer disease - a two-case study.Eur J Neurosci. 2020 Mar;51(5):1201-1209. doi: 10.1111/ejn.13749. Epub 2017 Nov 22.
• [393] Relationships of Cerebrospinal Fluid Alzheimer's Disease Biomarkers and COMT, DBH, and MAOB Single Nucleotide Polymorphisms.J Alzheimers Dis. 2020;73(1):135-145. doi: 10.3233/JAD-190991.
• [394] Genetic Overlap Between Alzheimer's Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes.Front Neurosci. 2019 Mar 13;13:220. doi: 10.3389/fnins.2019.00220. eCollection 2019.
• [395] The Role of Neuronal NLRP1 Inflammasome in Alzheimer's Disease: Bringing Neurons into the Neuroinflammation Game.Mol Neurobiol. 2019 Nov;56(11):7741-7753. doi: 10.1007/s12035-019-1638-7. Epub 2019 May 20.
• [396] Drug likeness, targets, molecular docking and ADMET studies for some indolizine derivatives.Pharmazie. 2018 Nov 1;73(11):635-642. doi: 10.1691/ph.2018.8061.
• [397] Neuregulin 1 regulates amyloid precursor protein cell surface expression and non-amyloidogenic processing.J Pharmacol Sci. 2018 Jun;137(2):146-153. doi: 10.1016/j.jphs.2018.05.004. Epub 2018 May 29.
• [398] -Hydroxybutyrate Ameliorates A-Induced Downregulation of TrkA Expression by Inhibiting HDAC1/3 in SH-SY5Y Cells.Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317519883496. doi: 10.1177/1533317519883496. Epub 2019 Oct 24.
• [399] Computational prediction of changes in brain metabolic fluxes during Parkinson's disease from mRNA expression.PLoS One. 2018 Sep 12;13(9):e0203687. doi: 10.1371/journal.pone.0203687. eCollection 2018.
• [400] Association of lectin-like oxidized low density lipoprotein receptor 1 (OLR1) polymorphisms with late-onset Alzheimer disease in Han Chinese.Ann Transl Med. 2018 May;6(10):172. doi: 10.21037/atm.2018.04.31.
• [401] The P2X7 receptor: a new therapeutic target in Alzheimer's disease.Expert Opin Ther Targets. 2019 Mar;23(3):165-176. doi: 10.1080/14728222.2019.1575811.
• [402] Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease.Mol Neurobiol. 2010 Jun;41(2-3):73-86. doi: 10.1007/s12035-010-8107-7. Epub 2010 Mar 2.
• [403] Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer's disease.Neurobiol Dis. 2019 Jan;121:138-147. doi: 10.1016/j.nbd.2018.09.020. Epub 2018 Sep 26.
• [404] Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target.Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):40-49. doi: 10.1111/bcpt.13094. Epub 2018 Aug 14.
• [405] Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.Iran J Pharm Res. 2017 Spring;16(2):442-450.
• [406] Development of Predictive Models for Identifying Potential S100A9 Inhibitors Based on Machine Learning Methods.Front Chem. 2019 Nov 25;7:779. doi: 10.3389/fchem.2019.00779. eCollection 2019.
• [407] GLUT12 Expression in Brain of Mouse Models of Alzheimer's Disease.Mol Neurobiol. 2020 Feb;57(2):798-805. doi: 10.1007/s12035-019-01743-1. Epub 2019 Aug 31.
• [408] Lymphoblast-derived integration-free iPSC line AD-TREM2-1 from a 67year-old Alzheimer's disease patient expressing the TREM2 p.R47H variant.Stem Cell Res. 2018 May;29:60-63. doi: 10.1016/j.scr.2018.03.011. Epub 2018 Mar 20.
• [409] Silencing of the Drosophila ortholog of SOX5 leads to abnormal neuronal development and behavioral impairment.Hum Mol Genet. 2017 Apr 15;26(8):1472-1482. doi: 10.1093/hmg/ddx051.
• [410] Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.PLoS One. 2019 Sep 23;14(9):e0222921. doi: 10.1371/journal.pone.0222921. eCollection 2019.
• [411] The sterol regulatory element-binding protein 2 is dysregulated by tau alterations in Alzheimer disease.Brain Pathol. 2019 Jul;29(4):530-543. doi: 10.1111/bpa.12691. Epub 2019 Jan 28.
• [412] Down-Regulation of Mir-107 Worsen Spatial Memory by Suppressing SYK Expression and Inactivating NF-B Signaling Pathway.Curr Alzheimer Res. 2019;16(2):135-145. doi: 10.2174/1567205016666181212154347.
• [413] Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.Hum Mol Genet. 2018 Aug 15;27(16):2874-2892. doi: 10.1093/hmg/ddy201.
• [414] Ca2+-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid- and tau in a mouse model of Alzheimer's disease.Hum Mol Genet. 2020 Jan 15;29(2):228-237. doi: 10.1093/hmg/ddz276.
• [415] Blockade of 4 integrins reduces leukocyte-endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer's disease.Sci Rep. 2019 Aug 19;9(1):12055. doi: 10.1038/s41598-019-48538-x.
• [416] VDAC1, mitochondrial dysfunction, and Alzheimer's disease.Pharmacol Res. 2018 May;131:87-101. doi: 10.1016/j.phrs.2018.03.010. Epub 2018 Mar 15.
• [417] The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau).Autophagy. 2019 Apr;15(4):583-598. doi: 10.1080/15548627.2018.1532258. Epub 2018 Oct 16.
• [418] DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex.Epigenetics Chromatin. 2018 Jul 25;11(1):41. doi: 10.1186/s13072-018-0211-3.
• [419] Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.PLoS One. 2012;7(10):e45841. doi: 10.1371/journal.pone.0045841. Epub 2012 Oct 3.
• [420] Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.Nat Genet. 2007 Jan;39(1):17-23. doi: 10.1038/ng1934.
• [421] CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice.Brain. 2019 Oct 1;142(10):3243-3264. doi: 10.1093/brain/awz241.
• [422] Changes of hippocampus proteomic profiles after blueberry extracts supplementation in APP/PS1 transgenic mice.Nutr Neurosci. 2020 Jan;23(1):75-84. doi: 10.1080/1028415X.2018.1471251. Epub 2018 May 21.
• [423] Amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) are characterised by differential activation of ER stress pathways: focus on UPR target genes.Cell Stress Chaperones. 2018 Sep;23(5):897-912. doi: 10.1007/s12192-018-0897-y. Epub 2018 May 4.
• [424] Regulation of HSF1 protein stabilization: An updated review.Eur J Pharmacol. 2018 Mar 5;822:69-77. doi: 10.1016/j.ejphar.2018.01.005. Epub 2018 Jan 16.
• [425] RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer's Disease and Parkinson's Disease Subjects, and Increased Expression of Genes From Disease-Activated Microglia.Front Neurosci. 2019 Mar 28;13:235. doi: 10.3389/fnins.2019.00235. eCollection 2019.
• [426] The Role of mPGES-1 in Inflammatory Brain Diseases.Biol Pharm Bull. 2017;40(5):557-563. doi: 10.1248/bpb.b16-01026.
• [427] Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients.Eur J Neurol. 2020 Mar;27(3):475-483. doi: 10.1111/ene.14117. Epub 2019 Dec 18.
• [428] Mitochondrial Cholesterol in Alzheimer's Disease and Niemann-Pick Type C Disease.Front Neurol. 2019 Nov 7;10:1168. doi: 10.3389/fneur.2019.01168. eCollection 2019.
• [429] Mutation and association analyses of dementia-causal genes in Han Chinese patients with early-onset and familial Alzheimer's disease.J Psychiatr Res. 2019 Jun;113:141-147. doi: 10.1016/j.jpsychires.2019.03.026. Epub 2019 Mar 30.
• [430] Periodic Variation of AAK1 in an A(1-42)-Induced Mouse Model of Alzheimer's Disease.J Mol Neurosci. 2018 Jun;65(2):179-189. doi: 10.1007/s12031-018-1085-3. Epub 2018 May 17.
• [431] Meta-Analysis of the Association between Variants in ABCA7 and Alzheimer's Disease.J Alzheimers Dis. 2018;63(4):1261-1267. doi: 10.3233/JAD-180107.
• [432] P-glycoprotein: a role in the export of amyloid- in Alzheimer's disease?.FEBS J. 2020 Feb;287(4):612-625. doi: 10.1111/febs.15148. Epub 2019 Dec 9.
• [433] Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.Alzheimers Dement. 2018 May;14(5):623-633. doi: 10.1016/j.jalz.2017.11.006. Epub 2017 Dec 20.
• [434] ABC efflux transporters in brain vasculature of Alzheimer's subjects.Brain Res. 2010 Oct 28;1358:228-38. doi: 10.1016/j.brainres.2010.08.034. Epub 2010 Aug 19.
• [435] CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.Exp Gerontol. 2017 Apr;90:83-89. doi: 10.1016/j.exger.2017.01.025. Epub 2017 Feb 9.
• [436] Retinoid X Receptor Alpha Nitro-ligand Z-10 and Its Optimized Derivative Z-36 Reduce -Amyloid Plaques in Alzheimer's Disease Mouse Model.Mol Pharm. 2019 Feb 4;16(2):480-488. doi: 10.1021/acs.molpharmaceut.8b00096. Epub 2018 Dec 31.
• [437] ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics.Curr Top Med Chem. 2019;19(10):795-811. doi: 10.2174/1568026619666190412121811.
• [438] Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.J Alzheimers Dis. 2019;72(2):525-535. doi: 10.3233/JAD-190721.
• [439] Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease.J Med Virol. 2004 Aug;73(4):605-11. doi: 10.1002/jmv.20133.
• [440] Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences.Front Mol Neurosci. 2017 Jan 31;10:3. doi: 10.3389/fnmol.2017.00003. eCollection 2017.
• [441] Mitochondrial oxidative stress index, activity of redox-sensitive aconitase and effects of endogenous anti- and pro-oxidants on its activity in control, Alzheimer's disease and Swedish Familial Alzheimer's disease brain.Free Radic Res. 2012 Dec;46(12):1490-5. doi: 10.3109/10715762.2012.728286. Epub 2012 Sep 27.
• [442] Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.J Alzheimers Dis. 2018;63(4):1433-1443. doi: 10.3233/JAD-171065.
• [443] Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.Cell Mol Life Sci. 2019 Aug;76(16):3055-3081. doi: 10.1007/s00018-019-03173-7. Epub 2019 Jun 24.
• [444] Effects of aluminium on -amyloid (1-42) and secretases (APP-cleaving enzymes) in rat brain.Neurochem Res. 2014 Jul;39(7):1338-45. doi: 10.1007/s11064-014-1317-z. Epub 2014 May 3.
• [445] Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A, tau, immunity and lipid processing.Nat Genet. 2019 Mar;51(3):414-430. doi: 10.1038/s41588-019-0358-2. Epub 2019 Feb 28.
• [446] ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.PLoS Biol. 2019 Jun 11;17(6):e3000313. doi: 10.1371/journal.pbio.3000313. eCollection 2019 Jun.
• [447] The metalloprotease ADAMTS4 generates N-truncated A4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease.Acta Neuropathol. 2019 Feb;137(2):239-257. doi: 10.1007/s00401-018-1929-5. Epub 2018 Nov 13.
• [448] Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression.Neuroimage. 2012 Nov 15;63(3):1681-94. doi: 10.1016/j.neuroimage.2012.08.002. Epub 2012 Aug 15.
• [449] Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease.Front Mol Neurosci. 2019 Jan 11;11:493. doi: 10.3389/fnmol.2018.00493. eCollection 2018.
• [450] Adrenomedullin, a Novel Target for Neurodegenerative Diseases.Mol Neurobiol. 2018 Dec;55(12):8799-8814. doi: 10.1007/s12035-018-1031-y. Epub 2018 Mar 29.
• [451] Amyloid and tau are involved in sleep disorder in Alzheimer's disease by orexinA and adenosine A(1) receptor.Int J Mol Med. 2019 Jan;43(1):435-442. doi: 10.3892/ijmm.2018.3935. Epub 2018 Oct 16.
• [452] Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.Neurobiol Aging. 2017 Dec;60:92-103. doi: 10.1016/j.neurobiolaging.2017.08.010. Epub 2017 Aug 18.
• [453] (2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17296-301. doi: 10.1073/pnas.1409513111. Epub 2014 Nov 17.
• [454] Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.Neuropharmacology. 2017 Apr;116:371-386. doi: 10.1016/j.neuropharm.2017.01.010. Epub 2017 Jan 13.
• [455] Blocking beta 2-adrenergic receptor inhibits dendrite ramification in a mouse model of Alzheimer's disease.Neural Regen Res. 2017 Sep;12(9):1499-1506. doi: 10.4103/1673-5374.215261.
• [456] AT2R Activation Prevents Microglia Pro-inflammatory Activation in a NOX-Dependent Manner: Inhibition of PKC Activation and p47(phox) Phosphorylation by PP2A.Mol Neurobiol. 2019 Apr;56(4):3005-3023. doi: 10.1007/s12035-018-1272-9. Epub 2018 Aug 3.
• [457] Acute Anti-Inflammatory Markers ITIH4 and AHSG in Mice Brain of a Novel Alzheimer's Disease Model.J Alzheimers Dis. 2019;68(4):1667-1675. doi: 10.3233/JAD-181218.
• [458] Tanshinone IIA ameliorates cognitive deficits by inhibiting endoplasmic reticulum stress-induced apoptosis in APP/PS1 transgenic mice.Neurochem Int. 2020 Feb;133:104610. doi: 10.1016/j.neuint.2019.104610. Epub 2019 Nov 26.
• [459] Delta-Aminolevulinate dehydratase and glutathione peroxidase activity in Alzheimer's disease: a case-control study.EXCLI J. 2019 Sep 25;18:866-875. doi: 10.17179/excli2019-1749. eCollection 2019.
• [460] Amyloid perturbs elevated heme flux induced with neuronal development.Alzheimers Dement (N Y). 2019 Jan 22;5:27-37. doi: 10.1016/j.trci.2018.12.003. eCollection 2019.
• [461] 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress.Am J Pathol. 2004 May;164(5):1655-62. doi: 10.1016/S0002-9440(10)63724-8.
• [462] 12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice.Biol Psychiatry. 2017 Jan 15;81(2):92-100. doi: 10.1016/j.biopsych.2016.05.023. Epub 2016 Jun 4.
• [463] 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease.Med Hypotheses. 2006;66(3):501-3. doi: 10.1016/j.mehy.2005.09.031. Epub 2005 Nov 8.
• [464] Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.J Alzheimers Dis. 2018;64(s1):S647-S657. doi: 10.3233/JAD-179908.
• [465] Elovanoids counteract oligomeric -amyloid-induced gene expression and protect photoreceptors.Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24317-24325. doi: 10.1073/pnas.1912959116. Epub 2019 Nov 11.
• [466] Elevated plasma angiogenesis factors in Alzheimer's disease.J Alzheimers Dis. 2015;45(1):245-52. doi: 10.3233/JAD-142409.
• [467] p35 Hemizygous Deletion in 5xFAD Mice Increases A Plaque Load in Males but Not in Females.Neuroscience. 2019 Oct 1;417:45-56. doi: 10.1016/j.neuroscience.2019.08.017. Epub 2019 Aug 14.
• [468] Human amyloid- enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.Alzheimers Res Ther. 2019 Jun 29;11(1):56. doi: 10.1186/s13195-019-0513-0.
• [469] Cross-talk between A and endothelial SSAO/VAP-1 accelerates vascular damage and A aggregation related to CAA-AD.Neurobiol Aging. 2015 Feb;36(2):762-75. doi: 10.1016/j.neurobiolaging.2014.09.030. Epub 2014 Oct 13.
• [470] The anaphase promoting complex is required for memory function in mice.Learn Mem. 2010 Dec 22;18(1):49-57. doi: 10.1101/lm.1998411. Print 2011 Jan.
• [471] The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.Front Immunol. 2018 Oct 16;9:2382. doi: 10.3389/fimmu.2018.02382. eCollection 2018.
• [472] Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis?.J Alzheimers Dis. 2017;60(3):1097-1106. doi: 10.3233/JAD-170389.
• [473] Mitochondrial transcription factor A (TFAM) rs1937 and AP endonuclease 1 (APE1) rs1130409 alleles are associated with reduced cognitive performance.Neurosci Lett. 2017 Apr 3;645:46-52. doi: 10.1016/j.neulet.2017.02.062. Epub 2017 Feb 24.
• [474] Apelin/APJ system: A novel promising target for neurodegenerative diseases.J Cell Physiol. 2020 Feb;235(2):638-657. doi: 10.1002/jcp.29001. Epub 2019 Jun 28.
• [475] Knockout of apolipoprotein A-I decreases parenchymal and vascular -amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.Neuropathol Appl Neurobiol. 2019 Dec;45(7):698-714. doi: 10.1111/nan.12556. Epub 2019 May 14.
• [476] Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease.J Alzheimers Dis. 2019;71(4):1217-1231. doi: 10.3233/JAD-190175.
• [477] Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.Drug Des Devel Ther. 2015 Sep 29;9:5421-31. doi: 10.2147/DDDT.S89279. eCollection 2015.
• [478] Higher Apolipoprotein C-III Levels in Cerebrospinal Fluid are Associated with Slower Cognitive Decline in Mild Cognitive Impairment.J Alzheimers Dis. 2019;67(3):961-969. doi: 10.3233/JAD-181096.
• [479] Downregulation of Aquaporin 9 Exacerbates Beta-amyloid-induced Neurotoxicity in Alzheimer's Disease Models In vitro and In vivo.Neuroscience. 2018 Dec 1;394:72-82. doi: 10.1016/j.neuroscience.2018.09.016. Epub 2018 Sep 26.
• [480] Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.Neurobiol Dis. 2019 Jul;127:432-448. doi: 10.1016/j.nbd.2019.02.015. Epub 2019 Apr 2.
• [481] Is the urea cycle involved in Alzheimer's disease?.J Alzheimers Dis. 2010;21(3):1013-21. doi: 10.3233/JAD-2010-100630.
• [482] Arrestins contribute to amyloid beta-induced cell death via modulation of autophagy and the 7nAch receptor in SH-SY5Y cells.Sci Rep. 2017 Jun 13;7(1):3446. doi: 10.1038/s41598-017-01798-x.
• [483] Croatian population data for arylsulfatase a pseudodeficiency-associated mutations in healthy subjects, and in patients with Alzheimer-type dementia and Down syndrome.Arch Med Res. 2002 Sep-Oct;33(5):473-7. doi: 10.1016/s0188-4409(02)00392-2.
• [484] A Novel Small Molecule Modulator of Amyloid Pathology.J Alzheimers Dis. 2016 May 4;53(1):273-87. doi: 10.3233/JAD-151160.
• [485] Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR.Front Aging Neurosci. 2019 Jan 9;10:424. doi: 10.3389/fnagi.2018.00424. eCollection 2018.
• [486] Quercetin reduces eIF2 phosphorylation by GADD34 induction.Neurobiol Aging. 2015 Sep;36(9):2509-18. doi: 10.1016/j.neurobiolaging.2015.05.006. Epub 2015 May 15.
• [487] Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.Biosci Rep. 2018 Jan 10;38(1):BSR20170862. doi: 10.1042/BSR20170862. Print 2018 Feb 28.
• [488] Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer's Disease? Molecular Mechanisms and Clinical Implications.Curr Med Chem. 2018;25(18):2166-2174. doi: 10.2174/0929867325666180129101049.
• [489] Using membrane-targeted green fluorescent protein to monitor neurotoxic protein-dependent degeneration of Drosophila eyes.J Neurosci Res. 2014 Sep;92(9):1100-9. doi: 10.1002/jnr.23395. Epub 2014 May 2.
• [490] Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging.Hum Brain Mapp. 2018 Jul;39(7):3005-3017. doi: 10.1002/hbm.24056. Epub 2018 Mar 25.
• [491] microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia.Ann Diagn Pathol. 2018 Jun;34:103-109. doi: 10.1016/j.anndiagpath.2018.03.006. Epub 2018 Mar 26.
• [492] Apoptotic gene expression in Alzheimer's disease hippocampal tissue.Am J Alzheimers Dis Other Demen. 2007 Aug-Sep;22(4):319-28. doi: 10.1177/1533317507302447.
• [493] Bajijiasu Ameliorates -Amyloid-Triggered Endoplasmic Reticulum Stress and Related Pathologies in an Alzheimer's Disease Model.Cell Physiol Biochem. 2018;46(1):107-117. doi: 10.1159/000488414. Epub 2018 Mar 20.
• [494] GWAS on family history of Alzheimer's disease.Transl Psychiatry. 2018 May 18;8(1):99. doi: 10.1038/s41398-018-0150-6.
• [495] Antiapoptosis effect of ZiShen prescription to increase learning and memory abilities of compound Alzheimer's disease model rats.J Cell Biochem. 2019 Jul;120(7):11241-11247. doi: 10.1002/jcb.28399. Epub 2019 Feb 20.
• [496] Reserve and Alzheimer's disease genetic risk: Effects on hospitalization and mortality.Alzheimers Dement. 2019 Jul;15(7):907-916. doi: 10.1016/j.jalz.2019.04.005.
• [497] Beta-asarone improves cognitive function by suppressing neuronal apoptosis in the beta-amyloid hippocampus injection rats.Biol Pharm Bull. 2010;33(5):836-43. doi: 10.1248/bpb.33.836.
• [498] Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease.Int Immunopharmacol. 2002 Dec;2(13-14):1833-40. doi: 10.1016/s1567-5769(02)00168-6.
• [499] Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.Autophagy. 2020 Jan;16(1):28-37. doi: 10.1080/15548627.2019.1630223. Epub 2019 Jun 18.
• [500] Impaired brain glucose metabolism in patients with Down syndrome.J Neural Transm Suppl. 1999;57:247-56. doi: 10.1007/978-3-7091-6380-1_16.
• [501] Profiling donepezil template into multipotent hybrids with antioxidant properties.J Enzyme Inhib Med Chem. 2018 Dec;33(1):583-606. doi: 10.1080/14756366.2018.1443326.
• [502] Secreted type of amyloid precursor protein induces glial differentiation by stimulating the BMP/Smad signaling pathway.Biochem Biophys Res Commun. 2014 May 9;447(3):394-9. doi: 10.1016/j.bbrc.2014.03.139. Epub 2014 Apr 13.
• [503] BMP6 expression in the adult rat central nervous system.J Chem Neuroanat. 2019 Jul;98:41-54. doi: 10.1016/j.jchemneu.2019.03.004. Epub 2019 Mar 27.
• [504] Advanced Yeast Models of Familial Alzheimer Disease Expressing FAD-Linked Presenilin to Screen Mutations and -Secretase Modulators.Methods Mol Biol. 2019;2049:403-417. doi: 10.1007/978-1-4939-9736-7_23.
• [505] The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice.Transl Psychiatry. 2017 Sep 26;7(9):e1239. doi: 10.1038/tp.2017.202.
• [506] Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.Nature. 2012 Jan 25;482(7384):216-20. doi: 10.1038/nature10821.
• [507] Resveratrol Abrogates Hypoxia-Induced Up-Regulation of Exosomal Amyloid- Partially by Inhibiting CD147.Neurochem Res. 2019 May;44(5):1113-1126. doi: 10.1007/s11064-019-02742-3. Epub 2019 Feb 15.
• [508] Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target.Int J Mol Sci. 2019 Jun 22;20(12):3050. doi: 10.3390/ijms20123050.
• [509] Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3 signaling pathways.Eur J Pharmacol. 2019 May 5;850:135-140. doi: 10.1016/j.ejphar.2019.02.020. Epub 2019 Feb 14.
• [510] Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease.Neuron. 2018 Dec 19;100(6):1337-1353.e5. doi: 10.1016/j.neuron.2018.10.031. Epub 2018 Nov 8.
• [511] Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.J Neuroinflammation. 2011 Jan 15;8(1):4. doi: 10.1186/1742-2094-8-4.
• [512] Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob's disease.Parkinsonism Relat Disord. 2019 Jun;63:162-168. doi: 10.1016/j.parkreldis.2019.02.011. Epub 2019 Feb 13.
• [513] Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease.Biochem Biophys Res Commun. 2013 Jan 11;430(2):670-5. doi: 10.1016/j.bbrc.2012.11.093. Epub 2012 Dec 2.
• [514] Micro-RNA-137 Inhibits Tau Hyperphosphorylation in Alzheimer's Disease and Targets the CACNA1C Gene in Transgenic Mice and Human Neuroblastoma SH-SY5Y Cells.Med Sci Monit. 2018 Aug 13;24:5635-5644. doi: 10.12659/MSM.908765.
• [515] Genome-wide association study of the rate of cognitive decline in Alzheimer's disease.Alzheimers Dement. 2014 Jan;10(1):45-52. doi: 10.1016/j.jalz.2013.01.008. Epub 2013 Mar 25.
• [516] A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism.Alzheimers Res Ther. 2017 Jul 14;9(1):50. doi: 10.1186/s13195-017-0277-3.
• [517] Oxidatively-mediated in silico epimerization of a highly amyloidogenic segment in the human calcitonin hormone (hCT(15-19)).Comput Biol Chem. 2019 Jun;80:259-269. doi: 10.1016/j.compbiolchem.2019.04.005. Epub 2019 Apr 8.
• [518] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [519] Loss of Ca(2+)/Calmodulin Dependent Protein Kinase Kinase 2 Leads to Aberrant Transferrin Phosphorylation and Trafficking: A Potential Biomarker for Alzheimer's Disease.Front Mol Biosci. 2018 Nov 20;5:99. doi: 10.3389/fmolb.2018.00099. eCollection 2018.
• [520] Role of Microbes in the Development of Alzheimer's Disease: State of the Art - An International Symposium Presented at the 2017 IAGG Congress in San Francisco.Front Genet. 2018 Sep 10;9:362. doi: 10.3389/fgene.2018.00362. eCollection 2018.
• [521] Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies.Clin Pharmacol Drug Dev. 2019 Apr;8(3):290-303. doi: 10.1002/cpdd.598. Epub 2018 Jul 27.
• [522] Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects.Sci Rep. 2018 Sep 3;8(1):13119. doi: 10.1038/s41598-018-31073-6.
• [523] Involvement of NLRC4 inflammasome through caspase-1 and IL-1 augments neuroinflammation and contributes to memory impairment in an experimental model of Alzheimer's like disease.Brain Res Bull. 2020 Jan;154:81-90. doi: 10.1016/j.brainresbull.2019.10.010. Epub 2019 Nov 9.
• [524] A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease.Acta Neuropathol Commun. 2019 Jul 30;7(1):124. doi: 10.1186/s40478-019-0765-8.
• [525] Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice.Exp Mol Med. 2010 May 31;42(5):386-94. doi: 10.3858/emm.2010.42.5.040.
• [526] A loss of function variant in CASP7 protects against Alzheimer's disease in homozygous APOE 4 allele carriers.BMC Genomics. 2016 Jun 23;17 Suppl 2(Suppl 2):445. doi: 10.1186/s12864-016-2725-z.
• [527] Machine Learning From Molecular Dynamics Trajectories to Predict Caspase-8 Inhibitors Against Alzheimer's Disease.Front Pharmacol. 2019 Jul 12;10:780. doi: 10.3389/fphar.2019.00780. eCollection 2019.
• [528] CART peptide activates the Nrf2/HO-1 antioxidant pathway and protects hippocampal neurons in a rat model of Alzheimer's disease.Biochem Biophys Res Commun. 2018 Jul 2;501(4):1016-1022. doi: 10.1016/j.bbrc.2018.05.101. Epub 2018 May 18.
• [529] Related genes and potential biomarkers for early diagnosis of Alzheimer's disease: a preliminary study based on DNA microarray.Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):90-5. doi: 10.1177/1533317513506774. Epub 2013 Dec 30.
• [530] NK Cells are Activated in Amnestic Mild Cognitive Impairment but not in Mild Alzheimer's Disease Patients.J Alzheimers Dis. 2015;46(1):93-107. doi: 10.3233/JAD-143054.
• [531] Elevations in the Levels of NF-B and Inflammatory Chemotactic Factors in the Brains with Alzheimer's Disease - One Mechanism May Involve 3 Nicotinic Acetylcholine Receptor.Curr Alzheimer Res. 2016;13(11):1290-1301. doi: 10.2174/1567205013666160703174254.
• [532] The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.Alzheimers Dement. 2015 Oct;11(10):1163-70. doi: 10.1016/j.jalz.2014.10.013. Epub 2014 Dec 9.
• [533] Does retinoic acid reverse cell cycle dysregulation in Alzheimer's disease lymphocytes?.Asian J Psychiatr. 2019 Jan;39:174-177. doi: 10.1016/j.ajp.2018.08.010. Epub 2018 Aug 16.
• [534] Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease.Acta Neuropathol Commun. 2018 Sep 7;6(1):88. doi: 10.1186/s40478-018-0592-3.
• [535] The small molecular CCR3 antagonist YM344031 attenuates neurodegenerative pathologies and improves learning and memory performance in a mouse model of Alzheimer's disease.Brain Res. 2019 Sep 15;1719:1-10. doi: 10.1016/j.brainres.2019.05.022. Epub 2019 May 20.
• [536] CD200 dysfunction in neuron contributes to synaptic deficits and cognitive impairment.Biochem Biophys Res Commun. 2019 Sep 3;516(4):1053-1059. doi: 10.1016/j.bbrc.2019.06.134. Epub 2019 Jul 3.
• [537] TMEM119 marks a subset of microglia in the human brain.Neuropathology. 2016 Feb;36(1):39-49. doi: 10.1111/neup.12235. Epub 2015 Aug 6.
• [538] The soluble transcobalamin receptor (sCD320) in relation to Alzheimer's disease and cognitive scores.Scand J Clin Lab Invest. 2017 Sep;77(5):332-337. doi: 10.1080/00365513.2017.1323345. Epub 2017 May 9.
• [539] Correlation of gene polymorphisms of CD36 and ApoE with susceptibility of Alzheimer disease: A case-control study.Medicine (Baltimore). 2018 Sep;97(38):e12470. doi: 10.1097/MD.0000000000012470.
• [540] Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases.Neurologia (Engl Ed). 2022 Mar;37(2):110-121. doi: 10.1016/j.nrl.2018.10.004. Epub 2019 Mar 11.
• [541] Association of CSF CD40 levels and synaptic degeneration across the Alzheimer's disease spectrum.Neurosci Lett. 2019 Feb 16;694:41-45. doi: 10.1016/j.neulet.2018.11.019. Epub 2018 Nov 15.
• [542] Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma.Apoptosis. 2015 Dec;20(12):1587-98. doi: 10.1007/s10495-015-1171-8.
• [543] Reducing INS-IGF1 signaling protects against non-cell autonomous vesicle rupture caused by SNCA spreading.Autophagy. 2020 May;16(5):878-899. doi: 10.1080/15548627.2019.1643657. Epub 2019 Jul 29.
• [544] Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease.Neurology. 2006 May 23;66(10):1506-10. doi: 10.1212/01.wnl.0000216274.58185.09.
• [545] Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease.Neuroscience. 2001;105(3):639-50. doi: 10.1016/s0306-4522(01)00219-6.
• [546] Genome-wide pathway analysis of a genome-wide association study on Alzheimer's disease.Neurol Sci. 2015 Jan;36(1):53-9. doi: 10.1007/s10072-014-1885-3. Epub 2014 Jul 19.
• [547] GSK3beta activity modifies the localization and function of presenilin 1.J Biol Chem. 2007 May 25;282(21):15823-32. doi: 10.1074/jbc.M610708200. Epub 2007 Mar 27.
• [548] Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer's Disease Therapeutic Agents.Mar Drugs. 2017 Nov 27;15(12):366. doi: 10.3390/md15120366.
• [549] The regulation of tau phosphorylation by PCTAIRE 3: implications for the pathogenesis of Alzheimer's disease.Neurobiol Dis. 2006 Aug;23(2):398-408. doi: 10.1016/j.nbd.2006.04.004.
• [550] Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.J Biomol Struct Dyn. 2020 Jan;38(1):248-262. doi: 10.1080/07391102.2019.1571947. Epub 2019 Feb 21.
• [551] A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66.
• [552] Author Correction: C/EBP regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease.Nat Commun. 2019 Nov 26;10(1):5452. doi: 10.1038/s41467-019-13553-z.
• [553] ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease.Future Med Chem. 2015;7(18):2451-67. doi: 10.4155/fmc.15.161. Epub 2015 Dec 15.
• [554] Complement gene single nucleotide polymorphisms and biomarker endophenotypes of Alzheimer's disease.J Alzheimers Dis. 2013;35(1):51-7. doi: 10.3233/JAD-121930.
• [555] Intracerebroventricular administration of adiponectin attenuates streptozotocin-induced memory impairment in rats.Physiol Int. 2017 Jun 1;104(2):150-157. doi: 10.1556/2060.104.2017.1.4. Epub 2017 Apr 11.
• [556] A monoclonal antibody targeting amyloid (A) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer's disease.PLoS One. 2018 May 21;13(5):e0195751. doi: 10.1371/journal.pone.0195751. eCollection 2018.
• [557] Diagnostic pathology of Alzheimer's disease from routine microscopy to immunohistochemistry and experimental correlations.Ann Diagn Pathol. 2017 Jun;28:24-29. doi: 10.1016/j.anndiagpath.2017.02.006. Epub 2017 Feb 13.
• [558] Effects of hCG on reduced numbers of hCG receptors in the prefrontal cortex and cerebellum of rat models of Alzheimer's disease.Biotech Histochem. 2019 Jul;94(5):360-365. doi: 10.1080/10520295.2019.1571228. Epub 2019 Feb 14.
• [559] Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro.J Proteome Res. 2013 Jun 7;12(6):2654-65. doi: 10.1021/pr400008f. Epub 2013 Apr 26.
• [560] Chitotriosidase enhances TGF-Smad signaling and uptake of -amyloid in N9 microglia.Neurosci Lett. 2018 Nov 20;687:99-103. doi: 10.1016/j.neulet.2018.09.037. Epub 2018 Sep 21.
• [561] Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.Mol Psychiatry. 2016 Nov;21(11):1608-1612. doi: 10.1038/mp.2015.218. Epub 2016 Feb 2.
• [562] M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.J Clin Invest. 2017 Feb 1;127(2):487-499. doi: 10.1172/JCI87526. Epub 2016 Dec 19.
• [563] Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.Psychopharmacology (Berl). 2008 Jun;198(2):251-9. doi: 10.1007/s00213-008-1124-9. Epub 2008 Mar 30.
• [564] Extracellular Vesicles Isolated from Familial Alzheimer's Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain.J Alzheimers Dis. 2019;72(2):575-585. doi: 10.3233/JAD-190656.
• [565] Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats.Front Pharmacol. 2019 Feb 5;10:73. doi: 10.3389/fphar.2019.00073. eCollection 2019.
• [566] Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An (123)I-FP-CIT SPECT study.Neuroimage Clin. 2020;25:102062. doi: 10.1016/j.nicl.2019.102062. Epub 2019 Nov 1.
• [567] Characterizing the new transcription regulator protein p60TRP.J Cell Biochem. 2004 Apr 1;91(5):1030-42. doi: 10.1002/jcb.20010.
• [568] Genomic and nongenomic signaling induced by 1,25(OH)2-vitamin D3 promotes the recovery of amyloid- phagocytosis by Alzheimer's disease macrophages.J Alzheimers Dis. 2012;29(1):51-62. doi: 10.3233/JAD-2012-110560.
• [569] Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.Eur J Med Chem. 2017 Jan 27;126:754-761. doi: 10.1016/j.ejmech.2016.11.003. Epub 2016 Nov 18.
• [570] The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease.J Neurochem. 2006 Feb;96(3):635-44. doi: 10.1111/j.1471-4159.2005.03552.x. Epub 2005 Dec 20.
• [571] An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect.Mol Cell Biol. 2018 Sep 28;38(20):e00011-18. doi: 10.1128/MCB.00011-18. Print 2018 Oct 15.
• [572] CNP and DPYSL2 mRNA expression and promoter methylation levels in brain of Alzheimer's disease patients.J Alzheimers Dis. 2013;33(2):349-55. doi: 10.3233/JAD-2012-121192.
• [573] [(18)F]FMPEP-d(2) PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease.Neurobiol Aging. 2018 Sep;69:199-208. doi: 10.1016/j.neurobiolaging.2018.05.013. Epub 2018 May 18.
• [574] Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer's Disease.Curr Neuropharmacol. 2019;17(2):176-183. doi: 10.2174/1570159X16666180702144644.
• [575] Neurotrophic interactions between neurons and astrocytes following AAV1-Rheb(S16H) transduction in the hippocampus in vivo.Br J Pharmacol. 2020 Feb;177(3):668-686. doi: 10.1111/bph.14882. Epub 2019 Dec 27.
• [576] Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.Alzheimers Res Ther. 2018 Jun 1;10(1):52. doi: 10.1186/s13195-018-0383-x.
• [577] Protective Effects of L-3-n-Butylphthalide Against H(2)O(2)-Induced Injury in Neural Stem Cells by Activation of PI3K/Akt and Mash1 Pathway.Neuroscience. 2018 Nov 21;393:164-174. doi: 10.1016/j.neuroscience.2018.10.003. Epub 2018 Oct 12.
• [578] The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases.Neurosci Lett. 2005 Jul 1-8;382(1-2):175-8. doi: 10.1016/j.neulet.2005.03.008. Epub 2005 Apr 2.
• [579] A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus.Eur J Neurosci. 2000 Jan;12(1):227-38. doi: 10.1046/j.1460-9568.2000.00908.x.
• [580] A human carboxypeptidase E/NF-1 gene mutation in an Alzheimer's disease patient leads to dementia and depression in mice.Transl Psychiatry. 2016 Dec 6;6(12):e973. doi: 10.1038/tp.2016.237.
• [581] Absence of Chlamydia pneumoniae in brain of vascular dementia patients.Neurobiol Aging. 2003 Oct;24(6):761-5. doi: 10.1016/s0197-4580(02)00236-1.
• [582] In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes.J Mol Neurosci. 2018 Mar;64(3):385-396. doi: 10.1007/s12031-018-1035-0. Epub 2018 Feb 13.
• [583] MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an A(1-42)-induced model of Alzheimer's disease.Aging Cell. 2020 Jan;19(1):e13046. doi: 10.1111/acel.13046. Epub 2019 Oct 17.
• [584] Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.Transl Psychiatry. 2019 Oct 22;9(1):272. doi: 10.1038/s41398-019-0581-8.
• [585] Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease.Cereb Cortex. 2017 Feb 1;27(2):1501-1511. doi: 10.1093/cercor/bhv332.
• [586] p38 MAPK-dependent alphaB-crystallin phosphorylation in Alzheimer's disease-like pathology in OXYS rats.Exp Gerontol. 2019 May;119:45-52. doi: 10.1016/j.exger.2019.01.017. Epub 2019 Jan 19.
• [587] Association of NAD(P)H:quinone oxidoreductase 1 polymorphism and Alzheimer's disease in Chinese.J Mol Neurosci. 2008 Mar;34(3):235-40. doi: 10.1007/s12031-008-9036-z. Epub 2008 Feb 6.
• [588] The T9861C Mutation in the mtDNA-Encoded Cytochrome C Oxidase Subunit III Gene Occurs in High Frequency but with Unequal Distribution in the Alzheimer's Disease Brain.J Alzheimers Dis. 2019;72(1):257-269. doi: 10.3233/JAD-190176.
• [589] Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimer's disease by evaluating protein interactions through molecular docking and dynamic simulations.Neurol Sci. 2018 Aug;39(8):1361-1374. doi: 10.1007/s10072-018-3430-2. Epub 2018 May 22.
• [590] Studies on Colony Stimulating Factor Receptor-1 and Ligands Colony Stimulating Factor-1 and Interleukin-34 in Alzheimer's Disease Brains and Human Microglia.Front Aging Neurosci. 2017 Aug 9;9:244. doi: 10.3389/fnagi.2017.00244. eCollection 2017.
• [591] Intracerebral GM-CSF contributes to transendothelial monocyte migration in APP/PS1 Alzheimer's disease mice.J Cereb Blood Flow Metab. 2016 Nov;36(11):1978-1991. doi: 10.1177/0271678X16660983. Epub 2016 Jul 21.
• [592] A novel hypothesis-unbiased method for Gene Ontology enrichment based on transcriptome data.PLoS One. 2017 Feb 15;12(2):e0170486. doi: 10.1371/journal.pone.0170486. eCollection 2017.
• [593] Elevation of casein kinase 1 associated with TDP-43 and tau pathologies in Alzheimer's disease.Brain Pathol. 2020 Mar;30(2):283-297. doi: 10.1111/bpa.12775. Epub 2019 Aug 22.
• [594] Altered expression of protein p42IP4/centaurin-alpha 1 in Alzheimer's disease brains and possible interaction of p42IP4 with nucleolin.Neuroreport. 2004 Jan 19;15(1):147-8. doi: 10.1097/00001756-200401190-00028.
• [595] Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease.Neurobiol Aging. 2013 Jul;34(7):1748-58. doi: 10.1016/j.neurobiolaging.2012.12.025. Epub 2013 Jan 29.
• [596] Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease.FASEB J. 2019 Jan;33(1):231-238. doi: 10.1096/fj.201801001. Epub 2018 Jun 20.
• [597] PM20D1 is aquantitative trait locus associated with Alzheimer's disease.Nat Med. 2018 May;24(5):598-603. doi: 10.1038/s41591-018-0013-y. Epub 2018 May 7.
• [598] The Effects of Cardiotrophin-1 on Early Synaptic Mitochondrial Dysfunction and Synaptic Pathology in APPswe/PS1dE9 Mice.J Alzheimers Dis. 2017;59(4):1255-1267. doi: 10.3233/JAD-170100.
• [599] GM6 Attenuates Alzheimer's Disease Pathology in APP Mice.Mol Neurobiol. 2019 Sep;56(9):6386-6396. doi: 10.1007/s12035-019-1517-2. Epub 2019 Feb 23.
• [600] Neuroprotective role of -enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X.Aging Cell. 2013 Aug;12(4):604-14. doi: 10.1111/acel.12093. Epub 2013 May 27.
• [601] Emerging roles of microglial cathepsins in neurodegenerative disease.Brain Res Bull. 2018 May;139:144-156. doi: 10.1016/j.brainresbull.2018.02.014. Epub 2018 Feb 15.
• [602] CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.Adv Clin Exp Med. 2018 Jun;27(6):849-856. doi: 10.17219/acem/68846.
• [603] Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer's Mice and in Human Patients.Curr Alzheimer Res. 2015;12(8):752-60. doi: 10.2174/1567205012666150710114256.
• [604] Depletion of CXCR2 inhibits -secretase activity and amyloid- production in a murine model of Alzheimer's disease.Cytokine. 2011 Feb;53(2):163-9. doi: 10.1016/j.cyto.2010.10.008. Epub 2010 Nov 16.
• [605] Electroacupuncture ameliorates spatial learning and memory impairment via attenuating NOX2-related oxidative stress in a rat model of Alzheimer's disease induced by A1-42.Cell Mol Biol (Noisy-le-grand). 2017 Apr 29;63(4):38-45. doi: 10.14715/cmb/2017.63.4.7.
• [606] Genetic Polymorphisms in Estrogen Metabolic Pathway Associated with Risks of Alzheimer's Disease: Evidence from a Southern Chinese Population.J Am Geriatr Soc. 2017 Feb;65(2):332-339. doi: 10.1111/jgs.14537. Epub 2017 Jan 19.
• [607] Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population.Neurosci Lett. 2016 Apr 8;618:77-82. doi: 10.1016/j.neulet.2016.02.053. Epub 2016 Mar 3.
• [608] Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective.Transl Neurosci. 2019 Nov 6;10:264-279. doi: 10.1515/tnsci-2019-0043. eCollection 2019.
• [609] Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer's Disease.Front Aging Neurosci. 2018 Mar 6;10:48. doi: 10.3389/fnagi.2018.00048. eCollection 2018.
• [610] Genetics of Alzheimer's disease. A rapidly evolving field.J Alzheimers Dis. 2007 Aug;12(1):73-92. doi: 10.3233/jad-2007-12108.
• [611] Early diagnosis of mild cognitive impairment and Alzheimer's with event-related potentials and event-related desynchronization in N-back working memory tasks.Comput Methods Programs Biomed. 2018 Oct;164:1-13. doi: 10.1016/j.cmpb.2018.06.011. Epub 2018 Jun 27.
• [612] CYP2J2 rs890293 polymorphism is associated with susceptibility to Alzheimer's disease in the Chinese Han population.Neurosci Lett. 2015 Apr 23;593:56-60. doi: 10.1016/j.neulet.2015.03.024. Epub 2015 Mar 18.
• [613] The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia.Front Pharmacol. 2019 May 22;10:540. doi: 10.3389/fphar.2019.00540. eCollection 2019.
• [614] RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.Mol Neurobiol. 2016 Jul;53(5):2857-2868. doi: 10.1007/s12035-015-9166-6. Epub 2015 Apr 16.
• [615] Neprilysin protects against cerebral amyloid angiopathy and A-induced degeneration of cerebrovascular smooth muscle cells.Brain Pathol. 2011 Sep;21(5):594-605. doi: 10.1111/j.1750-3639.2011.00486.x. Epub 2011 Apr 3.
• [616] Relevance of defensin -2 and defensins (HNP1-3) in Alzheimer's disease.Psychiatry Res. 2016 May 30;239:342-5. doi: 10.1016/j.psychres.2016.03.045. Epub 2016 Mar 31.
• [617] Neuroanatomical Distribution of DEK Protein in Corticolimbic Circuits Associated with Learning and Memory in Adult Male and Female Mice.Neuroscience. 2018 Feb 10;371:254-267. doi: 10.1016/j.neuroscience.2017.11.025. Epub 2017 Nov 23.
• [618] Elucidating the role of DEPTOR in Alzheimer's disease.Int J Mol Med. 2014 Nov;34(5):1195-200. doi: 10.3892/ijmm.2014.1895. Epub 2014 Aug 12.
• [619] Diacylglycerol kinase control of protein kinase C.Biochem J. 2019 Apr 18;476(8):1205-1219. doi: 10.1042/BCJ20180620.
• [620] The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe.J Clin Endocrinol Metab. 2007 Feb;92(2):636-40. doi: 10.1210/jc.2006-1331. Epub 2006 Nov 14.
• [621] A novel high-content imaging-based technique for measuring binding of Dickkopf-1 to low-density lipoprotein receptor-related protein 6.J Pharmacol Toxicol Methods. 2019 Jan-Feb;95:47-55. doi: 10.1016/j.vascn.2018.11.003. Epub 2018 Nov 23.
• [622] The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to A Plaques.Cell Rep. 2019 Apr 23;27(4):1293-1306.e6. doi: 10.1016/j.celrep.2019.03.099.
• [623] Relative D3 vitamin deficiency and consequent cognitive impairment in an animal model of Alzheimer's disease: Potential involvement of collapsin response mediator protein-2.Neuropharmacology. 2020 Mar 1;164:107910. doi: 10.1016/j.neuropharm.2019.107910. Epub 2019 Dec 12.
• [624] Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease.J Alzheimers Dis. 2006 Jul;9(2):167-81. doi: 10.3233/jad-2006-9209.
• [625] In silico analyses for molecular genetic mechanism and candidate genes in patients with Alzheimer's disease.Acta Neurol Belg. 2016 Dec;116(4):543-547. doi: 10.1007/s13760-016-0613-6. Epub 2016 Mar 2.
• [626] Overexpression of DNAse I in brain of patients with Down syndrome.J Neural Transm Suppl. 1999;57:353-62. doi: 10.1007/978-3-7091-6380-1_25.
• [627] Dynamin-2 in nervous system disorders.J Neurochem. 2014 Jan;128(2):210-23. doi: 10.1111/jnc.12455. Epub 2013 Oct 23.
• [628] Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation.J Alzheimers Dis. 2018;65(1):221-230. doi: 10.3233/JAD-180293.
• [629] Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.Adv Exp Med Biol. 2019;1128:227-248. doi: 10.1007/978-981-13-3540-2_11.
• [630] The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.J Neurochem. 2020 Jan;152(2):235-251. doi: 10.1111/jnc.14898. Epub 2019 Nov 4.
• [631] Elevated DRD4 promoter methylation increases the risk of Alzheimer's disease in males.Mol Med Rep. 2016 Sep;14(3):2732-8. doi: 10.3892/mmr.2016.5560. Epub 2016 Jul 27.
• [632] CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease.Alzheimers Dement. 2019 Feb;15(2):217-231. doi: 10.1016/j.jalz.2018.08.013. Epub 2018 Oct 12.
• [633] MKP-1 reduces A generation and alleviates cognitive impairments in Alzheimer's disease models.Signal Transduct Target Ther. 2019 Dec 6;4:58. doi: 10.1038/s41392-019-0091-4. eCollection 2019.
• [634] microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.Neurosci Lett. 2020 Jan 1;714:134541. doi: 10.1016/j.neulet.2019.134541. Epub 2019 Oct 9.
• [635] A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy.JAMA Neurol. 2015 Apr;72(4):414-22. doi: 10.1001/jamaneurol.2014.4040.
• [636] Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice.J Clin Invest. 2019 Feb 1;129(2):820-833. doi: 10.1172/JCI122954. Epub 2019 Jan 22.
• [637] Direct quantification of intact FIM in monkey plasma using a selective chromatography-tandem mass spectrometry method: Application in a pharmacokinetic study.Biomed Chromatogr. 2020 Feb;34(2):e4729. doi: 10.1002/bmc.4729. Epub 2020 Jan 14.
• [638] Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease.Brain. 2019 Mar 1;142(3):787-807. doi: 10.1093/brain/awy354.
• [639] PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions.Aging Cell. 2019 Jun;18(3):e12887. doi: 10.1111/acel.12887. Epub 2019 Mar 1.
• [640] Inhibition of the PERK-Dependent Unfolded Protein Response Signaling Pathway Involved in the Pathogenesis of Alzheimer's Disease.Curr Alzheimer Res. 2019;16(3):209-218. doi: 10.2174/1567205016666190228121157.
• [641] Suppression of eIF2 kinases alleviates Alzheimer's disease-related plasticity and memory deficits.Nat Neurosci. 2013 Sep;16(9):1299-305. doi: 10.1038/nn.3486. Epub 2013 Aug 11.
• [642] Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease.Sci Rep. 2019 Oct 28;9(1):15437. doi: 10.1038/s41598-019-51837-y.
• [643] Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders.Free Radic Biol Med. 2017 Oct;111:253-261. doi: 10.1016/j.freeradbiomed.2016.10.490. Epub 2016 Oct 24.
• [644] Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid- and Tau Pathology.J Alzheimers Dis. 2017;58(1):203-214. doi: 10.3233/JAD-161265.
• [645] Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases.Curr Mol Med. 2015;15(10):932-43. doi: 10.2174/1566524015666150921104804.
• [646] EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease.Alzheimers Res Ther. 2019 Dec 12;11(1):102. doi: 10.1186/s13195-019-0554-4.
• [647] Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease.Int J Clin Exp Pathol. 2015 Jul 1;8(7):7710-28. eCollection 2015.
• [648] The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.Curr Alzheimer Res. 2019;16(4):281-292. doi: 10.2174/1567205016666190228120254.
• [649] Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment.J Neuropathol Exp Neurol. 2007 May;66(5):389-98. doi: 10.1097/nen.0b013e3180517b28.
• [650] Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease.Neurobiol Dis. 2017 Oct;106:171-180. doi: 10.1016/j.nbd.2017.07.001. Epub 2017 Jul 4.
• [651] Estrogen-related receptor alpha is involved in Alzheimer's disease-like pathology.Exp Neurol. 2018 Jul;305:89-96. doi: 10.1016/j.expneurol.2018.04.003. Epub 2018 Apr 8.
• [652] Role of PTA in the prevention of Cu(amyloid-) induced ROS formation and amyloid- oligomerisation in the presence of Zn.Metallomics. 2019 Jun 19;11(6):1154-1161. doi: 10.1039/c9mt00011a.
• [653] Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.J Neurovirol. 2019 Oct;25(5):702-709. doi: 10.1007/s13365-018-0695-4. Epub 2019 Jan 4.
• [654] A Short Isoform of Coagulation Factor XII mRNA Is Expressed by Neurons in the Human Brain.Neuroscience. 2019 Aug 10;413:294-307. doi: 10.1016/j.neuroscience.2019.05.040. Epub 2019 Jun 8.
• [655] Coagulation factor XIIIa cross-links amyloid into dimers and oligomers and to blood proteins.J Biol Chem. 2019 Jan 11;294(2):390-396. doi: 10.1074/jbc.RA118.005352. Epub 2018 Nov 8.
• [656] Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease.J Biol Chem. 2001 Feb 2;276(5):3295-301. doi: 10.1074/jbc.M004776200. Epub 2000 Sep 29.
• [657] Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.PLoS One. 2016 Jul 20;11(7):e0158114. doi: 10.1371/journal.pone.0158114. eCollection 2016.
• [658] Regulation of Cell Polarity by PAR-1/MARK Kinase.Curr Top Dev Biol. 2017;123:365-397. doi: 10.1016/bs.ctdb.2016.11.001. Epub 2016 Dec 5.
• [659] Toll-like receptor 4 and protease-activated receptor 2 in physiology and pathophysiology of the nervous system: more than just receptor cooperation?.Neural Regen Res. 2019 Jul;14(7):1196-1201. doi: 10.4103/1673-5374.251290.
• [660] Par3 and aPKC regulate BACE1 endosome-to-TGN trafficking throughPACS1.Neurobiol Aging. 2017 Dec;60:129-140. doi: 10.1016/j.neurobiolaging.2017.08.024. Epub 2017 Sep 21.
• [661] pH-Induced Folding of the Caspase-Cleaved Par-4 Tumor Suppressor: Evidence of Structure Outside of the Coiled Coil Domain.Biomolecules. 2018 Dec 4;8(4):162. doi: 10.3390/biom8040162.
• [662] Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.Alzheimers Res Ther. 2018 Sep 25;10(1):98. doi: 10.1186/s13195-018-0426-3.
• [663] Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels.J Neurochem. 2018 Jul;146(2):186-197. doi: 10.1111/jnc.14342.
• [664] Fas-associated factor 1 and Parkinson's disease.Neurobiol Dis. 2008 Sep;31(3):309-15. doi: 10.1016/j.nbd.2008.05.006. Epub 2008 May 29.
• [665] The protective role of endogenous n-3 polyunsaturated fatty acids in Tau Alzheimer's disease mouse model.Int J Neurosci. 2019 Apr;129(4):325-336. doi: 10.1080/00207454.2018.1533824. Epub 2018 Nov 2.
• [666] Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.J Med Chem. 2014 Jul 10;57(13):5764-76. doi: 10.1021/jm500629e. Epub 2014 Jun 23.
• [667] A multimodal RAGE-specific inhibitor reduces amyloid -mediated brain disorder in a mouse model of Alzheimer disease.J Clin Invest. 2012 Apr;122(4):1377-92. doi: 10.1172/JCI58642. Epub 2012 Mar 12.
• [668] GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer's disease.Neuropharmacology. 2020 Mar 1;164:107899. doi: 10.1016/j.neuropharm.2019.107899. Epub 2019 Dec 3.
• [669] PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Exp Neurol. 2017 Sep;295:1-17. doi: 10.1016/j.expneurol.2017.05.005. Epub 2017 May 15.
• [670] Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer's disease.Redox Biol. 2019 Apr;22:101133. doi: 10.1016/j.redox.2019.101133. Epub 2019 Feb 1.
• [671] FKBP12 regulates the localization and processing of amyloid precursor protein in human cell lines.J Biosci. 2014 Mar;39(1):85-95. doi: 10.1007/s12038-013-9400-1.
• [672] Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer's disease.Mol Psychiatry. 2021 Mar;26(3):888-896. doi: 10.1038/s41380-019-0458-5. Epub 2019 Jul 22.
• [673] N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.Prog Neurobiol. 2020 Jan;184:101722. doi: 10.1016/j.pneurobio.2019.101722. Epub 2019 Nov 12.
• [674] Enhanced folate binding of cultured fibroblasts from Alzheimer's disease patients.Neurosci Lett. 2008 May 16;436(3):317-20. doi: 10.1016/j.neulet.2008.03.046. Epub 2008 Mar 21.
• [675] Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease.Curr Alzheimer Res. 2019;16(7):596-612. doi: 10.2174/1567205016666190725130134.
• [676] Influence of variation in the follicle-stimulating hormone receptor gene (FSHR) and age at menopause on the development of Alzheimer's disease in women.Dement Geriatr Cogn Disord. 2011;32(1):63-9. doi: 10.1159/000330472. Epub 2011 Aug 24.
• [677] Multitarget Drug Design, Molecular Docking and PLIF Studies of Novel Tacrine-Coumarin Hybrids for the Treatment of Alzheimer's Disease.Iran J Pharm Res. 2018 Fall;17(4):1217-1228.
• [678] FTO is involved in Alzheimer's disease by targeting TSC1-mTOR-Tau signaling.Biochem Biophys Res Commun. 2018 Mar 25;498(1):234-239. doi: 10.1016/j.bbrc.2018.02.201. Epub 2018 Mar 2.
• [679] Panaxadiol inhibits synaptic dysfunction in Alzheimer's disease and targets the Fyn protein in APP/PS1 mice and APP-SH-SY5Y cells.Life Sci. 2019 Mar 15;221:35-46. doi: 10.1016/j.lfs.2019.02.012. Epub 2019 Feb 5.
• [680] Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-induced Alzheimer's disease.Eur J Pharmacol. 2018 Jan 5;818:381-399. doi: 10.1016/j.ejphar.2017.11.012. Epub 2017 Nov 11.
• [681] Early-stage attenuation of phase-amplitude coupling in the hippocampus and medial prefrontal cortex in a transgenic rat model of Alzheimer's disease.J Neurochem. 2018 Mar;144(5):669-679. doi: 10.1111/jnc.14136. Epub 2017 Oct 10.
• [682] Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer's disease and Lewy body disorders.Neuropathol Appl Neurobiol. 2020 Apr;46(3):264-278. doi: 10.1111/nan.12577. Epub 2019 Oct 1.
• [683] Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer's disease.Theranostics. 2019 Apr 12;9(8):2268-2281. doi: 10.7150/thno.30649. eCollection 2019.
• [684] Potential interaction between the GARS-AIRS-GART Gene and CP2/LBP-1c/LSF transcription factor in Down syndrome-related Alzheimer disease.Cell Mol Neurobiol. 2007 Dec;27(8):1117-26. doi: 10.1007/s10571-007-9217-2. Epub 2007 Sep 28.
• [685] Dysregulation of TLR5 and TAM Ligands in the Alzheimer's Brain as Contributors to Disease Progression.Mol Neurobiol. 2019 Sep;56(9):6539-6550. doi: 10.1007/s12035-019-1540-3. Epub 2019 Mar 9.
• [686] Cognitive decline in Parkinson disease.Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3.
• [687] Effects of Transplanted Umbilical Cord Blood Mononuclear Cells Overexpressing GDNF on Spatial Memory and Hippocampal Synaptic Proteins in a Mouse Model of Alzheimer's Disease.J Alzheimers Dis. 2019;69(2):443-453. doi: 10.3233/JAD-190150.
• [688] Involvement of Oligodendrocytes in Tau Seeding and Spreading in Tauopathies.Front Aging Neurosci. 2019 May 28;11:112. doi: 10.3389/fnagi.2019.00112. eCollection 2019.
• [689] Differential Fasting Plasma Glucose and Ketone Body Levels in GHRKO versus 3xTg-AD Mice: A Potential Contributor to Aging-Related Cognitive Status?.Int J Endocrinol. 2017;2017:9684061. doi: 10.1155/2017/9684061. Epub 2017 May 30.
• [690] Disrupted hippocampal growth hormone secretagogue receptor 1 interaction with dopamine receptor D1 plays a role in Alzheimer's disease.Sci Transl Med. 2019 Aug 14;11(505):eaav6278. doi: 10.1126/scitranslmed.aav6278.
• [691] GLP-1's role in neuroprotection: a systematic review.Brain Inj. 2019;33(6):734-819. doi: 10.1080/02699052.2019.1587000. Epub 2019 Apr 2.
• [692] Drebrins and Connexins: A Biomedical Perspective.Adv Exp Med Biol. 2017;1006:225-247. doi: 10.1007/978-4-431-56550-5_13.
• [693] Proteostasis failure and cellular senescence in long-term cultured postmitotic rat neurons.Aging Cell. 2020 Jan;19(1):e13071. doi: 10.1111/acel.13071. Epub 2019 Nov 25.
• [694] Neuroprotective effects of INT-777 against A(1-42)-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice.Brain Behav Immun. 2018 Oct;73:533-545. doi: 10.1016/j.bbi.2018.06.018. Epub 2018 Jun 20.
• [695] Oxabicycloheptene Sulfonate Protects Against -Amyloid-induced Toxicity by Activation of PI3K/Akt and ERK Signaling Pathways Via GPER1 in C6 Cells.Neurochem Res. 2017 Aug;42(8):2246-2256. doi: 10.1007/s11064-017-2237-5. Epub 2017 Apr 4.
• [696] Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic Creutzfeldt-Jakob disease and the implication of glycolytic enzymes in prion-induced pathology.J Proteome Res. 2010 Nov 5;9(11):5646-57. doi: 10.1021/pr1004604. Epub 2010 Oct 13.
• [697] Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia.Acta Neuropathol Commun. 2018 Oct 19;6(1):108. doi: 10.1186/s40478-018-0612-3.
• [698] The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid .FEBS J. 2019 Jun;286(12):2355-2365. doi: 10.1111/febs.14819. Epub 2019 Apr 8.
• [699] APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease.Mol Psychiatry. 2016 Jul;21(7):916-24. doi: 10.1038/mp.2015.177. Epub 2015 Dec 1.
• [700] Development of a High-Throughput Screening-Compatible Assay for Discovery of GPR3 Inverse Agonists Using a cAMP Biosensor.SLAS Discov. 2020 Mar;25(3):287-298. doi: 10.1177/2472555219875101. Epub 2019 Sep 13.
• [701] Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia.Curr Neuropharmacol. 2020;18(1):2-13. doi: 10.2174/1570159X17666190704153807.
• [702] GPR3 and GPR6, novel molecular targets for cannabidiol.Biochem Biophys Res Commun. 2017 Aug 12;490(1):17-21. doi: 10.1016/j.bbrc.2017.05.165. Epub 2017 May 29.
• [703] Association of GPX1 and GPX4 polymorphisms with episodic memory and Alzheimer's disease.Neurosci Lett. 2018 Feb 14;666:32-37. doi: 10.1016/j.neulet.2017.12.026. Epub 2017 Dec 12.
• [704] Cellular levels of Grb2 and cytoskeleton stability are correlated in a neurodegenerative scenario.Dis Model Mech. 2017 May 1;10(5):655-669. doi: 10.1242/dmm.027748. Epub 2017 Mar 30.
• [705] APP depletion alters selective pre- and post-synaptic proteins.Mol Cell Neurosci. 2019 Mar;95:86-95. doi: 10.1016/j.mcn.2019.02.003. Epub 2019 Feb 11.
• [706] Collapsin response mediator protein 5 (CRMP5) causes social deficits and accelerates memory loss in an animal model of Alzheimer's disease.Neuropharmacology. 2019 Oct;157:107673. doi: 10.1016/j.neuropharm.2019.107673. Epub 2019 Jun 21.
• [707] NPTX2 and cognitive dysfunction in Alzheimer's Disease.Elife. 2017 Mar 23;6:e23798. doi: 10.7554/eLife.23798.
• [708] Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease.J Alzheimers Dis. 2007 Mar;11(1):97-116. doi: 10.3233/jad-2007-11113.
• [709] Probing the putative 7 nAChR/NMDAR complex in human and murine cortex and hippocampus: Different degrees of complex formation in healthy and Alzheimer brain tissue.PLoS One. 2017 Dec 20;12(12):e0189513. doi: 10.1371/journal.pone.0189513. eCollection 2017.
• [710] Unchanged type 1 metabotropic glutamate receptor availability in patients with Alzheimer's disease: A study using (11)C-ITMM positron emission tomography.Neuroimage Clin. 2019;22:101783. doi: 10.1016/j.nicl.2019.101783. Epub 2019 Mar 16.
• [711] Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease.J Chem Neuroanat. 2011 Oct;42(2):111-7. doi: 10.1016/j.jchemneu.2011.02.004. Epub 2011 Mar 17.
• [712] Amyloid-beta neurotoxicity and clearance are both regulated by glial group II metabotropic glutamate receptors.Neuropharmacology. 2017 Sep 1;123:274-286. doi: 10.1016/j.neuropharm.2017.05.008. Epub 2017 May 8.
• [713] Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer's Disease.Curr Top Med Chem. 2019;19(7):501-533. doi: 10.2174/1568026619666190304153353.
• [714] Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.Eur J Med Chem. 2019 Apr 15;168:58-77. doi: 10.1016/j.ejmech.2018.12.063. Epub 2019 Feb 13.
• [715] Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer's disease.Biomed Pharmacother. 2018 Jan;97:1096-1101. doi: 10.1016/j.biopha.2017.11.047. Epub 2017 Nov 10.
• [716] A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer's Disease and MCI Patients: Implications for Regenerative Medicine Approaches.Int J Mol Sci. 2017 Aug 19;18(8):1806. doi: 10.3390/ijms18081806.
• [717] Systemic hepcidin quantified with LC-MS/MS in dementia in association with disease pathology and severity and with structural changes in the brain.Peptides. 2019 Dec;122:170169. doi: 10.1016/j.peptides.2019.170169. Epub 2019 Sep 26.
• [718] Novel sulfamate derivatives of menthol: Synthesis, characterization, and cholinesterases and carbonic anhydrase enzymes inhibition properties.Arch Pharm (Weinheim). 2018 Nov;351(11):e1800209. doi: 10.1002/ardp.201800209. Epub 2018 Sep 26.
• [719] Inhibition of hematopoietic cell kinase dysregulates microglial function and accelerates early stage Alzheimer's disease-like neuropathology.Glia. 2018 Dec;66(12):2700-2718. doi: 10.1002/glia.23522. Epub 2018 Sep 12.
• [720] Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and A generation in Alzheimer's disease.Mol Neurodegener. 2012 Oct 3;7:50. doi: 10.1186/1750-1326-7-50.
• [721] Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer's Disease.J Alzheimers Dis. 2020;73(1):117-123. doi: 10.3233/JAD-190958.
• [722] Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease).Curr Alzheimer Res. 2016;13(12):1397-1406. doi: 10.2174/1567205013666160603005630.
• [723] Re-exploring the core genes and modules in the human frontal cortex during chronological aging: insights from network-based analysis of transcriptomic studies.Aging (Albany NY). 2018 Oct 20;10(10):2816-2831. doi: 10.18632/aging.101589.
• [724] Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease.J Alzheimers Dis. 2018;62(1):115-131. doi: 10.3233/JAD-171032.
• [725] Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.Aging Cell. 2020 Jan;19(1):e13081. doi: 10.1111/acel.13081. Epub 2019 Nov 25.
• [726] Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?.ChemMedChem. 2019 Jun 5;14(11):1067-1073. doi: 10.1002/cmdc.201900174. Epub 2019 May 2.
• [727] Alterations in the histaminergic system in Alzheimer's disease: a postmortem study.Neurobiol Aging. 2012 Nov;33(11):2585-98. doi: 10.1016/j.neurobiolaging.2011.12.026. Epub 2012 Jan 26.
• [728] Panax Notoginseng Saponins Ameliorate A-Mediated Neurotoxicity in C. elegans through Antioxidant Activities.Evid Based Complement Alternat Med. 2019 Jun 4;2019:7621043. doi: 10.1155/2019/7621043. eCollection 2019.
• [729] Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease.Neurosci Lett. 2009 Aug 28;460(2):180-4. doi: 10.1016/j.neulet.2009.05.058. Epub 2009 May 27.
• [730] Characterization of circRNA-Associated-ceRNA Networks in a Senescence-Accelerated Mouse Prone 8 Brain.Mol Ther. 2017 Sep 6;25(9):2053-2061. doi: 10.1016/j.ymthe.2017.06.009. Epub 2017 Jun 29.
• [731] HMGCS2 promotes autophagic degradation of the amyloid- precursor protein through ketone body-mediated mechanisms.Biochem Biophys Res Commun. 2017 Apr 29;486(2):492-498. doi: 10.1016/j.bbrc.2017.03.069. Epub 2017 Mar 18.
• [732] RNA editing alterations in a multi-ethnic Alzheimer disease cohort converge on immune and endocytic molecular pathways.Hum Mol Genet. 2019 Sep 15;28(18):3053-3061. doi: 10.1093/hmg/ddz110.
• [733] Immunohistochemical study of hnRNP B1 in the postmortem temporal cortices of patients with Alzheimer's disease.Neurosci Res. 2004 Dec;50(4):481-4. doi: 10.1016/j.neures.2004.08.013.
• [734] GSTM1 Null Genotype and GSTP1 Ile105Val Polymorphism Are Associated with Alzheimer's Disease: a Meta-Analysis.Mol Neurobiol. 2016 Mar;53(2):1355-1364. doi: 10.1007/s12035-015-9092-7. Epub 2015 Jan 30.
• [735] Heparanase protects the heart against chemical or ischemia/reperfusion injury.J Mol Cell Cardiol. 2019 Jun;131:29-40. doi: 10.1016/j.yjmcc.2019.04.008. Epub 2019 Apr 17.
• [736] Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease.PLoS One. 2019 Jul 8;14(7):e0218111. doi: 10.1371/journal.pone.0218111. eCollection 2019.
• [737] Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives.Bioorg Chem. 2019 Sep;90:103084. doi: 10.1016/j.bioorg.2019.103084. Epub 2019 Jun 26.
• [738] A Novel (18)F-Labeled Radioligand for Positron Emission Tomography Imaging of 11-Hydroxysteroid Dehydrogenase (11-HSD1): Synthesis and Preliminary Evaluation in Nonhuman Primates.ACS Chem Neurosci. 2019 May 15;10(5):2450-2458. doi: 10.1021/acschemneuro.8b00715. Epub 2019 Feb 19.
• [739] Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease.Neurobiol Aging. 2011 Nov;32(11):1964-76. doi: 10.1016/j.neurobiolaging.2009.12.014. Epub 2009 Dec 31.
• [740] In vitro study of interaction of 17-hydroxysteroid dehydrogenase type 10 and cyclophilin D and its potential implications for Alzheimer's disease.Sci Rep. 2019 Nov 13;9(1):16700. doi: 10.1038/s41598-019-53157-7.
• [741] Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease.Prostaglandins Leukot Essent Fatty Acids. 2011 Nov;85(5):197-203. doi: 10.1016/j.plefa.2011.04.021. Epub 2011 May 4.
• [742] Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.Int J Mol Sci. 2019 Oct 9;20(20):4976. doi: 10.3390/ijms20204976.
• [743] Jujuboside A promotes A clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPAR pathway.Theranostics. 2018 Jul 30;8(15):4262-4278. doi: 10.7150/thno.26164. eCollection 2018.
• [744] Phosphatase 2A Inhibition Affects Endoplasmic Reticulum and Mitochondria Homeostasis Via Cytoskeletal Alterations in Brain Endothelial Cells.Mol Neurobiol. 2017 Jan;54(1):154-168. doi: 10.1007/s12035-015-9640-1. Epub 2016 Jan 5.
• [745] Heat Shock Cognate 70 Inhibitor, VER-155008, Reduces Memory Deficits and Axonal Degeneration in a Mouse Model of Alzheimer's Disease.Front Pharmacol. 2018 Jan 30;9:48. doi: 10.3389/fphar.2018.00048. eCollection 2018.
• [746] Novel compound VB-037 inhibits A aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease.Neurochem Int. 2019 May;125:175-186. doi: 10.1016/j.neuint.2019.01.021. Epub 2019 Jan 29.
• [747] HSP22 and its role in human neurological disease.Curr Neurovasc Res. 2011 Nov;8(4):323-33. doi: 10.2174/156720211798121034.
• [748] Heat Shock Proteins in Alzheimer's Disease: Role and Targeting.Int J Mol Sci. 2018 Sep 1;19(9):2603. doi: 10.3390/ijms19092603.
• [749] Targeting neurogenesis ameliorates danger assessment in a mouse model of Alzheimer's disease.Behav Brain Res. 2014 Mar 15;261:193-201. doi: 10.1016/j.bbr.2013.12.028. Epub 2013 Dec 31.
• [750] Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease.J Alzheimers Dis. 2016 May 7;53(1):349-61. doi: 10.3233/JAD-160046.
• [751] Depression in Alzheimer's disease: the effect of serotonin receptor gene variation.Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):40-3. doi: 10.1002/ajmg.b.10068.
• [752] Neural activity, memory, and dementias: serotonergic markers.Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):132-141. doi: 10.1097/FBP.0000000000000279.
• [753] The effect of chronic stimulation of serotonin receptor type 7 on recognition, passive avoidance memory, hippocampal long-term potentiation, and neuronal apoptosis in the amyloid protein treated rat.Psychopharmacology (Berl). 2018 May;235(5):1513-1525. doi: 10.1007/s00213-018-4862-3. Epub 2018 Apr 10.
• [754] Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease.Neurobiol Aging. 2020 Mar;87:139.e1-139.e7. doi: 10.1016/j.neurobiolaging.2019.10.017. Epub 2019 Nov 1.
• [755] Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.J Alzheimers Dis. 2019;69(1):157-168. doi: 10.3233/JAD-180421.
• [756] Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice.Front Pharmacol. 2019 Sep 24;10:1044. doi: 10.3389/fphar.2019.01044. eCollection 2019.
• [757] Deletion of the type-1 interferon receptor in APPSWE/PS1E9 mice preserves cognitive function and alters glial phenotype.Acta Neuropathol Commun. 2016 Jul 11;4(1):72. doi: 10.1186/s40478-016-0341-4.
• [758] Modulation of Immune Responses toHerpes Simplex Virus Type1 by IFNL3 and IRF7 Polymorphisms: AStudy inAlzheimer's Disease.J Alzheimers Dis. 2017;60(3):1055-1063. doi: 10.3233/JAD-170520.
• [759] Lin28B regulates the fate of grafted mesenchymal stem cells and enhances their protective effects against Alzheimer's disease by upregulating IGF-2.J Cell Physiol. 2019 Dec;234(12):21860-21876. doi: 10.1002/jcp.28750. Epub 2019 May 8.
• [760] Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model.Aging Cell. 2013 Apr;12(2):257-68. doi: 10.1111/acel.12049. Epub 2013 Mar 11.
• [761] Circulating IGFBP-2: a novel biomarker for incident dementia.Ann Clin Transl Neurol. 2019 Sep;6(9):1659-1670. doi: 10.1002/acn3.50854. Epub 2019 Aug 2.
• [762] Stem Cell-Derived Neurons as Cellular Models of Sporadic Alzheimer's Disease.J Alzheimers Dis. 2019;67(3):893-910. doi: 10.3233/JAD-180833.
• [763] Amyloid precursor protein, an androgen-regulated gene, is targeted by RNA-binding protein PSF/SFPQ in neuronal cells.Genes Cells. 2019 Nov;24(11):719-730. doi: 10.1111/gtc.12721. Epub 2019 Oct 15.
• [764] Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?.Brain Pathol. 2017 May;27(3):266-275. doi: 10.1111/bpa.12388. Epub 2016 Jun 8.
• [765] Anti-interleukin-17A and anti-interleukin-23 antibodies may be effective against Alzheimer's disease: Role of neutrophils in the pathogenesis.Brain Behav. 2020 Jan;10(1):e01504. doi: 10.1002/brb3.1504. Epub 2019 Dec 17.
• [766] Genetic Determinants of Survival in Patientswith Alzheimers Disease.J Alzheimers Dis. 2015;45(2):651-8. doi: 10.3233/JAD-142442.
• [767] Association of interleukin-I beta and receptor antagonist gene polymorphisms with late onset Alzheimer's disease in Taiwan Chinese.Eur J Neurol. 2005 Aug;12(8):609-13. doi: 10.1111/j.1468-1331.2005.01033.x.
• [768] Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.Sci Rep. 2019 Feb 21;9(1):2460. doi: 10.1038/s41598-018-36650-3.
• [769] An integrative functional genomics framework for effective identification of novel regulatory variants in genome-phenome studies.Genome Med. 2018 Jan 29;10(1):7. doi: 10.1186/s13073-018-0513-x.
• [770] Neurotrophin Receptor p75 mRNA Level in Peripheral Blood Cells of Patients with Alzheimer's Disease.Neurotox Res. 2019 Jul;36(1):101-107. doi: 10.1007/s12640-019-00035-9. Epub 2019 Apr 11.
• [771] Assessment of IL-31 levels and disease severity in children with atopic dermatitis.Allergol Immunopathol (Madr). 2018 Jul-Aug;46(4):322-325. doi: 10.1016/j.aller.2017.10.005. Epub 2018 Mar 17.
• [772] Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.Front Neurosci. 2019 Oct 18;13:1112. doi: 10.3389/fnins.2019.01112. eCollection 2019.
• [773] Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells.Viruses. 2019 Feb 13;11(2):154. doi: 10.3390/v11020154.
• [774] Interleukin 9 alterations linked to alzheimer disease in african americans.Ann Neurol. 2019 Sep;86(3):407-418. doi: 10.1002/ana.25543. Epub 2019 Jul 22.
• [775] Elevating Integrin-linked Kinase expression has rescued hippocampal neurogenesis and memory deficits in an AD animal model.Brain Res. 2018 Sep 15;1695:65-77. doi: 10.1016/j.brainres.2018.05.024. Epub 2018 May 19.
• [776] Corrigendum: Involvement of insulin receptor substrates in cognitive impairment and Alzheimer's disease.Neural Regen Res. 2020 Jun;15(6):1165. doi: 10.4103/1673-5374.270163.
• [777] Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.Curr Alzheimer Res. 2017;14(12):1305-1317. doi: 10.2174/1567205014666170706112701.
• [778] Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.J Neurosci. 2012 Oct 24;32(43):15112-23. doi: 10.1523/JNEUROSCI.1729-12.2012.
• [779] Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling.Hum Exp Toxicol. 2018 Oct;37(10):1092-1104. doi: 10.1177/0960327118755256. Epub 2018 Feb 6.
• [780] IRF-8 is Involved in Amyloid-(1-40) (A(1-40))-induced Microglial Activation: a New Implication in Alzheimer's Disease.J Mol Neurosci. 2017 Oct;63(2):159-164. doi: 10.1007/s12031-017-0966-1. Epub 2017 Aug 31.
• [781] Involvement of insulin receptor substrates in cognitive impairment and Alzheimer's disease.Neural Regen Res. 2019 Aug;14(8):1330-1334. doi: 10.4103/1673-5374.253535.
• [782] CD11a expression distinguishes infiltrating myeloid cells from plaque-associated microglia in Alzheimer's disease.Glia. 2019 May;67(5):844-856. doi: 10.1002/glia.23575. Epub 2018 Dec 26.
• [783] Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity.Neurobiol Aging. 2007 Feb;28(2):226-37. doi: 10.1016/j.neurobiolaging.2005.12.002. Epub 2006 Jan 18.
• [784] On the association analysis of genome-sequencing data: A spatial clustering approach for partitioning the entire genome into nonoverlapping windows.Genet Epidemiol. 2017 May;41(4):332-340. doi: 10.1002/gepi.22040. Epub 2017 Mar 20.
• [785] Xestospongin C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease.J Alzheimers Dis. 2019;72(4):1217-1231. doi: 10.3233/JAD-190796.
• [786] Degradation of the type I inositol 1,4,5-trisphosphate receptor by caspase-3 in SH-SY5Y neuroblastoma cells undergoing apoptosis.J Neurochem. 2000 Nov;75(5):1852-61. doi: 10.1046/j.1471-4159.2000.0751852.x.
• [787] A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.Horm Behav. 2020 Feb;118:104640. doi: 10.1016/j.yhbeh.2019.104640. Epub 2019 Nov 28.
• [788] Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer's disease.Comput Biol Chem. 2019 Feb;78:431-439. doi: 10.1016/j.compbiolchem.2018.12.011. Epub 2018 Dec 26.
• [789] Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer's disease.Cell Death Dis. 2018 Jul 26;9(8):820. doi: 10.1038/s41419-018-0886-1.
• [790] Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease.J Neurochem. 2004 Nov;91(3):547-57. doi: 10.1111/j.1471-4159.2004.02771.x.
• [791] Cognitive recovery by chronic activation of the large-conductance calcium-activated potassium channel in a mouse model of Alzheimer's disease.Neuropharmacology. 2015 May;92:8-15. doi: 10.1016/j.neuropharm.2014.12.033. Epub 2015 Jan 8.
• [792] Targeted Downregulation of kdm4a Ameliorates Tau-engendered Defects in Drosophila melanogaster.J Korean Med Sci. 2019 Aug 26;34(33):e225. doi: 10.3346/jkms.2019.34.e225.
• [793] Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease.Neurobiol Aging. 2013 Apr;34(4):1309.e1-7. doi: 10.1016/j.neurobiolaging.2012.08.010. Epub 2012 Oct 1.
• [794] Amyloid beta-mediated KIF5A deficiency disrupts anterograde axonal mitochondrial movement.Neurobiol Dis. 2019 Jul;127:410-418. doi: 10.1016/j.nbd.2019.03.021. Epub 2019 Mar 25.
• [795] KIR2DS2/KIR2DL2/HLA-C1 Haplotype Is Associated with Alzheimer's Disease: Implication for the Role of Herpesvirus Infections.J Alzheimers Dis. 2019;67(4):1379-1389. doi: 10.3233/JAD-180777.
• [796] Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline.J Neurol Sci. 2019 May 15;400:188-193. doi: 10.1016/j.jns.2019.04.006. Epub 2019 Apr 5.
• [797] AMYPAD Diagnostic and Patient Management Study: Rationale and design.Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16.
• [798] Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.EMBO Mol Med. 2018 Mar;10(3):e8184. doi: 10.15252/emmm.201708184.
• [799] Whole exome sequence-based association analyses of plasma amyloid- in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.PLoS One. 2017 Jul 13;12(7):e0180046. doi: 10.1371/journal.pone.0180046. eCollection 2017.
• [800] Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.SLAS Discov. 2018 Jul;23(6):554-560. doi: 10.1177/2472555218757180. Epub 2018 Feb 8.
• [801] Neuropeptides in Alzheimer's Disease: An Update.Curr Alzheimer Res. 2019;16(6):544-558. doi: 10.2174/1567205016666190503152555.
• [802] Distinct Rab7-related Endosomal-Autophagic-Lysosomal Dysregulation Observed in Cortex and Hippocampus in APPswe/PSEN1dE9 Mouse Model of Alzheimer's Disease.Chin Med J (Engl). 2017 Dec 20;130(24):2941-2950. doi: 10.4103/0366-6999.220311.
• [803] Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.PLoS One. 2017 May 2;12(5):e0176760. doi: 10.1371/journal.pone.0176760. eCollection 2017.
• [804] Lipopolysaccharide-Binding Protein, Soluble CD14, and the Long-Term Risk of Alzheimer's Disease: A Nested Case-Control Pilot Study of Older Community Dwellers from the Three-City Cohort.J Alzheimers Dis. 2019;71(3):751-761. doi: 10.3233/JAD-190295.
• [805] The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease.J Alzheimers Dis. 2017;56(2):825-833. doi: 10.3233/JAD-160930.
• [806] Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease.J Neurol Sci. 2005 Nov 15;238(1-2):53-7. doi: 10.1016/j.jns.2005.06.017. Epub 2005 Aug 16.
• [807] Peripheral lipid oxidative stress markers are related to vascular risk factors and subcortical small vessel disease.Neurobiol Aging. 2017 Nov;59:91-97. doi: 10.1016/j.neurobiolaging.2017.06.029. Epub 2017 Jul 11.
• [808] N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain.Acta Neuropathol Commun. 2019 Nov 13;7(1):177. doi: 10.1186/s40478-019-0831-2.
• [809] Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease.J Neuropathol Exp Neurol. 2010 Mar;69(3):253-61. doi: 10.1097/NEN.0b013e3181d072cf.
• [810] LIF, a Novel Myokine, Protects Against Amyloid-Beta-Induced Neurotoxicity via Akt-Mediated Autophagy Signaling in Hippocampal Cells.Int J Neuropsychopharmacol. 2019 Jun 3;22(6):402-414. doi: 10.1093/ijnp/pyz016.
• [811] Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's diseases.Acta Neurol Scand. 2010 Jan;121(1):44-50. doi: 10.1111/j.1600-0404.2009.01179.x.
• [812] Circular RNA and Alzheimer's Disease.Adv Exp Med Biol. 2018;1087:239-243. doi: 10.1007/978-981-13-1426-1_19.
• [813] Inhibiting amyloid- cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design.Nat Chem. 2018 Dec;10(12):1213-1221. doi: 10.1038/s41557-018-0147-z. Epub 2018 Oct 8.
• [814] LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice.CNS Neurosci Ther. 2018 May;24(5):381-393. doi: 10.1111/cns.12809. Epub 2018 Feb 9.
• [815] Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.Am J Pathol. 2012 Feb;180(2):526-40. doi: 10.1016/j.ajpath.2011.10.027. Epub 2011 Dec 3.
• [816] Shared genetic architecture between metabolic traits and Alzheimer's disease: a large-scale genome-wide cross-trait analysis.Hum Genet. 2019 Mar;138(3):271-285. doi: 10.1007/s00439-019-01988-9. Epub 2019 Feb 25.
• [817] Changes of renin-angiotensin system-related aminopeptidases in early stage Alzheimer's disease.Exp Gerontol. 2017 Mar;89:1-7. doi: 10.1016/j.exger.2017.01.006. Epub 2017 Jan 7.
• [818] Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation.Mol Psychiatry. 2020 Feb;25(2):275-282. doi: 10.1038/s41380-019-0542-x. Epub 2019 Oct 8.
• [819] Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases.Pharmacogenomics J. 2018 May 22;18(3):351-358. doi: 10.1038/tpj.2017.28. Epub 2017 Jul 11.
• [820] Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signaling pathways in isolated brain cells.Phytomedicine. 2019 Jul;60:152881. doi: 10.1016/j.phymed.2019.152881. Epub 2019 Mar 10.
• [821] Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease.Neurosci Lett. 2009 Mar 20;452(3):277-80. doi: 10.1016/j.neulet.2009.01.071. Epub 2009 Feb 4.
• [822] Amelioration of amyloid -FcRIIb neurotoxicity and tau pathologies by targeting LYN.FASEB J. 2019 Mar;33(3):4300-4313. doi: 10.1096/fj.201800926R. Epub 2018 Dec 12.
• [823] Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster.FEBS J. 2016 Oct;283(19):3508-3522. doi: 10.1111/febs.13830.
• [824] Differing associations between A accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease.J Cereb Blood Flow Metab. 2018 Jan;38(1):103-115. doi: 10.1177/0271678X17690761. Epub 2017 Feb 2.
• [825] Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects against A toxicity via attenuating A-induced endoplasmic reticulum stress.J Neuroinflammation. 2019 Feb 13;16(1):35. doi: 10.1186/s12974-019-1429-0.
• [826] MAOA-VNTR Genotype Effects on Ventral Striatum-Hippocampus Network in Alzheimer's Disease: Analysis Using Structural Covariance Network and Correlation with Neurobehavior Performance.Mol Neurobiol. 2019 Jun;56(6):4518-4529. doi: 10.1007/s12035-018-1394-0. Epub 2018 Oct 18.
• [827] Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy.Autophagy. 2017;13(11):1969-1980. doi: 10.1080/15548627.2017.1371393. Epub 2017 Oct 4.
• [828] ApoE and SNAP-25 Polymorphisms Predict the Outcome of Multidimensional Stimulation Therapy Rehabilitation in Alzheimer's Disease.Neurorehabil Neural Repair. 2016 Oct;30(9):883-93. doi: 10.1177/1545968316642523. Epub 2016 Apr 13.
• [829] Role of ASK1/p38 Cascade in a Mouse Model of Alzheimer's Disease and Brain Aging.J Alzheimers Dis. 2018;61(1):259-263. doi: 10.3233/JAD-170645.
• [830] Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.J Med Chem. 2019 Jul 25;62(14):6645-6664. doi: 10.1021/acs.jmedchem.9b00537. Epub 2019 Jul 15.
• [831] Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.Acta Biomater. 2019 Mar 15;87:207-222. doi: 10.1016/j.actbio.2019.01.065. Epub 2019 Feb 1.
• [832] Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.Curr Alzheimer Res. 2005 Jan;2(1):3-18. doi: 10.2174/1567205052772713.
• [833] Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid- Aggregation Inhibitor.ACS Omega. 2017 Jan 31;2(1):243-250. doi: 10.1021/acsomega.6b00397. Epub 2017 Jan 25.
• [834] MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.J Biol Chem. 2006 Aug 18;281(33):23658-67. doi: 10.1074/jbc.M513646200. Epub 2006 Jun 14.
• [835] Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes.Transl Psychiatry. 2015 Jun 16;5(6):e584. doi: 10.1038/tp.2015.78.
• [836] Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain.Hum Mol Genet. 2015 Jan 15;24(2):540-58. doi: 10.1093/hmg/ddu475. Epub 2014 Sep 17.
• [837] Mapping the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III.Qual Life Res. 2019 Jan;28(1):131-139. doi: 10.1007/s11136-018-1991-4. Epub 2018 Sep 1.
• [838] Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation.Neuroscience. 2017 Mar 27;346:267-277. doi: 10.1016/j.neuroscience.2017.01.027. Epub 2017 Jan 29.
• [839] The amyloid precursor protein (APP) family members are key players in S-adenosylmethionine formation by MAT2A and modify BACE1 and PSEN1 gene expression-relevance for Alzheimer's disease.Mol Cell Proteomics. 2012 Nov;11(11):1274-88. doi: 10.1074/mcp.M112.019364. Epub 2012 Aug 9.
• [840] Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity.Biochemistry. 2000 Mar 28;39(12):3206-15. doi: 10.1021/bi992211q.
• [841] Ghrelin cascade changes in the peripheral blood of Japanese patients with Alzheimer's disease.J Psychiatr Res. 2018 Dec;107:79-85. doi: 10.1016/j.jpsychires.2018.10.011. Epub 2018 Oct 18.
• [842] Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.PLoS One. 2014 Mar 17;9(3):e91974. doi: 10.1371/journal.pone.0091974. eCollection 2014.
• [843] Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease.Mol Neurobiol. 2019 Jan;56(1):174-185. doi: 10.1007/s12035-018-1040-x. Epub 2018 Apr 23.
• [844] A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk.J Alzheimers Dis. 2017;56(3):1065-1074. doi: 10.3233/JAD-161113.
• [845] Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis.J Alzheimers Dis. 2019;67(1):393-410. doi: 10.3233/JAD-180941.
• [846] Low Cerebrospinal Fluid Levels of Melanotransferrin Are Associated With Conversion of Mild Cognitively Impaired Subjects to Alzheimer's Disease.Front Neurosci. 2019 Mar 8;13:181. doi: 10.3389/fnins.2019.00181. eCollection 2019.
• [847] Neurogenesis in Neurodegenerative Diseases: Role of MFG-E8.Front Neurosci. 2019 Jun 4;13:569. doi: 10.3389/fnins.2019.00569. eCollection 2019.
• [848] A comprehensive appraisal on Crocus chrysanthus (Herb.) Herb. flower extracts with HPLC-MS/MS profiles, antioxidant and enzyme inhibitory properties.J Pharm Biomed Anal. 2019 Feb 5;164:581-589. doi: 10.1016/j.jpba.2018.11.022. Epub 2018 Nov 12.
• [849] Alleviation of Neuropathology by Inhibition of Monoacylglycerol Lipase in APP Transgenic Mice Lacking CB2 Receptors.Mol Neurobiol. 2018 Jun;55(6):4802-4810. doi: 10.1007/s12035-017-0689-x. Epub 2017 Jul 21.
• [850] Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking.FASEB J. 2019 Feb;33(2):2910-2927. doi: 10.1096/fj.201801076R. Epub 2018 Oct 17.
• [851] In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease.Front Pharmacol. 2018 Aug 2;9:730. doi: 10.3389/fphar.2018.00730. eCollection 2018.
• [852] Genetic variations and humoral immune responses to myelin oligodendroglia glycoprotein in adult phenotypes of X-linked adrenoleukodystrophy.J Neuroimmunol. 2003 Feb;135(1-2):148-53. doi: 10.1016/s0165-5728(02)00445-9.
• [853] Myeloperoxidase Deficiency Inhibits Cognitive Decline in the 5XFAD Mouse Model of Alzheimer's Disease.Front Neurosci. 2019 Sep 24;13:990. doi: 10.3389/fnins.2019.00990. eCollection 2019.
• [854] Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer's disease.Acta Neuropathol Commun. 2018 Oct 26;6(1):113. doi: 10.1186/s40478-018-0615-0.
• [855] Direct Interaction of Selenoprotein R with Clusterin and Its Possible Role in Alzheimer's Disease.PLoS One. 2013 Jun 21;8(6):e66384. doi: 10.1371/journal.pone.0066384. Print 2013.
• [856] Myostatin Is Associated With Cognitive Decline in an Animal Model of Alzheimer's Disease.Mol Neurobiol. 2019 Mar;56(3):1984-1991. doi: 10.1007/s12035-018-1201-y. Epub 2018 Jul 7.
• [857] Melatonin receptor type 1A gene linked to Alzheimer's disease in old age.Sleep. 2018 Jul 1;41(7):zsy103. doi: 10.1093/sleep/zsy103.
• [858] Activation of MT2 receptor ameliorates dendritic abnormalities in Alzheimer's disease via C/EBP/miR-125b pathway.Aging Cell. 2019 Apr;18(2):e12902. doi: 10.1111/acel.12902. Epub 2019 Feb 1.
• [859] Variants of Base Excision Repair Genes MUTYH , PARP1 and XRCC1 in Alzheimer's Disease Risk.Neuropsychobiology. 2015;71(3):176-86. doi: 10.1159/000381985. Epub 2015 May 13.
• [860] Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4/MyD88/NF-B pathway in rats.Biomed Pharmacother. 2019 Mar;111:315-324. doi: 10.1016/j.biopha.2018.10.201. Epub 2018 Dec 24.
• [861] Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain.Eur J Neurosci. 2004 Dec;20(12):3489-97. doi: 10.1111/j.1460-9568.2004.03852.x.
• [862] Neuroprotective effects of N-acetyl cysteine on primary hippocampus neurons against hydrogen peroxide-induced injury are mediated via inhibition of mitogen-activated protein kinases signal transduction and antioxidative action.Mol Med Rep. 2018 May;17(5):6647-6654. doi: 10.3892/mmr.2018.8699. Epub 2018 Mar 7.
• [863] Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid.J Biol Chem. 2008 Jan 4;283(1):6-16. doi: 10.1074/jbc.M706124200. Epub 2007 Oct 6.
• [864] Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1.FEBS J. 2020 Jan;287(1):205-217. doi: 10.1111/febs.15027. Epub 2019 Aug 9.
• [865] Amyloid- Induces AMPA Receptor Ubiquitination and Degradation in Primary Neurons and Human Brains of Alzheimer's Disease.J Alzheimers Dis. 2018;62(4):1789-1801. doi: 10.3233/JAD-170879.
• [866] NEDD9 gene polymorphism influences the risk of Alzheimer disease and cognitive function in Chinese older persons.Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):88-90. doi: 10.1097/WAD.0b013e3182135ef3.
• [867] Valproic Acid Stimulates Hippocampal Neurogenesis via Activating the Wnt/-Catenin Signaling Pathway in the APP/PS1/Nestin-GFP Triple Transgenic Mouse Model of Alzheimer's Disease.Front Aging Neurosci. 2019 Mar 26;11:62. doi: 10.3389/fnagi.2019.00062. eCollection 2019.
• [868] Electrophysiological evidence of altered facial expressions recognition in Alzheimer's disease: A comprehensive ERP study.Clin Neurophysiol. 2019 Oct;130(10):1813-1824. doi: 10.1016/j.clinph.2019.06.229. Epub 2019 Jul 12.
• [869] The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo.Methods Mol Biol. 2019;1951:189-207. doi: 10.1007/978-1-4939-9130-3_15.
• [870] Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3.Neurobiol Aging. 2018 Jun;66:179.e17-179.e29. doi: 10.1016/j.neurobiolaging.2018.01.015. Epub 2018 Feb 2.
• [871] Genetic association between Notch4 polymorphisms and Alzheimer's disease in the Japanese population.J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):350-1. doi: 10.1093/gerona/62.4.350.
• [872] Neurochemical Characterization of PSA-NCAM(+) Cells in the Human Brain and Phenotypic Quantification in Alzheimer's Disease Entorhinal Cortex.Neuroscience. 2018 Feb 21;372:289-303. doi: 10.1016/j.neuroscience.2017.12.019.
• [873] Expression of Quinone Reductase-2 in the Cortex Is a Muscarinic Acetylcholine Receptor-Dependent Memory Consolidation Constraint.J Neurosci. 2015 Nov 25;35(47):15568-81. doi: 10.1523/JNEUROSCI.1170-15.2015.
• [874] Effects of NR1H3 genetic variation on the expression of liver X receptor and the progression of Alzheimer's disease.PLoS One. 2013 Nov 20;8(11):e80700. doi: 10.1371/journal.pone.0080700. eCollection 2013.
• [875] Association study of the GAB2 gene with the risk of developing Alzheimer's disease.Neurobiol Dis. 2008 Apr;30(1):103-6. doi: 10.1016/j.nbd.2007.12.006. Epub 2008 Jan 5.
• [876] Association of AEBP1 and NRN1 RNA expression with Alzheimer's disease and neurofibrillary tangle density in middle temporal gyrus.Brain Res. 2019 Sep 15;1719:217-224. doi: 10.1016/j.brainres.2019.06.004. Epub 2019 Jun 6.
• [877] Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease.Neurosci Lett. 1998 Jan 30;241(2-3):151-4. doi: 10.1016/s0304-3940(98)00019-6.
• [878] Key mechanisms underlying netrin-1 prevention of impaired spatial and object memory in A(1-42) CA1-injected rats.Clin Exp Pharmacol Physiol. 2019 Jan;46(1):86-93. doi: 10.1111/1440-1681.13020. Epub 2018 Sep 3.
• [879] The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer's Disease.J Alzheimers Dis. 2018;64(4):1149-1161. doi: 10.3233/JAD-180276.
• [880] Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.J Neurosci. 2015 Apr 15;35(15):5969-82. doi: 10.1523/JNEUROSCI.4668-14.2015.
• [881] Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran.J Psychoactive Drugs. 2017 Jul-Aug;49(3):242-251. doi: 10.1080/02791072.2017.1290303. Epub 2017 Mar 1.
• [882] Development and In Vivo Evaluation of a -Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics.J Nucl Med. 2019 Jul;60(7):1023-1030. doi: 10.2967/jnumed.118.220517. Epub 2019 Jan 10.
• [883] Cross-species microarray analysis with the OSCAR system suggests an INSR->Pax6->NQO1 neuro-protective pathway in aging and Alzheimer's disease.Nucleic Acids Res. 2007 Jul;35(Web Server issue):W105-14. doi: 10.1093/nar/gkm408. Epub 2007 Jun 1.
• [884] Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes.J Biol Chem. 1998 Feb 13;273(7):4112-8. doi: 10.1074/jbc.273.7.4112.
• [885] Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease?.Neurosci Lett. 2009 Jan 2;449(1):76-80. doi: 10.1016/j.neulet.2008.10.081. Epub 2008 Oct 28.
• [886] Theobromine-Induced Changes in A1 Purinergic Receptor Gene Expression and Distribution in a Rat Brain Alzheimer's Disease Model.J Alzheimers Dis. 2017;55(3):1273-1283. doi: 10.3233/JAD-160569.
• [887] P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer's disease model.J Exp Med. 2018 Jun 4;215(6):1649-1663. doi: 10.1084/jem.20171487. Epub 2018 May 3.
• [888] Role of purinergic receptors in the Alzheimer's disease.Purinergic Signal. 2018 Dec;14(4):331-344. doi: 10.1007/s11302-018-9629-0. Epub 2018 Oct 25.
• [889] Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.J Neural Transm (Vienna). 2008 Aug;115(8):1165-72. doi: 10.1007/s00702-008-0067-y. Epub 2008 May 28.
• [890] Association between Polymorphisms of the AKT1 Gene Promoter and Risk of the Alzheimer's Disease in a Chinese Han Population with Type 2 Diabetes.CNS Neurosci Ther. 2015 Aug;21(8):619-25. doi: 10.1111/cns.12430. Epub 2015 Jul 14.
• [891] p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis.J Biol Chem. 2008 May 16;283(20):14132-43. doi: 10.1074/jbc.M708034200. Epub 2008 Mar 17.
• [892] Aluminum-induced "mixed" cell death in mice cerebral tissue and potential intervention.Neurotox Res. 2020 Apr;37(4):835-846. doi: 10.1007/s12640-019-00123-w. Epub 2019 Nov 13.
• [893] Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Ann Neurol. 2020 Jan;87(1):30-39. doi: 10.1002/ana.25642.
• [894] Comprehensive analysis of the lncRNA-associated ceRNA network identifies neuroinflammation biomarkers for Alzheimer's disease.Mol Omics. 2019 Dec 2;15(6):459-469. doi: 10.1039/c9mo00129h.
• [895] Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.Curr Med Chem. 2018;25(29):3455-3481. doi: 10.2174/0929867325666180309110629.
• [896] Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.J Chem Inf Model. 2017 Feb 27;57(2):355-364. doi: 10.1021/acs.jcim.6b00551. Epub 2017 Jan 18.
• [897] Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.Eur J Med Chem. 2019 Feb 1;163:512-526. doi: 10.1016/j.ejmech.2018.12.013. Epub 2018 Dec 7.
• [898] Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.ACS Chem Neurosci. 2019 Mar 20;10(3):1765-1782. doi: 10.1021/acschemneuro.8b00648. Epub 2018 Dec 21.
• [899] Amyloid -induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.Alzheimers Res Ther. 2018 Feb 20;10(1):24. doi: 10.1186/s13195-018-0352-4.
• [900] Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.ACS Chem Neurosci. 2019 Jan 16;10(1):537-551. doi: 10.1021/acschemneuro.8b00376. Epub 2018 Oct 12.
• [901] Automated PDF highlighting to support faster curation of literature for Parkinson's and Alzheimer's disease.Database (Oxford). 2017 Jan 1;2017(1):bax027. doi: 10.1093/database/bax027.
• [902] Understanding the function of ABCA7 in Alzheimer's disease.Biochem Soc Trans. 2015 Oct;43(5):920-3. doi: 10.1042/BST20150105.
• [903] Altered microglia and neurovasculature in the Alzheimer's disease cerebellum.Neurobiol Dis. 2019 Dec;132:104589. doi: 10.1016/j.nbd.2019.104589. Epub 2019 Aug 24.
• [904] Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression.Sci Rep. 2017 Aug 22;7(1):9115. doi: 10.1038/s41598-017-09481-x.
• [905] Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Biochem Biophys Res Commun. 2009 Feb 6;379(2):272-6. doi: 10.1016/j.bbrc.2008.12.037. Epub 2008 Dec 25.
• [906] PEMT G523A (V175M) is associated with sporadic Alzheimer's disease in a Chinese population.J Mol Neurosci. 2012 Mar;46(3):505-8. doi: 10.1007/s12031-011-9630-3. Epub 2011 Sep 1.
• [907] Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity.J Biol Chem. 2015 May 15;290(20):12504-13. doi: 10.1074/jbc.M114.618157. Epub 2015 Mar 26.
• [908] Development of a High-Sensitivity Method for the Measurement of Human Nasal A42, Tau, and Phosphorylated Tau.J Alzheimers Dis. 2018;62(2):737-744. doi: 10.3233/JAD-170962.
• [909] Epitope mapping of anti-PGRMC1 antibodies reveals the non-conventional membrane topology of PGRMC1 on the cell surface.Sci Rep. 2019 Jan 24;9(1):653. doi: 10.1038/s41598-018-37441-6.
• [910] TTC7 and Hyccin Regulate Neuronal A42 Accumulation and its Associated Neural Deficits in A42-Expressing Drosophila.J Alzheimers Dis. 2018;65(3):1001-1010. doi: 10.3233/JAD-170907.
• [911] A cell-permeable tool for analysing APP intracellular domain function and manipulation of PIKfyve activity.Biosci Rep. 2016 Apr 15;36(2):e00319. doi: 10.1042/BSR20160040. Print 2016.
• [912] Protective effects of 5-HT(1A) receptor antagonist and 5-HT(2A) receptor agonist on the biochemical and histological features in a rat model of Alzheimer's disease.J Chem Neuroanat. 2019 Mar;96:140-147. doi: 10.1016/j.jchemneu.2019.01.008. Epub 2019 Jan 23.
• [913] Bee Venom Soluble Phospholipase A2 Exerts Neuroprotective Effects in a Lipopolysaccharide-Induced Mouse Model of Alzheimer's Disease via Inhibition of Nuclear Factor-Kappa B.Front Aging Neurosci. 2019 Nov 1;11:287. doi: 10.3389/fnagi.2019.00287. eCollection 2019.
• [914] Meta-analysis of the association between urokinase-plasminogen activator gene rs2227564 polymorphism and Alzheimer's disease.Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):517-23. doi: 10.1177/1533317513494450. Epub 2013 Jun 28.
• [915] Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains.Brain Res. 2002 Feb 1;926(1-2):69-79. doi: 10.1016/s0006-8993(01)03298-x.
• [916] Suppressing aberrant phospholipase D1 signaling in 3xTg Alzheimer's disease mouse model promotes synaptic resilience.Sci Rep. 2019 Dec 4;9(1):18342. doi: 10.1038/s41598-019-54974-6.
• [917] PLD3 in Alzheimer's Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses.Mol Neurobiol. 2016 Aug;53(6):4034-4045. doi: 10.1007/s12035-015-9353-5. Epub 2015 Jul 21.
• [918] Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice.PLoS One. 2019 Jul 15;14(7):e0219691. doi: 10.1371/journal.pone.0219691. eCollection 2019.
• [919] Phospholipid transfer protein (PLTP) deficiency accelerates memory dysfunction through altering amyloid precursor protein (APP) processing in a mouse model of Alzheimer's disease.Hum Mol Genet. 2015 Oct 1;24(19):5388-403. doi: 10.1093/hmg/ddv262. Epub 2015 Jul 9.
• [920] Kinetic Isotope Effects and Transition State Structure for Human Phenylethanolamine N-Methyltransferase.ACS Chem Biol. 2017 Feb 17;12(2):342-346. doi: 10.1021/acschembio.6b00922. Epub 2016 Dec 28.
• [921] Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology.Brain Pathol. 2018 Nov;28(6):933-946. doi: 10.1111/bpa.12592. Epub 2018 Feb 21.
• [922] Synthesis of (11)C-labeled DNA polymerase- inhibitor 5-methoxyflavone and PET/CT imaging thereof.Nucl Med Biol. 2019 Nov-Dec;78-79:17-22. doi: 10.1016/j.nucmedbio.2019.10.005. Epub 2019 Oct 23.
• [923] In vivo and in vitro studies on the roles of p38 mitogen-activated protein kinase and NADPH-cytochrome P450 reductase in Alzheimer's disease.Exp Ther Med. 2017 Nov;14(5):4755-4760. doi: 10.3892/etm.2017.5182. Epub 2017 Sep 22.
• [924] Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.Autophagy. 2020 Jan;16(1):52-69. doi: 10.1080/15548627.2019.1596488. Epub 2019 Apr 6.
• [925] PPAR Gamma Coactivator 1 Beta (PGC-1) Reduces Mammalian Target of Rapamycin (mTOR) Expression via a SIRT1-Dependent Mechanism in Neurons.Cell Mol Neurobiol. 2017 Jul;37(5):879-887. doi: 10.1007/s10571-016-0425-5. Epub 2016 Sep 15.
• [926] Normalization of gene expression using SYBR green qPCR: a case for paraoxonase 1 and 2 in Alzheimer's disease brains.J Neurosci Methods. 2011 Aug 30;200(1):14-9. doi: 10.1016/j.jneumeth.2011.05.026. Epub 2011 Jun 13.
• [927] The dynamics of CD147 in Alzheimer's disease development and pathology.J Alzheimers Dis. 2011;26(4):593-605. doi: 10.3233/JAD-2011-110584.
• [928] Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110.
• [929] MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.EMBO J. 2014 Aug 1;33(15):1667-80. doi: 10.15252/embj.201387576. Epub 2014 Jul 7.
• [930] Elevation of pS262-Tau and Demethylated PP2A in Retina Occurs Earlier than in Hippocampus During Hyperhomocysteinemia.J Alzheimers Dis. 2019;68(1):367-381. doi: 10.3233/JAD-180978.
• [931] Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease.Subst Use Misuse. 2010 Sep;45(11):1809-26. doi: 10.3109/10826084.2010.482449.
• [932] Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases.Prog Neurobiol. 2012 May;97(2):220-38. doi: 10.1016/j.pneurobio.2011.11.002. Epub 2011 Dec 7.
• [933] Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result.Front Aging Neurosci. 2018 Dec 11;10:409. doi: 10.3389/fnagi.2018.00409. eCollection 2018.
• [934] Peroxiredoxin 4 ameliorates amyloid beta oligomer-mediated apoptosis by inhibiting ER-stress in HT-22 hippocampal neuron cells.Cell Biol Toxicol. 2019 Dec;35(6):573-588. doi: 10.1007/s10565-019-09477-5. Epub 2019 May 30.
• [935] Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain.J Neurochem. 2007 Dec;103(6):2462-70. doi: 10.1111/j.1471-4159.2007.04942.x. Epub 2007 Oct 1.
• [936] Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer's Disease Hippocampus.J Alzheimers Dis. 2018;63(3):1173-1189. doi: 10.3233/JAD-171008.
• [937] Scallop-derived plasmalogens attenuate the activation of PKC associated with the brain inflammation.Biochem Biophys Res Commun. 2018 Sep 5;503(2):837-842. doi: 10.1016/j.bbrc.2018.06.084. Epub 2018 Jun 21.
• [938] PKC deficits in Alzheimer's disease brains and skin fibroblasts.J Alzheimers Dis. 2015;43(2):491-509. doi: 10.3233/JAD-141221.
• [939] The protein arginine methyltransferase PRMT5 regulates A-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.J Neurochem. 2015 Sep;134(5):969-77. doi: 10.1111/jnc.13191. Epub 2015 Jul 15.
• [940] Activated protein C in neuroprotection and malaria.Curr Opin Hematol. 2019 Sep;26(5):320-330. doi: 10.1097/MOH.0000000000000528.
• [941] Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer's disease.Neurobiol Aging. 2015 Apr;36(4):1629-1638. doi: 10.1016/j.neurobiolaging.2015.01.001. Epub 2015 Jan 7.
• [942] N-myc downstream-regulated gene 2 deficiency aggravates memory impairment in Alzheimer's disease.Behav Brain Res. 2020 Feb 3;379:112384. doi: 10.1016/j.bbr.2019.112384. Epub 2019 Nov 25.
• [943] A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.Sci Rep. 2019 Dec 5;9(1):18393. doi: 10.1038/s41598-019-54846-z.
• [944] Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease.J Neuropathol Exp Neurol. 2007 Jun;66(6):469-80. doi: 10.1097/01.jnen.0000240472.43038.27.
• [945] PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.Neurobiol Aging. 2012 Sep;33(9):2215-9. doi: 10.1016/j.neurobiolaging.2011.09.017. Epub 2011 Oct 19.
• [946] Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease.J Neurosci. 2005 Nov 2;25(44):10180-7. doi: 10.1523/JNEUROSCI.3591-05.2005.
• [947] PGE(2)-EP3 signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of Alzheimer's disease.Neurobiol Aging. 2017 Feb;50:13-24. doi: 10.1016/j.neurobiolaging.2016.10.012. Epub 2016 Oct 17.
• [948] Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease.Alzheimers Dement. 2008 Jan;4(1):6-13. doi: 10.1016/j.jalz.2007.10.015. Epub 2007 Dec 21.
• [949] Commentary on Giralt et al.: PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease.Exp Neurol. 2019 Jan;311:313-317. doi: 10.1016/j.expneurol.2018.08.011. Epub 2018 Aug 29.
• [950] A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease.Sci Rep. 2017 Oct 17;7(1):13333. doi: 10.1038/s41598-017-13831-0.
• [951] Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.Exp Gerontol. 2018 Apr;104:66-71. doi: 10.1016/j.exger.2018.02.005. Epub 2018 Feb 5.
• [952] The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation.Sci Rep. 2017 Sep 18;7(1):11771. doi: 10.1038/s41598-017-12236-3.
• [953] Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship?.J Inorg Biochem. 2001 Nov;87(1-2):51-6. doi: 10.1016/s0162-0134(01)00314-2.
• [954] Differential Expression of mRNAs in the Brain Tissues of Patients with Alzheimer's Disease Based on GEO Expression Profile and Its Clinical Significance.Biomed Res Int. 2019 Feb 26;2019:8179145. doi: 10.1155/2019/8179145. eCollection 2019.
• [955] In silico, NMR and pharmacological evaluation of an hydroxyoxindole cholinesterase inhibitor.Bioorg Med Chem. 2019 Jan 15;27(2):354-363. doi: 10.1016/j.bmc.2018.12.007. Epub 2018 Dec 10.
• [956] RACK-1 expression and cytokine production in leukocytes obtained from AD patients.Aging Clin Exp Res. 2006 Apr;18(2):153-7. doi: 10.1007/BF03327432.
• [957] GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability.Sci Rep. 2016 May 19;6:26116. doi: 10.1038/srep26116.
• [958] Apolipoprotein E 4 Specifically Modulates the Hippocampus Functional Connectivity Network in Patients With Amnestic Mild Cognitive Impairment.Front Aging Neurosci. 2018 Sep 27;10:289. doi: 10.3389/fnagi.2018.00289. eCollection 2018.
• [959] Diet and Alzheimer's dementia - Nutritional approach to modulate inflammation.Pharmacol Biochem Behav. 2019 Sep;184:172743. doi: 10.1016/j.pbb.2019.172743. Epub 2019 Jul 26.
• [960] Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.EPMA J. 2017 Sep 4;8(3):255-259. doi: 10.1007/s13167-017-0110-x. eCollection 2017 Sep.
• [961] Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease.Aging (Albany NY). 2019 Dec 9;11(23):11673-11685. doi: 10.18632/aging.102571. Epub 2019 Dec 9.
• [962] Role of N-terminal residues in A interactions with integrin receptor and cell surface.Biochim Biophys Acta. 2014 Oct;1838(10):2568-77. doi: 10.1016/j.bbamem.2014.06.011. Epub 2014 Jun 21.
• [963] APC/C(Cdh1)-Rock2 pathway controls dendritic integrity and memory.Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4513-4518. doi: 10.1073/pnas.1616024114. Epub 2017 Apr 10.
• [964] Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.Mol Neurodegener. 2016 Jan 12;11:3. doi: 10.1186/s13024-016-0071-x.
• [965] Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against -amyloid.Sci Signal. 2019 Jun 25;12(587):eaaw9318. doi: 10.1126/scisignal.aaw9318.
• [966] Heat-Resistant Aphanizomenon flos-aquae (AFA) Extract (Klamin) as a Functional Ingredient in Food Strategy for Prevention of Oxidative Stress.Oxid Med Cell Longev. 2019 Nov 11;2019:9481390. doi: 10.1155/2019/9481390. eCollection 2019.
• [967] Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.J Neurosci. 2015 Oct 14;35(41):14042-56. doi: 10.1523/JNEUROSCI.2781-15.2015.
• [968] Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease.J Alzheimers Dis. 2011;27(2):291-7. doi: 10.3233/JAD-2011-110794.
• [969] Nogo-A expression in the human hippocampus in normal aging and in Alzheimer disease.J Neuropathol Exp Neurol. 2006 May;65(5):433-44. doi: 10.1097/01.jnen.0000222894.59293.98.
• [970] Novel roles for Nogo receptor in inflammation and disease.Trends Neurosci. 2008 May;31(5):221-6. doi: 10.1016/j.tins.2008.02.002. Epub 2008 Apr 18.
• [971] Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease.CNS Neurosci Ther. 2017 Jun;23(6):457-461. doi: 10.1111/cns.12696. Epub 2017 Apr 17.
• [972] Glial S100A6 Degrades -amyloid Aggregation through Targeting Competition with Zinc Ions.Aging Dis. 2019 Aug 1;10(4):756-769. doi: 10.14336/AD.2018.0912. eCollection 2019 Aug.
• [973] The S100B story: from biomarker to active factor in neural injury.J Neurochem. 2019 Jan;148(2):168-187. doi: 10.1111/jnc.14574. Epub 2018 Nov 12.
• [974] Serum amyloid A1 is involved in amyloid plaque aggregation and memory decline in amyloid beta abundant condition.Transgenic Res. 2019 Dec;28(5-6):499-508. doi: 10.1007/s11248-019-00166-x. Epub 2019 Aug 12.
• [975] Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice.Neuroscience. 2016 Sep 22;332:160-9. doi: 10.1016/j.neuroscience.2016.06.049. Epub 2016 Jul 5.
• [976] Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid -associated neural degeneration in Alzheimer's disease.Brain Pathol. 2013 May;23(3):274-84. doi: 10.1111/j.1750-3639.2012.00644.x. Epub 2012 Nov 1.
• [977] Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology.Neurosci Lett. 2003 Dec 4;352(2):146-50. doi: 10.1016/j.neulet.2003.08.041.
• [978] Candidate gene analysis of semaphorins in patients with Alzheimer's disease.Neurol Sci. 2010 Apr;31(2):169-73. doi: 10.1007/s10072-009-0200-1. Epub 2009 Dec 3.
• [979] Comparative Serum Proteomic Analysis of the Effects of Sodium Selenate on a Mouse Model of Alzheimer's Disease.Biol Trace Elem Res. 2019 Dec;192(2):263-276. doi: 10.1007/s12011-019-01676-9. Epub 2019 Feb 21.
• [980] Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease.Am J Pathol. 1993 Sep;143(3):886-93.
• [981] Pigment Epithelium-Derived Factor Plays a Role in Alzheimer's Disease by Negatively Regulating A42.Neurotherapeutics. 2018 Jul;15(3):728-741. doi: 10.1007/s13311-018-0628-1.
• [982] Chronic Cerebral Hypoperfusion Activates the Coagulation and Complement Cascades in Alzheimer's Disease Mice.Neuroscience. 2019 Sep 15;416:126-136. doi: 10.1016/j.neuroscience.2019.07.050. Epub 2019 Aug 5.
• [983] TRPC6 mRNA levels in peripheral leucocytes of patients with Alzheimer's disease and mild cognitive impairment: A case-control study.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:279-284. doi: 10.1016/j.pnpbp.2019.01.009. Epub 2019 Jan 23.
• [984] Early Presymptomatic Changes in the Proteome of Mitochondria-Associated Membrane in the APP/PS1 Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2018 Oct;55(10):7839-7857. doi: 10.1007/s12035-018-0955-6. Epub 2018 Feb 22.
• [985] mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid- Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons.J Alzheimers Dis. 2017;56(3):1015-1036. doi: 10.3233/JAD-161029.
• [986] Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.Cell Cycle. 2018;17(19-20):2321-2334. doi: 10.1080/15384101.2018.1515554. Epub 2018 Sep 20.
• [987] Optimized turmeric extract reduces -Amyloid and phosphorylated Tau protein burden in Alzheimer's transgenic mice.Curr Alzheimer Res. 2012 May;9(4):500-6. doi: 10.2174/156720512800492459.
• [988] At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor?.Adv Exp Med Biol. 2020;1131:699-718. doi: 10.1007/978-3-030-12457-1_28.
• [989] Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases.Eur J Pharmacol. 2020 Jan 15;867:172847. doi: 10.1016/j.ejphar.2019.172847. Epub 2019 Dec 5.
• [990] Distinct patterns of sirtuin expression during progression of Alzheimer's disease.Neuromolecular Med. 2014 Jun;16(2):405-14. doi: 10.1007/s12017-014-8288-8. Epub 2014 Jan 25.
• [991] Emerging Roles of Sirtuin 6 in Alzheimer's Disease.J Mol Neurosci. 2018 Feb;64(2):157-161. doi: 10.1007/s12031-017-1005-y. Epub 2017 Dec 19.
• [992] Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans.Alzheimers Dement. 2017 Feb;13(2):119-129. doi: 10.1016/j.jalz.2016.09.002. Epub 2016 Oct 20.
• [993] Role of monocarboxylate transporter 4 in Alzheimer disease.Neurotoxicology. 2020 Jan;76:191-199. doi: 10.1016/j.neuro.2019.11.006. Epub 2019 Nov 16.
• [994] Kinetic modeling of [(18) F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.J Neurochem. 2018 Mar;144(6):791-804. doi: 10.1111/jnc.14291. Epub 2018 Mar 25.
• [995] Family-based genome scan for age at onset of late-onset Alzheimer's disease in whole exome sequencing data.Genes Brain Behav. 2015 Nov;14(8):607-17. doi: 10.1111/gbb.12250. Epub 2015 Sep 23.
• [996] Region- and age-specific changes in glutamate transport in the APP23 mouse model for Alzheimer's disease.J Alzheimers Dis. 2011;24(2):287-300. doi: 10.3233/JAD-2011-101005.
• [997] Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures.Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21800-21811. doi: 10.1073/pnas.1903566116. Epub 2019 Oct 7.
• [998] Arundic Acid Increases Expression and Function of Astrocytic Glutamate Transporter EAAT1 Via the ERK, Akt, and NF-B Pathways.Mol Neurobiol. 2018 Jun;55(6):5031-5046. doi: 10.1007/s12035-017-0709-x. Epub 2017 Aug 15.
• [999] Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease.J Pharm Sci. 2019 Jul;108(7):2484-2489. doi: 10.1016/j.xphs.2019.02.016. Epub 2019 Feb 27.
• [1000] NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease.Hum Mol Genet. 2015 Jun 1;24(11):3058-81. doi: 10.1093/hmg/ddv059. Epub 2015 Feb 15.
• [1001] Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2018 Dec;55(12):8936-8952. doi: 10.1007/s12035-018-1030-z. Epub 2018 Apr 4.
• [1002] Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease.Fluids Barriers CNS. 2019 Dec 17;16(1):38. doi: 10.1186/s12987-019-0158-1.
• [1003] Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease via Angiotensin AT1 Receptor.Am J Hypertens. 2017 Feb;30(2):141-150. doi: 10.1093/ajh/hpw099. Epub 2016 Aug 29.
• [1004] Relevance of A42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale.Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.
• [1005] CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.Alzheimers Res Ther. 2019 Dec 17;11(1):105. doi: 10.1186/s13195-019-0564-2.
• [1006] Molecular Interaction of Anti-Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co-Transporter 2.J Cell Biochem. 2017 Nov;118(11):3855-3865. doi: 10.1002/jcb.26036. Epub 2017 May 23.
• [1007] Impaired expression of GABA transporters in the human Alzheimer's disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus.Neuroscience. 2017 May 20;351:108-118. doi: 10.1016/j.neuroscience.2017.03.041. Epub 2017 Apr 4.
• [1008] Disturbed neurotransmitter transporter expression in Alzheimer's disease brain.J Alzheimers Dis. 2011;26(4):755-66. doi: 10.3233/JAD-2011-110002.
• [1009] System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40.J Neurosci. 2006 Mar 22;26(12):3345-56. doi: 10.1523/JNEUROSCI.5186-05.2006.
• [1010] Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes.Pharm Res. 2018 Nov 28;36(1):17. doi: 10.1007/s11095-018-2546-7.
• [1011] A 14bp indel variation in the NCX1 gene modulates the age at onset in late-onset Alzheimer's disease.J Neural Transm (Vienna). 2012 Mar;119(3):383-6. doi: 10.1007/s00702-011-0696-4. Epub 2011 Aug 11.
• [1012] Increased permeability of the blood-brain barrier and Alzheimer's disease-like alterations in slit-2 transgenic mice.J Alzheimers Dis. 2015;43(2):535-48. doi: 10.3233/JAD-141215.
• [1013] Genome-wide network-based pathway analysis of CSF t-tau/A1-42 ratio in the ADNI cohort.BMC Genomics. 2017 May 30;18(1):421. doi: 10.1186/s12864-017-3798-z.
• [1014] Tunable regulatory activities of 1,10-phenanthroline derivatives towards acid sphingomyelinase and Zn(ii)-amyloid-.Chem Commun (Camb). 2019 May 21;55(42):5847-5850. doi: 10.1039/c9cc01005j.
• [1015] Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.PLoS One. 2015 May 4;10(5):e0125597. doi: 10.1371/journal.pone.0125597. eCollection 2015.
• [1016] SNARE Complex Polymorphisms Associate with Alterations of Visual Selective Attention in Alzheimer's Disease.J Alzheimers Dis. 2019;69(1):179-188. doi: 10.3233/JAD-190147.
• [1017] -Synuclein Induces Human Cortical Astrocyte Proliferation and Subsequent BDNF Expression and Release.Neuroscience. 2019 Jul 1;410:41-54. doi: 10.1016/j.neuroscience.2019.04.057. Epub 2019 May 10.
• [1018] The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk.J Alzheimers Dis. 2019;68(4):1535-1547. doi: 10.3233/JAD-181116.
• [1019] Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease.Nat Commun. 2018 Apr 16;9(1):1479. doi: 10.1038/s41467-018-03674-2.
• [1020] Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease.J Neurosci. 2019 Nov 27;39(48):9645-9659. doi: 10.1523/JNEUROSCI.0524-19.2019. Epub 2019 Oct 22.
• [1021] Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography-mass spectrometry targeted metabonomic profiling.Eur J Nutr. 2017 Feb;56(1):29-43. doi: 10.1007/s00394-015-1053-4. Epub 2015 Oct 1.
• [1022] Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies.J Exp Med. 2018 Dec 3;215(12):3038-3056. doi: 10.1084/jem.20180539. Epub 2018 Oct 29.
• [1023] Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease.Neurobiol Dis. 2019 Oct;130:104511. doi: 10.1016/j.nbd.2019.104511. Epub 2019 Jun 15.
• [1024] Somatostatin Maintains Permeability and Integrity of Blood-Brain Barrier in -Amyloid Induced Toxicity.Mol Neurobiol. 2019 Jan;56(1):292-306. doi: 10.1007/s12035-018-1045-5. Epub 2018 Apr 26.
• [1025] Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease.Acta Neuropathol. 2015 Apr;129(4):541-63. doi: 10.1007/s00401-015-1394-3. Epub 2015 Feb 13.
• [1026] Reduction of the immunostainable length of the hippocampal dentate granule cells' primary cilia in 3xAD-transgenic mice producing human A(1-42) and tau.Biochem Biophys Res Commun. 2012 Oct 12;427(1):218-22. doi: 10.1016/j.bbrc.2012.09.056. Epub 2012 Sep 17.
• [1027] The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to -amyloid peptide.J Biol Chem. 2017 Dec 15;292(50):20669-20682. doi: 10.1074/jbc.M117.792911. Epub 2017 Oct 20.
• [1028] Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function.J Alzheimers Dis. 2017;59(3):929-939. doi: 10.3233/JAD-170245.
• [1029] Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders.Neuromolecular Med. 2017 Mar;19(1):154-160. doi: 10.1007/s12017-016-8439-1. Epub 2016 Sep 19.
• [1030] Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.J Biol Chem. 2013 May 24;288(21):15418-29. doi: 10.1074/jbc.M112.448183. Epub 2013 Apr 12.
• [1031] SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging.J Neurosci Res. 2002 Nov 1;70(3):264-73. doi: 10.1002/jnr.10353.
• [1032] Microglia-derived ASC specks cross-seed amyloid- in Alzheimer's disease.Nature. 2017 Dec 20;552(7685):355-361. doi: 10.1038/nature25158.
• [1033] Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer's disease.PLoS One. 2014 May 1;9(5):e94576. doi: 10.1371/journal.pone.0094576. eCollection 2014.
• [1034] No association of Tachykinin receptor 2 (TACR2) polymorphisms with Alzheimer's disease.Neurobiol Aging. 2011 Mar;32(3):544-5. doi: 10.1016/j.neurobiolaging.2009.03.007. Epub 2009 Apr 18.
• [1035] Gene mutations in a Han Chinese Alzheimer's disease cohort.Brain Behav. 2019 Jan;9(1):e01180. doi: 10.1002/brb3.1180. Epub 2018 Dec 14.
• [1036] Classification of Clinically Diagnosed Alzheimer's Disease Associated with Diabetes Based on Amyloid and Tau PET Results.J Alzheimers Dis. 2019;71(1):261-271. doi: 10.3233/JAD-190620.
• [1037] Systematic Analysis and Biomarker Study for Alzheimer's Disease.Sci Rep. 2018 Nov 26;8(1):17394. doi: 10.1038/s41598-018-35789-3.
• [1038] Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.PLoS One. 2013 Apr 22;8(4):e59749. doi: 10.1371/journal.pone.0059749. Print 2013.
• [1039] Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.J Alzheimers Dis. 2017;58(1):23-35. doi: 10.3233/JAD-161116.
• [1040] Expression of telomere repeat binding factor 1 and TRF2 in Alzheimer's disease and correlation with clinical parameters.Neurol Res. 2019 Jun;41(6):504-509. doi: 10.1080/01616412.2019.1580456. Epub 2019 Feb 14.
• [1041] Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease.Neurobiol Aging. 2012 Aug;33(8):1633-41. doi: 10.1016/j.neurobiolaging.2011.03.005. Epub 2011 Apr 21.
• [1042] Genomics of Alzheimer Disease: A Review.JAMA Neurol. 2016 Jul 1;73(7):867-74. doi: 10.1001/jamaneurol.2016.0301.
• [1043] Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology.Mol Pharm. 2019 Feb 4;16(2):583-594. doi: 10.1021/acs.molpharmaceut.8b00870. Epub 2019 Jan 17.
• [1044] Increased Transforming Growth Factor 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies isCorrelated with Disease Severity andSoluble A42 Load.J Alzheimers Dis. 2017;56(1):157-166. doi: 10.3233/JAD-160781.
• [1045] Altered expression of transforming growth factor-beta in Alzheimer's disease.Neurology. 1995 Aug;45(8):1561-9. doi: 10.1212/wnl.45.8.1561.
• [1046] A functional variant in the miR-142 promoter modulating its expression and conferring risk of Alzheimer disease.Hum Mutat. 2019 Nov;40(11):2131-2145. doi: 10.1002/humu.23872. Epub 2019 Aug 7.
• [1047] Effect of Some Growth Factors on Tissue Transglutaminase Overexpression Induced by -Amyloid in Olfactory Ensheathing Cells.Mol Neurobiol. 2017 Nov;54(9):6785-6794. doi: 10.1007/s12035-016-0152-4. Epub 2016 Oct 18.
• [1048] Genomic deletion of TLR2 induces aggravated white matter damage and deteriorated neurobehavioral functions in mouse models of Alzheimer's disease.Aging (Albany NY). 2019 Sep 11;11(17):7257-7273. doi: 10.18632/aging.102260. Epub 2019 Sep 11.
• [1049] Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia-mediated neurodegeneration.J Biol Chem. 2017 Aug 11;292(32):13415-13427. doi: 10.1074/jbc.M117.784983. Epub 2017 Jun 27.
• [1050] A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.Alzheimers Dement (N Y). 2019 Jan 23;5:20-26. doi: 10.1016/j.trci.2018.11.001. eCollection 2019.
• [1051] Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer's disease puzzle.Neural Regen Res. 2019 Jul;14(7):1144-1147. doi: 10.4103/1673-5374.247443.
• [1052] Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer's Disease.Front Neurosci. 2019 Feb 4;13:49. doi: 10.3389/fnins.2019.00049. eCollection 2019.
• [1053] Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein.J Biol Chem. 2012 Aug 17;287(34):29125-33. doi: 10.1074/jbc.M112.362038. Epub 2012 Jul 3.
• [1054] Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease.Mol Neurobiol. 2018 May;55(5):4333-4344. doi: 10.1007/s12035-017-0547-x. Epub 2017 Jun 19.
• [1055] High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study.J Neurol. 2017 Mar;264(3):503-511. doi: 10.1007/s00415-016-8378-7. Epub 2016 Dec 30.
• [1056] Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.J Neuropathol Exp Neurol. 2020 Jan 1;79(1):22-33. doi: 10.1093/jnen/nlz107.
• [1057] Genetic risk factors for depression in Alzheimer`s disease patients.Curr Alzheimer Res. 2013 Jan;10(1):72-81.
• [1058] Tph2 Genetic Ablation Contributes to Senile Plaque Load and Astrogliosis in APP/PS1 Mice.Curr Alzheimer Res. 2019;16(3):219-232. doi: 10.2174/1567205016666190301110110.
• [1059] Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases.Neurosci Lett. 1999 Apr 2;264(1-3):157-60. doi: 10.1016/s0304-3940(99)00095-6.
• [1060] The small chaperone protein p23 and its cleaved product p19 in cellular stress.J Mol Neurosci. 2012 Feb;46(2):303-14. doi: 10.1007/s12031-011-9574-7. Epub 2011 Jun 21.
• [1061] Common Variant in TREM1 Influencing Brain Amyloid Deposition in Mild Cognitive Impairment and Alzheimer's Disease.Neurotox Res. 2020 Mar;37(3):661-668. doi: 10.1007/s12640-019-00105-y. Epub 2019 Nov 13.
• [1062] Rational Design of Specific Recognition Molecules for Simultaneously Monitoring of Endogenous Polysulfide and Hydrogen Sulfide in the Mouse Brain.Angew Chem Int Ed Engl. 2019 Sep 23;58(39):13948-13953. doi: 10.1002/anie.201907210. Epub 2019 Aug 14.
• [1063] TRPC1 Null Exacerbates Memory Deficit and Apoptosis Induced by Amyloid-.J Alzheimers Dis. 2018;63(2):761-772. doi: 10.3233/JAD-180077.
• [1064] Multiple molecular mechanisms form a positive feedback loop driving amyloid 42 peptide-induced neurotoxicity via activation of the TRPM2 channel in hippocampal neurons.Cell Death Dis. 2018 Feb 7;9(2):195. doi: 10.1038/s41419-018-0270-1.
• [1065] Activation of transient receptor potential melastatin 7 (TRPM7) channel increases basal autophagy and reduces amyloid -peptide.Biochem Biophys Res Commun. 2017 Nov 4;493(1):494-499. doi: 10.1016/j.bbrc.2017.08.163. Epub 2017 Sep 1.
• [1066] Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging.JAMA Neurol. 2019 Nov 1;76(11):1340-1351. doi: 10.1001/jamaneurol.2019.2462.
• [1067] Immunohistochemistry and in situ hybridization of T-cell acute lymphoblastic leukemia-associated antigen 1 in human brain tissues.Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):59-63. doi: 10.1159/000017102.
• [1068] miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3 in Alzheimer's disease.J Cell Biochem. 2019 Jun;120(6):9936-9946. doi: 10.1002/jcb.28276. Epub 2018 Dec 16.
• [1069] Thioredoxin system as a gatekeeper in caspase-6 activation and nuclear lamina integrity: Implications for Alzheimer's disease.Free Radic Biol Med. 2019 Apr;134:567-580. doi: 10.1016/j.freeradbiomed.2019.02.010. Epub 2019 Feb 12.
• [1070] Thioredoxin-Interacting Protein (TXNIP) Associated NLRP3 Inflammasome Activation in Human Alzheimer's Disease Brain.J Alzheimers Dis. 2019;68(1):255-265. doi: 10.3233/JAD-180814.
• [1071] Geographical Distribution and Diversity of Gut Microbial NADH:Ubiquinone Oxidoreductase Sequence Associated with Alzheimer's Disease.J Alzheimers Dis. 2018;61(4):1531-1540. doi: 10.3233/JAD-170764.
• [1072] Metabolite Profiling by Hyphenated Liquid Chromatographic Mass Spectrometric Technique (HPLC-DAD-ESI-Q-TOF-MS/MS) and Neurobiological Potential of Haplophyllum sahinii and H. vulcanicum Extracts.Chem Biodivers. 2019 Sep;16(9):e1900333. doi: 10.1002/cbdv.201900333. Epub 2019 Aug 8.
• [1073] Neuropathological findings in cerebral B-protein amyloidosis. Differences and similarities in those cases presenting as a cerebral hemorrhage and those presenting as a dementia of the Alzheimer type.Clin Neurol Neurosurg. 1992;94 Suppl:S52-3. doi: 10.1016/0303-8467(92)90021-t.
• [1074] Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1E9 mouse model of Alzheimer's disease.Hum Mol Genet. 2017 Oct 15;26(20):4042-4054. doi: 10.1093/hmg/ddx295.
• [1075] Deletion of Specific Sphingolipids in Distinct Neurons Improves Spatial Memory in a Mouse Model of Alzheimer's Disease.Front Mol Neurosci. 2018 Jun 20;11:206. doi: 10.3389/fnmol.2018.00206. eCollection 2018.
• [1076] USP10 is a critical factor for Tau-positive stress granule formation in neuronal cells.Sci Rep. 2019 Jul 22;9(1):10591. doi: 10.1038/s41598-019-47033-7.
• [1077] Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer's Disease.J Alzheimers Dis. 2019;72(2):425-441. doi: 10.3233/JAD-190635.
• [1078] Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170.
• [1079] Gender-Specific Expression of Ubiquitin-Specific Peptidase 9 Modulates Tau Expression and Phosphorylation: Possible Implications for Tauopathies.Mol Neurobiol. 2017 Dec;54(10):7979-7993. doi: 10.1007/s12035-016-0299-z. Epub 2016 Nov 23.
• [1080] Alterations of Transcription of Genes Coding Anti-oxidative and Mitochondria-Related Proteins in Amyloid Toxicity: Relevance to Alzheimer's Disease.Mol Neurobiol. 2020 Mar;57(3):1374-1388. doi: 10.1007/s12035-019-01819-y. Epub 2019 Nov 16.
• [1081] A systematic review and meta-analysis of the associations of vitamin D receptor genetic variants with two types of most common neurodegenerative disorders.Aging Clin Exp Res. 2020 Jan;32(1):21-27. doi: 10.1007/s40520-019-01135-4. Epub 2019 Mar 12.
• [1082] WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by A oligomers.Exp Neurol. 2015 Feb;264:14-25. doi: 10.1016/j.expneurol.2014.11.005. Epub 2014 Nov 20.
• [1083] Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts.J Alzheimers Dis. 2015;45(3):851-64. doi: 10.3233/JAD-142214.
• [1084] Network-Driven Proteogenomics Unveils an Aging-Related Imbalance in the Olfactory IB-NFB p65 Complex Functionality in Tg2576 Alzheimer's Disease Mouse Model.Int J Mol Sci. 2017 Oct 27;18(11):2260. doi: 10.3390/ijms18112260.
• [1085] Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders.PLoS One. 2017 Jul 26;12(7):e0180319. doi: 10.1371/journal.pone.0180319. eCollection 2017.
• [1086] Suppression of lncRNA-ATB prevents amyloid--induced neurotoxicity in PC12 cells via regulating miR-200/ZNF217 axis.Biomed Pharmacother. 2018 Dec;108:707-715. doi: 10.1016/j.biopha.2018.08.155. Epub 2018 Sep 21.
• [1087] Intermediate phenotypes identify divergent pathways to Alzheimer's disease.PLoS One. 2010 Jun 21;5(6):e11244. doi: 10.1371/journal.pone.0011244.
• [1088] Pericyte-derived bone morphogenetic protein 4 underlies white matter damage after chronic hypoperfusion.Brain Pathol. 2018 Jul;28(4):521-535. doi: 10.1111/bpa.12523. Epub 2017 May 31.
• [1089] Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.Mol Neurobiol. 2019 Aug;56(8):5799-5814. doi: 10.1007/s12035-019-1487-4. Epub 2019 Jan 25.
• [1090] BARHL1 Is Downregulated in Alzheimer's Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways.Genes (Basel). 2017 Sep 28;8(10):245. doi: 10.3390/genes8100245.
• [1091] Lipoprotein-associated phospholipase A2: The story continues.Med Res Rev. 2020 Jan;40(1):79-134. doi: 10.1002/med.21597. Epub 2019 May 29.
• [1092] Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain.Neuroscience. 2006 Jul 7;140(3):879-88. doi: 10.1016/j.neuroscience.2006.02.049. Epub 2006 Apr 3.
• [1093] Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice.Mol Ther. 2017 Jan 4;25(1):140-152. doi: 10.1016/j.ymthe.2016.10.010. Epub 2017 Jan 4.
• [1094] The Alu-rich genomic architecture of SPAST predisposes to diverse and functionally distinct disease-associated CNV alleles.Am J Hum Genet. 2014 Aug 7;95(2):143-61. doi: 10.1016/j.ajhg.2014.06.014. Epub 2014 Jul 24.
• [1095] ATP Binding Cassette Subfamily A Member 2 (ABCA2) Expression and Methylation are Associated with Alzheimer's Disease. Med Sci Monit. 2017 Dec 10;23:5851-5861.
• [1096] Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals.Int J Mol Sci. 2019 Apr 3;20(7):1664. doi: 10.3390/ijms20071664.
• [1097] Wilson's disease and other neurological copper disorders.Lancet Neurol. 2015 Jan;14(1):103-13. doi: 10.1016/S1474-4422(14)70190-5.
• [1098] Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease.Neurosci Lett. 2005 Feb 10;374(2):124-8. doi: 10.1016/j.neulet.2004.10.038.
• [1099] Curcumin Ameliorates Memory Deficits by Enhancing Lactate Content and MCT2 Expression in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease.Anat Rec (Hoboken). 2019 Feb;302(2):332-338. doi: 10.1002/ar.23969. Epub 2018 Nov 9.
• [1100] Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer.Mol Psychiatry. 2009 Jun;14(6):563-89. doi: 10.1038/mp.2009.2. Epub 2009 Feb 10.
• [1101] Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression.J Alzheimers Dis. 2017;55(2):763-776. doi: 10.3233/JAD-160330.
• [1102] Reduced CaM Kinase II and CaM Kinase IV Activities Underlie Cognitive Deficits in NCKX2 Heterozygous Mice.Mol Neurobiol. 2018 May;55(5):3889-3900. doi: 10.1007/s12035-017-0596-1. Epub 2017 May 25.
• [1103] Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype.JAMA Neurol. 2019 Sep 1;76(9):1099-1108. doi: 10.1001/jamaneurol.2019.1456.
• [1104] Brain-derived neurotrophic factor gene variants and Alzheimer disease: an association study in an Alzheimer disease Italian population.Rejuvenation Res. 2013 Feb;16(1):57-66. doi: 10.1089/rej.2012.1381.
• [1105] Housefly (Musca domestica) larvae powder, preventing oxidative stress injury via regulation of UCP4 and CyclinD1 and modulation of JNK and P38 signaling in APP/PS1 mice.Food Funct. 2019 Jan 22;10(1):235-243. doi: 10.1039/c8fo02052c.
• [1106] Mitoferrin-1 is Involved in the Progression of Alzheimer's Disease Through Targeting Mitochondrial Iron Metabolism in a Caenorhabditis elegans Model of Alzheimer's Disease.Neuroscience. 2018 Aug 10;385:90-101. doi: 10.1016/j.neuroscience.2018.06.011. Epub 2018 Jun 13.
• [1107] Appoptosin Mediates Lesions Induced by Oxidative Stress Through the JNK-FoxO1 Pathway.Front Aging Neurosci. 2019 Sep 4;11:243. doi: 10.3389/fnagi.2019.00243. eCollection 2019.
• [1108] MSUT2 is a determinant of susceptibility to tau neurotoxicity.Hum Mol Genet. 2011 May 15;20(10):1989-99. doi: 10.1093/hmg/ddr079. Epub 2011 Feb 25.
• [1109] Genetic association of SLC2A14 polymorphism with Alzheimer's disease in a Han Chinese population.J Mol Neurosci. 2012 Jul;47(3):481-4. doi: 10.1007/s12031-012-9748-y. Epub 2012 Mar 16.
• [1110] Transcript Analysis of Zebrafish GLUT3 Genes, slc2a3a and slc2a3b, Define Overlapping as Well as Distinct Expression Domains in the Zebrafish (Danio rerio) Central Nervous System.Front Mol Neurosci. 2019 Aug 27;12:199. doi: 10.3389/fnmol.2019.00199. eCollection 2019.
• [1111] Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer's disease.J Alzheimers Dis. 2013;34(2):399-405. doi: 10.3233/JAD-121621.
• [1112] Obesity and age-related alterations in the gene expression of zinc-transporter proteins in the human brain.Transl Psychiatry. 2016 Jun 14;6(6):e838. doi: 10.1038/tp.2016.83.
• [1113] Altered expression of ZnT10 in Alzheimer's disease brain.PLoS One. 2013 May 31;8(5):e65475. doi: 10.1371/journal.pone.0065475. Print 2013.
• [1114] Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of Drosophila ameliorates A42-induced Alzheimer's disease-like symptoms.Neurobiol Aging. 2013 Nov;34(11):2604-12. doi: 10.1016/j.neurobiolaging.2013.05.029. Epub 2013 Jul 2.
• [1115] Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients.J Alzheimers Dis. 2010;20(2):465-75. doi: 10.3233/JAD-2010-1385.
• [1116] Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.CNS Neurosci Ther. 2013 Feb;19(2):91-7. doi: 10.1111/cns.12036. Epub 2012 Dec 4.
• [1117] A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer's Disease.J Alzheimers Dis. 2019;71(4):1163-1174. doi: 10.3233/JAD-190700.
• [1118] Association of alleles carried at TNFA -850 and BAT1 -22 with Alzheimer's disease.J Neuroinflammation. 2008 Aug 20;5:36. doi: 10.1186/1742-2094-5-36.
• [1119] Histone deacetylase-mediated regulation of endolysosomal pH.J Biol Chem. 2018 May 4;293(18):6721-6735. doi: 10.1074/jbc.RA118.002025. Epub 2018 Mar 22.
• [1120] Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004 Aug 13;279(33):34674-81. doi: 10.1074/jbc.M402324200. Epub 2004 May 17.
• [1121] Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease.PLoS One. 2017 Jan 6;12(1):e0167273. doi: 10.1371/journal.pone.0167273. eCollection 2017.
• [1122] Preclinical Development of Crocus sativus-Based Botanical Lead IIIM-141 for Alzheimer's Disease: Chemical Standardization, Efficacy, Formulation Development, Pharmacokinetics, and Safety Pharmacology.ACS Omega. 2018 Aug 20;3(8):9572-9585. doi: 10.1021/acsomega.8b00841. eCollection 2018 Aug 31.
• [1123] Alcohol Dehydrogenase 1B Suppresses -Amyloid-Induced Neuron Apoptosis.Front Aging Neurosci. 2019 Jun 5;11:135. doi: 10.3389/fnagi.2019.00135. eCollection 2019.
• [1124] Hypertension accelerates cerebral tissue PO(2) disruption in Alzheimer's disease.Neurosci Lett. 2020 Jan 10;715:134626. doi: 10.1016/j.neulet.2019.134626. Epub 2019 Nov 11.
• [1125] Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.J Neurosci. 2011 Feb 9;31(6):2313-20. doi: 10.1523/JNEUROSCI.4717-10.2011.
• [1126] Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.J Alzheimers Dis. 2019;68(1):33-38. doi: 10.3233/JAD-181043.
• [1127] Sensitive electrochemical detection of amyloid beta peptide in human serum using an interdigitated chain-shaped electrode.Biosens Bioelectron. 2019 Nov 1;144:111694. doi: 10.1016/j.bios.2019.111694. Epub 2019 Sep 7.
• [1128] Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease.Neuroscience. 2003;121(2):307-14. doi: 10.1016/s0306-4522(03)00438-x.
• [1129] Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.PLoS Genet. 2014 Oct 23;10(10):e1004758. doi: 10.1371/journal.pgen.1004758. eCollection 2014 Oct.
• [1130] Asymmetric dimethylarginine exacerbates A-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease.Free Radic Biol Med. 2015 Feb;79:117-26. doi: 10.1016/j.freeradbiomed.2014.12.002. Epub 2014 Dec 12.
• [1131] Free d-aspartate triggers NMDA receptor-dependent cell death in primary cortical neurons and perturbs JNK activation, Tau phosphorylation, and protein SUMOylation in the cerebral cortex of mice lacking d-aspartate oxidase activity.Exp Neurol. 2019 Jul;317:51-65. doi: 10.1016/j.expneurol.2019.02.014. Epub 2019 Feb 26.
• [1132] Role of interleukin 1-beta in the inflammatory response in a fatty acid amide hydrolase-knockout mouse model of Alzheimer's disease.Biochem Pharmacol. 2018 Nov;157:202-209. doi: 10.1016/j.bcp.2018.09.009. Epub 2018 Sep 6.
• [1133] Glutaminase C Regulates Microglial Activation and Pro-inflammatory Exosome Release: Relevance to the Pathogenesis of Alzheimer's Disease.Front Cell Neurosci. 2019 Jun 28;13:264. doi: 10.3389/fncel.2019.00264. eCollection 2019.
• [1134] Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling.Neurobiol Aging. 2019 Jan;73:123-134. doi: 10.1016/j.neurobiolaging.2018.09.018. Epub 2018 Sep 25.
• [1135] Alterations in Serum Zinc and Polyunsaturated Fatty Acid Concentrations in Treatment-Naive HIV-Diagnosed Alcohol-Dependent Subjects with Liver Injury.AIDS Res Hum Retroviruses. 2019 Jan;35(1):92-99. doi: 10.1089/AID.2018.0124. Epub 2018 Dec 11.
• [1136] Role of Resveratrol and Selenium on Oxidative Stress and Expression of Antioxidant and Anti-Aging Genes in Immortalized Lymphocytes from Alzheimer's Disease Patients.Nutrients. 2019 Jul 31;11(8):1764. doi: 10.3390/nu11081764.
• [1137] H- and C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.J Neural Transm (Vienna). 2015 Apr;122(4):541-50. doi: 10.1007/s00702-015-1387-3. Epub 2015 Mar 6.
• [1138] Metabolomic Assays of Postmortem Brain Extracts: Pitfalls in Extrapolation of Concentrations of Glucose and Amino Acids to Metabolic Dysregulation In Vivo in Neurological Diseases.Neurochem Res. 2019 Oct;44(10):2239-2260. doi: 10.1007/s11064-018-2611-y. Epub 2018 Aug 16.
• [1139] Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.Free Radic Biol Med. 2011 Jun 1;50(11):1526-35. doi: 10.1016/j.freeradbiomed.2011.02.035. Epub 2011 Mar 5.
• [1140] Histopathological features of a patient with Charcot-Marie-Tooth disease type 2U/AD-CMTax-MARS.J Peripher Nerv Syst. 2016 Dec;21(4):370-374. doi: 10.1111/jns.12193.
• [1141] Regulation of methionine adenosyltransferase catalytic activity and messenger RNA in SH-SY5Y human neuroblastoma cells.Biochem Pharmacol. 1998 Mar 1;55(5):567-71. doi: 10.1016/s0006-2952(97)00514-5.
• [1142] Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2.Stem Cell Res. 2014 Nov;13(3 Pt A):442-53. doi: 10.1016/j.scr.2014.10.001. Epub 2014 Oct 12.
• [1143] Oxidation of methionine 35 reduces toxicity of the amyloid beta-peptide(1-42) in neuroblastoma cells (IMR-32) via enzyme methionine sulfoxide reductase A expression and function.Neurochem Int. 2010 Mar;56(4):597-602. doi: 10.1016/j.neuint.2010.01.002. Epub 2010 Jan 11.
• [1144] Mitochondrial methionine sulfoxide reductase B2 links oxidative stress to Alzheimer's disease-like pathology.Exp Neurol. 2019 Aug;318:145-156. doi: 10.1016/j.expneurol.2019.05.006. Epub 2019 May 9.
• [1145] Methionine synthase polymorphism is a risk factor for Alzheimer disease.Neuroreport. 2003 Jul 18;14(10):1391-4. doi: 10.1097/01.wnr.0000073683.00308.0e.
• [1146] NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.BMC Med Genet. 2004 Mar 17;5:6. doi: 10.1186/1471-2350-5-6.
• [1147] The role of NAT2 gene polymorphism in aetiology of the most frequent neurodegenerative diseases with dementia.Neurol Neurochir Pol. 2007 Sep-Oct;41(5):388-94.
• [1148] Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces -secretase (BACE1) levels and A generation.J Biol Chem. 2012 Mar 9;287(11):8424-33. doi: 10.1074/jbc.M111.310136. Epub 2012 Jan 20.
• [1149] NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.Behav Brain Res. 2018 Feb 26;339:140-152. doi: 10.1016/j.bbr.2017.11.030. Epub 2017 Nov 23.
• [1150] NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies.PLoS Biol. 2016 Jun 2;14(6):e1002472. doi: 10.1371/journal.pbio.1002472. eCollection 2016 Jun.
• [1151] Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis.J Nutr Biochem. 2019 May;67:123-137. doi: 10.1016/j.jnutbio.2019.01.015. Epub 2019 Feb 11.
• [1152] A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis.PLoS One. 2010 Nov 30;5(11):e14169. doi: 10.1371/journal.pone.0014169.
• [1153] Polymorphisms of the cholesterol 24-hydroxylase (CYP46A1) gene and the risk of Alzheimer's disease in a Chinese population.Int Psychogeriatr. 2006 Mar;18(1):37-45. doi: 10.1017/S1041610205003108.
• [1154] Abnormal circadian locomotor rhythms and Per gene expression in six-month-old triple transgenic mice model of Alzheimer's disease.Neurosci Lett. 2018 May 29;676:13-18. doi: 10.1016/j.neulet.2018.04.008. Epub 2018 Apr 4.
• [1155] Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex.J Neurosci Res. 1997 Dec 15;50(6):937-45. doi: 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E.
• [1156] Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.Neurobiol Aging. 2012 May;33(5):1015.e7-23. doi: 10.1016/j.neurobiolaging.2010.08.003. Epub 2010 Oct 27.
• [1157] An aberrant protein complex in CSF as a biomarker of Alzheimer disease.Neurology. 2008 Jun 3;70(23):2212-8. doi: 10.1212/01.wnl.0000312383.39973.88. Epub 2008 Apr 30.
• [1158] Nicotine versus 6-hydroxy-l-nicotine against chlorisondamine induced memory impairment and oxidative stress in the rat hippocampus.Biomed Pharmacother. 2017 Feb;86:102-108. doi: 10.1016/j.biopha.2016.12.008. Epub 2016 Dec 9.
• [1159] Proteomic Analysis of Early Diabetic Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases.Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2264-2274. doi: 10.1167/iovs.17-23678.
• [1160] Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b.
• [1161] Mapping and molecular characterization of novel monoclonal antibodies to conformational epitopes on NH2 and COOH termini of mammalian tryptophanyl-tRNA synthetase reveal link of the epitopes to aggregation and Alzheimer's disease.Mol Immunol. 2007 Jan;44(4):541-57. doi: 10.1016/j.molimm.2006.02.006. Epub 2006 Apr 17.
• [1162] Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies.Neurology. 2006 Jan 24;66(2 Suppl 1):S86-92. doi: 10.1212/01.wnl.0000193882.46003.6d.
• [1163] Diagnostics and Treatments of Iron-Related CNS Diseases.Adv Exp Med Biol. 2019;1173:179-194. doi: 10.1007/978-981-13-9589-5_10.
• [1164] Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies.Front Aging Neurosci. 2018 Apr 26;10:122. doi: 10.3389/fnagi.2018.00122. eCollection 2018.
• [1165] Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.Clin Chem Lab Med. 2019 Nov 26;57(12):1875-1881. doi: 10.1515/cclm-2019-0428.
• [1166] The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.J Neuroimaging. 2019 Nov;29(6):712-720. doi: 10.1111/jon.12643. Epub 2019 Jun 14.
• [1167] Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2224-2245. doi: 10.1016/j.bbadis.2019.04.019. Epub 2019 May 2.
• [1168] Age, but Not Amyloidosis, Induced Changes in Global Levels of Histone Modifications in Susceptible and Disease-Resistant Neurons in Alzheimer's Disease Model Mice.Front Aging Neurosci. 2019 Apr 3;11:68. doi: 10.3389/fnagi.2019.00068. eCollection 2019.
• [1169] Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration.J Alzheimers Dis. 2018;61(4):1477-1483. doi: 10.3233/JAD-170722.
• [1170] Association between selected cholesterol-related gene polymorphisms and Alzheimer's disease in a Turkish cohort.Mol Biol Rep. 2019 Apr;46(2):1701-1707. doi: 10.1007/s11033-019-04619-8. Epub 2019 Jan 25.
• [1171] Association of COL25A1 with comorbid antisocial personality disorder and substance dependence.Biol Psychiatry. 2012 Apr 15;71(8):733-40. doi: 10.1016/j.biopsych.2011.12.011. Epub 2012 Jan 31.
• [1172] CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.Neurobiol Aging. 2017 Nov;59:1-9. doi: 10.1016/j.neurobiolaging.2017.06.028. Epub 2017 Jul 11.
• [1173] A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders.Adv Exp Med Biol. 2020;1131:131-161. doi: 10.1007/978-3-030-12457-1_6.
• [1174] NRBF2 is involved in the autophagic degradation process of APP-CTFs in Alzheimer disease models.Autophagy. 2017;13(12):2028-2040. doi: 10.1080/15548627.2017.1379633.
• [1175] Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimer's Disease.Front Neurosci. 2019 Nov 29;13:1273. doi: 10.3389/fnins.2019.01273. eCollection 2019.
• [1176] Genetic variation associated with the occurrence and progression of neurological disorders.Neurotoxicology. 2017 Jul;61:243-264. doi: 10.1016/j.neuro.2016.09.018. Epub 2016 Oct 3.
• [1177] Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies.J Neuropathol Exp Neurol. 2011 Apr;70(4):264-80. doi: 10.1097/NEN.0b013e318211c86a.
• [1178] Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain.Structure. 2018 Aug 7;26(8):1137-1143.e3. doi: 10.1016/j.str.2018.05.008. Epub 2018 Jun 28.
• [1179] In Silico Insights towards the Identification of NLRP3 Druggable Hot Spots.Int J Mol Sci. 2019 Oct 9;20(20):4974. doi: 10.3390/ijms20204974.
• [1180] Generation of induced pluripotent stem cell line (ZZUi0013-A) from a 65-year-old patient with a novel MEOX2 gene mutation in Alzheimer's disease.Stem Cell Res. 2019 Jan;34:101366. doi: 10.1016/j.scr.2018.101366. Epub 2018 Dec 27.
• [1181] Genes associated with the progression of neurofibrillary tangles in Alzheimer's disease.Transl Psychiatry. 2014 Jun 10;4(6):e396. doi: 10.1038/tp.2014.35.
• [1182] Enhanced amyloid- generation by -secretase complex in DRM microdomains with reduced cholesterol levels.Hum Mol Genet. 2020 Feb 1;29(3):382-393. doi: 10.1093/hmg/ddz297.
• [1183] Transethnic genome-wide scan identifies novel Alzheimer's disease loci.Alzheimers Dement. 2017 Jul;13(7):727-738. doi: 10.1016/j.jalz.2016.12.012. Epub 2017 Feb 7.
• [1184] NLRP12 autoinflammatory disease: a Chinese case series and literature review.Clin Rheumatol. 2017 Jul;36(7):1661-1667. doi: 10.1007/s10067-016-3410-y. Epub 2016 Sep 16.
• [1185] Alternative cleavage and polyadenylation of genes associated with protein turnover and mitochondrial function are deregulated in Parkinson's, Alzheimer's and ALS disease.BMC Med Genomics. 2019 May 9;12(1):60. doi: 10.1186/s12920-019-0509-4.
• [1186] Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease.Neurosci Lett. 2009 Sep 11;461(1):54-9. doi: 10.1016/j.neulet.2009.05.051. Epub 2009 May 27.
• [1187] Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia.Adv Sci (Weinh). 2018 Dec 12;6(4):1801586. doi: 10.1002/advs.201801586. eCollection 2019 Feb 20.
• [1188] Inhibition of casein kinase 1/improves cognitive-affective behavior and reduces amyloid load in the APP-PS1 mouse model of Alzheimer's disease.Sci Rep. 2019 Sep 24;9(1):13743. doi: 10.1038/s41598-019-50197-x.
• [1189] Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia?.Neurochem Int. 2018 Sep;118:134-144. doi: 10.1016/j.neuint.2018.04.004. Epub 2018 Apr 10.
• [1190] PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease.Neurosci Lett. 2017 Apr 3;645:40-45. doi: 10.1016/j.neulet.2017.02.027. Epub 2017 Feb 14.
• [1191] Expression patterns of prune2 is regulated by Notch and retinoic acid signaling pathways in the zebrafish embryogenesis.Gene Expr Patterns. 2017 Jan;23-24:45-51. doi: 10.1016/j.gep.2017.03.002. Epub 2017 Mar 11.
• [1192] Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease.Traffic. 2018 Apr;19(4):253-262. doi: 10.1111/tra.12547. Epub 2018 Feb 5.
• [1193] Reducing ADAMTS-3 Inhibits Amyloid Deposition in App Knock-in Mouse.Biol Pharm Bull. 2019;42(3):354-356. doi: 10.1248/bpb.b18-00899.
• [1194] A photoelectrochemical sandwich immunoassay for protein S100, a biomarker for Alzheimer's disease, using an ITO electrode modified with a reduced graphene oxide-gold conjugate and CdS-labeled secondary antibody.Mikrochim Acta. 2019 Jan 16;186(2):117. doi: 10.1007/s00604-018-3159-x.
• [1195] Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain.Neurosci Lett. 2019 Jul 27;706:164-168. doi: 10.1016/j.neulet.2019.05.034. Epub 2019 May 19.
• [1196] Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?.J Mol Neurosci. 2019 Oct;69(2):343-350. doi: 10.1007/s12031-019-01363-3. Epub 2019 Jul 2.
• [1197] SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments.Acta Neuropathol Commun. 2019 Feb 15;7(1):21. doi: 10.1186/s40478-019-0663-0.
• [1198] Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer's Disease.ACS Chem Neurosci. 2019 Oct 16;10(10):4199-4212. doi: 10.1021/acschemneuro.9b00460. Epub 2019 Sep 30.
• [1199] Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1.Acta Neuropathol Commun. 2016 Feb 25;4:16. doi: 10.1186/s40478-016-0282-y.
• [1200] Metal Binding by GMP-1 and Its Pyrimido [1, 2]benzimidazole Analogs Confirms Protection Against Amyloid- Associated Neurotoxicity.J Alzheimers Dis. 2020;73(2):695-705. doi: 10.3233/JAD-190695.
• [1201] A pectin from fruits of Lycium barbarum L. decreases -amyloid peptide production through modulating APP processing.Carbohydr Polym. 2018 Dec 1;201:65-74. doi: 10.1016/j.carbpol.2018.08.050. Epub 2018 Aug 15.
• [1202] Down-regulated TMED10 in Alzheimer disease induces autophagy via ATG4B activation.Autophagy. 2019 Sep;15(9):1495-1505. doi: 10.1080/15548627.2019.1586249. Epub 2019 Mar 19.
• [1203] TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimer's Disease.J Alzheimers Dis. 2017;58(4):1027-1033. doi: 10.3233/JAD-170190.
• [1204] Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.JAMA Neurol. 2020 Feb 1;77(2):215-224. doi: 10.1001/jamaneurol.2019.3812.
• [1205] ADAMTS-4 in central nervous system pathologies.J Neurosci Res. 2017 Sep;95(9):1703-1711. doi: 10.1002/jnr.24021. Epub 2017 Jan 13.
• [1206] MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2.Brain Res. 2012 May 21;1455:103-13. doi: 10.1016/j.brainres.2011.10.051. Epub 2011 Nov 4.
• [1207] The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.Neurosci Lett. 2018 Nov 1;686:205-210. doi: 10.1016/j.neulet.2018.08.024. Epub 2018 Aug 22.
• [1208] Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.Brain Pathol. 2019 Mar;29(2):164-175. doi: 10.1111/bpa.12647. Epub 2018 Oct 5.
• [1209] Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.Nat Genet. 2011 May;43(5):436-41. doi: 10.1038/ng.801. Epub 2011 Apr 3.
• [1210] Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.Theranostics. 2017 Sep 1;7(15):3624-3637. doi: 10.7150/thno.21408. eCollection 2017.
• [1211] Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.Acta Neuropathol Commun. 2019 Dec 3;7(1):195. doi: 10.1186/s40478-019-0848-6.
• [1212] Tracking Effects of SIL1 Increase: Taking a Closer Look Beyond the Consequences of Elevated Expression Level.Mol Neurobiol. 2018 Mar;55(3):2524-2546. doi: 10.1007/s12035-017-0494-6. Epub 2017 Apr 11.
• [1213] Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies.Genes (Basel). 2018 Jan 25;9(2):63. doi: 10.3390/genes9020063.
• [1214] Removing dysfunctional mitochondria from axons independent of mitophagy under pathophysiological conditions.Autophagy. 2017 Oct 3;13(10):1792-1794. doi: 10.1080/15548627.2017.1356552. Epub 2017 Aug 16.
• [1215] Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004 Oct 1;64(19):7156-68. doi: 10.1158/0008-5472.CAN-04-1121.
• [1216] Excess Synaptojanin 1 Contributes to Place Cell Dysfunction and Memory Deficits in the Aging Hippocampus in Three Types of Alzheimer's Disease.Cell Rep. 2018 Jun 5;23(10):2967-2975. doi: 10.1016/j.celrep.2018.05.011.
• [1217] Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382. doi: 10.1007/s00259-019-04305-8. Epub 2019 Mar 27.
• [1218] The Adaptor Protein Alix is Involved in the Interaction Between the Ubiquitin Ligase NEDD4-1 and its Targets, ABCG1 and ABCG4.Int J Mol Sci. 2019 Jun 2;20(11):2714. doi: 10.3390/ijms20112714.
• [1219] Potential roles of PINK1 for increased PGC-1-mediated mitochondrial fatty acid oxidation and their associations with Alzheimer disease and diabetes.Mitochondrion. 2014 Sep;18:41-8. doi: 10.1016/j.mito.2014.09.005. Epub 2014 Sep 23.
• [1220] Translational study of Alzheimer's disease (AD) biomarkers from brain tissues in APP/PS1 mice and serum of AD patients.J Alzheimers Dis. 2015;45(1):269-82. doi: 10.3233/JAD-142805.
• [1221] Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese.Mol Neurobiol. 2017 Jan;54(1):308-318. doi: 10.1007/s12035-015-9649-5. Epub 2016 Jan 6.
• [1222] A disease-modifying treatment for Alzheimer's disease: focus on the trans-sulfuration pathway.Rev Neurosci. 2020 Apr 28;31(3):319-334. doi: 10.1515/revneuro-2019-0076.
• [1223] Isolation of hNap1BP which interacts with human Nap1 (NCKAP1) whose expression is down-regulated in Alzheimer's disease.Gene. 2001 Jun 27;271(2):159-69. doi: 10.1016/s0378-1119(01)00521-2.
• [1224] A novel Alzheimer disease locus located near the gene encoding tau protein.Mol Psychiatry. 2016 Jan;21(1):108-17. doi: 10.1038/mp.2015.23. Epub 2015 Mar 17.
• [1225] A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease.Neurosci Lett. 2010 Jan 1;468(1):1-2. doi: 10.1016/j.neulet.2009.10.040. Epub 2009 Oct 22.
• [1226] ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells.Biochem Biophys Res Commun. 2007 Jan 5;352(1):111-7. doi: 10.1016/j.bbrc.2006.10.181. Epub 2006 Nov 9.
• [1227] Estrogen regulation of the neprilysin gene through a hormone-responsive element.J Mol Neurosci. 2009 Sep;39(1-2):22-6. doi: 10.1007/s12031-008-9168-1. Epub 2009 Jan 6.
• [1228] A disintegrin and metalloproteinase with thrombospondin motifs 2 cleaves and inactivates Reelin in the postnatal cerebral cortex and hippocampus, but not in the cerebellum.Mol Cell Neurosci. 2019 Oct;100:103401. doi: 10.1016/j.mcn.2019.103401. Epub 2019 Sep 3.
• [1229] Retinoic acid-induced upregulation of the metalloendopeptidase nardilysin is accelerated by co-expression of the brain-specific protein p42(IP4) (centaurin 1; ADAP1) in neuroblastoma cells.Neurochem Int. 2011 Nov;59(6):936-44. doi: 10.1016/j.neuint.2011.07.004. Epub 2011 Jul 23.
• [1230] Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease.Neurobiol Aging. 2014 Aug;35(8):1785-91. doi: 10.1016/j.neurobiolaging.2014.02.018. Epub 2014 Mar 1.
• [1231] Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.Ann Neurol. 2010 Aug;68(2):220-30. doi: 10.1002/ana.22052.
• [1232] acn-1, a C. elegans homologue of ACE, genetically interacts with the let-7 microRNA and other heterochronic genes.Cell Cycle. 2017 Oct 2;16(19):1800-1809. doi: 10.1080/15384101.2017.1344798. Epub 2017 Sep 21.
• [1233] The Adiponectin Homolog Osmotin Enhances Neurite Outgrowth and Synaptic Complexity via AdipoR1/NgR1 Signaling in Alzheimer's Disease.Mol Neurobiol. 2018 Aug;55(8):6673-6686. doi: 10.1007/s12035-017-0847-1. Epub 2018 Jan 15.
• [1234] Direct evidence for binding of aluminum to NAP anti-amyloid peptide and its analogs.Eur J Mass Spectrom (Chichester). 2020 Apr;26(2):106-116. doi: 10.1177/1469066719877714. Epub 2019 Sep 24.
• [1235] Promoter DNA hypermethylation - Implications for Alzheimer's disease.Neurosci Lett. 2019 Oct 15;711:134403. doi: 10.1016/j.neulet.2019.134403. Epub 2019 Jul 24.
• [1236] Microbiome-Mediated Upregulation of MicroRNA-146a in Sporadic Alzheimer's Disease.Front Neurol. 2018 Mar 19;9:145. doi: 10.3389/fneur.2018.00145. eCollection 2018.
• [1237] Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study.J Alzheimers Dis. 2020;73(2):759-768. doi: 10.3233/JAD-191005.
• [1238] Amyloid beta induces cellular relocalization and production of agrin and glypican-1.Brain Res. 2009 Mar 13;1260:38-46. doi: 10.1016/j.brainres.2008.12.063. Epub 2009 Jan 7.
• [1239] Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease.Clin Biochem. 2020 Feb;76:24-30. doi: 10.1016/j.clinbiochem.2019.11.011. Epub 2019 Nov 28.
• [1240] Type I interferon (IFN)-inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer's disease.J Neuroinflammation. 2019 Nov 26;16(1):236. doi: 10.1186/s12974-019-1639-5.
• [1241] Suppression of AIMP1 protects cognition in Alzheimer's disease model mice 3xTg-AD.Neuroreport. 2017 Jan 18;28(2):82-86. doi: 10.1097/WNR.0000000000000710.
• [1242] Prostaglandin A1 Inhibits the Cognitive Decline of APP/PS1 Transgenic Mice via PPAR/ABCA1-dependent Cholesterol Efflux Mechanisms.Neurotherapeutics. 2019 Apr;16(2):505-522. doi: 10.1007/s13311-018-00704-1.
• [1243] Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans.J Neuroimmune Pharmacol. 2018 Jun;13(2):254-264. doi: 10.1007/s11481-018-9781-x. Epub 2018 Mar 7.
• [1244] The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies.Behav Brain Res. 2019 Oct 17;372:112004. doi: 10.1016/j.bbr.2019.112004. Epub 2019 Jun 1.
• [1245] Whole-Transcriptome Analysis of APP/PS1 Mouse Brain and Identification of circRNA-miRNA-mRNA Networks to Investigate AD Pathogenesis.Mol Ther Nucleic Acids. 2019 Dec 6;18:1049-1062. doi: 10.1016/j.omtn.2019.10.030. Epub 2019 Nov 6.
• [1246] Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?.Autophagy. 2019 Feb;15(2):368-371. doi: 10.1080/15548627.2018.1509609. Epub 2018 Sep 13.
• [1247] Cholesterol-related genes in Alzheimer's disease.Biochim Biophys Acta. 2010 Aug;1801(8):762-73. doi: 10.1016/j.bbalip.2010.05.009. Epub 2010 May 24.
• [1248] Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and promotes survival of cerebellar granule neurons.J Neurosci. 2003 Jul 2;23(13):5887-96. doi: 10.1523/JNEUROSCI.23-13-05887.2003.
• [1249] Gene expression variance in hippocampal tissue of temporal lobe epilepsy patients corresponds to differential memory performance.Neurobiol Dis. 2016 Feb;86:121-30. doi: 10.1016/j.nbd.2015.11.011. Epub 2015 Nov 26.
• [1250] Association analysis of 528 intra-genic SNPs in a region of chromosome 10 linked to late onset Alzheimer's disease.Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):727-31. doi: 10.1002/ajmg.b.30670.
• [1251] The association of DRD2 -141C and ANKK1 TaqIA polymorphisms with alcohol dependence in Korean population classified by the Lesch typology.Alcohol Alcohol. 2013 Jul-Aug;48(4):426-32. doi: 10.1093/alcalc/agt029. Epub 2013 Apr 4.
• [1252] Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.Alzheimers Dement. 2019 Oct;15(10):1333-1347. doi: 10.1016/j.jalz.2019.06.4950. Epub 2019 Aug 28.
• [1253] The intracellular localization of amyloid beta protein precursor (AbetaPP) intracellular domain associated protein-1 (AIDA-1) is regulated by AbetaPP and alternative splicing.J Alzheimers Dis. 2004 Feb;6(1):67-78. doi: 10.3233/jad-2004-6108.
• [1254] Inhibition of Histone Acetylation by ANP32A Induces Memory Deficits.J Alzheimers Dis. 2018;63(4):1537-1546. doi: 10.3233/JAD-180090.
• [1255] The Molecular Misreading of APP and UBB Induces a Humoral Immune Response in Alzheimer's Disease Patients with Diagnostic Ability.Mol Neurobiol. 2020 Feb;57(2):1009-1020. doi: 10.1007/s12035-019-01809-0. Epub 2019 Oct 26.
• [1256] A genetic variant near adaptor-related protein complex 2 alpha 2 subunit gene is associated with coronary artery disease in a Chinese population.BMC Cardiovasc Disord. 2018 Aug 7;18(1):161. doi: 10.1186/s12872-018-0905-2.
• [1257] Expression of the neuronal adaptor protein X11alpha protects against memory dysfunction in a transgenic mouse model of Alzheimer's disease.J Alzheimers Dis. 2010;20(1):31-6. doi: 10.3233/JAD-2009-1341.
• [1258] Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease.J Neurosci. 2008 Dec 31;28(53):14392-400. doi: 10.1523/JNEUROSCI.2481-08.2008.
• [1259] GSK3 Interactions with Amyloid Genes: An Autopsy Verification and Extension.Neurotox Res. 2015 Oct;28(3):232-8. doi: 10.1007/s12640-015-9541-0. Epub 2015 Jul 21.
• [1260] Genome structure and chromosomal mapping of the gene for Fe65L2 interacting with Alzheimer's beta-amyloid precursor protein.Biochem Biophys Res Commun. 1999 May 10;258(2):385-9. doi: 10.1006/bbrc.1999.0639.
• [1261] In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease.SLAS Discov. 2017 Jul;22(6):676-685. doi: 10.1177/2472555217697964. Epub 2017 Mar 17.
• [1262] APH-1A Component of -Secretase Forms an Internal Water and Ion-Containing Cavity.ACS Chem Neurosci. 2019 Jun 19;10(6):2931-2938. doi: 10.1021/acschemneuro.9b00150. Epub 2019 Apr 23.
• [1263] The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer's disease.Acta Neuropathol Commun. 2019 Jan 31;7(1):13. doi: 10.1186/s40478-019-0660-3.
• [1264] HDX-MS reveals orthosteric and allosteric changes in apolipoprotein-D structural dynamics upon binding of progesterone.Protein Sci. 2019 Feb;28(2):365-374. doi: 10.1002/pro.3534. Epub 2018 Dec 20.
• [1265] Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population.Neurosci Lett. 2004 Jun 10;363(2):139-43. doi: 10.1016/j.neulet.2004.03.066.
• [1266] Evidence that the rab5 effector APPL1 mediates APP-CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease.Mol Psychiatry. 2016 May;21(5):707-16. doi: 10.1038/mp.2015.97. Epub 2015 Jul 21.
• [1267] Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease.Cells. 2019 Jan 27;8(2):90. doi: 10.3390/cells8020090.
• [1268] A modulates actin cytoskeleton via SHIP2-mediated phosphoinositide metabolism.Sci Rep. 2019 Oct 29;9(1):15557. doi: 10.1038/s41598-019-51914-2.
• [1269] The Arc Gene Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.Mol Neurobiol. 2018 Feb;55(2):1217-1226. doi: 10.1007/s12035-017-0397-6. Epub 2017 Jan 20.
• [1270] Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice.J Clin Invest. 2017 May 1;127(5):1646-1650. doi: 10.1172/JCI85504. Epub 2017 Mar 27.
• [1271] The left frontal cortex supports reserve in aging by enhancing functional network efficiency.Alzheimers Res Ther. 2018 Mar 6;10(1):28. doi: 10.1186/s13195-018-0358-y.
• [1272] G proteins, p60TRP, and neurodegenerative diseases.Mol Neurobiol. 2013 Jun;47(3):1103-11. doi: 10.1007/s12035-013-8410-1. Epub 2013 Jan 24.
• [1273] Complex regulation of acute and chronic neuroinflammatory responses in mouse models deficient for nuclear factor kappa B p50 subunit.Neurobiol Dis. 2014 Apr;64:16-29. doi: 10.1016/j.nbd.2013.12.003. Epub 2013 Dec 15.
• [1274] Defect of branched-chain amino acid metabolism promotes the development of Alzheimer's disease by targeting the mTOR signaling.Biosci Rep. 2018 Jul 2;38(4):BSR20180127. doi: 10.1042/BSR20180127. Print 2018 Aug 31.
• [1275] P60TRP interferes with the GPCR/secretase pathway to mediate neuronal survival and synaptogenesis.J Cell Mol Med. 2011 Nov;15(11):2462-77. doi: 10.1111/j.1582-4934.2010.01248.x.
• [1276] Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation.Neurobiol Aging. 2012 Aug;33(8):1843.e9-17. doi: 10.1016/j.neurobiolaging.2011.12.036. Epub 2012 Feb 1.
• [1277] Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease.J Neural Transm Suppl. 2001;(61):263-72. doi: 10.1007/978-3-7091-6262-0_21.
• [1278] The Molecular Chaperone Artemin Efficiently Blocks Fibrillization of TAU Protein In Vitro.Cell J. 2018 Jan;19(4):569-577. doi: 10.22074/cellj.2018.4510. Epub 2017 Nov 4.
• [1279] Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and (18)F-FDG PET.Radiology. 2018 Jul;288(1):198-206. doi: 10.1148/radiol.2018170575. Epub 2018 May 15.
• [1280] Targeting Neuroplasticity, Cardiovascular, and Cognitive-Associated Genomic Variants in Familial Alzheimer's Disease.Mol Neurobiol. 2019 May;56(5):3235-3243. doi: 10.1007/s12035-018-1298-z. Epub 2018 Aug 15.
• [1281] Genetic association to the amyloid plaque associated protein gene COL25A1 in Alzheimer's disease.Neurobiol Aging. 2010 Mar;31(3):409-15. doi: 10.1016/j.neurobiolaging.2008.04.009. Epub 2008 May 22.
• [1282] Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis.Neuroscience. 2005;133(2):437-51. doi: 10.1016/j.neuroscience.2005.02.029.
• [1283] Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: from structural insights to post-transcriptional regulatory roles.Mol Cell Neurosci. 2013 Sep;56:436-46. doi: 10.1016/j.mcn.2012.12.002. Epub 2012 Dec 14.
• [1284] Plasma ATG5 is increased in Alzheimer's disease.Sci Rep. 2019 Mar 18;9(1):4741. doi: 10.1038/s41598-019-41347-2.
• [1285] A genome-wide association study of aging.Neurobiol Aging. 2011 Nov;32(11):2109.e15-28. doi: 10.1016/j.neurobiolaging.2011.05.026. Epub 2011 Jul 22.
• [1286] Phospholipids and calmodulin modulate the inhibition of PMCA activity by tau.Biochim Biophys Acta Mol Cell Res. 2017 Jun;1864(6):1028-1035. doi: 10.1016/j.bbamcr.2016.10.023. Epub 2016 Nov 3.
• [1287] Therapeutic Potential of Selectively Targeting the (2C)-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.Front Psychiatry. 2017 Aug 14;8:144. doi: 10.3389/fpsyt.2017.00144. eCollection 2017.
• [1288] Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression inthe Cerebral Cortex of an Alzheimer's Disease Mouse Model.J Alzheimers Dis. 2017;56(1):47-61. doi: 10.3233/JAD-160677.
• [1289] Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease.Hum Mol Genet. 2015 Nov 15;24(22):6492-504. doi: 10.1093/hmg/ddv358. Epub 2015 Sep 10.
• [1290] ATP5H/KCTD2 locus is associated with Alzheimer's disease risk.Mol Psychiatry. 2014 Jun;19(6):682-7. doi: 10.1038/mp.2013.86. Epub 2013 Jul 16.
• [1291] Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.Neurobiol Aging. 2005 Aug-Sep;26(8):1145-51. doi: 10.1016/j.neurobiolaging.2004.10.003. Epub 2004 Dec 22.
• [1292] Human ApoE 2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.J Alzheimers Dis. 2016 Jun 18;53(3):1015-31. doi: 10.3233/JAD-160307.
• [1293] Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity.BMC Med Genet. 2018 May 11;19(1):75. doi: 10.1186/s12881-018-0603-z.
• [1294] Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene.Ann Hum Genet. 2012 Sep;76(5):342-51. doi: 10.1111/j.1469-1809.2012.00721.x.
• [1295] Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score.PLoS Med. 2017 Mar 21;14(3):e1002258. doi: 10.1371/journal.pmed.1002258. eCollection 2017 Mar.
• [1296] The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer's Disease.J Alzheimers Dis. 2019;68(3):1211-1228. doi: 10.3233/JAD-181139.
• [1297] DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer's Disease.J Alzheimers Dis. 2018;66(3):927-934. doi: 10.3233/JAD-180592.
• [1298] HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.Mol Neurobiol. 2017 Jan;54(1):188-199. doi: 10.1007/s12035-015-9644-x. Epub 2016 Jan 6.
• [1299] Anandamide Effects in a Streptozotocin-Induced Alzheimer's Disease-Like Sporadic Dementia in Rats.Front Neurosci. 2018 Sep 21;12:653. doi: 10.3389/fnins.2018.00653. eCollection 2018.
• [1300] Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of -Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer's Disease.Front Aging Neurosci. 2019 Jan 22;11:3. doi: 10.3389/fnagi.2019.00003. eCollection 2019.
• [1301] Bag5 protects neuronal cells from amyloid -induced cell death.J Mol Neurosci. 2015 Apr;55(4):815-20. doi: 10.1007/s12031-014-0433-1. Epub 2014 Nov 1.
• [1302] Functional enrichment analysis of three Alzheimer's disease genome-wide association studies identities DAB1 as a novel candidate liability/protective gene.Biochem Biophys Res Commun. 2015 Aug 7;463(4):490-5. doi: 10.1016/j.bbrc.2015.05.044. Epub 2015 May 29.
• [1303] Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice.Acta Neuropathol Commun. 2015 Sep 4;3:54. doi: 10.1186/s40478-015-0233-z.
• [1304] BAP31 deficiency contributes to the formation of amyloid- plaques in Alzheimer's disease by reducing the stability of RTN3.FASEB J. 2019 Apr;33(4):4936-4946. doi: 10.1096/fj.201801702R. Epub 2018 Dec 31.
• [1305] Interactions between BIM Protein and Beta-Amyloid May Reveal a Crucial Missing Link between Alzheimer's Disease and Neuronal Cell Death.ACS Chem Neurosci. 2019 Aug 21;10(8):3555-3564. doi: 10.1021/acschemneuro.9b00177. Epub 2019 Jun 12.
• [1306] Intranasal administration of TAT-haFGF() attenuates disease progression in a mouse model of Alzheimer's disease.Neuroscience. 2012 Oct 25;223:225-37. doi: 10.1016/j.neuroscience.2012.08.003. Epub 2012 Aug 9.
• [1307] Anti-inflammatory potential of thymosin 4 in the central nervous system: implications for progressive neurodegenerative diseases.Expert Opin Biol Ther. 2018 Jul;18(sup1):165-169. doi: 10.1080/14712598.2018.1486817.
• [1308] Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study.Lancet Neurol. 2016 Jul;15(8):811-819. doi: 10.1016/S1474-4422(16)30030-8. Epub 2016 May 11.
• [1309] Comparative profiling of cortical gene expression in Alzheimer's disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation.Sci Rep. 2017 Dec 19;7(1):17762. doi: 10.1038/s41598-017-17999-3.
• [1310] FE65 regulates and interacts with the Bloom syndrome protein in dynamic nuclear spheres - potential relevance to Alzheimer's disease.J Cell Sci. 2013 Jun 1;126(Pt 11):2480-92. doi: 10.1242/jcs.121004. Epub 2013 Apr 9.
• [1311] Vincamine Alleviates Amyloid- 25-35 Peptides-induced Cytotoxicity in PC12 Cells.Pharmacogn Mag. 2017 Jan-Mar;13(49):123-128. doi: 10.4103/0973-1296.196309.
• [1312] ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology.Acta Neuropathol. 2014;127(6):825-43. doi: 10.1007/s00401-014-1282-2. Epub 2014 Apr 27.
• [1313] Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.Curr Alzheimer Res. 2017;14(7):696-708. doi: 10.2174/1567205014666170117101537.
• [1314] Dysregulation of Autophagy, Mitophagy, and Apoptosis Genes in the CA3 Region of the Hippocampus in the Ischemic Model of Alzheimer's Disease in the Rat.J Alzheimers Dis. 2019;72(4):1279-1286. doi: 10.3233/JAD-190966.
• [1315] BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2.J Biol Chem. 2009 Jun 5;284(23):15815-25. doi: 10.1074/jbc.M109.006403. Epub 2009 Apr 14.
• [1316] Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.J Alzheimers Dis. 2016 Feb 26;52(1):43-50. doi: 10.3233/JAD-151073.
• [1317] BAG-1M co-activates BACE1 transcription through NF-B and accelerates A production and memory deficit in Alzheimer's disease mouse model.Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2398-2407. doi: 10.1016/j.bbadis.2017.05.014. Epub 2017 May 11.
• [1318] Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain.J Neuroinflammation. 2017 Mar 6;14(1):48. doi: 10.1186/s12974-017-0814-9.
• [1319] Central CRF system perturbation in an Alzheimer's disease knockin mouse model.Neurobiol Aging. 2012 Nov;33(11):2678-91. doi: 10.1016/j.neurobiolaging.2012.01.002. Epub 2012 Feb 14.
• [1320] Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease.Alzheimers Dement. 2019 Mar;15(3):429-440. doi: 10.1016/j.jalz.2018.10.006. Epub 2019 Jan 2.
• [1321] The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease.Neurochem Res. 1999 Jun;24(6):767-74. doi: 10.1023/a:1020783614031.
• [1322] A human-specific de novo protein-coding gene associated with human brain functions.PLoS Comput Biol. 2010 Mar 26;6(3):e1000734. doi: 10.1371/journal.pcbi.1000734.
• [1323] Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.J Neurosci. 2000 Oct 15;20(20):7505-9. doi: 10.1523/JNEUROSCI.20-20-07505.2000.
• [1324] Expression of the newly identified gene CAC1 in the hippocampus of Alzheimer's disease patients.J Mol Neurosci. 2012 Jun;47(2):207-18. doi: 10.1007/s12031-012-9717-5. Epub 2012 Mar 14.
• [1325] Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites.Alzheimers Dement. 2020 Feb;16(2):251-261. doi: 10.1016/j.jalz.2019.07.017. Epub 2020 Jan 6.
• [1326] Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52.Nat Commun. 2014 Mar 25;5:3496. doi: 10.1038/ncomms4496.
• [1327] AP180 N-Terminal Homology (ANTH) and Epsin N-Terminal Homology (ENTH) Domains: Physiological Functions and Involvement in Disease.Adv Exp Med Biol. 2019;1111:55-76. doi: 10.1007/5584_2018_218.
• [1328] Calmodulin-like skin protein suppresses the increase in senescence-associated -galactosidase induced by hydrogen peroxide or ultraviolet irradiation in keratinocytes.Cell Biol Int. 2019 Jul;43(7):835-843. doi: 10.1002/cbin.11159. Epub 2019 May 18.
• [1329] Alterations of Ca?responsive proteins within cholinergic neurons in aging and Alzheimer's disease.Neurobiol Aging. 2014 Jun;35(6):1325-33. doi: 10.1016/j.neurobiolaging.2013.12.017. Epub 2013 Dec 25.
• [1330] A Comprehensive Analysis of the CaMK2A Gene and Susceptibility to Alzheimer's Disease in the Han Chinese Population.Front Aging Neurosci. 2019 Apr 11;11:84. doi: 10.3389/fnagi.2019.00084. eCollection 2019.
• [1331] Genistein protects hippocampal neurons against injury by regulating calcium/calmodulin dependent protein kinase IV protein levels in Alzheimer's disease model rats.Neural Regen Res. 2017 Sep;12(9):1479-1484. doi: 10.4103/1673-5374.215260.
• [1332] Modulating Conformation of A-Peptide: An Effective Way to Prevent Protein-Misfolding Disease.Inorg Chem. 2018 Nov 5;57(21):13533-13543. doi: 10.1021/acs.inorgchem.8b02115. Epub 2018 Oct 22.
• [1333] Adenovirus E1A inhibits IFN-induced resistance to cytolysis by natural killer cells.J Immunol. 1993 May 15;150(10):4315-22.
• [1334] Deficiency of CARD8 is associated with increased Alzheimer's disease risk in women.Dement Geriatr Cogn Disord. 2008;26(3):247-50. doi: 10.1159/000160956. Epub 2008 Oct 8.
• [1335] Involvement of glucose related energy crisis and endoplasmic reticulum stress: Insinuation of streptozotocin induced Alzheimer's like pathology.Cell Signal. 2018 Jan;42:211-226. doi: 10.1016/j.cellsig.2017.10.018. Epub 2017 Nov 7.
• [1336] Calpastatin Mediates Development of Alzheimer's Disease in Diabetes.J Alzheimers Dis. 2019;68(3):1051-1059. doi: 10.3233/JAD-190004.
• [1337] Blood transcriptomic biomarkers of Alzheimer's disease patients treated with EHT 0202.J Alzheimers Dis. 2013;34(2):469-83. doi: 10.3233/JAD-121501.
• [1338] Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease.Acta Pharmacol Sin. 2018 Sep;39(9):1421-1438. doi: 10.1038/aps.2017.210. Epub 2018 May 17.
• [1339] Cerebellin 4, a synaptic protein, enhances inhibitory activity and resistance of neurons to amyloid- toxicity.Neurobiol Aging. 2015 Feb;36(2):1057-71. doi: 10.1016/j.neurobiolaging.2014.11.006. Epub 2014 Nov 15.
• [1340] Haptoglobin phenotypes in dementia of the Alzheimer type.Hum Hered. 1986;36(2):93-6. doi: 10.1159/000153606.
• [1341] Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.Neurology. 2011 Jan 4;76(1):69-79. doi: 10.1212/WNL.0b013e318204a397. Epub 2010 Dec 1.
• [1342] Genome-wide association study of Alzheimer's disease.Transl Psychiatry. 2012 May 15;2(5):e117. doi: 10.1038/tp.2012.45.
• [1343] Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.Lancet Neurol. 2020 Jan;19(1):61-70. doi: 10.1016/S1474-4422(19)30393-X. Epub 2019 Nov 6.
• [1344] Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.Alzheimers Dement (Amst). 2017 Apr 23;8:60-72. doi: 10.1016/j.dadm.2017.04.003. eCollection 2017.
• [1345] Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis.Cytokine. 2010 May;50(2):181-5. doi: 10.1016/j.cyto.2010.02.016. Epub 2010 Mar 16.
• [1346] Peripheral Blood Mononuclear Cells of Alzheimer's Disease Patients Control CCL4 and CXCL10 Levels in a Human Blood Brain Barrier Model.Curr Alzheimer Res. 2017;14(11):1215-1228. doi: 10.2174/1567205014666170417110337.
• [1347] Polymorphonuclear Neutrophil Functions are Differentially Altered in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease Patients.J Alzheimers Dis. 2017;60(1):23-42. doi: 10.3233/JAD-170124.
• [1348] CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration.J Neurol. 2009 Aug;256(8):1379-81. doi: 10.1007/s00415-009-5138-y. Epub 2009 May 5.
• [1349] Cyclin C expression is involved in the pathogenesis of Alzheimer's disease.Neurobiol Aging. 2003 May-Jun;24(3):427-35. doi: 10.1016/s0197-4580(02)00132-x.
• [1350] Hippocampal expression of cell-adhesion glycoprotein neuroplastin is altered in Alzheimer's disease.J Cell Mol Med. 2019 Feb;23(2):1602-1607. doi: 10.1111/jcmm.13998. Epub 2018 Nov 28.
• [1351] Blood-brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals.Eur J Epidemiol. 2019 Jun;34(6):579-590. doi: 10.1007/s10654-019-00498-2. Epub 2019 Mar 4.
• [1352] Estrogen receptor variants modify risk for Alzheimer's disease in a multiethnic female cohort.J Alzheimers Dis. 2014;40(1):83-93. doi: 10.3233/JAD-130551.
• [1353] Subtyping of circulating exosome-bound amyloid reflects brain plaque deposition.Nat Commun. 2019 Mar 8;10(1):1144. doi: 10.1038/s41467-019-09030-2.
• [1354] High complement levels in astrocyte-derived exosomes of Alzheimer disease.Ann Neurol. 2018 Mar;83(3):544-552. doi: 10.1002/ana.25172. Epub 2018 Mar 10.
• [1355] Alzheimer's disease and HLA-A2: linking neurodegenerative to immune processes through an in silico approach.Biomed Res Int. 2014;2014:791238. doi: 10.1155/2014/791238. Epub 2014 Aug 17.
• [1356] Regulatory mechanism of microRNA-377 on CDH13 expression in the cell model of Alzheimer's disease.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2801-2808. doi: 10.26355/eurrev_201805_14979.
• [1357] CDK5RAP2 gene and tau pathophysiology in late-onset sporadic Alzheimer's disease.Alzheimers Dement. 2018 Jun;14(6):787-796. doi: 10.1016/j.jalz.2017.12.004. Epub 2018 Jan 19.
• [1358] Characterization of CDNF-Secreting ARPE-19 Cell Clones for Encapsulated Cell Therapy.Cell Transplant. 2019 Apr;28(4):413-424. doi: 10.1177/0963689719827943. Epub 2019 Mar 6.
• [1359] Gullibility may be a warning sign of Alzheimer's disease dementia.Int Psychogeriatr. 2019 Mar;31(3):363-370. doi: 10.1017/S1041610218000844. Epub 2018 Jun 25.
• [1360] Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan.Lett Appl Microbiol. 2018 Jun;66(6):464-471. doi: 10.1111/lam.12882. Epub 2018 Apr 16.
• [1361] Astrocytic CCAAT/Enhancer-binding protein delta contributes to reactive oxygen species formation in neuroinflammation.Redox Biol. 2018 Jun;16:104-112. doi: 10.1016/j.redox.2018.02.011. Epub 2018 Feb 16.
• [1362] Regional Cerebral Blood Flow in the Posterior Cingulate and Precuneus and the Entorhinal Cortical Atrophy Score Differentiate Mild Cognitive Impairment and Dementia Due to Alzheimer Disease.AJNR Am J Neuroradiol. 2019 Oct;40(10):1658-1664. doi: 10.3174/ajnr.A6219. Epub 2019 Sep 12.
• [1363] Genetic association of CUGBP2 and DNMBP with Alzheimer' s disease in the Chinese Han population.Curr Alzheimer Res. 2015;12(3):228-32. doi: 10.2174/156720501203150317151426.
• [1364] Sex-dependent co-occurrence of hypoxia and -amyloid plaques in hippocampus and entorhinal cortex is reversed by long-term treatment with ubiquinol and ascorbic acid in the 3Tg-AD mouse model of Alzheimer's disease.Mol Cell Neurosci. 2018 Oct;92:67-81. doi: 10.1016/j.mcn.2018.06.005. Epub 2018 Jun 25.
• [1365] Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.J Biol Chem. 2012 Apr 27;287(18):14897-911. doi: 10.1074/jbc.M111.299545. Epub 2012 Mar 6.
• [1366] Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer's disease mouse model.Oncotarget. 2018 Jan 31;9(12):10681-10697. doi: 10.18632/oncotarget.24369. eCollection 2018 Feb 13.
• [1367] Reduction of chromatin assembly factor 1 p60 and C21orf2 protein, encoded on chromosome 21, in Down syndrome brain.J Neural Transm Suppl. 2003;(67):117-28. doi: 10.1007/978-3-7091-6721-2_10.
• [1368] Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer's Disease.Front Aging Neurosci. 2018 Feb 6;10:27. doi: 10.3389/fnagi.2018.00027. eCollection 2018.
• [1369] Identifying unexpected therapeutic targets via chemical-protein interactome.PLoS One. 2010 Mar 8;5(3):e9568. doi: 10.1371/journal.pone.0009568.
• [1370] Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease.Brain Res. 1999 Oct 16;845(1):1-5. doi: 10.1016/s0006-8993(99)01767-9.
• [1371] Microglial motility in Alzheimer's disease and after A42 immunotherapy: a human post-mortem study.Acta Neuropathol Commun. 2019 Nov 8;7(1):174. doi: 10.1186/s40478-019-0828-x.
• [1372] Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications.Neuroscientist. 2020 Apr;26(2):170-184. doi: 10.1177/1073858419871214. Epub 2019 Sep 16.
• [1373] A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.Proteomics Clin Appl. 2018 Jan;12(1). doi: 10.1002/prca.201700131. Epub 2017 Nov 23.
• [1374] Different chromogranin immunoreactivity between prion and a-beta amyloid plaque.Neuroreport. 2003 Apr 15;14(5):755-8. doi: 10.1097/00001756-200304150-00019.
• [1375] Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.Alzheimers Res Ther. 2018 Aug 28;10(1):86. doi: 10.1186/s13195-018-0410-y.
• [1376] Effect of tau-pathology on charged multivesicular body protein 2b (CHMP2B).Brain Res. 2019 Mar 1;1706:224-236. doi: 10.1016/j.brainres.2018.11.008. Epub 2018 Nov 8.
• [1377] Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease.J Alzheimers Dis. 2002 Apr;4(2):71-6. doi: 10.3233/jad-2002-4201.
• [1378] The Emerging Roles of CIB1 in Cancer.Cell Physiol Biochem. 2017;43(4):1413-1424. doi: 10.1159/000481873. Epub 2017 Oct 11.
• [1379] Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging.Alzheimer Dis Assoc Disord. 2019 Jan-Mar;33(1):7-14. doi: 10.1097/WAD.0000000000000294.
• [1380] CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits.Neurobiol Aging. 2019 Mar;75:198-208. doi: 10.1016/j.neurobiolaging.2018.11.023. Epub 2018 Dec 6.
• [1381] Upregulation of Cisd2 attenuates Alzheimer's-related neuronal loss in mice.J Pathol. 2020 Mar;250(3):299-311. doi: 10.1002/path.5374. Epub 2020 Jan 13.
• [1382] Open-closed motion of Mint2 regulates APP metabolism.J Mol Cell Biol. 2013 Feb;5(1):48-56. doi: 10.1093/jmcb/mjs033. Epub 2012 Jun 21.
• [1383] Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia.Neuroscience. 2015 Aug 27;302:121-37. doi: 10.1016/j.neuroscience.2014.09.052. Epub 2014 Oct 5.
• [1384] Differences in structure and function between human and murine tau.Biochim Biophys Acta Mol Basis Dis. 2019 Aug 1;1865(8):2024-2030. doi: 10.1016/j.bbadis.2018.08.010. Epub 2018 Aug 12.
• [1385] A Curcumin Analog Reduces Levels of the Alzheimer's Disease-Associated Amyloid- Protein by Modulating APP Processing and Autophagy.J Alzheimers Dis. 2019;72(3):761-771. doi: 10.3233/JAD-190562.
• [1386] Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis.Am J Pathol. 2015 Oct;185(10):2777-89. doi: 10.1016/j.ajpath.2015.06.021. Epub 2015 Aug 28.
• [1387] Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals.JAMA Neurol. 2015 Nov;72(11):1313-23. doi: 10.1001/jamaneurol.2015.1700.
• [1388] The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment.J Cell Mol Med. 2019 May;23(5):3280-3292. doi: 10.1111/jcmm.14214. Epub 2019 Feb 22.
• [1389] C-type lectin-like receptor 2 and zonulin are associated with mild cognitive impairment and Alzheimer's disease.Acta Neurol Scand. 2020 Mar;141(3):250-255. doi: 10.1111/ane.13196. Epub 2019 Nov 25.
• [1390] Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer's disease.Aging Cell. 2020 Feb;19(2):e13078. doi: 10.1111/acel.13078. Epub 2019 Dec 4.
• [1391] Decrease in p3-Alc37 and p3-Alc40, products of Alcadein generated by -secretase cleavages, in aged monkeys and patients with Alzheimer's disease.Alzheimers Dement (N Y). 2019 Nov 7;5:740-750. doi: 10.1016/j.trci.2019.09.015. eCollection 2019.
• [1392] Genetics of clusterin isoform expression and Alzheimer's disease risk.PLoS One. 2012;7(4):e33923. doi: 10.1371/journal.pone.0033923. Epub 2012 Apr 10.
• [1393] Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.
• [1394] Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down Syndrome and Alzheimer's disease.Neurosci Lett. 1998 Jul 17;251(1):45-8. doi: 10.1016/s0304-3940(98)00488-1.
• [1395] BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid.J Invest Dermatol. 2019 Feb;139(2):293-299. doi: 10.1016/j.jid.2018.09.010. Epub 2018 Oct 10.
• [1396] Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.Eur J Hum Genet. 2010 Dec;18(12):1315-21. doi: 10.1038/ejhg.2010.105. Epub 2010 Jul 21.
• [1397] Lack of association of mortalin (HSPA9) and other mitochondria-related genes with risk of Parkinson's and Alzheimer's diseases.Neurobiol Aging. 2017 Jan;49:215.e9-215.e10. doi: 10.1016/j.neurobiolaging.2016.09.017. Epub 2016 Oct 3.
• [1398] Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer's disease-related proteins.Mol Neurodegener. 2018 Jun 28;13(1):34. doi: 10.1186/s13024-018-0266-4.
• [1399] Genetic association of the cytochrome c oxidase-related genes with Alzheimer's disease in Han Chinese.Neuropsychopharmacology. 2018 Oct;43(11):2264-2276. doi: 10.1038/s41386-018-0144-3. Epub 2018 Jul 6.
• [1400] Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease.J Neural Transm (Vienna). 2009 Dec;116(12):1635-41. doi: 10.1007/s00702-009-0324-8. Epub 2009 Oct 14.
• [1401] Copper in Glucose Intolerance, Cognitive Decline, and Alzheimer Disease.Alzheimer Dis Assoc Disord. 2019 Jan-Mar;33(1):77-85. doi: 10.1097/WAD.0000000000000280.
• [1402] The Proteome of the Dentate Terminal Zone of the Perforant Path Indicates Presynaptic Impairment in Alzheimer Disease.Mol Cell Proteomics. 2020 Jan;19(1):128-141. doi: 10.1074/mcp.RA119.001737. Epub 2019 Nov 7.
• [1403] Targeting Apolipoprotein E/Amyloid Binding by Peptoid CPO_A17-21P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline.Sci Rep. 2017 Aug 14;7(1):8009. doi: 10.1038/s41598-017-08604-8.
• [1404] PPAR/-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1E9 astrocytes.Glia. 2019 Jan;67(1):146-159. doi: 10.1002/glia.23534. Epub 2018 Nov 19.
• [1405] Concurrent Alzheimer's pathology in patients with clinical normal pressure hydrocephalus.J Neurosurg Sci. 2020 Apr;64(2):130-132. doi: 10.23736/S0390-5616.18.04350-3. Epub 2018 Feb 13.
• [1406] PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein.J Biol Chem. 2005 Apr 8;280(14):13824-32. doi: 10.1074/jbc.M411933200. Epub 2005 Jan 25.
• [1407] Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data.Neuroimage. 2018 Dec;183:504-521. doi: 10.1016/j.neuroimage.2018.08.042. Epub 2018 Aug 18.
• [1408] Evolutionary origin of a Kunitz-type trypsin inhibitor domain inserted in the amyloid beta precursor protein of Alzheimer's disease.J Mol Evol. 1992 Jun;34(6):536-43. doi: 10.1007/BF00160466.
• [1409] Lipid and Alzheimer's disease genes associated with healthy aging and longevity in healthy oldest-old.Oncotarget. 2017 Mar 28;8(13):20612-20621. doi: 10.18632/oncotarget.15296.
• [1410] Genetic data and cognitively defined late-onset Alzheimer's disease subgroups.Mol Psychiatry. 2020 Nov;25(11):2942-2951. doi: 10.1038/s41380-018-0298-8. Epub 2018 Dec 4.
• [1411] The potential inhibitory effect of -casein on the aggregation and deposition of A(1-42) fibrils in Alzheimer's disease: insight from in-vitro and in-silico studies.J Biomol Struct Dyn. 2018 Jun;36(8):2118-2130. doi: 10.1080/07391102.2017.1345326. Epub 2017 Jul 4.
• [1412] Cystatin F is a biomarker of prion pathogenesis in mice.PLoS One. 2017 Feb 8;12(2):e0171923. doi: 10.1371/journal.pone.0171923. eCollection 2017.
• [1413] Structural elucidation and bioactivities of a novel arabinogalactan from Coreopsis tinctoria.Carbohydr Polym. 2019 Sep 1;219:219-228. doi: 10.1016/j.carbpol.2019.05.019. Epub 2019 May 7.
• [1414] Enhancer variants associated with Alzheimer's disease affect gene expression via chromatin looping.BMC Med Genomics. 2019 Sep 9;12(1):128. doi: 10.1186/s12920-019-0574-8.
• [1415] The sterol carrier protein SCP-x/pro-SCP-2 gene has transcriptional activity and regulates the Alzheimer disease gamma-secretase.J Biol Chem. 2007 Jul 6;282(27):19742-52. doi: 10.1074/jbc.M611426200. Epub 2007 May 7.
• [1416] Polymorphisms of CHAT but not TFAM or VR22 are Associated with Alzheimer Disease Risk.Med Sci Monit. 2016 Jun 7;22:1924-35. doi: 10.12659/msm.895984.
• [1417] Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.J Food Drug Anal. 2019 Apr;27(2):551-564. doi: 10.1016/j.jfda.2018.11.009. Epub 2019 Jan 12.
• [1418] -Catenin is genetically and biologically associated with cortical cataract and future Alzheimer-related structural and functional brain changes.PLoS One. 2012;7(9):e43728. doi: 10.1371/journal.pone.0043728. Epub 2012 Sep 11.
• [1419] Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A(42) and T-Tau assays for Alzheimer's disease diagnosis.J Neurol. 2019 Sep;266(9):2304-2311. doi: 10.1007/s00415-019-09418-6. Epub 2019 Jun 10.
• [1420] Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APP(SWE)/PS1(E9) Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease.Front Cell Neurosci. 2018 Nov 6;12:397. doi: 10.3389/fncel.2018.00397. eCollection 2018.
• [1421] Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway.Exp Neurol. 2014 Nov;261:698-709. doi: 10.1016/j.expneurol.2014.07.023. Epub 2014 Aug 13.
• [1422] KIBRA and APOE Gene Variants Affect Brain Functional Network Connectivity in Healthy Older People.J Gerontol A Biol Sci Med Sci. 2019 Oct 4;74(11):1725-1733. doi: 10.1093/gerona/glz004.
• [1423] A MicroRNA Derived from Adenovirus Virus-Associated RNAII Promotes Virus Infection via Posttranscriptional Gene Silencing.J Virol. 2019 Jan 4;93(2):e01265-18. doi: 10.1128/JVI.01265-18. Print 2019 Jan 15.
• [1424] Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.Pharmacogenet Genomics. 2011 Apr;21(4):225-30. doi: 10.1097/FPC.0b013e32833f984c.
• [1425] Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against Neurodegeneration.J Mol Neurosci. 2015 Jul;56(3):593-6. doi: 10.1007/s12031-015-0542-5. Epub 2015 Apr 1.
• [1426] The -amyloid peptide compromises Reelin signaling in Alzheimer's disease.Sci Rep. 2016 Aug 17;6:31646. doi: 10.1038/srep31646.
• [1427] MicroRNA-26a/Death-Associated Protein Kinase1 Signaling Induces Synucleinopathy andDopaminergic Neuron Degeneration in Parkinson's Disease.Biol Psychiatry. 2019 May 1;85(9):769-781. doi: 10.1016/j.biopsych.2018.12.008. Epub 2018 Dec 19.
• [1428] Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease.J Alzheimers Dis. 2015;43(4):1137-48. doi: 10.3233/JAD-141875.
• [1429] RNA-Seq analysis of the parietal cortex in Alzheimer's disease reveals alternatively spliced isoforms related to lipid metabolism.Neurosci Lett. 2013 Mar 1;536:90-5. doi: 10.1016/j.neulet.2012.12.042. Epub 2013 Jan 7.
• [1430] ATM phosphorylation of the actin-binding protein drebrin controls oxidation stress-resistance in mammalian neurons and C. elegans.Nat Commun. 2019 Jan 30;10(1):486. doi: 10.1038/s41467-019-08420-w.
• [1431] Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss.Hippocampus. 2015 Jul;25(7):813-26. doi: 10.1002/hipo.22405. Epub 2015 Jan 8.
• [1432] Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.J Neuroimmunol. 2018 Jun 15;319:80-92. doi: 10.1016/j.jneuroim.2018.03.009. Epub 2018 Mar 17.
• [1433] Identification of prefrontal cortex protein alterations in Alzheimer's disease.Oncotarget. 2018 Jan 24;9(13):10847-10867. doi: 10.18632/oncotarget.24303. eCollection 2018 Feb 16.
• [1434] Nuclear and mitochondrial DNA oxidation in Alzheimer's disease.Free Radic Res. 2012 Apr;46(4):565-76. doi: 10.3109/10715762.2011.648188. Epub 2012 Jan 23.
• [1435] Dihydroceramide Desaturase 1 Inhibitors Reduce Amyloid- Levels in Primary Neurons from an Alzheimer's Disease Transgenic Model.Pharm Res. 2018 Feb 6;35(3):49. doi: 10.1007/s11095-017-2312-2.
• [1436] Diaphanous 1 (DIAPH1) is Highly Expressed in the Aged Human Medial Temporal Cortex and Upregulated in Myeloid Cells During Alzheimer's Disease.J Alzheimers Dis. 2018;64(3):995-1007. doi: 10.3233/JAD-180088.
• [1437] A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans.J Clin Endocrinol Metab. 2018 May 1;103(5):1818-1826. doi: 10.1210/jc.2017-01196.
• [1438] Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer's disease as a mitophagy receptor.Aging Cell. 2019 Feb;18(1):e12860. doi: 10.1111/acel.12860. Epub 2018 Nov 28.
• [1439] 5-Methoxyindole-2-carboxylic acid (MICA) suppresses A-mediated pathology in C. elegans.Exp Gerontol. 2018 Jul 15;108:215-225. doi: 10.1016/j.exger.2018.04.021. Epub 2018 Apr 27.
• [1440] Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease.Neurobiol Aging. 1999 May-Jun;20(3):287-95. doi: 10.1016/s0197-4580(99)00035-4.
• [1441] Crocin-protected malathion-induced spatial memory deficits by inhibiting TAU protein hyperphosphorylation and antiapoptotic effects.Nutr Neurosci. 2020 Mar;23(3):221-236. doi: 10.1080/1028415X.2018.1492772. Epub 2019 Feb 21.
• [1442] Dynamic SAP102 expression in the hippocampal subregions of rats and APP/PS1 mice of various ages.J Anat. 2018 Jun;232(6):987-996. doi: 10.1111/joa.12807. Epub 2018 Mar 25.
• [1443] Ceruloplasmin, a Potential Therapeutic Agent for Alzheimer's Disease.Antioxid Redox Signal. 2018 May 10;28(14):1323-1337. doi: 10.1089/ars.2016.6883. Epub 2017 Oct 17.
• [1444] Detection of A oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe(3)O(4) magnetic nanoparticles and BaYF(5):Yb,Er nanoparticles as upconversion fluorescence labels.Talanta. 2017 Aug 1;170:350-357. doi: 10.1016/j.talanta.2017.04.021. Epub 2017 Apr 14.
• [1445] Beta-Amyloid Increases the Expression Levels of Tid1 Responsible for Neuronal Cell Death and Amyloid Beta Production.Mol Neurobiol. 2020 Feb;57(2):1099-1114. doi: 10.1007/s12035-019-01807-2. Epub 2019 Nov 4.
• [1446] Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer's disease and obesity.Am J Med Genet B Neuropsychiatr Genet. 2014 Jun;165B(4):283-93. doi: 10.1002/ajmg.b.32234. Epub 2014 May 1.
• [1447] Increased Expression of the Large Conductance, Calcium-Activated K+ (BK) Channel in Adult-Onset Neuronal Ceroid Lipofuscinosis.PLoS One. 2015 Apr 23;10(4):e0125205. doi: 10.1371/journal.pone.0125205. eCollection 2015.
• [1448] Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).Neurosci Lett. 1999 Jul 9;269(2):115-9. doi: 10.1016/s0304-3940(99)00426-7.
• [1449] Dedicator of Cytokinesis 2 in Cell Signaling Regulation and Disease Development.J Cell Physiol. 2017 Aug;232(8):1931-1940. doi: 10.1002/jcp.25512. Epub 2017 Feb 28.
• [1450] Quantitative profiling of cytokines and chemokines in DOCK8-deficient and atopic dermatitis patients.Allergy. 2019 Feb;74(2):370-379. doi: 10.1111/all.13610. Epub 2018 Oct 15.
• [1451] S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model.PLoS One. 2010 Jan 21;5(1):e8840. doi: 10.1371/journal.pone.0008840.
• [1452] Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression.J Neurochem. 2007 Nov;103(3):1132-44. doi: 10.1111/j.1471-4159.2007.04829.x. Epub 2007 Aug 7.
• [1453] SNP Variation in MicroRNA Biogenesis Pathway Genes as a New Innovation Strategy for Alzheimer Disease Diagnostics: A Study of 10 Candidate Genes in an Understudied Population From the Eastern Mediterranean.Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):203-9. doi: 10.1097/WAD.0000000000000135.
• [1454] Association of DSC1, a gene modulated by adrenergic stimulation, with Alzheimer's disease.Neurosci Lett. 2006 Nov 20;408(3):203-8. doi: 10.1016/j.neulet.2006.09.005. Epub 2006 Oct 2.
• [1455] Increased cortical capillary transit time heterogeneity in Alzheimer's disease: a DSC-MRI perfusion study.Neurobiol Aging. 2017 Feb;50:107-118. doi: 10.1016/j.neurobiolaging.2016.11.004. Epub 2016 Nov 19.
• [1456] Insights from modeling the tertiary structure of human BACE2.J Proteome Res. 2004 Sep-Oct;3(5):1069-72. doi: 10.1021/pr049905s.
• [1457] Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.J Clin Med. 2018 Dec 28;8(1):28. doi: 10.3390/jcm8010028.
• [1458] Dystonin/BPAG1 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.Neurol Sci. 2019 Aug;40(8):1577-1582. doi: 10.1007/s10072-019-03879-3. Epub 2019 Apr 8.
• [1459] Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease.Hippocampus. 2014 Apr;24(4):363-8. doi: 10.1002/hipo.22245. Epub 2014 Jan 28.
• [1460] Identification of genomic organisation, sequence variants and analysis of the role of the human dishevelled 1 gene in late onset Alzheimer's disease.Mol Psychiatry. 2002;7(1):104-9. doi: 10.1038/sj.mp.4000941.
• [1461] Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes.Neuroimage Clin. 2019;23:101859. doi: 10.1016/j.nicl.2019.101859. Epub 2019 May 13.
• [1462] Long Noncoding RNA EBF3-AS Promotes Neuron Apoptosis in Alzheimer's Disease.DNA Cell Biol. 2018 Mar;37(3):220-226. doi: 10.1089/dna.2017.4012. Epub 2018 Jan 3.
• [1463] Cerebral Perfusion Insufficiency and Relationships with Cognitive Deficits in Alzheimer's Disease: A Multiparametric Neuroimaging Study.Sci Rep. 2018 Jan 24;8(1):1541. doi: 10.1038/s41598-018-19387-x.
• [1464] Association analysis of polymorphisms in STARD6 and near ECHDC3 in Alzheimer's disease patients carrying the APOE 4 Allele.Neuropsychiatr Dis Treat. 2019 Jan 11;15:213-218. doi: 10.2147/NDT.S186705. eCollection 2019.
• [1465] Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-APPswe Mice Without Inducing Microhemorrhage.J Alzheimers Dis. 2017;59(4):1393-1413. doi: 10.3233/JAD-170056.
• [1466] Interactome mapping suggests new mechanistic details underlying Alzheimer's disease.Genome Res. 2011 Mar;21(3):364-76. doi: 10.1101/gr.114280.110. Epub 2010 Dec 16.
• [1467] Genetic Risk as a Marker of Amyloid- and Tau Burden in Cerebrospinal Fluid.J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.
• [1468] Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis.Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):50-5. doi: 10.1002/ajmg.b.30767.
• [1469] Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer's Disease.J Alzheimers Dis. 2016 Sep 6;54(2):669-78. doi: 10.3233/JAD-160036.
• [1470] Electroacupuncture Improves Synaptic Function in SAMP8 Mice Probably via Inhibition of the AMPK/eEF2K/eEF2 Signaling Pathway.Evid Based Complement Alternat Med. 2019 Sep 18;2019:8260815. doi: 10.1155/2019/8260815. eCollection 2019.
• [1471] Impact of Swiprosin-1/Efhd2 on Adult Hippocampal Neurogenesis.Stem Cell Reports. 2018 Feb 13;10(2):347-355. doi: 10.1016/j.stemcr.2017.12.010. Epub 2018 Jan 11.
• [1472] Candidate gene discovery procedure after follow-up confirmatory analyses of candidate regions of interests for Alzheimer's disease in the NIMH sibling dataset.Dis Markers. 2008;24(6):293-309. doi: 10.1155/2008/736409.
• [1473] Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease.Exp Neurol. 1997 Oct;147(2):316-32. doi: 10.1006/exnr.1997.6600.
• [1474] Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease.Neurobiol Dis. 2012 Mar;45(3):902-12. doi: 10.1016/j.nbd.2011.12.007. Epub 2011 Dec 11.
• [1475] Protective effect of ISO? against advanced glycation end product aggravation of PC12 cell injury induced by A1?0.Mol Med Rep. 2019 Sep;20(3):2135-2142. doi: 10.3892/mmr.2019.10483. Epub 2019 Jul 9.
• [1476] Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression.J Biol Chem. 2009 Jan 9;284(2):1106-15. doi: 10.1074/jbc.M807325200. Epub 2008 Nov 18.
• [1477] Double stranded RNA activated EIF2 alpha kinase (EIF2AK2; PKR) is associated with Alzheimer's disease.Neurobiol Aging. 2008 Aug;29(8):1160-6. doi: 10.1016/j.neurobiolaging.2007.02.023. Epub 2007 Apr 8.
• [1478] Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE.PLoS Genet. 2011 Feb;7(2):e1001308. doi: 10.1371/journal.pgen.1001308. Epub 2011 Feb 17.
• [1479] eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease.PLoS One. 2010 Sep 28;5(9):e13030. doi: 10.1371/journal.pone.0013030.
• [1480] Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome.Brain Pathol. 2016 Sep;26(5):593-605. doi: 10.1111/bpa.12335. Epub 2015 Dec 14.
• [1481] Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine perspective.Genomics. 2020 Mar;112(2):1290-1299. doi: 10.1016/j.ygeno.2019.07.018. Epub 2019 Aug 1.
• [1482] HuD regulates coding and noncoding RNA to induce APPA processing.Cell Rep. 2014 Jun 12;7(5):1401-1409. doi: 10.1016/j.celrep.2014.04.050. Epub 2014 May 22.
• [1483] Protein inhibitor of activated STAT1 Ser(503) phosphorylation-mediated Elk-1 SUMOylation promotes neuronal survival in APP/PS1 mice.Br J Pharmacol. 2019 Jun;176(11):1793-1810. doi: 10.1111/bph.14656. Epub 2019 Apr 24.
• [1484] Evidence of recessive Alzheimer disease loci in a Caribbean Hispanic data set: genome-wide survey of runs of homozygosity.JAMA Neurol. 2013 Oct;70(10):1261-7. doi: 10.1001/jamaneurol.2013.3545.
• [1485] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [1486] Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009 Jun 5;1274:66-76. doi: 10.1016/j.brainres.2009.04.009. Epub 2009 Apr 15.
• [1487] Non-parametric Survival Analysis of EPG5 Gene with Age at Onset of Alzheimer's Disease.J Mol Neurosci. 2016 Dec;60(4):436-444. doi: 10.1007/s12031-016-0821-9. Epub 2016 Sep 1.
• [1488] Quantitative proteomics reveals EVA1A-related proteins involved in neuronal differentiation.Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600294. Epub 2017 Feb 21.
• [1489] Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimer's disease.BMC Med Genomics. 2018 Sep 14;11(Suppl 3):76. doi: 10.1186/s12920-018-0390-6.
• [1490] Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer's disease.J Psychiatr Res. 2019 Dec;119:102-106. doi: 10.1016/j.jpsychires.2019.10.002. Epub 2019 Oct 3.
• [1491] FABP7 Protects Astrocytes Against ROS Toxicity via Lipid Droplet Formation.Mol Neurobiol. 2019 Aug;56(8):5763-5779. doi: 10.1007/s12035-019-1489-2. Epub 2019 Jan 24.
• [1492] Small Molecule Inhibits Metal-Dependent and -Independent Multifaceted Toxicity of Alzheimer's Disease.ACS Chem Neurosci. 2019 Aug 21;10(8):3611-3621. doi: 10.1021/acschemneuro.9b00216. Epub 2019 Jun 12.
• [1493] Neuronal expression of ILEI/FAM3C and its reduction in Alzheimer's disease.Neuroscience. 2016 Aug 25;330:236-46. doi: 10.1016/j.neuroscience.2016.05.050. Epub 2016 May 30.
• [1494] Identification and characterisation of the novel amyloid-beta peptide-induced protein p17.FEBS Lett. 2009 Oct 6;583(19):3247-53. doi: 10.1016/j.febslet.2009.09.018. Epub 2009 Sep 13.
• [1495] Lymphocytes of patients with Alzheimer's disease display different DNA damage repair kinetics and expression profiles of DNA repair and stress response genes.Int J Mol Sci. 2013 Jun 10;14(6):12380-400. doi: 10.3390/ijms140612380.
• [1496] Neuronal expression of F-box and leucine-rich-repeat protein 2 decreases over Braak stages in the brains of Alzheimer's disease patients.Neurodegener Dis. 2013;11(1):1-12. doi: 10.1159/000336016. Epub 2012 Mar 27.
• [1497] F-box/LRR-repeat protein 7 is genetically associated with Alzheimer's disease.Ann Clin Transl Neurol. 2015 Aug;2(8):810-20. doi: 10.1002/acn3.223. Epub 2015 Jun 18.
• [1498] SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function.Aging Cell. 2010 Dec;9(6):1018-31. doi: 10.1111/j.1474-9726.2010.00632.x. Epub 2010 Oct 29.
• [1499] F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy.Hum Mol Genet. 2015 Nov 15;24(22):6314-30. doi: 10.1093/hmg/ddv340. Epub 2015 Aug 26.
• [1500] Candidate-based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in A and TAU proteostasis.Hum Mol Genet. 2019 Mar 1;28(5):718-735. doi: 10.1093/hmg/ddy376.
• [1501] Glycosaminoglycans from Alzheimer's disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau.PLoS One. 2019 Jan 4;14(1):e0209573. doi: 10.1371/journal.pone.0209573. eCollection 2019.
• [1502] Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington's Disease.Cell Physiol Biochem. 2018;48(2):605-617. doi: 10.1159/000491889. Epub 2018 Jul 18.
• [1503] Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein.Hum Mol Genet. 2000 Sep 22;9(15):2281-9. doi: 10.1093/oxfordjournals.hmg.a018919.
• [1504] Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease.Oncotarget. 2017 Dec 22;9(5):6128-6143. doi: 10.18632/oncotarget.23640. eCollection 2018 Jan 19.
• [1505] Pin1 facilitates isoproterenolinduced cardiac fibrosis and collagen deposition by promoting oxidative stress and activating the MEK1/2ERK1/2 signal transduction pathway in rats.Int J Mol Med. 2018 Mar;41(3):1573-1583. doi: 10.3892/ijmm.2017.3354. Epub 2017 Dec 29.
• [1506] The Value of FLG Null Mutations in Predicting Treatment Response in Atopic Dermatitis: An Observational Study in Finnish Patients.Acta Derm Venereol. 2017 Apr 6;97(4):456-463. doi: 10.2340/00015555-2578.
• [1507] In silico-guided identification of potential inhibitors against (2)m aggregation in dialysis-related amyloidosis.J Biomol Struct Dyn. 2020 Aug;38(13):3927-3941. doi: 10.1080/07391102.2019.1668852. Epub 2019 Sep 27.
• [1508] Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia.EMBO J. 2017 Oct 2;36(19):2815-2828. doi: 10.15252/embj.201796821. Epub 2017 Aug 2.
• [1509] Fragile X gene expansions are not associated with dementia.Neurobiol Aging. 2014 Nov;35(11):2637-2638. doi: 10.1016/j.neurobiolaging.2014.04.027. Epub 2014 May 2.
• [1510] Mechanistic complexities of bone loss in Alzheimer's disease: a review.Connect Tissue Res. 2020 Jan;61(1):4-18. doi: 10.1080/03008207.2019.1624734. Epub 2019 Jun 11.
• [1511] KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas.Brain. 2012 Apr;135(Pt 4):1027-41. doi: 10.1093/brain/aws045. Epub 2012 Mar 16.
• [1512] Genome-wide profiling reveals functional diversification of FosB gene targets in the hippocampus of an Alzheimer's disease mouse model.PLoS One. 2018 Feb 6;13(2):e0192508. doi: 10.1371/journal.pone.0192508. eCollection 2018.
• [1513] Meta-Analysis of Transcriptome Data Related to Hippocampus Biopsies and iPSC-Derived Neuronal Cells from Alzheimer's Disease Patients Reveals an Association with FOXA1 and FOXA2 Gene Regulatory Networks.J Alzheimers Dis. 2016;50(4):1065-82. doi: 10.3233/JAD-150733.
• [1514] No genetic association between Fyn kinase gene polymorphisms (-93A/G, IVS10+37T/C and Ex12+894T/G) and Japanese sporadic Alzheimer's disease.Neurosci Lett. 2004 Apr 22;360(1-2):109-11. doi: 10.1016/j.neulet.2004.02.046.
• [1515] Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.Neurobiol Aging. 2015 Feb;36(2):1221.e15-28. doi: 10.1016/j.neurobiolaging.2014.09.003. Epub 2014 Sep 6.
• [1516] Genome-wide and gene-based association implicates FRMD6 in Alzheimer disease.Hum Mutat. 2012 Mar;33(3):521-9. doi: 10.1002/humu.22009. Epub 2012 Jan 23.
• [1517] Mitochondrial Ferritin Deletion Exacerbates -Amyloid-Induced Neurotoxicity in Mice.Oxid Med Cell Longev. 2017;2017:1020357. doi: 10.1155/2017/1020357. Epub 2017 Jan 16.
• [1518] Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.Curr Alzheimer Res. 2018;15(7):691-700. doi: 10.2174/1567205015666180110113238.
• [1519] A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model.Neurotox Res. 2010 May;17(4):360-79. doi: 10.1007/s12640-009-9112-3. Epub 2009 Sep 16.
• [1520] Silencing of Long Noncoding RNA SOX21-AS1 Relieves Neuronal Oxidative Stress Injury in Mice with Alzheimer's Disease by Upregulating FZD3/5 via the Wnt Signaling Pathway.Mol Neurobiol. 2019 May;56(5):3522-3537. doi: 10.1007/s12035-018-1299-y. Epub 2018 Aug 24.
• [1521] WNT5A signaling contributes to A-induced neuroinflammation and neurotoxicity.PLoS One. 2011;6(8):e22920. doi: 10.1371/journal.pone.0022920. Epub 2011 Aug 17.
• [1522] Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.Cereb Cortex. 2018 Jul 1;28(7):2391-2404. doi: 10.1093/cercor/bhx141.
• [1523] Changes in hippocampal GABABR1 subunit expression in Alzheimer's patients: association with Braak staging.Acta Neuropathol. 2005 May;109(5):467-74. doi: 10.1007/s00401-005-0985-9. Epub 2005 Mar 10.
• [1524] NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer's disease astrocytes.Glia. 2020 Mar;68(3):589-599. doi: 10.1002/glia.23741. Epub 2019 Oct 31.
• [1525] Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients.J Cell Sci. 2002 Aug 1;115(Pt 15):3131-8. doi: 10.1242/jcs.115.15.3131.
• [1526] CR6-interacting factor 1 is a key regulator in A-induced mitochondrial disruption and pathogenesis of Alzheimer's disease.Cell Death Differ. 2015 Jun;22(6):959-73. doi: 10.1038/cdd.2014.184. Epub 2014 Nov 7.
• [1527] Effect of Chinese herbal compound GAPT on the early brain glucose metabolism of APP/PS1 transgenic mice.Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419841482. doi: 10.1177/2058738419841482.
• [1528] Solution NMR structure and ligand identification of human Gas7 SH3 domain reveal a typical SH3 fold but a non-canonical ligand-binding mode.Biochem Biophys Res Commun. 2019 Sep 3;516(4):1190-1195. doi: 10.1016/j.bbrc.2019.07.004. Epub 2019 Jul 9.
• [1529] Regulatory role of Golgi brefeldin A resistance factor-1 in amyloid precursor protein trafficking, cleavage and A formation.J Cell Biochem. 2019 Sep;120(9):15604-15615. doi: 10.1002/jcb.28827. Epub 2019 May 20.
• [1530] Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications.Sci Rep. 2017 Apr 18;7:46263. doi: 10.1038/srep46263.
• [1531] MiR-16 attenuates -amyloid-induced neurotoxicity through targeting -site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer's disease cell model.Neuroreport. 2018 Nov 7;29(16):1365-1372. doi: 10.1097/WNR.0000000000001118.
• [1532] GDF11 Rejuvenates Cerebrovascular Structure and Function in an Animal Model of Alzheimer's Disease.J Alzheimers Dis. 2018;62(2):807-819. doi: 10.3233/JAD-170474.
• [1533] Synergistic promoting effects of bone morphogenetic protein 12/connective tissue growth factor on functional differentiation of tendon derived stem cells and patellar tendon window defect regeneration.J Biomech. 2018 Jan 3;66:95-102. doi: 10.1016/j.jbiomech.2017.11.004. Epub 2017 Nov 7.
• [1534] Deficiency of GDNF Receptor GFR1 in Alzheimer's Neurons Results in Neuronal Death.J Neurosci. 2014 Sep 24;34(39):13127-38. doi: 10.1523/JNEUROSCI.2582-13.2014.
• [1535] Role of human GKN1 on APP processing in gastric cancer.Biochimie. 2017 Apr;135:149-153. doi: 10.1016/j.biochi.2017.02.007. Epub 2017 Feb 16.
• [1536] Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.Acta Neuropathol. 2017 May;133(5):839-856. doi: 10.1007/s00401-017-1685-y. Epub 2017 Feb 28.
• [1537] Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative in silico and molecular modeling approach.J Biomol Struct Dyn. 2020 Jun;38(9):2533-2545. doi: 10.1080/07391102.2019.1635530. Epub 2019 Jul 4.
• [1538] Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer's Disease Therapeutic Target.Mol Neurobiol. 2019 Jan;56(1):378-393. doi: 10.1007/s12035-018-1068-y. Epub 2018 Apr 27.
• [1539] GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026. Epub 2013 Apr 4.
• [1540] Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer's disease.Sci Rep. 2018 Feb 9;8(1):2759. doi: 10.1038/s41598-018-21256-6.
• [1541] Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin.Int J Nanomedicine. 2017 Apr 7;12:2857-2869. doi: 10.2147/IJN.S132472. eCollection 2017.
• [1542] Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's.Neurobiol Aging. 2004 Aug;25(7):853-9. doi: 10.1016/j.neurobiolaging.2003.10.006.
• [1543] Reduction of Ether-Type Glycerophospholipids, Plasmalogens, by NF-B Signal Leading to Microglial Activation.J Neurosci. 2017 Apr 12;37(15):4074-4092. doi: 10.1523/JNEUROSCI.3941-15.2017. Epub 2017 Mar 14.
• [1544] Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease.Mol Biol Cell. 2008 Jul;19(7):3052-69. doi: 10.1091/mbc.e07-11-1106. Epub 2008 May 14.
• [1545] Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease.Neurology. 2018 Nov 6;91(19):e1799-e1808. doi: 10.1212/WNL.0000000000006457. Epub 2018 Oct 10.
• [1546] Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and -Amyloid plaques in an early-onset Alzheimer's disease mouse model.Aging (Albany NY). 2019 Dec 4;11(23):11591-11608. doi: 10.18632/aging.102558. Epub 2019 Dec 4.
• [1547] Genetic and Expression Analysis of COPI Genes and Alzheimer's Disease Susceptibility.Front Genet. 2019 Sep 19;10:866. doi: 10.3389/fgene.2019.00866. eCollection 2019.
• [1548] Tuning GABAergic Inhibition: Gephyrin Molecular Organization and Functions.Neuroscience. 2020 Jul 15;439:125-136. doi: 10.1016/j.neuroscience.2019.07.036. Epub 2019 Jul 26.
• [1549] The Membrane Glycoprotein M6a Endocytic/Recycling Pathway Involves Clathrin-Mediated Endocytosis and Affects Neuronal Synapses.Front Mol Neurosci. 2017 Sep 20;10:296. doi: 10.3389/fnmol.2017.00296. eCollection 2017.
• [1550] Significant association between GPR50 hypomethylation and AD in males.Mol Med Rep. 2019 Aug;20(2):1085-1092. doi: 10.3892/mmr.2019.10366. Epub 2019 Jun 6.
• [1551] Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
• [1552] Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's disease.Mol Psychiatry. 2013 May;18(5):568-75. doi: 10.1038/mp.2012.81. Epub 2012 Jun 19.
• [1553] Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides A(1-42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.Front Aging Neurosci. 2018 Oct 1;10:297. doi: 10.3389/fnagi.2018.00297. eCollection 2018.
• [1554] Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease.Dement Geriatr Cogn Disord. 2009;28(6):521-7. doi: 10.1159/000254757. Epub 2009 Dec 10.
• [1555] Structural insight into GRIP1-PDZ6 in Alzheimer's disease: study from protein expression data to molecular dynamics simulations.J Biomol Struct Dyn. 2017 Aug;35(10):2235-2247. doi: 10.1080/07391102.2016.1214085. Epub 2016 Aug 1.
• [1556] In silico identification of natural product inhibitors for -secretase activating protein, a therapeutic target for Alzheimer's disease.J Cell Biochem. 2019 Jun;120(6):10323-10336. doi: 10.1002/jcb.28316. Epub 2018 Dec 19.
• [1557] GSKIP-Mediated Anchoring Increases Phosphorylation of Tau by PKA but Not by GSK3beta via cAMP/PKA/GSKIP/GSK3/Tau Axis Signaling in Cerebrospinal Fluid and iPS Cells in Alzheimer Disease.J Clin Med. 2019 Oct 21;8(10):1751. doi: 10.3390/jcm8101751.
• [1558] Explorative genetic association study of GSTT2B copy number variant in complex disease risks.Ann Hum Biol. 2016 May;43(3):279-84. doi: 10.3109/03014460.2015.1049206. Epub 2015 Jul 24.
• [1559] MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8523-8532. doi: 10.26355/eurrev_201910_19166.
• [1560] GULP1/CED-6 ameliorates amyloid- toxicity in a Drosophila model of Alzheimer's disease.Oncotarget. 2017 Aug 8;8(59):99274-99283. doi: 10.18632/oncotarget.20062. eCollection 2017 Nov 21.
• [1561] Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, -GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment.Brain Res. 2017 Jan 1;1654(Pt A):66-76. doi: 10.1016/j.brainres.2016.10.011. Epub 2016 Oct 17.
• [1562] Long-standing balancing selection in the THBS4 gene: influence on sex-specific brain expression and gray matter volumes in Alzheimer disease.Hum Mutat. 2013 May;34(5):743-53. doi: 10.1002/humu.22301. Epub 2013 Apr 2.
• [1563] Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.Alzheimers Dement. 2015 Dec;11(12):1439-1451. doi: 10.1016/j.jalz.2015.05.015. Epub 2015 Jun 12.
• [1564] Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases.J Alzheimers Dis. 2017;57(2):395-409. doi: 10.3233/JAD-160804.
• [1565] Hemoglobin binding to A beta and HBG2 SNP association suggest a role in Alzheimer's disease.Neurobiol Aging. 2008 Feb;29(2):185-93. doi: 10.1016/j.neurobiolaging.2006.10.017. Epub 2006 Dec 8.
• [1566] Network-guided analysis of hippocampal proteome identifies novel proteins that colocalize with A in a mice model of early-stage Alzheimer's disease.Neurobiol Dis. 2019 Dec;132:104603. doi: 10.1016/j.nbd.2019.104603. Epub 2019 Sep 5.
• [1567] HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q.BMC Med Genet. 2009 Sep 15;10:90. doi: 10.1186/1471-2350-10-90.
• [1568] MicroRNA-98 reduces amyloid -protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer's disease mice.Int J Mol Med. 2019 Jan;43(1):91-102. doi: 10.3892/ijmm.2018.3957. Epub 2018 Oct 24.
• [1569] HHEX_23 AA Genotype Exacerbates Effect of Diabetes on Dementia and Alzheimer Disease: A Population-Based Longitudinal Study.PLoS Med. 2015 Jul 14;12(7):e1001853. doi: 10.1371/journal.pmed.1001853. eCollection 2015 Jul.
• [1570] Immune hyperreactivity of A plaque-associated microglia in Alzheimer's disease.Neurobiol Aging. 2017 Jul;55:115-122. doi: 10.1016/j.neurobiolaging.2017.03.021. Epub 2017 Mar 27.
• [1571] Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.Oncotarget. 2017 Apr 11;8(15):24077-24087. doi: 10.18632/oncotarget.15269.
• [1572] Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease.Mol Neurobiol. 2016 Jul;53(5):3227-3234. doi: 10.1007/s12035-015-9229-8. Epub 2015 Jun 6.
• [1573] MicroRNA 7 Impairs Insulin Signaling and Regulates A Levels through Posttranscriptional Regulation of the Insulin Receptor Substrate 2, Insulin Receptor, Insulin-Degrading Enzyme, and Liver X Receptor Pathway.Mol Cell Biol. 2019 Oct 28;39(22):e00170-19. doi: 10.1128/MCB.00170-19. Print 2019 Nov 15.
• [1574] Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.Brain. 2016 Feb;139(Pt 2):526-46. doi: 10.1093/brain/awv356. Epub 2015 Dec 14.
• [1575] Hook proteins: association with Alzheimer pathology and regulatory role of hook3 in amyloid beta generation.PLoS One. 2015 Mar 23;10(3):e0119423. doi: 10.1371/journal.pone.0119423. eCollection 2015.
• [1576] Knockdown of heterochromatin protein 1 binding protein 3 recapitulates phenotypic, cellular, and molecular features of aging.Aging Cell. 2019 Feb;18(1):e12886. doi: 10.1111/acel.12886. Epub 2018 Dec 13.
• [1577] Role of hippocalcin in mediating A toxicity.Biochim Biophys Acta. 2012 Aug;1822(8):1247-57. doi: 10.1016/j.bbadis.2012.04.007. Epub 2012 Apr 20.
• [1578] Production of transgenic pig as an Alzheimer's disease model using a multi-cistronic vector system.PLoS One. 2017 Jun 6;12(6):e0177933. doi: 10.1371/journal.pone.0177933. eCollection 2017.
• [1579] Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.J Alzheimers Dis. 2017;58(1):185-192. doi: 10.3233/JAD-161298.
• [1580] Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease.Circulation. 2015 Jun 9;131(23):2061-2069. doi: 10.1161/CIRCULATIONAHA.115.015489. Epub 2015 Apr 10.
• [1581] HSP70-2 (HSPA1B) is associated with noncognitive symptoms in late-onset Alzheimer's disease.J Geriatr Psychiatry Neurol. 2003 Sep;16(3):146-50. doi: 10.1177/0891988703256051.
• [1582] The Effect of Human HSP70 Administration on a Mouse Model of Alzheimer's Disease Strongly Depends on Transgenicity and Age.J Alzheimers Dis. 2019;67(4):1391-1404. doi: 10.3233/JAD-180987.
• [1583] The phosphorylation of Hsp20 enhances its association with amyloid- to increase protection against neuronal cell death.Mol Cell Neurosci. 2014 Jul;61:46-55. doi: 10.1016/j.mcn.2014.05.002. Epub 2014 May 20.
• [1584] Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.Mol Cell Biol. 2010 Oct;30(19):4626-43. doi: 10.1128/MCB.01493-09. Epub 2010 Aug 2.
• [1585] Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer's Disease Brain.Mol Neurobiol. 2019 Jul;56(7):4601-4619. doi: 10.1007/s12035-018-1383-3. Epub 2018 Oct 25.
• [1586] Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease.Life Sci. 2018 Aug 15;207:428-435. doi: 10.1016/j.lfs.2018.06.032. Epub 2018 Jun 30.
• [1587] ORP150-CHIP chaperone antagonism control BACE1-mediated amyloid processing.J Cell Biochem. 2018 Jun;119(6):4615-4626. doi: 10.1002/jcb.26630. Epub 2018 Feb 27.
• [1588] Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer's disease models.PLoS One. 2018 May 8;13(5):e0196929. doi: 10.1371/journal.pone.0196929. eCollection 2018.
• [1589] Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.Eur J Med Chem. 2017 Jan 5;125:736-750. doi: 10.1016/j.ejmech.2016.09.057. Epub 2016 Sep 19.
• [1590] Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex.Neurosci Lett. 1998 Mar 13;244(2):69-72. doi: 10.1016/s0304-3940(98)00138-4.
• [1591] SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase.J Biol Chem. 2013 Aug 23;288(34):24691-704. doi: 10.1074/jbc.M113.469692. Epub 2013 Jul 16.
• [1592] Secreted calmodulin-like skin protein inhibits neuronal death in cell-based Alzheimer's disease models via the heterotrimeric Humanin receptor.Cell Death Dis. 2013 Mar 21;4(3):e555. doi: 10.1038/cddis.2013.80.
• [1593] IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis.PLoS One. 2012;7(3):e33271. doi: 10.1371/journal.pone.0033271. Epub 2012 Mar 8.
• [1594] LMD proteomics provides evidence for hippocampus field-specific motor protein abundance changes with relevance to Alzheimer's disease.Biochim Biophys Acta Proteins Proteom. 2017 Jun;1865(6):703-714. doi: 10.1016/j.bbapap.2017.03.013. Epub 2017 Apr 2.
• [1595] A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP.Front Cell Neurosci. 2019 Oct 1;13:435. doi: 10.3389/fncel.2019.00435. eCollection 2019.
• [1596] Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein.J Neurochem. 2007 May;101(3):757-70. doi: 10.1111/j.1471-4159.2006.04368.x.
• [1597] Antecedent ADHD, dementia, and metabolic dysregulation: A U.S. based cohort analysis.Neurochem Int. 2018 Jan;112:255-258. doi: 10.1016/j.neuint.2017.08.005. Epub 2017 Aug 12.
• [1598] Enhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes.Hum Mol Genet. 2017 Oct 15;26(20):3973-3988. doi: 10.1093/hmg/ddx284.
• [1599] LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.J Neuroimmunol. 2017 Dec 15;313:1-9. doi: 10.1016/j.jneuroim.2017.09.010. Epub 2017 Sep 28.
• [1600] Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease.J Alzheimers Dis. 2006 Aug;9(3):225-33. doi: 10.3233/jad-2006-9301.
• [1601] LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide.Brain. 2005 Aug;128(Pt 8):1778-89. doi: 10.1093/brain/awh531. Epub 2005 Apr 27.
• [1602] Variants in Antiviral Genes are Risk Factors for Cognitive Decline and Dementia.J Alzheimers Dis. 2015;46(3):655-63. doi: 10.3233/JAD-142718.
• [1603] Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.BMC Genomics. 2013 Nov 25;14:831. doi: 10.1186/1471-2164-14-831.
• [1604] Differential Phagocytic Properties of CD45(low) Microglia and CD45(high) Brain Mononuclear Phagocytes-Activation and Age-Related Effects.Front Immunol. 2018 Mar 2;9:405. doi: 10.3389/fimmu.2018.00405. eCollection 2018.
• [1605] Extracellular Vesicles: A Possible Link between HIV and Alzheimer's Disease-Like Pathology in HIV Subjects?.Cells. 2019 Aug 24;8(9):968. doi: 10.3390/cells8090968.
• [1606] miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain.EMBO Mol Med. 2016 Sep 1;8(9):1005-18. doi: 10.15252/emmm.201606520. Print 2016 Sep.
• [1607] Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome.Neuroreport. 2011 Oct 26;22(15):767-72. doi: 10.1097/WNR.0b013e32834ae348.
• [1608] Kalirin-7 prevents dendritic spine dysgenesis induced by amyloid beta-derived oligomers.Eur J Neurosci. 2019 May;49(9):1091-1101. doi: 10.1111/ejn.14311. Epub 2019 Jan 20.
• [1609] The MiRP2-Kv3.4 potassium channel: muscling in on Alzheimer's disease.Mol Pharmacol. 2007 Sep;72(3):499-501. doi: 10.1124/mol.107.039206. Epub 2007 Jun 26.
• [1610] Inhibition of the Neuronal Calcium Sensor DREAM Modulates Presenilin-2 Endoproteolysis.Front Mol Neurosci. 2018 Dec 3;11:449. doi: 10.3389/fnmol.2018.00449. eCollection 2018.
• [1611] The Brief Memory and Executive Test (BMET): A cognitive screening tool to detect and differentiate vascular cognitive impairment and Alzheimer's disease.Int J Geriatr Psychiatry. 2018 Feb;33(2):e273-e279. doi: 10.1002/gps.4787. Epub 2017 Sep 7.
• [1612] Genome-wide association interaction analysis for Alzheimer's disease.Neurobiol Aging. 2014 Nov;35(11):2436-2443. doi: 10.1016/j.neurobiolaging.2014.05.014. Epub 2014 May 28.
• [1613] microRNA-592 blockade inhibits oxidative stress injury in Alzheimer's disease astrocytes via the KIAA0319-mediated Keap1/Nrf2/ARE signaling pathway.Exp Neurol. 2020 Feb;324:113128. doi: 10.1016/j.expneurol.2019.113128. Epub 2019 Nov 21.
• [1614] Primate-specific miR-603 is implicated in the risk and pathogenesis of Alzheimer's disease.Aging (Albany NY). 2016 Feb;8(2):272-90. doi: 10.18632/aging.100887.
• [1615] Kidins220 Correlates with Tau inAlzheimer's Disease Brain andCerebrospinal Fluid.J Alzheimers Dis. 2017;55(4):1327-1333. doi: 10.3233/JAD-160639.
• [1616] Single nucleotide polymorphisms in piRNA-pathway genes: an insight into genetic determinants of human diseases.Mol Genet Genomics. 2020 Jan;295(1):1-12. doi: 10.1007/s00438-019-01612-5. Epub 2019 Oct 14.
• [1617] Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease.J Alzheimers Dis. 2017;60(4):1511-1524. doi: 10.3233/JAD-170094.
• [1618] KIF6 719Arg allele is associated with statin effects on cholesterol levels in amnestic mild cognitive impairment and Alzheimer's disease patients.J Alzheimers Dis. 2013;33(1):111-6. doi: 10.3233/JAD-2012-121015.
• [1619] Kinesin light chain-1 serine-460 phosphorylation is altered in Alzheimer's disease and regulates axonal transport and processing of the amyloid precursor protein.Acta Neuropathol Commun. 2019 Dec 5;7(1):200. doi: 10.1186/s40478-019-0857-5.
• [1620] MicroRNA-25 aggravates A1-42-induced hippocampal neuron injury in Alzheimer's disease by downregulating KLF2 via the Nrf2 signaling pathway in a mouse model.J Cell Biochem. 2019 Sep;120(9):15891-15905. doi: 10.1002/jcb.28861. Epub 2019 May 29.
• [1621] Krppel-like factor 8 ameliorates Alzheimer's disease by activating -catenin.J Mol Neurosci. 2014 Feb;52(2):231-41. doi: 10.1007/s12031-013-0131-4. Epub 2013 Oct 11.
• [1622] Structural Basis for Recruitment of DAPK1 to the KLHL20 E3 Ligase.Structure. 2019 Sep 3;27(9):1395-1404.e4. doi: 10.1016/j.str.2019.06.005. Epub 2019 Jul 3.
• [1623] Keratinocyte Proline-Rich Protein DeficiencyinAtopic Dermatitis Leads to Barrier Disruption.J Invest Dermatol. 2019 Sep;139(9):1867-1875.e7. doi: 10.1016/j.jid.2019.02.030. Epub 2019 Mar 21.
• [1624] Buccal cell cytokeratin 14 identifies mild cognitive impairment and Alzheimer' s disease in the AIBL study of aging.Curr Alzheimer Res. 2015;12(3):233-41. doi: 10.2174/1567205012666150302154650.
• [1625] Fluorescence Self-Quenching from Reporter Dyes Informs on the Structural Properties of Amyloid Clusters Formed in Vitro and in Cells.Nano Lett. 2017 Jan 11;17(1):143-149. doi: 10.1021/acs.nanolett.6b03686. Epub 2016 Dec 8.
• [1626] Differential distribution of laminins in Alzheimer disease and normal human brain tissue.J Neurosci Res. 2002 Jul 15;69(2):243-56. doi: 10.1002/jnr.10292.
• [1627] Integrated analysis of human genetic association study and mouse transcriptome suggests LBH and SHF genes as novel susceptible genes for amyloid- accumulation in Alzheimer's disease.Hum Genet. 2018 Jul;137(6-7):521-533. doi: 10.1007/s00439-018-1906-z. Epub 2018 Jul 13.
• [1628] X-ray-induced chromatid damage in cells from Down syndrome and Alzheimer disease patients in relation to DNA repair and cancer proneness.Cancer Genet Cytogenet. 1993 Oct 1;70(1):25-30. doi: 10.1016/0165-4608(93)90127-8.
• [1629] The Role of Methylated Circulating Nucleic Acids as a Potential Biomarker in Alzheimer's Disease.Mol Neurobiol. 2019 Apr;56(4):2440-2449. doi: 10.1007/s12035-018-1229-z. Epub 2018 Jul 21.
• [1630] Association between Single-Nucleotide Polymorphisms of the hOGG1,NEIL1,APEX1, FEN1,LIG1, and LIG3 Genes and Alzheimer's Disease Risk.Neuropsychobiology. 2016;73(2):98-107. doi: 10.1159/000444643. Epub 2016 Mar 25.
• [1631] Expression of nucleotide excision repair in Alzheimer's disease is higher in brain tissue than in blood.Neurosci Lett. 2018 Apr 13;672:53-58. doi: 10.1016/j.neulet.2018.02.043. Epub 2018 Feb 21.
• [1632] Autoantibodies to band 3 during aging and disease and aging interventions.Ann N Y Acad Sci. 1994 May 31;719:419-47. doi: 10.1111/j.1749-6632.1994.tb56847.x.
• [1633] Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment.PLoS One. 2016 Jan 7;11(1):e0146449. doi: 10.1371/journal.pone.0146449. eCollection 2016.
• [1634] Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction.Neurobiol Dis. 2008 Jun;30(3):408-419. doi: 10.1016/j.nbd.2008.02.012. Epub 2008 Mar 12.
• [1635] Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.Sci Rep. 2019 Nov 20;9(1):17222. doi: 10.1038/s41598-019-53638-9.
• [1636] Upregulation of microRNA-196a improves cognitive impairment and alleviates neuronal damage in hippocampus tissues of Alzheimer's disease through downregulating LRIG3 expression.J Cell Biochem. 2019 Oct;120(10):17811-17821. doi: 10.1002/jcb.29047. Epub 2019 May 22.
• [1637] LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer's disease.Mol Neurodegener. 2012 Jun 26;7:31. doi: 10.1186/1750-1326-7-31.
• [1638] Genome-wide haplotype association study identify TNFRSF1A, CASP7, LRP1B, CDH1 and TG genes associated with Alzheimer's disease in Caribbean Hispanic individuals.Oncotarget. 2015 Dec 15;6(40):42504-14. doi: 10.18632/oncotarget.6391.
• [1639] Lib, transcriptionally induced in senile plaque-associated astrocytes, promotes glial migration through extracellular matrix.Biochem Biophys Res Commun. 2005 Sep 23;335(2):631-6. doi: 10.1016/j.bbrc.2005.07.117.
• [1640] Association of LRRTM3 polymorphisms with late-onset Alzheimer's disease in Han Chinese.Exp Gerontol. 2014 Apr;52:18-22. doi: 10.1016/j.exger.2014.01.013. Epub 2014 Jan 21.
• [1641] Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1.Ann Neurol. 2016 Dec;80(6):823-833. doi: 10.1002/ana.24775. Epub 2016 Sep 30.
• [1642] U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease.Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16562-7. doi: 10.1073/pnas.1310249110. Epub 2013 Sep 10.
• [1643] Discriminating Alzheimer's disease progression using a new hippocampal marker from T1-weighted MRI: The local surface roughness.Hum Brain Mapp. 2019 Apr 1;40(5):1666-1676. doi: 10.1002/hbm.24478. Epub 2018 Nov 19.
• [1644] Genome-wide association study identifies two loci influencing plasma neurofilament light levels.BMC Med Genomics. 2018 May 10;11(1):47. doi: 10.1186/s12920-018-0364-8.
• [1645] Lynx1 and A1-42 bind competitively to multiple nicotinic acetylcholine receptor subtypes.Neurobiol Aging. 2016 Oct;46:13-21. doi: 10.1016/j.neurobiolaging.2016.06.009. Epub 2016 Jun 17.
• [1646] Alteration of scaffold: Possible role of MACF1 in Alzheimer's disease pathogenesis.Med Hypotheses. 2019 Sep;130:109259. doi: 10.1016/j.mehy.2019.109259. Epub 2019 Jun 5.
• [1647] Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes.J Alzheimers Dis. 2017;56(4):1525-1539. doi: 10.3233/JAD-161032.
• [1648] Brain site-specific gene expression analysis in Alzheimer's disease patients.Eur J Clin Invest. 2006 Nov;36(11):820-30. doi: 10.1111/j.1365-2362.2006.01722.x.
• [1649] Regulation of amyloid precursor protein processing by the Beclin 1 complex.PLoS One. 2010 Jun 15;5(6):e11102. doi: 10.1371/journal.pone.0011102.
• [1650] Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR- in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice.Mol Cell Neurosci. 2019 Sep;99:103390. doi: 10.1016/j.mcn.2019.103390. Epub 2019 Jul 2.
• [1651] Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers.Front Aging Neurosci. 2018 May 29;10:155. doi: 10.3389/fnagi.2018.00155. eCollection 2018.
• [1652] Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.J Med Chem. 2017 Oct 12;60(19):8083-8102. doi: 10.1021/acs.jmedchem.7b00843. Epub 2017 Sep 20.
• [1653] Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology.J Cell Biol. 2017 Oct 2;216(10):3291-3305. doi: 10.1083/jcb.201612148. Epub 2017 Aug 7.
• [1654] N-homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer's disease and vascular dementia.J Pathol. 2019 Jul;248(3):291-303. doi: 10.1002/path.5254. Epub 2019 Mar 19.
• [1655] A hydrophobic low-complexity region regulates aggregation of the yeast pyruvate kinase Cdc19 into amyloid-like aggregates in vitro.J Biol Chem. 2018 Jul 20;293(29):11424-11432. doi: 10.1074/jbc.RA117.001628. Epub 2018 May 31.
• [1656] Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease.Acta Neuropsychiatr. 2020 Apr;32(2):65-71. doi: 10.1017/neu.2019.39. Epub 2019 Dec 26.
• [1657] Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling.EMBO Rep. 2011 Mar;12(3):216-22. doi: 10.1038/embor.2010.210. Epub 2011 Feb 4.
• [1658] Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks.Genome Med. 2018 Feb 26;10(1):14. doi: 10.1186/s13073-018-0523-8.
• [1659] MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer's disease.Psychiatry Clin Neurosci. 2018 Mar;72(3):160-167. doi: 10.1111/pcn.12618. Epub 2017 Dec 1.
• [1660] -synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.Neurobiol Dis. 2011 Jan;41(1):71-82. doi: 10.1016/j.nbd.2010.08.022. Epub 2010 Sep 9.
• [1661] Short-Term Fish Oil Treatment Changes the Composition of Phospholipids While Not Affecting the Expression of Mfsd2a Omega-3 Transporter in the Brain and Liver of the 5xFAD Mouse Model of Alzheimer's Disease.Nutrients. 2018 Sep 6;10(9):1250. doi: 10.3390/nu10091250.
• [1662] An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.EMBO Mol Med. 2015 Feb;7(2):175-89. doi: 10.15252/emmm.201404438.
• [1663] Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.Sci Rep. 2017 Oct 23;7(1):13753. doi: 10.1038/s41598-017-12974-4.
• [1664] Three-way interaction model to trace the mechanisms involved in Alzheimer's disease transgenic mice.PLoS One. 2017 Sep 21;12(9):e0184697. doi: 10.1371/journal.pone.0184697. eCollection 2017.
• [1665] Expression of Aquaporin 1 and Aquaporin 4 in the Temporal Neocortex of Patients with Parkinson's Disease.Brain Pathol. 2017 Mar;27(2):160-168. doi: 10.1111/bpa.12369. Epub 2016 Apr 6.
• [1666] Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease.Acta Neuropathol. 2020 Mar;139(3):463-484. doi: 10.1007/s00401-019-02103-y. Epub 2019 Dec 4.
• [1667] Genotype-based association test for general pedigrees: the genotype-PDT.Genet Epidemiol. 2003 Nov;25(3):203-13. doi: 10.1002/gepi.10258.
• [1668] Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP.Front Aging Neurosci. 2019 Sep 24;11:244. doi: 10.3389/fnagi.2019.00244. eCollection 2019.
• [1669] Immune blood biomarkers of Alzheimer disease patients.J Neuroimmunol. 2009 May 29;210(1-2):67-72. doi: 10.1016/j.jneuroim.2009.02.015. Epub 2009 Mar 28.
• [1670] Mov10 suppresses retroelements and regulates neuronal development and function in the developing brain.BMC Biol. 2017 Jun 29;15(1):54. doi: 10.1186/s12915-017-0387-1.
• [1671] Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.FASEB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub 2009 Apr 15.
• [1672] Wechsler adult intelligence scale-4th edition digit span performance in subjective cognitive complaints, amnestic mild cognitive impairment, and probable dementia of the Alzheimer type.Clin Neuropsychol. 2019 Nov;33(8):1436-1444. doi: 10.1080/13854046.2019.1585574. Epub 2019 Mar 31.
• [1673] Deficiency of the Mre11 DNA repair complex in Alzheimer's disease brains.Brain Res Mol Brain Res. 2004 Sep 10;128(1):1-7. doi: 10.1016/j.molbrainres.2004.05.023.
• [1674] MS4A Cluster in Alzheimer's Disease.Mol Neurobiol. 2015;51(3):1240-8. doi: 10.1007/s12035-014-8800-z. Epub 2014 Jul 1.
• [1675] Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.Age (Dordr). 2016 Apr;38(2):41. doi: 10.1007/s11357-016-9885-2. Epub 2016 Mar 22.
• [1676] Intrahippocampal Transplantation of Undifferentiated Human Chorionic- Derived Mesenchymal Stem Cells Does Not Improve Learning and Memory in the Rat Model of Sporadic Alzheimer Disease.Curr Stem Cell Res Ther. 2019;14(2):184-190. doi: 10.2174/1574888X13666180723111249.
• [1677] Methionine Sulfoxide Reductase-B3 Risk Allele Implicated in Alzheimer's Disease Associates with Increased Odds for Brain Infarcts.J Alzheimers Dis. 2019;68(1):357-365. doi: 10.3233/JAD-180977.
• [1678] Metal-dependent interactions of metallothionein-3 -domain with amyloid- peptide and related physiological implications.J Inorg Biochem. 2019 Jul;196:110693. doi: 10.1016/j.jinorgbio.2019.110693. Epub 2019 Apr 13.
• [1679] Loss of forebrain MTCH2 decreases mitochondria motility and calcium handling and impairs hippocampal-dependent cognitive functions.Sci Rep. 2017 Mar 9;7:44401. doi: 10.1038/srep44401.
• [1680] Overexpression of MTERF4 promotes the amyloidogenic processing of APP by inhibiting ADAM10.Biochem Biophys Res Commun. 2017 Jan 22;482(4):928-934. doi: 10.1016/j.bbrc.2016.11.135. Epub 2016 Nov 25.
• [1681] Association analysis of CbetaS 844ins68 and MTHFD1 G1958A polymorphisms with Alzheimer's disease in Chinese.J Neural Transm (Vienna). 2010 Apr;117(4):499-503. doi: 10.1007/s00702-010-0383-x. Epub 2010 Mar 9.
• [1682] MxA polymorphisms are associated with risk and age-at-onset in Alzheimer disease and accelerated cognitive decline in Chinese elders.Rejuvenation Res. 2012 Oct;15(5):516-22. doi: 10.1089/rej.2012.1328. Epub 2012 Sep 21.
• [1683] Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.Brain Res. 2010 Jul 23;1345:182-9. doi: 10.1016/j.brainres.2010.05.007. Epub 2010 May 10.
• [1684] Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process.Neurobiol Aging. 2017 May;53:59-66. doi: 10.1016/j.neurobiolaging.2017.01.011. Epub 2017 Jan 18.
• [1685] The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease.Curr Opin Lipidol. 2019 Jun;30(3):192-197. doi: 10.1097/MOL.0000000000000593.
• [1686] Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex disparities.Alzheimers Res Ther. 2019 Jan 12;11(1):5. doi: 10.1186/s13195-018-0458-8.
• [1687] Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):823-8. doi: 10.1073/pnas.0608251104. Epub 2007 Jan 10.
• [1688] Pituitary adenylate cyclase-activating polypeptide protects against -amyloid toxicity.Neurobiol Aging. 2014 Sep;35(9):2064-71. doi: 10.1016/j.neurobiolaging.2014.03.022. Epub 2014 Mar 22.
• [1689] Haplotype of single nucleotide polymorphisms in exon 6 of the MZF-1 gene and Alzheimer's disease.J Alzheimers Dis. 2013;34(2):439-47. doi: 10.3233/JAD-121546.
• [1690] Human brain nascent polypeptide-associated complex alpha subunit is decreased in patients with Alzheimer' s disease and Down syndrome.J Investig Med. 2002 Jul;50(4):293-301. doi: 10.2310/6650.2002.33287.
• [1691] Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis.J Neurosci. 2007 Jul 4;27(27):7141-53. doi: 10.1523/JNEUROSCI.4599-06.2007.
• [1692] Role of aberrant nitric oxide synthase-3 expression in cerebrovascular degeneration and vascular-mediated injury in Alzheimer's disease.Ann N Y Acad Sci. 2000 Apr;903:61-71. doi: 10.1111/j.1749-6632.2000.tb06351.x.
• [1693] A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice.J Alzheimers Dis. 2017;58(2):389-400. doi: 10.3233/JAD-161236.
• [1694] Alzheimer's Disease Risk Variant rs2373115 Regulates GAB2 and NARS2 Expression in Human Brain Tissues.J Mol Neurosci. 2018 Sep;66(1):37-43. doi: 10.1007/s12031-018-1144-9. Epub 2018 Aug 7.
• [1695] Family-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease.J Neuroimmunol. 2017 Sep 15;310:60-65. doi: 10.1016/j.jneuroim.2017.06.010. Epub 2017 Jun 27.
• [1696] miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer's disease.Brain Res. 2015 Oct 22;1624:95-102. doi: 10.1016/j.brainres.2015.07.022. Epub 2015 Jul 23.
• [1697] Investigations into geriatric psychiatry challenges: AAGP Senior Investigator Award 2000.Am J Geriatr Psychiatry. 2000 Fall;8(4):276-83.
• [1698] Real-Time Detection of Spatial Disorientation in Persons with Mild Cognitive Impairment and Dementia.Gerontology. 2020;66(1):85-94. doi: 10.1159/000500971. Epub 2019 Jul 30.
• [1699] Characterization of neurocalcin delta membrane binding by biophysical methods.Colloids Surf B Biointerfaces. 2019 Feb 1;174:291-299. doi: 10.1016/j.colsurfb.2018.11.017. Epub 2018 Nov 12.
• [1700] A-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease.Nat Commun. 2015 Nov 27;6:8836. doi: 10.1038/ncomms9836.
• [1701] Non-SMC condensin I complex, subunit D2 gene polymorphisms are associated with Parkinson's disease: a Han Chinese study.Genome. 2014 May;57(5):253-7. doi: 10.1139/gen-2014-0032. Epub 2014 Aug 11.
• [1702] Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins.Am J Med Genet. 2001 Dec 8;105(8):724-8. doi: 10.1002/ajmg.1608.
• [1703] Frontotemporal dementia and mitochondrial DNA transitions.Neurobiol Dis. 2004 Mar;15(2):306-11. doi: 10.1016/j.nbd.2003.11.004.
• [1704] Investigations on the point mutations at nt 5460 of the mtDNA in different neurodegenerative and neuromuscular diseases.Eur Neurol. 1996;36(3):149-53. doi: 10.1159/000117233.
• [1705] SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease.Aging Cell. 2018 Feb;17(1):e12679. doi: 10.1111/acel.12679. Epub 2017 Nov 11.
• [1706] Profile of neuronal exosomes in HIV cognitive impairment exposes sex differences.AIDS. 2019 Sep 1;33(11):1683-1692. doi: 10.1097/QAD.0000000000002272.
• [1707] Lower Expression of Ndfip1 Is Associated With Alzheimer Disease Pathogenesis Through Decreasing DMT1 Degradation and Increasing Iron Influx.Front Aging Neurosci. 2018 Jun 8;10:165. doi: 10.3389/fnagi.2018.00165. eCollection 2018.
• [1708] l-Dopa and dopamine conjugated naphthalenediimides modulate amyloid toxicity.Org Biomol Chem. 2018 Nov 7;16(41):7682-7692. doi: 10.1039/c8ob01691g. Epub 2018 Oct 4.
• [1709] Overrepresentation of glutamate signaling in Alzheimer's disease: network-based pathway enrichment using meta-analysis of genome-wide association studies.PLoS One. 2014 Apr 22;9(4):e95413. doi: 10.1371/journal.pone.0095413. eCollection 2014.
• [1710] Association of gene expression and methylation of UQCRC1 to the predisposition of Alzheimer's disease in a Chinese population.J Psychiatr Res. 2016 May;76:143-7. doi: 10.1016/j.jpsychires.2016.02.010. Epub 2016 Feb 18.
• [1711] Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer's disease.Mol Brain. 2019 Jan 28;12(1):8. doi: 10.1186/s13041-019-0430-y.
• [1712] Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease.J Alzheimers Dis. 2014;39(2):347-55. doi: 10.3233/JAD-131499.
• [1713] Isolation and expression analysis of Alzheimer's disease-related gene xb51 in zebrafish.Dev Dyn. 2008 Dec;237(12):3921-6. doi: 10.1002/dvdy.21806.
• [1714] Pin1-dependent prolyl isomerization modulates the stress-induced phosphorylation of high molecular weight neurofilament protein.J Biol Chem. 2008 Sep 26;283(39):26737-47. doi: 10.1074/jbc.M801633200. Epub 2008 Jul 17.
• [1715] Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease.J Neural Transm Suppl. 2003;(67):149-58. doi: 10.1007/978-3-7091-6721-2_13.
• [1716] Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid- secretion via deregulated lysosomal exocytosis.Nat Commun. 2013;4:2734. doi: 10.1038/ncomms3734.
• [1717] Leveraging existing data sets to generate new insights into Alzheimer's disease biology in specific patient subsets.Sci Rep. 2015 Sep 23;5:14324. doi: 10.1038/srep14324.
• [1718] Differential Roles of Environmental Enrichment in Alzheimer's Type of Neurodegeneration and Physiological Aging.Front Aging Neurosci. 2017 Jul 26;9:245. doi: 10.3389/fnagi.2017.00245. eCollection 2017.
• [1719] NFATc2 Modulates Microglial Activation in the APP/PS1 Mouse Model of Alzheimer's Disease.J Alzheimers Dis. 2017;58(3):775-787. doi: 10.3233/JAD-151203.
• [1720] Ca(2+), Astrocyte Activation and Calcineurin/NFAT Signaling in Age-Related Neurodegenerative Diseases.Front Aging Neurosci. 2018 Jul 9;10:199. doi: 10.3389/fnagi.2018.00199. eCollection 2018.
• [1721] Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation.J Neurosci. 2010 Feb 17;30(7):2636-49. doi: 10.1523/JNEUROSCI.4456-09.2010.
• [1722] Brain in situ hybridization maps as a source for reverse-engineering transcriptional regulatory networks: Alzheimer's disease insights.Gene. 2016 Jul 15;586(1):77-86. doi: 10.1016/j.gene.2016.03.045. Epub 2016 Apr 3.
• [1723] Neuroglobin Expression in the Brain: a Story of Tissue Homeostasis Preservation.Mol Neurobiol. 2019 Mar;56(3):2101-2122. doi: 10.1007/s12035-018-1212-8. Epub 2018 Jul 10.
• [1724] Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens.Nat Genet. 2018 Dec;50(12):1716-1727. doi: 10.1038/s41588-018-0254-1. Epub 2018 Nov 5.
• [1725] Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of Alzheimer's disease.PLoS One. 2011;6(6):e20573. doi: 10.1371/journal.pone.0020573. Epub 2011 Jun 6.
• [1726] Epigenetic mechanisms underlying the effects of triptolide and tripchlorolide on the expression of neuroligin-1 in the hippocampus of APP/PS1 transgenic mice.Pharm Biol. 2019 Dec;57(1):453-459. doi: 10.1080/13880209.2019.1629463.
• [1727] Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome.Biochem Biophys Res Commun. 2002 Aug 30;296(4):970-5. doi: 10.1016/s0006-291x(02)02035-1.
• [1728] NIR fluorescent probes with good water-solubility for detection of amyloid beta aggregates in Alzheimer's disease.J Mater Chem B. 2019 Sep 18;7(36):5535-5540. doi: 10.1039/c9tb01012b.
• [1729] Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.Lancet Neurol. 2011 Sep;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9. Epub 2011 Jul 27.
• [1730] The function of BMP4 during neurogenesis in the adult hippocampus in Alzheimer's disease.Ageing Res Rev. 2013 Jan;12(1):157-64. doi: 10.1016/j.arr.2012.05.002. Epub 2012 Jun 12.
• [1731] Alzheimer disease detection from structural MR images using FCM based weighted probabilistic neural network.Brain Imaging Behav. 2019 Feb;13(1):87-110. doi: 10.1007/s11682-018-9831-2.
• [1732] Increased expression of p130 in Alzheimer disease.Neurochem Res. 2007 Apr-May;32(4-5):639-44. doi: 10.1007/s11064-006-9146-3. Epub 2006 Sep 28.
• [1733] Association study of cholesterol-related genes in Alzheimer's disease.Neurogenetics. 2007 Aug;8(3):179-88. doi: 10.1007/s10048-007-0087-z. Epub 2007 Mar 27.
• [1734] Conformational analysis of apolipoprotein E3/E4 heteromerization.FEBS J. 2019 May;286(10):1986-1998. doi: 10.1111/febs.14794. Epub 2019 Mar 13.
• [1735] Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment.Glia. 2016 Feb;64(2):317-29. doi: 10.1002/glia.22931. Epub 2015 Oct 14.
• [1736] Calcilytic NPS 2143 Reduces Amyloid Secretion and Increases sAPP Release from PSEN1 Mutant iPSC-Derived Neurons.J Alzheimers Dis. 2019;72(3):885-899. doi: 10.3233/JAD-190602.
• [1737] Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.
• [1738] RKIP-Mediated NF-B Signaling is involved in ELF-MF-mediated improvement in AD rat.Int J Med Sci. 2018 Nov 5;15(14):1658-1666. doi: 10.7150/ijms.28411. eCollection 2018.
• [1739] Magnetic resonance imaging of noradrenergic neurons.Brain Struct Funct. 2019 May;224(4):1609-1625. doi: 10.1007/s00429-019-01858-0. Epub 2019 Mar 22.
• [1740] Autophagy protein NRBF2 has reduced expression in Alzheimer's brains and modulates memory and amyloid-beta homeostasis in mice.Mol Neurodegener. 2019 Nov 27;14(1):43. doi: 10.1186/s13024-019-0342-4.
• [1741] NrCAM is a marker for substrate-selective activation of ADAM10 in Alzheimer's disease.EMBO Mol Med. 2019 Apr;11(4):e9695. doi: 10.15252/emmm.201809695.
• [1742] Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases.Int J Mol Sci. 2016 Dec 13;17(12):2086. doi: 10.3390/ijms17122086.
• [1743] NRG3 gene is associated with the risk and age at onset of Alzheimer disease.J Neural Transm (Vienna). 2014 Feb;121(2):183-92. doi: 10.1007/s00702-013-1091-0. Epub 2013 Sep 24.
• [1744] The nuclear cofactor receptor interacting protein-140 (RIP140) regulates the expression of genes involved in A generation.Neurobiol Aging. 2016 Nov;47:180-191. doi: 10.1016/j.neurobiolaging.2016.08.003. Epub 2016 Aug 12.
• [1745] Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease.Alzheimers Res Ther. 2019 Mar 21;11(1):28. doi: 10.1186/s13195-019-0475-2.
• [1746] Association between presenilin-1 -48C/T polymorphism and Down's syndrome.Neurosci Lett. 2004 Aug 26;367(1):88-91. doi: 10.1016/j.neulet.2004.05.086.
• [1747] Potential roles of neurotensin on cognition in conditions of obese-insulin resistance.Neuropeptides. 2018 Dec;72:12-22. doi: 10.1016/j.npep.2018.09.002. Epub 2018 Sep 8.
• [1748] 3-(Benzyloxy)-1-(5-[(18)F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain.Future Med Chem. 2017 Jun;9(10):983-994. doi: 10.4155/fmc-2017-0023. Epub 2017 Jun 20.
• [1749] Oxidative damage to RNA and expression patterns of MTH1 in the hippocampi of senescence-accelerated SAMP8 mice and Alzheimer's disease patients.Neurochem Res. 2011 Aug;36(8):1558-65. doi: 10.1007/s11064-011-0484-4. Epub 2011 May 3.
• [1750] Effects of Zn2+ binding on the structural and dynamic properties of amyloid peptide associated with Alzheimer's disease: Asp1 or Glu11?.ACS Chem Neurosci. 2013 Nov 20;4(11):1458-68. doi: 10.1021/cn4001445. Epub 2013 Sep 13.
• [1751] Numb endocytic adapter proteins regulate the transport and processing of the amyloid precursor protein in an isoform-dependent manner: implications for Alzheimer disease pathogenesis.J Biol Chem. 2008 Sep 12;283(37):25492-25502. doi: 10.1074/jbc.M802072200. Epub 2008 Jul 2.
• [1752] Altered Nup153 Expression Impairs the Function of Cultured Hippocampal Neural Stem Cells Isolated from a Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2019 Aug;56(8):5934-5949. doi: 10.1007/s12035-018-1466-1. Epub 2019 Jan 28.
• [1753] miRNA-dependent target regulation: functional characterization of single-nucleotide polymorphisms identified in genome-wide association studies of Alzheimer's disease.Alzheimers Res Ther. 2016 May 24;8(1):20. doi: 10.1186/s13195-016-0186-x.
• [1754] A TAP2 genotype associated with Alzheimer's disease in APOE4 carriers.Neurobiol Aging. 2007 Apr;28(4):519-23. doi: 10.1016/j.neurobiolaging.2006.02.011. Epub 2006 Apr 3.
• [1755] Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?.Neurosci Biobehav Rev. 2019 May;100:180-207. doi: 10.1016/j.neubiorev.2019.02.014. Epub 2019 Feb 25.
• [1756] OCIAD2 activates -secretase to enhance amyloid production by interacting with nicastrin.Cell Mol Life Sci. 2014 Jul;71(13):2561-76. doi: 10.1007/s00018-013-1515-x. Epub 2013 Nov 24.
• [1757] Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.Brain. 2019 Apr 1;142(4):1077-1092. doi: 10.1093/brain/awz011.
• [1758] Structural Basis for Achieving GSK-3 Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.J Med Chem. 2019 Nov 14;62(21):9600-9617. doi: 10.1021/acs.jmedchem.9b01030. Epub 2019 Oct 21.
• [1759] Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer's disease: In vitro and in vivo evaluation.Int J Biol Macromol. 2017 Dec;105(Pt 1):131-142. doi: 10.1016/j.ijbiomac.2017.07.021. Epub 2017 Jul 8.
• [1760] Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.
• [1761] Early and Persistent O-GlcNAc Protein Modification in the Streptozotocin Model of Alzheimer's Disease.J Alzheimers Dis. 2018;61(1):237-249. doi: 10.3233/JAD-170211.
• [1762] Molecular identification of AMY, an Alzheimer disease amyloid-associated protein.J Neuropathol Exp Neurol. 2003 Nov;62(11):1108-17. doi: 10.1093/jnen/62.11.1108.
• [1763] Understanding the interactions of different substrates with wild-type and mutant acylaminoacyl peptidase using molecular dynamics simulations.J Biomol Struct Dyn. 2018 Dec;36(16):4285-4302. doi: 10.1080/07391102.2017.1414634. Epub 2017 Dec 20.
• [1764] Amyloid- deposition and olfactory dysfunction in an Alzheimer's disease model.J Alzheimers Dis. 2013;37(4):699-712. doi: 10.3233/JAD-122443.
• [1765] A-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer's disease.Mol Neurodegener. 2015 Mar 19;10:13. doi: 10.1186/s13024-015-0007-x.
• [1766] CSF biomarkers -amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.J Neurol Sci. 2017 Nov 15;382:91-95. doi: 10.1016/j.jns.2017.09.039. Epub 2017 Sep 28.
• [1767] Light-Induced Pupillary Responses in Alzheimer's Disease.Front Neurol. 2019 Apr 12;10:360. doi: 10.3389/fneur.2019.00360. eCollection 2019.
• [1768] Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease.J Clin Lab Anal. 2010;24(3):182-6. doi: 10.1002/jcla.20379.
• [1769] Identification of Alzheimer's Disease Autoantibodies and Their Target Biomarkers by Phage Microarrays.J Proteome Res. 2019 Jul 5;18(7):2940-2953. doi: 10.1021/acs.jproteome.9b00258. Epub 2019 Jun 7.
• [1770] A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs).J Biochem. 2017 Dec 1;162(6):391-394. doi: 10.1093/jb/mvx058.
• [1771] Astrocytic Orosomucoid-2 Modulates Microglial Activation and Neuroinflammation.J Neurosci. 2017 Mar 15;37(11):2878-2894. doi: 10.1523/JNEUROSCI.2534-16.2017. Epub 2017 Feb 13.
• [1772] Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.Acta Neuropathol. 2017 May;133(5):731-749. doi: 10.1007/s00401-016-1663-9. Epub 2017 Jan 12.
• [1773] Genetic linkage in the mouse of genes involved in Down syndrome and Alzheimer's disease in man.Brain Res. 1987 Sep;388(3):215-21. doi: 10.1016/0169-328x(87)90028-3.
• [1774] Hypothalamic vasopressin and oxytocin mRNA expression in relation to depressive state in Alzheimer's disease: a difference with major depressive disorder.J Neuroendocrinol. 2009 Aug;21(8):722-9. doi: 10.1111/j.1365-2826.2009.01890.x. Epub 2009 Jun 4.
• [1775] Older Adults With a Combination of Vision and Hearing Impairment Experience Higher Rates of Cognitive Impairment, Functional Dependence, and Worse Outcomes Across a Set of Quality Indicators.J Aging Health. 2019 Jan;31(1):85-108. doi: 10.1177/0898264317723407. Epub 2017 Aug 13.
• [1776] Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.Hum Mol Genet. 2009 May 15;18(10):1849-59. doi: 10.1093/hmg/ddp101. Epub 2009 Mar 3.
• [1777] Small Molecule Inhibition of Protein Disulfide Isomerase in Neuroblastoma Cells Induces an Oxidative Stress Response and Apoptosis Pathways.ACS Chem Neurosci. 2019 Sep 18;10(9):4068-4075. doi: 10.1021/acschemneuro.9b00301. Epub 2019 Aug 8.
• [1778] Induction of peptidylarginine deiminase 2 and 3 by dibutyryl cAMP via cAMP-PKA signaling in human astrocytoma U-251MG cells.J Neurosci Res. 2017 Jul;95(7):1503-1512. doi: 10.1002/jnr.23959. Epub 2016 Oct 5.
• [1779] Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease.Brain Pathol. 2020 Mar;30(2):319-331. doi: 10.1111/bpa.12779. Epub 2019 Sep 8.
• [1780] SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians.PLoS One. 2013;8(4):e58618. doi: 10.1371/journal.pone.0058618. Epub 2013 Apr 2.
• [1781] Nuclear Tau, p53 and Pin1 Regulate PARN-Mediated Deadenylation and Gene Expression.Front Mol Neurosci. 2019 Oct 15;12:242. doi: 10.3389/fnmol.2019.00242. eCollection 2019.
• [1782] Establishment of TUSMi008-A, an induced pluripotent stem cell (iPSC) line from a 76-year old Alzheimer's disease (AD) patient with PAXIP1 gene mutation.Stem Cell Res. 2019 Apr;36:101391. doi: 10.1016/j.scr.2019.101391. Epub 2019 Jan 26.
• [1783] Pyruvate carboxylase and pentose phosphate fluxes are reduced in APP-PS1 mouse model of Alzheimer's disease: a C NMR study.J Alzheimers Dis. 2014;41(2):387-99. doi: 10.3233/JAD-122449.
• [1784] Enhanced antigen retrieval of amyloid immunohistochemistry: re-evaluation of amyloid pathology in Alzheimer disease and its mouse model.J Histochem Cytochem. 2012 Oct;60(10):761-9. doi: 10.1369/0022155412456379. Epub 2012 Jul 21.
• [1785] PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease.Neuroscience. 1998 Oct;86(4):1055-63. doi: 10.1016/s0306-4522(98)00130-4.
• [1786] A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease.J Neurochem. 2014 Feb;128(3):419-30. doi: 10.1111/jnc.12454. Epub 2013 Oct 24.
• [1787] The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.J Alzheimers Dis. 2017;58(2):449-462. doi: 10.3233/JAD-161061.
• [1788] MiR-21 attenuates apoptosis-triggered by amyloid- via modulating PDCD4/ PI3K/AKT/GSK-3 pathway in SH-SY5Y cells.Biomed Pharmacother. 2018 May;101:1003-1007. doi: 10.1016/j.biopha.2018.02.043. Epub 2018 Mar 22.
• [1789] Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.Exp Neurol. 2003 Aug;182(2):322-34. doi: 10.1016/s0014-4886(03)00042-6.
• [1790] Decreased levels of PDI and P5 in oligodendrocytes in Alzheimer's disease.Neuropathology. 2017 Dec;37(6):495-501. doi: 10.1111/neup.12395. Epub 2017 Jul 21.
• [1791] Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14670-5. doi: 10.1073/pnas.0903563106. Epub 2009 Aug 10.
• [1792] Dynamin-like protein 1 cleavage by calpain in Alzheimer's disease.Aging Cell. 2019 Jun;18(3):e12912. doi: 10.1111/acel.12912. Epub 2019 Feb 14.
• [1793] Dysregulation of dynorphins in Alzheimer disease.Neurobiol Aging. 2007 Nov;28(11):1700-8. doi: 10.1016/j.neurobiolaging.2006.07.002. Epub 2006 Aug 17.
• [1794] PIN-1 promoter polymorphisms in mild cognitive impairment and susceptibility to Alzheimer's disease: a preliminary report.Aging Clin Exp Res. 2007 Oct;19(5):406-9. doi: 10.1007/BF03324722.
• [1795] Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection.Neurosci Biobehav Rev. 2019 Feb;97:47-69. doi: 10.1016/j.neubiorev.2018.09.025. Epub 2018 Nov 3.
• [1796] Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.J Neurosci. 2008 May 7;28(19):5007-17. doi: 10.1523/JNEUROSCI.0590-08.2008.
• [1797] Changes in the expression of prefoldin subunit 5 depending on synaptic plasticity in the mouse hippocampus.Neurosci Lett. 2019 Nov 1;712:134484. doi: 10.1016/j.neulet.2019.134484. Epub 2019 Sep 7.
• [1798] ABCB1 genotype and CSF beta-amyloid in Alzheimer disease.J Geriatr Psychiatry Neurol. 2011 Jun;24(2):63-6. doi: 10.1177/0891988711402325. Epub 2011 Apr 8.
• [1799] SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection.PLoS Pathog. 2013;9(11):e1003775. doi: 10.1371/journal.ppat.1003775. Epub 2013 Nov 21.
• [1800] Antagonistic Activity of Naphthoquinone-Based Hybrids toward Amyloids Associated with Alzheimer's Disease and Type-2 Diabetes.ACS Chem Neurosci. 2019 Aug 21;10(8):3510-3520. doi: 10.1021/acschemneuro.9b00123. Epub 2019 Jul 8.
• [1801] Genetic Analysis of PICK1 Gene in Alzheimer's Disease: A Study for Finding a New Gene Target.Front Neurol. 2019 Jan 9;9:1169. doi: 10.3389/fneur.2018.01169. eCollection 2018.
• [1802] Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes.Front Aging Neurosci. 2018 Oct 22;10:332. doi: 10.3389/fnagi.2018.00332. eCollection 2018.
• [1803] Insight into the structural stability of wild-type and histidine mutants in Pin1 by experimental and computational methods.Sci Rep. 2019 Jun 10;9(1):8413. doi: 10.1038/s41598-019-44926-5.
• [1804] Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment.J Proteome Res. 2019 Apr 5;18(4):1542-1552. doi: 10.1021/acs.jproteome.8b00818. Epub 2018 Dec 7.
• [1805] Incidence of dementia in relation to genetic variants at PITX2, ZFHX3, and ApoE 4 in atrial fibrillation patients.Pacing Clin Electrophysiol. 2015 Feb;38(2):171-7. doi: 10.1111/pace.12537. Epub 2014 Dec 12.
• [1806] Direct interaction of Alzheimer's disease-related presenilin 1 with armadillo protein p0071.J Biol Chem. 1999 Apr 2;274(14):9141-8. doi: 10.1074/jbc.274.14.9141.
• [1807] Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme.PLoS One. 2015 Dec 4;10(12):e0143518. doi: 10.1371/journal.pone.0143518. eCollection 2015.
• [1808] Association study of interferon-, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease.Am J Geriatr Psychiatry. 2010 Nov;18(11):983-7. doi: 10.1097/JGP.0b013e3181e70c05.
• [1809] Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.Alzheimers Res Ther. 2019 Feb 2;11(1):16. doi: 10.1186/s13195-019-0469-0.
• [1810] APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease.Am J Hum Genet. 1991 Sep;49(3):511-7.
• [1811] PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing.Nat Immunol. 2018 Sep;19(9):942-953. doi: 10.1038/s41590-018-0179-y. Epub 2018 Aug 13.
• [1812] Impact of working situation on mental and physical health for informal caregivers of older people with Alzheimer's disease in Italy. Results from the UP-TECH longitudinal study.Aging Ment Health. 2021 Jan;25(1):22-31. doi: 10.1080/13607863.2019.1667295. Epub 2019 Sep 23.
• [1813] Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease.Mol Neurodegener. 2017 Nov 6;12(1):82. doi: 10.1186/s13024-017-0219-3.
• [1814] Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis.Ophthalmology. 2019 Apr;126(4):497-510. doi: 10.1016/j.ophtha.2018.08.009. Epub 2018 Aug 13.
• [1815] White matter architecture in major depression with anxious distress symptoms.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109664. doi: 10.1016/j.pnpbp.2019.109664. Epub 2019 May 31.
• [1816] Common Variants in PLXNA4 and Correlation to CSF-related Phenotypes in Alzheimer's Disease.Front Neurosci. 2018 Dec 18;12:946. doi: 10.3389/fnins.2018.00946. eCollection 2018.
• [1817] Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia.Ann Neurol. 2018 Jul;84(1):78-88. doi: 10.1002/ana.25266. Epub 2018 Jul 3.
• [1818] POLD1 deficiency is involved in cognitive function impairment in AD patients and SAMP8 mice.Biomed Pharmacother. 2019 Jun;114:108833. doi: 10.1016/j.biopha.2019.108833. Epub 2019 Apr 9.
• [1819] Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades.Neurochem Int. 2008 May;52(6):920-34. doi: 10.1016/j.neuint.2007.11.003. Epub 2007 Nov 23.
• [1820] Endoplasmic reticulum-associated SKN-1A/Nrf1 mediates a cytoplasmic unfolded protein response and promotes longevity.Elife. 2019 Apr 11;8:e44425. doi: 10.7554/eLife.44425.
• [1821] Therapeutic Effects of Transplantation of As-MiR-937-Expressing Mesenchymal Stem Cells in Murine Model of Alzheimer's Disease.Cell Physiol Biochem. 2015;37(1):321-30. doi: 10.1159/000430356. Epub 2015 Aug 24.
• [1822] Protective effects of melatonin on mitochondrial biogenesis and mitochondrial structure and function in the HEK293-APPswe cell model of Alzheimer's disease.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3542-3550. doi: 10.26355/eurrev_201904_17723.
• [1823] Explorative results from multistep screening for potential genetic risk loci of Alzheimer's disease in the longitudinal VITA study cohort.J Neural Transm (Vienna). 2018 Jan;125(1):77-87. doi: 10.1007/s00702-017-1796-6. Epub 2017 Oct 12.
• [1824] Epigenetic drug discovery for Alzheimer's disease.Expert Opin Drug Discov. 2014 Sep;9(9):1059-86. doi: 10.1517/17460441.2014.930124. Epub 2014 Jul 3.
• [1825] The anteroposterior and primary-to-posterior limbic ratios as MRI-derived volumetric markers of Alzheimer's disease.J Neurol Sci. 2017 Jul 15;378:110-119. doi: 10.1016/j.jns.2017.04.046. Epub 2017 Apr 27.
• [1826] Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease.Neurochem Res. 2002 Oct;27(10):1035-48. doi: 10.1023/a:1020952704398.
• [1827] Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease.J Alzheimers Dis. 2018;62(4):1549-1565. doi: 10.3233/JAD-170988.
• [1828] Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study.CNS Neurol Disord Drug Targets. 2017;16(9):1027-1038. doi: 10.2174/1871527316666171023153837.
• [1829] Tyrosol Reduces Amyloid- Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer's Disease Model Mice.J Alzheimers Dis. 2019;70(3):937-952. doi: 10.3233/JAD-190098.
• [1830] Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.Neurobiol Aging. 2019 Sep;81:234-243. doi: 10.1016/j.neurobiolaging.2019.06.008. Epub 2019 Jul 2.
• [1831] Association between CAG repeat length in the PPP2R2B gene and Alzheimer disease in the Japanese population.Neurosci Lett. 2011 Jan 10;487(3):354-7. doi: 10.1016/j.neulet.2010.10.055. Epub 2010 Oct 26.
• [1832] Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.Mol Cell Neurosci. 2017 Sep;83:83-91. doi: 10.1016/j.mcn.2017.07.002. Epub 2017 Jul 15.
• [1833] CNB-001, a synthetic pyrazole derivative of curcumin, suppresses lipopolysaccharide-induced nitric oxide production through the inhibition of NF-B and p38 MAPK pathways in microglia.Eur J Pharmacol. 2018 Jan 15;819:190-197. doi: 10.1016/j.ejphar.2017.12.008. Epub 2017 Dec 6.
• [1834] A variant in PPP4R3A protects against alzheimer-related metabolic decline.Ann Neurol. 2017 Dec;82(6):900-911. doi: 10.1002/ana.25094. Epub 2017 Dec 4.
• [1835] The intellectual disability gene PQBP1 rescues Alzheimer's disease pathology.Mol Psychiatry. 2018 Oct;23(10):2090-2110. doi: 10.1038/s41380-018-0253-8. Epub 2018 Oct 3.
• [1836] Inheritance pattern of platelet membrane fluidity in Alzheimer disease.Am J Hum Genet. 1989 Jun;44(6):799-805.
• [1837] Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer's Disease.Curr Alzheimer Res. 2018;15(8):764-776. doi: 10.2174/1567205015666180223093020.
• [1838] Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome.J Neural Transm Suppl. 2001;(61):223-35. doi: 10.1007/978-3-7091-6262-0_18.
• [1839] Effective litmus gene test for monitoring the quality of blood samples: Application to Alzheimer's disease diagnostics.Sci Rep. 2017 Dec 4;7(1):16848. doi: 10.1038/s41598-017-17293-2.
• [1840] Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients.J Alzheimers Dis. 2016 May 30;53(3):831-41. doi: 10.3233/JAD-160220.
• [1841] Profiling of differentially expressed circular RNAs in peripheral blood mononuclear cells from Alzheimer's disease patients.Metab Brain Dis. 2020 Jan;35(1):201-213. doi: 10.1007/s11011-019-00497-y. Epub 2019 Dec 13.
• [1842] Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort.J Neurol. 2014 Nov;261(11):2085-92. doi: 10.1007/s00415-014-7456-y. Epub 2014 Aug 10.
• [1843] Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.Cell Mol Neurobiol. 2017 May;37(4):717-728. doi: 10.1007/s10571-016-0407-7. Epub 2016 Jul 18.
• [1844] The PKR activator PACT is induced by A: involvement in Alzheimer's disease.Brain Pathol. 2012 Mar;22(2):219-29. doi: 10.1111/j.1750-3639.2011.00520.x. Epub 2011 Sep 16.
• [1845] Lipidized Prolactin-Releasing Peptide Agonist Attenuates Hypothermia-Induced Tau Hyperphosphorylation in Neurons.J Alzheimers Dis. 2019;67(4):1187-1200. doi: 10.3233/JAD-180837.
• [1846] APOE 4 Carriers Show Delayed Recovery of Verbal Memory and Smaller Entorhinal Volume in the First Year After Ischemic Stroke.J Alzheimers Dis. 2019;71(1):245-259. doi: 10.3233/JAD-190566.
• [1847] PRND 3'UTR polymorphism may be associated with behavioral disturbances in Alzheimer disease.Prion. 2012 Jan-Mar;6(1):73-80. doi: 10.4161/pri.6.1.18428.
• [1848] Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimer's Disease: From Animal Models to the Human Pathology.Cells. 2019 Nov 13;8(11):1430. doi: 10.3390/cells8111430.
• [1849] CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer's disease.Alzheimers Res Ther. 2016 Apr 19;8(1):15. doi: 10.1186/s13195-016-0183-0.
• [1850] Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimer's disease.Exp Mol Med. 2019 Nov 15;51(11):1-17. doi: 10.1038/s12276-019-0326-z.
• [1851] PrP-grafted antibodies bind certain amyloid -protein aggregates, but do not prevent toxicity.Brain Res. 2019 May 1;1710:125-135. doi: 10.1016/j.brainres.2018.12.038. Epub 2018 Dec 26.
• [1852] Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A-induced impaired axonal transport.Mol Neurodegener. 2017 Feb 28;12(1):23. doi: 10.1186/s13024-017-0164-1.
• [1853] Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid beta-resistant nerve cells.J Biol Chem. 2007 Oct 19;282(42):30523-34. doi: 10.1074/jbc.M700869200. Epub 2007 Aug 29.
• [1854] A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease.Alzheimers Dement. 2014 Nov;10(6):646-55. doi: 10.1016/j.jalz.2013.12.014. Epub 2014 Feb 1.
• [1855] A comprehensive analysis on preservation patterns of gene co-expression networks during Alzheimer's disease progression.BMC Bioinformatics. 2017 Dec 20;18(1):579. doi: 10.1186/s12859-017-1946-8.
• [1856] Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuse.Drug Alcohol Depend. 2018 May 1;186:159-166. doi: 10.1016/j.drugalcdep.2017.12.042. Epub 2018 Mar 2.
• [1857] Effect of intraperitoneal or intracerebroventricular injection of streptozotocin on learning and memory in mice.Exp Ther Med. 2018 Sep;16(3):2375-2380. doi: 10.3892/etm.2018.6487. Epub 2018 Jul 19.
• [1858] Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2019 Sep;56(9):6017-6034. doi: 10.1007/s12035-019-1479-4. Epub 2019 Feb 1.
• [1859] Evidence for altered Numb isoform levels in Alzheimer's disease patients and a triple transgenic mouse model.J Alzheimers Dis. 2011;24(2):349-61. doi: 10.3233/JAD-2011-101797.
• [1860] PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease.J Neurosci. 2019 Jun 12;39(24):4636-4656. doi: 10.1523/JNEUROSCI.0116-19.2019. Epub 2019 Apr 4.
• [1861] Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease.J Autoimmun. 2012 Jun;38(4):369-80. doi: 10.1016/j.jaut.2012.03.004. Epub 2012 May 2.
• [1862] Direct reprogramming of fibroblasts into neural stem cells by single non-neural progenitor transcription factor Ptf1a.Nat Commun. 2018 Jul 20;9(1):2865. doi: 10.1038/s41467-018-05209-1.
• [1863] What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.Neurobiol Aging. 2020 Jan;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. Epub 2019 Sep 19.
• [1864] X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.J Med Chem. 2017 Nov 22;60(22):9299-9319. doi: 10.1021/acs.jmedchem.7b01292. Epub 2017 Nov 8.
• [1865] Negative regulation of AbetaPP gene expression by pur-alpha.J Alzheimers Dis. 2008 Sep;15(1):71-82. doi: 10.3233/jad-2008-15106.
• [1866] Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease.Mol Psychiatry. 2020 Dec;25(12):3380-3398. doi: 10.1038/s41380-019-0483-4. Epub 2019 Aug 20.
• [1867] Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103.Sci Rep. 2015 Jul 30;5:12584. doi: 10.1038/srep12584.
• [1868] RAB10: an Alzheimer's disease resilience locus and potential drug target.Clin Interv Aging. 2018 Dec 28;14:73-79. doi: 10.2147/CIA.S159148. eCollection 2019.
• [1869] A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of -amyloid production.Cell Rep. 2013 Dec 26;5(6):1536-51. doi: 10.1016/j.celrep.2013.12.005.
• [1870] Rab21, a Novel PS1 Interactor, Regulates -Secretase Activity via PS1 Subcellular Distribution.Mol Neurobiol. 2018 May;55(5):3841-3855. doi: 10.1007/s12035-017-0606-3. Epub 2017 May 25.
• [1871] Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.J Chem Neuroanat. 2011 Oct;42(2):102-10. doi: 10.1016/j.jchemneu.2011.05.012. Epub 2011 Jun 12.
• [1872] Targeted Quantitative Proteomic Approach for High-Throughput Quantitative Profiling of Small GTPases in Brain Tissues of Alzheimer's Disease Patients.Anal Chem. 2019 Oct 1;91(19):12307-12314. doi: 10.1021/acs.analchem.9b02485. Epub 2019 Sep 10.
• [1873] Application of Weighted Gene Co-Expression Network Analysis to Explore the Key Genes in Alzheimer's Disease.J Alzheimers Dis. 2018;65(4):1353-1364. doi: 10.3233/JAD-180400.
• [1874] Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease.Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):243-50. doi: 10.1159/000051266.
• [1875] App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.J Neurosci. 2003 Jul 30;23(17):6788-92. doi: 10.1523/JNEUROSCI.23-17-06788.2003.
• [1876] Role of Rab GTPases in Alzheimer's Disease.ACS Chem Neurosci. 2019 Feb 20;10(2):828-838. doi: 10.1021/acschemneuro.8b00387. Epub 2018 Oct 11.
• [1877] Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.Am J Pathol. 2000 Jul;157(1):277-86. doi: 10.1016/s0002-9440(10)64538-5.
• [1878] Modifying Rap1-signalling by targeting Pde6 is neuroprotective in models of Alzheimer's disease.Mol Neurodegener. 2018 Sep 26;13(1):50. doi: 10.1186/s13024-018-0283-3.
• [1879] The enhancement of amyloid precursor protein and beta-site amyloid cleavage enzyme 1 interaction: amyloid-beta production with aging.Int J Mol Med. 2010 Mar;25(3):401-7. doi: 10.3892/ijmm_00000358.
• [1880] The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair.Neurobiol Dis. 2006 Sep;23(3):708-16. doi: 10.1016/j.nbd.2006.06.005. Epub 2006 Jul 24.
• [1881] RAD52 is required for RNA-templated recombination repair in post-mitotic neurons.J Biol Chem. 2018 Jan 26;293(4):1353-1362. doi: 10.1074/jbc.M117.808402. Epub 2017 Dec 7.
• [1882] Adrenomedullin Expression in Alzheimer's Brain.Curr Alzheimer Res. 2016;13(4):428-38. doi: 10.2174/1567205013666160229112725.
• [1883] Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology.PLoS One. 2013;8(1):e53349. doi: 10.1371/journal.pone.0053349. Epub 2013 Jan 8.
• [1884] Chemerin-9 Peptide Enhances Memory and Ameliorates A(1-42)-Induced Object Memory Impairment in Mice.Biol Pharm Bull. 2020 Feb 1;43(2):272-283. doi: 10.1248/bpb.b19-00510. Epub 2019 Nov 19.
• [1885] Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer's disease.Nat Commun. 2017 Oct 13;8(1):909. doi: 10.1038/s41467-017-00867-z.
• [1886] Cold Shock Induced Protein RBM3 but Not Mild Hypothermia Protects Human SH-SY5Y Neuroblastoma Cells From MPP(+)-Induced Neurotoxicity.Front Neurosci. 2018 May 3;12:298. doi: 10.3389/fnins.2018.00298. eCollection 2018.
• [1887] Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study.PLoS Med. 2017 Mar 28;14(3):e1002272. doi: 10.1371/journal.pmed.1002272. eCollection 2017 Mar.
• [1888] Regulator of calcineurin 1 is a novel RNA-binding protein to regulate neuronal apoptosis.Mol Psychiatry. 2021 Apr;26(4):1361-1375. doi: 10.1038/s41380-019-0487-0. Epub 2019 Aug 27.
• [1889] MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.PLoS One. 2013;8(1):e54222. doi: 10.1371/journal.pone.0054222. Epub 2013 Jan 17.
• [1890] Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models.Neurosci Biobehav Rev. 2019 Feb;97:112-137. doi: 10.1016/j.neubiorev.2018.09.027. Epub 2018 Oct 9.
• [1891] The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.PLoS One. 2017 Sep 6;12(9):e0184262. doi: 10.1371/journal.pone.0184262. eCollection 2017.
• [1892] Selection for depression-specific dementia cases with replication in two cohorts.PLoS One. 2019 May 31;14(5):e0216413. doi: 10.1371/journal.pone.0216413. eCollection 2019.
• [1893] Serum folic acid and RFC A80G polymorphism in Alzheimer's disease and vascular dementia.Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):38-44. doi: 10.1177/1533317513505131.
• [1894] Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer's Disease.Cell Transplant. 2017 Apr 13;26(4):693-702. doi: 10.3727/096368916X694184. Epub 2016 Nov 30.
• [1895] Regucalcin confers resistance to amyloid- toxicity in neuronally differentiated PC12 cells.FEBS Open Bio. 2018 Jan 20;8(3):349-360. doi: 10.1002/2211-5463.12374. eCollection 2018 Mar.
• [1896] Alternative Processing of the Amyloid Precursor Protein Family by Rhomboid Protease RHBDL4.J Biol Chem. 2016 Oct 14;291(42):21903-21912. doi: 10.1074/jbc.M116.753582. Epub 2016 Aug 25.
• [1897] Effect of site-specific amino acid D-isomerization on -sheet transition and fibril formation profiles of Tau microtubule-binding repeat peptides.Biochem Biophys Res Commun. 2019 Jan 1;508(1):184-190. doi: 10.1016/j.bbrc.2018.11.043. Epub 2018 Nov 22.
• [1898] Increase of zinc finger protein 179 in response to CCAAT/enhancer binding protein delta conferring an antiapoptotic effect in astrocytes of Alzheimer's disease.Mol Neurobiol. 2015 Feb;51(1):370-82. doi: 10.1007/s12035-014-8714-9. Epub 2014 May 1.
• [1899] The novel cytosolic RING finger protein dactylidin is up-regulated in brains of patients with Alzheimer's disease.Eur J Neurosci. 2005 Mar;21(5):1289-98. doi: 10.1111/j.1460-9568.2005.03977.x.
• [1900] Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.Neurology. 2018 Feb 27;90(9):e754-e762. doi: 10.1212/WNL.0000000000005030. Epub 2018 Jan 31.
• [1901] Housekeepers for accurate transcript expression analysis in Alzheimer's disease autopsy brain tissue.Alzheimers Dement. 2010 Nov;6(6):465-74. doi: 10.1016/j.jalz.2009.11.002.
• [1902] Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer's Disease.Acta Naturae. 2017 Jul-Sep;9(3):64-70.
• [1903] The Rps23rg gene family originated through retroposition of the ribosomal protein s23 mRNA and encodes proteins that decrease Alzheimer's beta-amyloid level and tau phosphorylation.Hum Mol Genet. 2010 Oct 1;19(19):3835-43. doi: 10.1093/hmg/ddq302. Epub 2010 Jul 22.
• [1904] A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.Am J Hum Genet. 2006 Jan;78(1):78-88. doi: 10.1086/498851. Epub 2005 Nov 15.
• [1905] Tau drives translational selectivity by interacting with ribosomal proteins.Acta Neuropathol. 2019 Apr;137(4):571-583. doi: 10.1007/s00401-019-01970-9. Epub 2019 Feb 13.
• [1906] Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants.Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2342-2357. doi: 10.1007/s00259-018-4075-3. Epub 2018 Jun 26.
• [1907] DHA Selectively Protects SAMP-8-Associated Cognitive Deficits Through Inhibition of JNK.Mol Neurobiol. 2019 Mar;56(3):1618-1627. doi: 10.1007/s12035-018-1185-7. Epub 2018 Jun 17.
• [1908] N-Acetylcysteine Prevents the Spatial Memory Deficits and the Redox-Dependent RyR2 Decrease Displayed by an Alzheimer's Disease Rat Model.Front Aging Neurosci. 2018 Dec 6;10:399. doi: 10.3389/fnagi.2018.00399. eCollection 2018.
• [1909] Polymorphisms Within RYR3 Gene Are Associated With Risk and Age at Onset of Hypertension, Diabetes, and Alzheimer's Disease.Am J Hypertens. 2018 Jun 11;31(7):818-826. doi: 10.1093/ajh/hpy046.
• [1910] Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.PLoS One. 2017 Jul 14;12(7):e0181486. doi: 10.1371/journal.pone.0181486. eCollection 2017.
• [1911] Functional segregation of executive control network and frontoparietal network in Alzheimer's disease.Cortex. 2019 Nov;120:36-48. doi: 10.1016/j.cortex.2019.04.026. Epub 2019 May 18.
• [1912] Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families.Neurobiol Aging. 2011 Feb;32(2):249-56. doi: 10.1016/j.neurobiolaging.2009.02.014. Epub 2009 Mar 27.
• [1913] Genetic polymorphisms of lipid metabolism gene SAR1 homolog B and the risk of Alzheimer's disease and vascular dementia.J Formos Med Assoc. 2016 Jan;115(1):38-44. doi: 10.1016/j.jfma.2015.01.008. Epub 2015 Feb 19.
• [1914] The roles of S-nitrosylation and S-glutathionylation in Alzheimer's disease.Methods Enzymol. 2019;626:499-538. doi: 10.1016/bs.mie.2019.08.004.
• [1915] Decreased expression of suprabasin induces aberrant differentiation and apoptosis of epidermal keratinocytes: Possible role for atopic dermatitis.J Dermatol Sci. 2019 Sep;95(3):107-112. doi: 10.1016/j.jdermsci.2019.07.009. Epub 2019 Jul 27.
• [1916] Transcriptome differences between the frontal cortex and hippocampus of wild-type and humanized presenilin-1 transgenic mice.Am J Geriatr Psychiatry. 2005 Dec;13(12):1041-51. doi: 10.1176/appi.ajgp.13.12.1041.
• [1917] Contribution of syndecans to cellular internalization and fibrillation of amyloid-(1-42).Sci Rep. 2019 Feb 4;9(1):1393. doi: 10.1038/s41598-018-37476-9.
• [1918] Ganglioside-Dependent Neural Stem Cell Proliferation in Alzheimer's Disease Model Mice.ASN Neuro. 2015 Dec 23;7(6):1759091415618916. doi: 10.1177/1759091415618916. Print 2015 Nov-Dec.
• [1919] Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.J Alzheimers Dis. 2019;72(4):1059-1075. doi: 10.3233/JAD-190475.
• [1920] A single-nucleotide polymorphism in tumor suppressor gene SEL1L as a predictive and prognostic marker for pancreatic ductal adenocarcinoma in Caucasians.Mol Carcinog. 2012 May;51(5):433-8. doi: 10.1002/mc.20808. Epub 2011 Jun 7.
• [1921] Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer's disease.Neurochem Res. 2005 Aug;30(8):1009-19. doi: 10.1007/s11064-005-6787-6.
• [1922] Selenoprotein P and its potential role in Alzheimer's disease.Hormones (Athens). 2020 Mar;19(1):73-79. doi: 10.1007/s42000-019-00112-w. Epub 2019 Jun 27.
• [1923] Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology.J Alzheimers Dis. 2017;55(2):749-762. doi: 10.3233/JAD-151208.
• [1924] Detecting genetic association through shortest paths in a bidirected graph.Genet Epidemiol. 2017 Sep;41(6):481-497. doi: 10.1002/gepi.22051. Epub 2017 Jun 19.
• [1925] Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer's Disease.Int J Mol Sci. 2019 Feb 13;20(4):803. doi: 10.3390/ijms20040803.
• [1926] Identification of septins in neurofibrillary tangles in Alzheimer's disease.Am J Pathol. 1998 Nov;153(5):1551-60. doi: 10.1016/S0002-9440(10)65743-4.
• [1927] SEPT8 modulates -amyloidogenic processing of APP by affecting the sorting and accumulation of BACE1.J Cell Sci. 2016 Jun 1;129(11):2224-38. doi: 10.1242/jcs.185215. Epub 2016 Apr 15.
• [1928] PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.Neurobiol Aging. 2017 Jul;55:99-114. doi: 10.1016/j.neurobiolaging.2017.03.016. Epub 2017 Mar 31.
• [1929] Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease.Proc Natl Acad Sci U S A. 1989 Nov;86(21):8284-8. doi: 10.1073/pnas.86.21.8284.
• [1930] Association studies between the plasmin genes and late-onset Alzheimer's disease.Neurobiol Aging. 2007 Jul;28(7):1041-3. doi: 10.1016/j.neurobiolaging.2006.05.028. Epub 2006 Jul 7.
• [1931] Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease.J Biol Chem. 2006 Sep 29;281(39):29268-77. doi: 10.1074/jbc.M600690200. Epub 2006 Jul 17.
• [1932] Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.Sci Rep. 2019 Jun 19;9(1):8795. doi: 10.1038/s41598-019-45129-8.
• [1933] Association of genetic variants in senataxin and Alzheimer's disease in a Chinese Han population in Taiwan.Chin J Physiol. 2014 Apr 30;57(2):83-9. doi: 10.4077/CJP.2014.BAC228.
• [1934] Exome sequencing in an Italian family with Alzheimer's disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H.Alzheimers Res Ther. 2018 Oct 12;10(1):106. doi: 10.1186/s13195-018-0435-2.
• [1935] Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0.
• [1936] BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation?.FEBS J. 2011 Oct;278(20):3893-904. doi: 10.1111/j.1742-4658.2011.08209.x. Epub 2011 Jul 5.
• [1937] Inhibition of sphingomyelin synthase 1 ameliorates alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1.Exp Neurol. 2019 Jan;311:67-79. doi: 10.1016/j.expneurol.2018.09.012. Epub 2018 Sep 20.
• [1938] The Protective Effects of PSM-04 Against Beta Amyloid-Induced Neurotoxicity in Primary Cortical Neurons and an Animal Model of Alzheimer's Disease.Front Pharmacol. 2019 Jan 24;10:2. doi: 10.3389/fphar.2019.00002. eCollection 2019.
• [1939] Up-regulation of NSP3 by Oligomeric A Accelerates Neuronal Death Through Cas-independent Rap1A Activation.Neuroscience. 2018 Aug 21;386:182-193. doi: 10.1016/j.neuroscience.2018.06.035. Epub 2018 Jun 30.
• [1940] Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.FEBS J. 2010 Jul;277(14):3051-67. doi: 10.1111/j.1742-4658.2010.07719.x. Epub 2010 Jun 22.
• [1941] Solution structures of the SH3 domains from Shank scaffold proteins and their interactions with Cav1.3 calcium channels.FEBS Lett. 2018 Aug;592(16):2786-2797. doi: 10.1002/1873-3468.13209. Epub 2018 Aug 12.
• [1942] Identification of Sidt2 as a lysosomal cation-conducting protein.FEBS Lett. 2017 Jan;591(1):76-87. doi: 10.1002/1873-3468.12528. Epub 2017 Jan 2.
• [1943] Ethanol Activation of PKA Mediates Single-Minded 2 Expression in Neuronal Cells.Mol Neurobiol. 2015 Dec;52(3):1234-1244. doi: 10.1007/s12035-014-8924-1. Epub 2014 Oct 17.
• [1944] Intact global cognitive and olfactory ability predicts lack of transition to dementia.Alzheimers Dement. 2020 Feb;16(2):326-334. doi: 10.1016/j.jalz.2019.08.200. Epub 2020 Jan 4.
• [1945] Improvement of memory deficits in the rat model of Alzheimer's disease by erythropoietin-loaded solid lipid nanoparticles.Neurobiol Learn Mem. 2019 Dec;166:107082. doi: 10.1016/j.nlm.2019.107082. Epub 2019 Sep 5.
• [1946] microRNA-34a (miRNA-34a) Mediated Down-Regulation of the Post-synaptic Cytoskeletal Element SHANK3 in Sporadic Alzheimer's Disease (AD).Front Neurol. 2019 Feb 6;10:28. doi: 10.3389/fneur.2019.00028. eCollection 2019.
• [1947] Does plasma phoenixin level associate with cognition? Comparison between subjective memory complaint, mild cognitive impairment, and mild Alzheimer's disease.Int Psychogeriatr. 2017 May 29:1-8. doi: 10.1017/S1041610217000825. Online ahead of print.
• [1948] Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.J Neurosci. 2016 Aug 17;36(33):8653-67. doi: 10.1523/JNEUROSCI.1429-16.2016.
• [1949] Parkin and synphilin-1 isoform expression changes in Lewy body diseases.Neurobiol Dis. 2007 Jun;26(3):681-7. doi: 10.1016/j.nbd.2007.03.007. Epub 2007 Mar 27.
• [1950] RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.J Biol Chem. 2018 Jul 13;293(28):11047-11066. doi: 10.1074/jbc.RA118.001747. Epub 2018 May 25.
• [1951] Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing.Mol Neurodegener. 2012 Jun 18;7:30. doi: 10.1186/1750-1326-7-30.
• [1952] Downregulation of SNX27 expression does not exacerbate amyloidogenesis in the APP/PS1 Alzheimer's disease mouse model.Neurobiol Aging. 2019 May;77:144-153. doi: 10.1016/j.neurobiolaging.2019.01.011. Epub 2019 Jan 25.
• [1953] Overexpression of SNX3 Decreases Amyloid- Peptide Production by Reducing Internalization of Amyloid Precursor Protein.Neurodegener Dis. 2018;18(1):26-37. doi: 10.1159/000486199. Epub 2018 Feb 7.
• [1954] SNX8 Enhances Non-amyloidogenic APP Trafficking and Attenuates A Accumulation and Memory Deficits in an AD Mouse.Front Cell Neurosci. 2019 Sep 6;13:410. doi: 10.3389/fncel.2019.00410. eCollection 2019.
• [1955] Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.PLoS One. 2016 Dec 22;11(12):e0168812. doi: 10.1371/journal.pone.0168812. eCollection 2016.
• [1956] Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters.Neuropsychobiology. 2019;78(2):79-85. doi: 10.1159/000497164. Epub 2019 May 16.
• [1957] Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP).Transl Psychiatry. 2013 May 14;3(5):e256. doi: 10.1038/tp.2013.13.
• [1958] Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16. doi: 10.1002/ajmg.b.30503.
• [1959] Early Impairments of Hippocampal Neurogenesis in 5xFAD Mouse Model of Alzheimer's Disease Are Associated with Altered Expression of SOXB Transcription Factors.J Alzheimers Dis. 2018;65(3):963-976. doi: 10.3233/JAD-180277.
• [1960] MicroRNA-129-5p alleviates nerve injury and inflammatory response of Alzheimer's disease via downregulating SOX6.Cell Cycle. 2019 Nov;18(22):3095-3110. doi: 10.1080/15384101.2019.1669388. Epub 2019 Sep 29.
• [1961] Modulation of SPARC/Hevin Proteins in Alzheimer's Disease Brain Injury.J Alzheimers Dis. 2019;68(2):695-710. doi: 10.3233/JAD-181032.
• [1962] Novel SPAST deletion and reduced DPY30 expression in a Spastic Paraplegia type 4 kindred.BMC Med Genet. 2014 Apr 1;15:39. doi: 10.1186/1471-2350-15-39.
• [1963] A Meta-Analysis of Alzheimer's Disease Brain Transcriptomic Data.J Alzheimers Dis. 2019;68(4):1635-1656. doi: 10.3233/JAD-181085.
• [1964] Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10. doi: 10.1046/j.1365-2990.2003.00453.x.
• [1965] Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide.Glia. 2019 Mar;67(3):498-511. doi: 10.1002/glia.23558. Epub 2018 Nov 28.
• [1966] Conformational Dynamics of Transmembrane Domain 3 of Presenilin 1 Is Associated with the Trimming Activity of -Secretase.J Neurosci. 2019 Oct 23;39(43):8600-8610. doi: 10.1523/JNEUROSCI.0838-19.2019. Epub 2019 Sep 16.
• [1967] BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease.Neurobiol Aging. 2014 Jul;35(7):1596-604. doi: 10.1016/j.neurobiolaging.2014.01.007. Epub 2014 Jan 13.
• [1968] The splicing regulatory protein p18SRP is down-regulated in Alzheimer's disease brain.J Mol Neurosci. 2004;24(2):269-76. doi: 10.1385/JMN:24:2:269.
• [1969] A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age.Phytomedicine. 2018 Jan 15;39:42-48. doi: 10.1016/j.phymed.2017.08.015. Epub 2017 Aug 18.
• [1970] SRSF1 and PTBP1 Are trans-Acting Factors That Suppress the Formation of a CD33 Splicing Isoform Linked to Alzheimer's Disease Risk.Mol Cell Biol. 2019 Aug 27;39(18):e00568-18. doi: 10.1128/MCB.00568-18. Print 2019 Sep 15.
• [1971] CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility.Hum Mol Genet. 2014 May 15;23(10):2729-36. doi: 10.1093/hmg/ddt666. Epub 2013 Dec 30.
• [1972] Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease.J Neurochem. 2012 Oct;123(1):159-71. doi: 10.1111/j.1471-4159.2012.07873.x. Epub 2012 Aug 16.
• [1973] Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model.Mol Ther Nucleic Acids. 2019 Dec 6;18:681-695. doi: 10.1016/j.omtn.2019.10.002. Epub 2019 Oct 10.
• [1974] Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration.Brain. 2020 May 1;143(5):1332-1340. doi: 10.1093/brain/awz358.
• [1975] Brain gangliosides of a transgenic mouse model of Alzheimer's disease with deficiency in GD3-synthase: expression of elevated levels of a cholinergic-specific ganglioside, GT1a.ASN Neuro. 2013 May 30;5(2):141-8. doi: 10.1042/AN20130006.
• [1976] A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.Neurobiol Aging. 2016 Jan;37:208.e1-208.e9. doi: 10.1016/j.neurobiolaging.2015.09.009. Epub 2015 Sep 25.
• [1977] STIM1 deficiency is linked to Alzheimer's disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca(2+) entry.J Mol Med (Berl). 2018 Oct;96(10):1061-1079. doi: 10.1007/s00109-018-1677-y. Epub 2018 Aug 7.
• [1978] On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases.Front Mol Neurosci. 2018 Mar 22;11:87. doi: 10.3389/fnmol.2018.00087. eCollection 2018.
• [1979] Anti-neuroinflammatory effects of a food-grade phenolic-enriched maple syrup extract in a mouse model of Alzheimer's disease.Nutr Neurosci. 2021 Sep;24(9):710-719. doi: 10.1080/1028415X.2019.1672009. Epub 2019 Oct 4.
• [1980] The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases.Front Neurosci. 2017 May 16;11:254. doi: 10.3389/fnins.2017.00254. eCollection 2017.
• [1981] SCG10 promotes non-amyloidogenic processing of amyloid precursor protein by facilitating its trafficking to the cell surface.Hum Mol Genet. 2013 Dec 15;22(24):4888-900. doi: 10.1093/hmg/ddt339. Epub 2013 Jul 17.
• [1982] Targeting STOX1 in the therapy of preeclampsia.Expert Opin Ther Targets. 2016 Dec;20(12):1433-1443. doi: 10.1080/14728222.2016.1253682. Epub 2016 Nov 8.
• [1983] Specificity for latent C termini links the E3 ubiquitin ligase CHIP to caspases.Nat Chem Biol. 2019 Aug;15(8):786-794. doi: 10.1038/s41589-019-0322-6. Epub 2019 Jul 18.
• [1984] Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease.J Neurosci Res. 2004 Mar 1;75(5):698-703. doi: 10.1002/jnr.20028.
• [1985] Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer's disease.Neuroscience. 2006;138(2):511-22. doi: 10.1016/j.neuroscience.2005.11.017. Epub 2006 Jan 18.
• [1986] SUCLG2 identified as both a determinator of CSF A1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.Hum Mol Genet. 2014 Dec 15;23(24):6644-58. doi: 10.1093/hmg/ddu372. Epub 2014 Jul 15.
• [1987] Polymorphisms of small ubiquitin-related modifier genes are associated with risk of Alzheimer's disease in Korean: A case-control study.J Neurol Sci. 2016 May 15;364:122-7. doi: 10.1016/j.jns.2016.03.023. Epub 2016 Mar 19.
• [1988] The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance.ACS Chem Neurosci. 2019 Sep 18;10(9):3927-3938. doi: 10.1021/acschemneuro.9b00351. Epub 2019 Aug 23.
• [1989] Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models.Behav Brain Res. 2017 Mar 30;322(Pt B):288-298. doi: 10.1016/j.bbr.2016.06.002. Epub 2016 Jun 2.
• [1990] Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry.Amino Acids. 2011 Mar;40(3):765-79. doi: 10.1007/s00726-010-0645-9. Epub 2010 Jun 19.
• [1991] DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer's disease.J Psychiatr Res. 2017 Sep;92:74-80. doi: 10.1016/j.jpsychires.2017.04.003. Epub 2017 Apr 11.
• [1992] Age-related changes in gene expression are accelerated in Alzheimer's disease.Synapse. 2011 Sep;65(9):971-4. doi: 10.1002/syn.20933. Epub 2011 Apr 11.
• [1993] Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.Ann Neurol. 2019 Feb;85(2):259-271. doi: 10.1002/ana.25392. Epub 2019 Jan 7.
• [1994] Synaptopodin Deficiency Ameliorates Symptoms in the 3xTg Mouse Model of Alzheimer's Disease.J Neurosci. 2019 May 15;39(20):3983-3992. doi: 10.1523/JNEUROSCI.2920-18.2019. Epub 2019 Mar 14.
• [1995] Mitsugumin 29 is transcriptionally induced in senile plaque-associated astrocytes.Brain Res. 2012 Mar 2;1441:9-16. doi: 10.1016/j.brainres.2011.12.062. Epub 2012 Jan 12.
• [1996] TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease.Neurobiol Aging. 2009 Jul;30(7):1052-60. doi: 10.1016/j.neurobiolaging.2007.10.014. Epub 2007 Dec 11.
• [1997] Further examination of the candidate genes in chromosome 12p13 locus for late-onset Alzheimer disease.Neurogenetics. 2008 May;9(2):127-38. doi: 10.1007/s10048-008-0122-8. Epub 2008 Mar 14.
• [1998] Intranasal TAT-haFGF Improves Cognition and Amyloid- Pathology in an APP/PS1 Mouse Model of Alzheimer's Disease.J Alzheimers Dis. 2016;51(4):985-90. doi: 10.3233/JAD-151121.
• [1999] Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.Cancer Res. 2002 Aug 1;62(15):4273-81.
• [2000] SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications.Clin Chim Acta. 2010 Mar;411(5-6):375-80. doi: 10.1016/j.cca.2009.12.002. Epub 2009 Dec 11.
• [2001] Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.Cell Mol Life Sci. 2019 Mar;76(5):1005-1025. doi: 10.1007/s00018-018-2998-2. Epub 2019 Jan 1.
• [2002] Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system.J Neuropathol Exp Neurol. 1996 Aug;55(8):889-95. doi: 10.1097/00005072-199608000-00004.
• [2003] Association of the transcobalamin II gene 776C ?G polymorphism with Alzheimer's type dementia: dependence on the 5, 10-methylenetetrahydrofolate reductase 1298A ?C polymorphism genotype.Ann Clin Biochem. 2015 Jul;52(Pt 4):448-55. doi: 10.1177/0004563214561770. Epub 2014 Nov 13.
• [2004] Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of A(40) plaques in Alzheimer's disease.Int J Nanomedicine. 2017 Dec 13;12:8749-8768. doi: 10.2147/IJN.S144545. eCollection 2017.
• [2005] Exploring the bi-directional relationship between autophagy and Alzheimer's disease.CNS Neurosci Ther. 2020 Feb;26(2):155-166. doi: 10.1111/cns.13216. Epub 2019 Sep 10.
• [2006] Differential regional and cellular distribution of TFF3 peptide in the human brain.Amino Acids. 2015 May;47(5):1053-63. doi: 10.1007/s00726-015-1938-9. Epub 2015 Feb 18.
• [2007] Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting A Accumulation.CNS Neurol Disord Drug Targets. 2015;14(3):360-9. doi: 10.2174/1871527314666150225141521.
• [2008] MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.Cancer Res. 2011 Jan 15;71(2):583-92. doi: 10.1158/0008-5472.CAN-10-2587. Epub 2011 Jan 11.
• [2009] Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.
• [2010] Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease [corrected].PLoS One. 2013 Jul 5;8(7):e68361. doi: 10.1371/journal.pone.0068361. Print 2013.
• [2011] Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation.Front Neurol. 2019 Jan 8;9:1158. doi: 10.3389/fneur.2018.01158. eCollection 2018.
• [2012] Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.J Alzheimers Dis. 2018;66(3):1265-1273. doi: 10.3233/JAD-180752.
• [2013] Ginsenoside Rg1 and Acori Graminei Rhizoma Attenuates Neuron Cell Apoptosis by Promoting the Expression of miR-873-5p in Alzheimer's Disease.Neurochem Res. 2018 Aug;43(8):1529-1538. doi: 10.1007/s11064-018-2567-y. Epub 2018 Jun 20.
• [2014] Ginsenoside Rg3 Prevents Cognitive Impairment by Improving Mitochondrial Dysfunction in the Rat Model of Alzheimer's Disease.J Agric Food Chem. 2019 Sep 11;67(36):10048-10058. doi: 10.1021/acs.jafc.9b03793. Epub 2019 Aug 27.
• [2015] Apathy in Preclinical Alzheimer's Disease: Psychometric Validation of the Apathy Evaluation Scale.Am J Alzheimers Dis Other Demen. 2019 Feb;34(1):16-22. doi: 10.1177/1533317518794020. Epub 2018 Aug 14.
• [2016] Male-specific epistasis between WWC1 and TLN2 genes is associated with Alzheimer's disease.Neurobiol Aging. 2018 Dec;72:188.e3-188.e12. doi: 10.1016/j.neurobiolaging.2018.08.001. Epub 2018 Aug 9.
• [2017] Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain.J Neurochem. 2006 Jul;98(1):34-44. doi: 10.1111/j.1471-4159.2006.03801.x.
• [2018] Distinct microglia profile in Creutzfeldt-Jakob disease and Alzheimer's disease is independent of disease kinetics.Neuropathology. 2018 Dec;38(6):591-600. doi: 10.1111/neup.12517. Epub 2018 Oct 15.
• [2019] Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease.ASN Neuro. 2010 Jul 12;2(3):e00037. doi: 10.1042/AN20100010.
• [2020] Knockdown of TNFAIP1 prevents di-(2-ethylhexyl) phthalate-induced neurotoxicity by activating CREB pathway.Chemosphere. 2020 Feb;241:125114. doi: 10.1016/j.chemosphere.2019.125114. Epub 2019 Oct 14.
• [2021] Increased Hyaluronan and TSG-6 in Association with Neuropathologic Changes of Alzheimer's Disease.J Alzheimers Dis. 2019;67(1):91-102. doi: 10.3233/JAD-180797.
• [2022] Overexpression of TIPE2, a Negative Regulator of Innate and Adaptive Immunity, Attenuates Cognitive Deficits in APP/PS1 Mice.J Neuroimmune Pharmacol. 2019 Sep;14(3):519-529. doi: 10.1007/s11481-019-09861-2. Epub 2019 Jul 8.
• [2023] Amelioration of amyloid--induced deficits by DcR3 in an Alzheimer's disease model.Mol Neurodegener. 2017 Apr 24;12(1):30. doi: 10.1186/s13024-017-0173-0.
• [2024] Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.J Alzheimers Dis. 2019;69(4):1213-1220. doi: 10.3233/JAD-190187.
• [2025] Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids.Biochem Biophys Res Commun. 1998 Jul 9;248(1):168-73. doi: 10.1006/bbrc.1998.8866.
• [2026] Toll-interacting protein deficiency promotes neurodegeneration via impeding autophagy completion in high-fat diet-fed ApoE(-/-) mouse model.Brain Behav Immun. 2017 Jan;59:200-210. doi: 10.1016/j.bbi.2016.10.002. Epub 2016 Oct 5.
• [2027] Amyloid-beta impairs TOM1-mediated IL-1R1 signaling.Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):21198-21206. doi: 10.1073/pnas.1914088116. Epub 2019 Sep 30.
• [2028] Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease.J Alzheimers Dis. 2018;61(2):793-801. doi: 10.3233/JAD-170613.
• [2029] ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and decreases APP-BP1-induced cell proliferation and neuronal apoptosis.J Neurochem. 2003 May;85(3):801-9. doi: 10.1046/j.1471-4159.2003.01727.x.
• [2030] Alterations in adult hippocampal neurogenesis, aberrant protein s-nitrosylation, and associated spatial memory loss in streptozotocin-induced diabetes mellitus type 2 mice.Iran J Basic Med Sci. 2017 Oct;20(10):1159-1165. doi: 10.22038/IJBMS.2017.9366.
• [2031] Estrogen receptor 1 PvuII and XbaI polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis.Genet Mol Res. 2015 Aug 10;14(3):9361-9. doi: 10.4238/2015.August.10.17.
• [2032] Gender-related increase of tropomyosin-1 abundance in platelets of Alzheimer's disease and mild cognitive impairment patients.J Proteomics. 2018 Apr 30;178:73-81. doi: 10.1016/j.jprot.2017.12.018. Epub 2017 Dec 24.
• [2033] Effect of Chlorogenic Acids on Cognitive Function in Mild Cognitive Impairment: A Randomized Controlled Crossover Trial.J Alzheimers Dis. 2019;72(4):1209-1216. doi: 10.3233/JAD-190757.
• [2034] Regulation of RAGE splicing by hnRNP A1 and Tra2-1 and its potential role in AD pathogenesis.J Neurochem. 2015 Apr;133(2):187-98. doi: 10.1111/jnc.13069. Epub 2015 Mar 2.
• [2035] No difference in expression of apoptosis-related proteins and apoptotic morphology in control, pathologically aged and Alzheimer's disease cases.Neurobiol Dis. 2006 May;22(2):323-33. doi: 10.1016/j.nbd.2005.11.010. Epub 2006 Jan 9.
• [2036] KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.Curr Neuropharmacol. 2018;16(5):618-626. doi: 10.2174/1570159X15666170630164226.
• [2037] Increased expression of tripartite motif (TRIM) like 2 promotes tumoral growth in human oral cancer.Biochem Biophys Res Commun. 2019 Jan 22;508(4):1133-1138. doi: 10.1016/j.bbrc.2018.12.060. Epub 2018 Dec 13.
• [2038] A Candidate Regulatory Variant at the TREM Gene Cluster Confer Alzheimer's Disease Risk by Modulating Both Amyloid- Pathology and Neuronal Degeneration.Front Neurosci. 2019 Jul 17;13:742. doi: 10.3389/fnins.2019.00742. eCollection 2019.
• [2039] A Missense Variant in TREML2 Reduces Risk of Alzheimer's Disease in a Han Chinese Population.Mol Neurobiol. 2017 Mar;54(2):977-982. doi: 10.1007/s12035-016-9706-8. Epub 2016 Jan 21.
• [2040] Review: Vascular dementia: clinicopathologic and genetic considerations.Neuropathol Appl Neurobiol. 2018 Apr;44(3):247-266. doi: 10.1111/nan.12472. Epub 2018 Mar 1.
• [2041] Susceptibility of brain atrophy to TRIB3 in Alzheimer's disease, evidence from functional prioritization in imaging genetics.Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3162-3167. doi: 10.1073/pnas.1706100115. Epub 2018 Mar 6.
• [2042] Positive and negative regulation of adenovirus infection by CAR-like soluble protein, CLSP.Gene Ther. 2007 Aug;14(16):1199-207. doi: 10.1038/sj.gt.3302975. Epub 2007 May 31.
• [2043] Association study of the chemokine, CXC motif, ligand 1 (CXCL1) gene with sporadic Alzheimer's disease in a Japanese population.Neurosci Lett. 2005 May 13;379(3):149-51. doi: 10.1016/j.neulet.2004.12.056. Epub 2005 Jan 25.
• [2044] Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation.Front Aging Neurosci. 2019 Jan 25;10:432. doi: 10.3389/fnagi.2018.00432. eCollection 2018.
• [2045] In vivo regulation of the A disintegrin and metalloproteinase 10 (ADAM10) by the tetraspanin 15.Cell Mol Life Sci. 2018 Sep;75(17):3251-3267. doi: 10.1007/s00018-018-2791-2. Epub 2018 Mar 8.
• [2046] Tetraspanin 3: A central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein.Biochim Biophys Acta Mol Cell Res. 2017 Jan;1864(1):217-230. doi: 10.1016/j.bbamcr.2016.11.003. Epub 2016 Nov 3.
• [2047] Male microchimerism in the human female brain.PLoS One. 2012;7(9):e45592. doi: 10.1371/journal.pone.0045592. Epub 2012 Sep 26.
• [2048] Caenorhabditis elegans hub genes that respond to amyloid beta are homologs of genes involved in human Alzheimer's disease.PLoS One. 2019 Jul 10;14(7):e0219486. doi: 10.1371/journal.pone.0219486. eCollection 2019.
• [2049] Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease.Transl Psychiatry. 2019 Jan 31;9(1):55. doi: 10.1038/s41398-019-0394-9.
• [2050] CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein.Biochem Biophys Res Commun. 2017 Aug 26;490(3):876-881. doi: 10.1016/j.bbrc.2017.06.134. Epub 2017 Jun 21.
• [2051] Association between DCHS2 gene and mild cognitive impairment and Alzheimer's disease in an elderly Brazilian sample.Int J Geriatr Psychiatry. 2016 Dec;31(12):1337-1344. doi: 10.1002/gps.4440. Epub 2016 Feb 14.
• [2052] Molecular genetics of the transcription factor GLIS3 identifies its dual function in beta cells and neurons.Genomics. 2018 Mar;110(2):98-111. doi: 10.1016/j.ygeno.2017.09.001. Epub 2017 Sep 11.
• [2053] Glial Draper Rescues A Toxicity in a Drosophila Model of Alzheimer's Disease.J Neurosci. 2017 Dec 6;37(49):11881-11893. doi: 10.1523/JNEUROSCI.0862-17.2017. Epub 2017 Nov 6.
• [2054] Genetics of Alzheimer's disease.Adv Genet. 2014;87:245-94. doi: 10.1016/B978-0-12-800149-3.00005-6.